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Abstract 
Osteoarthritis (OA) is a disease of the whole joint, and subchondral bone changes are a 
universal OA feature. The cellular mechanisms of subchondral bone sclerosis in late OA 
joints implicate altered osteoblast and osteoclast activities, however the roles of the most 
abundant bone cells, the osteocytes, and their immature progenitors, the mesenchymal 
stem cells (MSCs) are not understood. The cell fraction characterised by the CD45-
CD271+ phenotype represents a reservoir of native bone-resident MSCs in humans, 
however it consists of topographically different subsets, whose relative contributions to 
bone formation in OA remain unclear. The aim of this study was to investigate gene 
expression profiles and topographical features of osteocytes, MSCs and their subsets in 
femoral head OA bone. 
Compared to healthy cancellous bone, CD45-CD271+ MSCs resident in OA bone were 
more abundant (3.4-fold, p<0.05) and had significantly (p<0.05) higher expression of 
osteogenic genes, such as runt related transcription factor 2 (RUNX2, 7-fold) and 
osteonectin (SPARC, 5-fold) indicating their osteogenic commitment. Furthermore, 
chondrogenic genes were significantly (p<0.05) decreased (SOX9, 5-fold and UDP-
glucose 6-dehydrogenase, UGDH, 14-fold). The native OA osteocytes transcriptional 
profile was consistent with their early, embedding stage of development, evidenced by 
significantly (p<0.01) higher levels of podoplanin (E11, 9-fold) and matrix 
metalloproteinase-14 (MMP14, 4-fold) compared to healthy bone osteocytes. Active bone 
formation in OA was evident as an accumulation and co-localisation of CD271+ MSCs 
and immature E11+ osteocytes in areas of bone sclerosis. Additionally, transcriptional and 
immunohistochemical analysis demonstrated that both MSCs and osteocytes in OA-
affected bone favoured bone formation by elevated expression of the osteoclastogenesis 
inhibitor osteoprotegerin. 
To define osteogenically-committed MSC subset, CD56 was chosen as a candidate 
molecule. Dual immunofluorescence confirmed co-localisation of CD271 and CD56 at 
the bone surface. CD271+CD56+ cells were significantly more abundant in OA bone 
compared to healthy bone (8-fold, p<0.0001) and also accumulated in OA sclerotic areas, 
having the unique topography in proximity to active bone formation sites. The 
CD271+CD56+ MSC subset displayed significantly (p<0.01) over 100-fold higher 
expression of osteogenesis- and chondrogenesis-related genes, including osteopontin 
 vii 
(SPP1), osteocalcin (BGLAP) and SOX9, compared to a donor-matched CD271+CD146+ 
subset, whilst the predominant CD271+CD146-CD56- subset represented a 
transcriptionally ‘intermediate’ MSC population with the highest levels of stromal-
derived factor 1 (CXCL12) transcript. While all three subsets were multipotential, their 
native gene expression traits were lost after in vitro culture. 
This study implicates native bone-resident MSCs in subchondral bone sclerosis in late-
stage hip OA. It defines the CD271+CD56+ osteogenically-committed MSC subset that 
has bone-lining topography and therefore the closest proximity to bone formation sites. 
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Chapter 1 General introduction 
1.1 Osteoarthritis 
1.1.1 Osteoarthritis: an introduction 
Osteoarthritis (OA) is the most common degenerative joint disease and represents one of 
the leading cause of pain and disability and is a major public health problem (WHO 
Scientific Group, 2003). The growing age of the population in developed and developing 
countries, as well as increased risk factors for OA, particularly obesity and a sedentary 
lifestyle may lead to a substantial increase in the number of people living with hip or knee 
OA over the coming decades (De Angelis and Chen, 2013).  
Osteoarthritis is considered the planet’s oldest known disease, with evidence recovered 
from burial grounds around the world showing arthritic disease in 50-70 million year 
dinosaurs as well as skeletal changes in Neanderthal man (100,000 – 35,000 B.C.) (Wells, 
1973; Buchanan et al., 2003).  But despite its widespread occurrence in ancient skeletons 
and early reference by Hippocrates (460-375 B.C.), it was only in the 18th century that 
clinicians formally recognised OA as a malady (Buchanan et al., 2003).  The delay was 
in part due to the few obvious physical signs but also because of the confusion in 
nomenclature, OA being initially grouped together with rheumatoid arthritis until the 19th 
century. Today there are clear criteria established for the clinical appearance or rheumatic 
conditions, although more research must be undertaken for a clear understanding of their 
pathogenesis. 
Osteoarthritis affects many diarthrodial joints (Figure 1.1) and is characterised by cell 
stress and extracellular matrix degradation initiated by micro- and macro-injury which 
subsequently activates a maladaptive tissue repair (Kraus et al., 2015; Martel-Pelletier et 
al., 2016). Given its continuous and evolving complexity, several definitions are widely 
used to describe OA. This condition manifests first on a molecular level as abnormal joint 
tissue metabolism followed by anatomic, and/or physiologic derangements, characterized 
by articular cartilage degradation, bone remodelling, osteophyte formation, joint 
inflammation and loss of normal joint function (Kraus et al., 2015). Clinically OA is 
characterized by joint pain, swelling and stiffness that leads to activity limitations, 
participation restrictions, sleep interruption, fatigue and depression or anxious mood, and 
ultimately loss of independence and reduced quality of life. 
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Figure 1.1. Common joints affected by OA. Any joint can be affected by OA but the 
disease occurs most commonly in joints that have experienced repetitive stress or injury, 
with the highest prevalence in hip, knee and ankle. Other small joints like small joints of 
the fingers and the bases of the thumb and big toe can also be affected.  
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1.1.2 Epidemiology and risk factors 
Epidemiological studies have been used to describe the distribution of OA in the 
population and to examine risk factors for its occurrence and progression. But the 
incidence and prevalence of OA, depending on the definition used and it can be described 
pathologically, radiographically, or clinically. Due to the various definitions of OA that 
are used, the reported prevalence and incidence rates vary across studies, however an 
estimated 8.75 million people aged 45 years and over (33%) in the UK have sought 
treatment for osteoarthritis (60% female, 40% male) (Arthritis Research UK, 2013).  
Osteoarthritis is undisputedly a complex disease with a multifactorial pathogenesis. The 
risk factors commonly associated with the initiation and progression of OA can be divided 
into person-level risk factors, those that act at the level of individual susceptibility, and 
joint-level factors, those that alter the biomechanical stability of individual joints (Palazzo 
et al., 2016) (Figure 1.2). Person-level risk factors include increasing age, gender, obesity 
and genetic factors while the predominant joint-level factors are joint injury, repetitive 
joint use through occupation or leisure and joint malalignment (Palazzo et al., 2016; 
Martel-Pelletier et al., 2016). 
Risk of developing OA increases with age. A third of women and almost a quarter of men 
between 45 and 64 have sought treatment for OA, this rises to almost half of people aged 
75 and over (Arthritis Research UK, 2013). Sex differences in the development, 
prevalence, and incidence of hip and knee OA have long been known, with females 
generally at a higher risk (Srikanth et al., 2005). However, it is important to note that 
females had more severe radiographic knee OA than males, while no significant 
differences were found between sexes in the severity of hip and hand OA (Srikanth et al., 
2005). The high prevalence in women may be associated with various factors, including 
genetics, women more often reported a family history of OA than men (49% vs. 37%) 
(Van Tunen et al., 2018). Furthermore, anatomical differences and body composition 
have also been reported to account for the aforementioned increase in prevalence amongst 
women, gender-specific hormones, such as estrogen, being known to influence the 
incidence and severity of OA (Boyan et al., 2013). While prior to menopause, the OA 
incidence was shown to be similar in women and men, after menopause, however, the 
prevalence is much greater in females than age-matched males (Nevitt and Felson, 1996). 
In addition, some studies revealed sex-related difference in cartilage matrix composition, 
women shown to have a thinner and more reduced volume of cartilage in the knee than 
men (Maleki-Fischbach and Jordan, 2010). 
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Obesity and high body mass index are important risk factors for OA. Obesity is associated 
with the incidence and progression of OA of both weight-bearing and non-weight-bearing 
joints (Lementowski and Zelicof, 2008). Increased joint loading leads to changes in body 
composition with detrimental effects related to low grade’ chronic inflammation (Wluka 
et al., 2013). Behavioural factors may also play a role in OA development, such as 
diminished physical activity and subsequent loss of protective muscle strength. 
According to data from the Framingham Study, a community study of OA, among women 
with a baseline body mass index (BMI) greater than or equal to 25, weight loss was 
associated with a significantly lower risk of knee OA (Felson et al., 1997). Estimations 
based on data from the same study indicate that weight reduction by 5 kg over a 10 year 
period decreased the risk of developing knee OA by 50% (Felson et al., 1992; Christensen 
et al., 2006). 
A hereditary component of OA development has long been recognized, with several 
genes shown to be directly associated with OA (Valdes and Spector, 2010) and many 
more have been determined to be associated with contributing factors, such as excessive 
inflammation and obesity (Valdes and Spector, 2011). Genetic factors account for 60% 
of hand and hip OA and 40% of knee OA (Martel-Pelletier et al., 2016). Many genes 
could play a role in the disease onset and so could provide targets for future 
pharmacological treatments (e.g., genes encoded for vitamin D receptor, insulin-like 
growth factor 1, type 2 collagen, growth differentiation factor 5) (Palotie et al., 1989; 
Chapman et al., 2008; Evangelou et al., 2009). Genetic studies aim to identify which 
genetic variants at which genetic locations (loci) influence the risk of disease. The past 
decade has seen a number of contributions to the genetic influence in OA in the form of 
genome-wide association studies (GWAS). Genes such as GDF5, ASPN, FRZB and 
PTGS2 have been identified in these studies. One of the most powerful GWAS performed 
on OA was published in 2012 called arcOGEN and involved the analysis of over 7400 
OA cases, 80% of whom had undergone total joint replacement (arcOGEN Consortium 
et al., 2012). This study identified 11 loci associated with OA susceptibility of OA and 
highlighted key biological pathways through which OA genetic susceptibility is 
operating, such as skeletogenesis or development and differentiation of osteoblasts and 
chondrocytes (Reynard and Loughlin, 2013). In another recent study on 199 target genes, 
it was revealed that only two variants (in the COL11A1 and VEGF genes) reached the 
significance level after adjustment for multiple tests (Rodriguez-Fontenla et al., 2014). 
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Trauma or surgical repair of traumatic injuries involving the articular cartilage, ligaments, 
or menisci (knee) can result in alterations of joint biomechanics and accelerate OA. For 
example in individuals who have sustained significant joint injuries, the risk of post-
traumatic OA ranges from about 20% to more than 50% (Anderson et al., 2011). Joint 
deformations are also known to be a contributing factor for OA development. Valgus 
malalignment at the knee has been shown to increase the incidence and risk of 
radiographic progression of knee osteoarthritis involving the lateral compartment (Felson 
et al., 2013). While these causes are common occurrence in knee, mechanical load or 
abnormal stresses cause almost all disease in hip OA (Felson, 2013). Abnormalities in the 
shape of the hip bones, such as hip dysplasia and femoroacetabular impingement, are 
central to OA pathogenesis of this joint (Martel-Pelletier et al., 2016) and were shown to 
represent major risk factors predisposing to later-life hip OA (Felson, 2013). 
However, joint damage may occur even in the absence of obvious trauma, such as 
prolonged small injuries, especially in individuals whose occupation or lifestyle involves 
frequent squatting, stair-climbing, or kneeling. Other life style associated factors may also 
be play a part in OA development, such as smoking. Interestingly, some studies indicated 
that smoking may have contradictory effects on OA, with an inverse relationship 
observed between smoking and OA (Hui et al., 2011). However, while the effects 
mediated through the nicotine sensitive acetylcholine receptor may help prevent disease, 
similar receptors on neuronal cells may, when excited, induce musculoskeletal pain 
(Felson and Zhang, 2015) indirectly affecting the disease. 
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Figure 1.2. Risk factors for OA development. OA is a multifactorial disease and the 
interactions between systemic factors that act on the person level and the local factors 
that act at the joint level play an important role in the development and prognosis of OA. 
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1.1.3 Classification and pathogenesis 
Historically OA has been classified as ‘primary’ and ‘secondary’ (Table 1.1). Primary 
OA is usually of unknown aetiology, where the disease onset may be initiated by no 
apparent factor (idiopathic) while secondary OA occurs when the triggering factor was 
apparent, such as trauma or congenital deformity (Altman et al., 1986). However, most 
patients cannot fit easily into these proposed OA subgroups due to the complexity of the 
influencing factors and intra-articular distribution of the disease. Various classifications 
have been proposed depending on the main underlying pathophysiological mechanisms, 
clinically relevant patient characteristics, stage of the disease, involved joints and degree 
of inflammation. 
A more comprehensive classification suggests its onset may be initiated at different 
anatomical locations, such as cartilage, ligaments, meniscus, synovium or bone 
(McGonagle et al., 2010). The historical view of OA places cartilage and chondrocyte 
behaviour in a central position in the OA disease process. As noted in Table 1.1, articular 
cartilage can be damaged by normal wear and tear (primary OA) or following 
pathological insults, such as injury or trauma (secondary OA). Osteoarthritic cartilage is 
characterised by initial degenerative changes in the extracellular matrix leading to 
softening of the cartilage, fibrillation of the superficial layers, fissuring and reduced 
cartilage thickness, all of which become more pronounced with time, leading to complete 
cartilage destruction, eventually leaving the underlying subchondral bone completely 
exposed (Pritzker et al., 2006). A central role in these pathological features is played by 
the deviant behaviour of resident chondrocytes. In an attempt to initiate repair caused by 
pathological stimulation, chondrocytes compensate by increasing synthesis of matrix 
molecules (collagen, proteoglycans and hyaluronate) and proliferate forming clusters in 
the deeper layers of the cartilage, therefore being able to maintain the integrity of the 
articular cartilage at the early stages of disease (Goldring and Goldring, 2007). However, 
as the disease progresses this increase in anabolic and catabolic activity leads to 
chondrocytes senescence and failure to maintain homeostasis between synthesis and 
degradation of the extracellular matrix component (Loeser, 2009). As the proteoglycans 
and then the collagen network breakdown, cartilage integrity is disrupted (Goldring and 
Goldring, 2010). 
However, alternative routes have also been described to lead to OA. For example, the 
idea of OA originating in bone, also known as osteogenic OA (McGonagle et al., 2010), 
has been long proposed by the early studies of Radin and Paul, who suggested that the 
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pathogenesis of OA could be attributed to a primary alteration in periarticular bone (Radin 
et al., 1970). According to this hypothesis, the pathogenesis of OA was initiated by an 
increase in the thickness, volume and stiffness in the subchondral bone which in turn 
shifted the weight-bearing burden to the overlying articular cartilage resulting in 
alterations in chondrocyte function and cartilage matrix deterioration (Goldring, 2012). 
In support to this theory, work in the early 1990s by Dieppe et al. provided evidence that 
changes in bone turnover assessed scintigraphically preceded detectable radiographic 
changes (McCrae et al., 1992; Dieppe et al., 1993). More importantly, these scintigraphic 
bone changes may be responsible for the pain associated with the disease and were 
predictive of the progression of anatomical changes in OA, such as the subsequent 
development of osteophytes and subchondral bone sclerosis. 
Despite being a multifactorial and complex disease, the pathological changes observed in 
OA joints show common features that affect the entire joint structure leading to pain, 
deformity and complete loss of function. As mentioned, defining OA has long been 
centred on the wear and tear concept which was commonly associated with changes in 
the articular cartilage. However, this idea has evolved and OA is now considered a disease 
of the whole joint, including alterations in articular cartilage, subchondral bone, 
ligaments, capsule and synovial membrane (Loeser et al., 2012).  
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Table 1.1. Classification of subsets of OA, adapted from (Altman, 1991) 
I. Primary (idiopathic) 
A. Localized 
1. Hands: nodal (Heberden’s and 
Bouchard’s nodes), nonnodal 
(erosive IP arthritis), S-MC, S-T  
2. Feet: hallux valgus, hallux rigidus, 
hammer/cockup toes, talo-navicular 
joint 
3. Knee: 
a. Medial compartment  
b. Lateral compartment  
c. Patellofemoral compartment  
4. Hip: 
a. Eccentric (superior) 
b. Concentric (axial, medial) 
c. Diffuse (coxae senilis) 
5. Spine (cervical and lumbar) 
a. Apophyseal 
b. Intervertebral (disc) 
c. Spondylosis (osteophytes) 
d. Ligamentous (hyperostosis 
[Forestier’s disease, or 
DISH]) 
6. Other joints: shoulder, 
temporomandibular, sacroiliac, ankle, 
wrist, acromioclavicular 
B. Generalized (includes 3 or more areas 
listed above) 
1. Small (peripheral) and spine 
2. Large (central) and spine 




B. Congenital or developmental diseases 
1. Localized 
a. Hip diseases: LCPD, DDH, 
SCFE, shallow acetabulum 
b. Mechanical and local factors: 
obesity, leg length inequality, 
extreme valgus/varus 
deformity, hypermobility 
syndromes, scoliosis  
2. Generalized 
a. Bone dysplasias: epiphyseal 
dysplasia, spondylo-
apophyseal dysplasia 




C. Calcium deposition disease 
1. Calcium pyrophosphate deposition 
disease 
2. Apatite arthropathy 
3. Destructive arthropathy (shoulder, 
knee) 
D. Other bone and joint disorders: 
avascular necrosis, rheumatoid arthritis, 
gouty arthritis, septic arthritis, Paget’s 
disease, osteopetrosis, osteochondritis 
E. Other diseases 
1. Endocrine diseases: diabetes mellitus, 
acromegaly, hypothyroidism, 
hyperparathyroidism 
2. Neuropathic arthropathy (Charcot 
joints) 
3. Miscellaneous: frostbite 
Legend: DDH – Developmental Dysplasia of the Hip; DISH – Diffuse idiopathic 
skeletal hyperostosis; IP – Interphalangeal; LCPD – Legg–Calvé–Perthes Disease; 





Currently, there is no cure for this debilitating condition and most of the treatments focus 
on reducing symptoms and improving the functional status, with joint replacement as the 
ultimate consequence and current surgical treatment for OA. According to the 
Osteoarthritis Research Society International (OARSI), the mainstay of OA treatments 
involves a combination of physical measures, drug therapy, and surgery (Zhang et al., 
2008; Zhang, Ouyang, Crispin R Dass, et al., 2016) as outlined in Figure 1.3. These lines 
of treatments described in the following sections are also in line with other international 
guidelines, such as European League Against Rheumatism (EULAR) in Europe, 
American College of Rheumatology (ACR in United States) and National Institute for 
Health and Care Excellence (NICE) in the UK. 
As first-line management of mild to moderate OA, non-surgical treatment of OA is 
recommended including land-based exercise, weight management and strengthening with 
water-based exercise, self-management and education (Zhang et al., 2008). 
Pharmacological interventions are also used in combination as a treatment option aimed 
mainly at relieving pain and reduce inflammation. The most common pharmacological 
agents used for OA treatment are acetaminophen, non-steroidal anti-inflammatory drugs 
(NSAIDs), opioid analgesics, serotonin-norepinephrine reuptake inhibitors (SNRIs), and 
intra-articular injections (Martel-Pelletier et al., 2016). However, these traditional OA 
therapeutic agents are limited to control the symptoms and so far, none can reverse the 
damage in the OA joint and have modest benefits on pain and function, leaving the 
surgical interventions as final options to restore joint function. 
The therapeutic approaches described in the following paragraphs involve surgical and 
cellular-based procedures that were shown to be limited to younger subjects with isolated 
chondral defects and do not work for generalised OA. A common surgical technique is 
the microfracture at sites of focal full-thickness defects. This technique is usually adopted 
at early stages and it involves drilling holes in the subchondral plate at the chondral defect 
site which in turn triggers the migration of bone marrow (BM) cells to the articular surface 
through stimulation of inflammatory response (Steadman et al., 1999). The technique is 
inexpensive and easy to do and is the most widely used regenerative approach with the 
purpose to provide an enriched environment for tissue regeneration. However, the 
resultant tissue is inferior fibrocartilage containing type I collagen or hybrid repair 
cartilage tissue, not the normal hyaline cartilage (type II collagen) (Mollon et al., 2013). 
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Furthermore, the observed subchondral bone overgrowth (25%–49%) might limit 
durability and the long-term outcome of the microfracture (Mithoefer et al., 2009). 
Since these procedures have drawbacks, tissue engineering has led to the development of 
more advanced regenerative techniques. Autologous chondrocyte implantation (ACI) 
used for focal cartilage damage involves the transplantation of chondrocytes that are 
harvested from non-weight-bearing cartilage from the patient (Brittberg, 2008). However, 
this technique has some concerns as well since it causes not only donor site morbidity but 
also chondrocyte dedifferentiation in the transplanted site leading to the expression of 
type I collagen rather than type II collagen that may result in fibrocartilage rather than the 
desired hyaline-like cartilage (Jakobsen et al., 2005).  
Other therapeutic approaches include mosaicplasty, a procedure similar to the ACI 
technique that involves the use of autologous osteochondral grafts; the use of other 
sources of cells, growth factors, and implantation of cells into three-dimensional scaffolds 
or matrices that support growth, differentiation, and maintenance of a chondrogenic 
phenotype  are also increasingly used in therapy (Mollon et al., 2013). However, the 
results are disappointingly minimal and only offer short-term benefits and no evidence 
exists that the above techniques modify the development of OA. Furthermore, the 
majority of cellular therapies have a major drawback regarding their cost. The isolation, 
expansion and production of advanced medicinal products for cellular therapies are 
labour intensive, costly and require facilities that are GMP certified. 
Joint replacement is well established for advanced OA of the knee and hip joints and is 
considered in cases of advanced disease with severe pain and functional limitations where 
other treatment options have failed (Dieppe and Lohmander, 2005). In the UK, according 
to NICE total hip replacement surgeries are only recommended for people with end-stage 
arthritis, if they have 10-year revision rates of 5% or lower (NICE, 2014). The main 
concern in the long-term outcome of total hip and knee replacements is survival of the 
prosthesis however, a recent study showed that over half of hip replacements last 25 years 
(Evans et al., 2019). The prosthesis may fail for various reasons, but the most common is 
aseptic loosening caused by osteolysis when polyethene wear debris trigger an 
inflammatory response leading to bone erosion (Katz, 2006). Furthermore, a small 
minority of joint arthroplasties may become infected. While the incidence is only 1% of 
total hip replacements (Engesæter et al., 2011), periprosthetic infections represent a 
challenging and serious complication with unpredictable responses to the standard of care 
(Tande and Patel, 2014).  
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Emergent therapy for advanced OA is knee joint distraction (KJD) which is associated 
with cartilage regeneration (Van Valburg et al., 2000; van der Woude et al., 2016). 
Spontaneous cartilage regeneration also occurs in advanced OA following wedge 
osteotomies (Koshino et al., 2003). The basis for joint regeneration in such advanced 
disease is incompletely understood but is likely to involve endogenous joint repair 
mechanisms. The unsatisfactory effects associated with the traditional OA drugs warrant 
continuous research into novel approaches, such as biologics and gene therapeutic 
interventions. Gene therapy enables the spatiotemporal control and persistent synthesis 
of gene products at target sites. While this approach holds great potential and prospects 
with several preclinical studies already confirming its safety and efficacy, only few 
clinical trials have been conducted and no gene products have been approved for OA 
treatment (Zhang, Ouyang, Crispin R. Dass, et al., 2016). 
 
 
Figure 1.3. The OA treatment pyramid. Non-surgical interventions are commonly 
recommended as a first-line treatment comprising of education, exercise and weight 
control with the addition of pharmacological and surgical interventions when needed as 
a second and third line of treatment. Adapted from (Roos and Juhl, 2012) 
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1.1.6 Pathophysiology of OA 
For a better understanding of OA disease mechanisms, it is important to describe the 
complex structures of the joint. Human joints join adjacent bones to form functional 
units that are uniquely adapted to permit constrained joint motion. Depending on the 
degree of motion, joint can be classified into immovable, or synarthroses, such as the 
distal tibiofibular joint and the skull bones; slightly movable, or amphiarthrosis, 
representing joints with a restricted degree of motion, such as the vertebrae; and freely 
movable, or diarthroses/ diarthrodial joints. Archetypal examples of diarthrodial joints 
are the knee, hip, and small joints of the fingers, comprising of numerous components 
that work in a synchronised manner to facilitate movement of the body. These 
components are structured into distinct elements including the two articulating bones 
stabilised by the tendons, ligaments, and menisci (in knee joints); the articular cartilage 
covering the adjacent bone surfaces to allow smooth movement with minimal friction, 
the synovial lining of the joint cavity that secrete synovial fluid for lubrication and 
nourishing of the joint (Smith, 2011). 
1.1.6.1 Osteochondral unit 
An important component of joints commonly affected by OA is the osteochondral unit 
(Goldring and Goldring, 2016a). This unit is a complex structure represented by the 
articular cartilage, the subchondral bone beneath the cartilage which is separated by a 
thin layer of calcified cartilage that persists after growth plate closure (Figure 1.4). The 
importance of osteochondral unit stems in its unique capability of transferring loads 
during weight-bearing and joint motion. Although the biomechanical coupling within 
the osteochondral unit is well established, their biochemical interaction is still unclear. 
The permeability of calcified cartilage and subchondral bone plates may allow 
crossover communication as evident from studies showing connecting channels 
between subchondral bone and cartilage (Pan et al., 2009). This is particularly 
important for advanced OA in which the osteochondral junction is breached thus 




Figure 1.4. The structure of osteochondral unit in normal human joint. The 
osteochondral unit comprises of the articular cartilage separated by the subchondral 
bone by calcified cartilage and a tidemark. The subchondral bone is composed by a 
cortical subchondral plate underlying the calcified cartilage (marked by the dotted line) 
and trabecular bone. 
1.1.6.2 Subchondral bone 
The subchondral bone represents the bony components lying deep to articular cartilage 
separated by a zone of calcified cartilage (Li et al., 2013). As illustrated in Figure 1.4, 
the calcified cartilage is separated by the overlying articular cartilage by the so-called 
tidemark and the underlying subchondral bone by a cement line (Goldring, 2012). 
Although the subchondral bone is not clearly defined, it resembles a thin, dome-like 
structure, composed of the subchondral bone plate and the subchondral trabecular bone 
underneath (Burr, 2004) (Figure 1.4). The subchondral bone plate is a thin mineralised 
cortical bone layer lying immediately underneath the calcified cartilage (Milz and Putz, 
1994). Arising from the subchondral bone plate is a network of subchondral trabecular 
bone, together with the deeper trabecular structure acting as a buttress, providing 
important shock absorbing and supportive functions to the joint (Madry et al., 2010). 
The distinction between the subchondral bone plate and subchondral trabecular bone 
is not always clear but differences in their mechanical properties and ability to adapt 
to mechanical load have been previously documented (Choi et al., 1990; Burr, 2004). 
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Moreover, relative to the subchondral bone plate, subchondral trabecular bone is more 
porous and metabolically active, containing blood vessels, sensory nerves, and BM 
(Suri and Walsh, 2012). 
1.1.6.3 Pathological changes in OA osteochondral unit 
The pathophysiology of OA is complex and multifactorial, with numerous genetic, 
biological, and biomechanical components (Glyn-Jones et al., 2015). While the disease 
process may be initiated at a single-tissue level, due to the intimate physiological and 
functional association of joint tissues, OA eventually affects the whole joint (Loeser et 
al., 2012). Alteration in the composition or structure of any of the individual components 
results in ‘joint failure’ characterised by disruption of joint integrity and loss of function 
(Goldring and Goldring, 2016b), a classic description of OA pathology. The structural 
changes of the individual joint tissues can occur either spontaneously following trauma 
or injury, or can evolve over time mediated by cellular or microenvironmental factors that 
contribute together to alterations in the composition, structure and material properties of 
the joint tissues. 
The articular cartilage undergoes changes in its conformation and structure, starting with 
softening and surface fibrillation, ulceration and deep fissures as the disease progresses. 
Cartilage degradation, specifically involving alterations in the collagen and aggrecan 
content, is central to OA pathology. Studies showed important roles played by 
Adamalysin with Thrombospondin Motifs 5 (ADAMTS-5) in aggrecan degradation and 
the collagenolytic matrix metalloproteinase MMP-13 in collagen degradation (Troeberg 
and Nagase, 2012). Ultimately these deleterious processes lead to complete loss of 
articular cartilage thereby exposing the calcified cartilage and subchondral bone (Martel-
Pelletier et al., 2016) (Figure 1.5). Furthermore, subchondral bone eburnation and 
sclerosis occurs (Figure 1.5) together with the development of subchondral bone cysts 
and osteophytes (Suri and Walsh, 2012). 
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Figure 1.5. Structure of the normal (A) and pathophysiological changes in OA 
osteochondral unit (B). During OA progression the entire joint structure is ultimately 
affected, including the articular cartilage and subchondral bone. Fibrillation and 
progressive loss of cartilage expose the subchondral bone which consequently increases 
its volume and becomes sclerotic. Image modified from (Netter et al., 2005).  
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1.1.7 Bone-related changes in OA 
Although the pathological process can initially target a single tissue with further 
progress to encompass the whole joint including articular cartilage and bone, as 
mentioned before and reviewed in detail by published literature (Martel-Pelletier et al., 
2016), the work in this thesis is focused on bone associated OA pathology, which 
therefore will be described in more detail below. 
1.1.7.1 Subchondral bone 
Subchondral bone is believed to play a pivotal role in OA pathogenesis, pronounced 
changes being a common sight in the structure and composition of periarticular bone, i.e. 
both the subchondral plate and trabecular bone in OA (Weinans et al., 2012). However, 
as mentioned in Section 1.1.4, it is still unclear whether these alterations act as a trigger 
or a secondary consequence to cartilage degeneration (Madry et al., 2010). Subchondral 
bone commonly associated with OA involve microarchitectural alterations, including an 
increase in the number of trabeculae and bone volume consequently leading to a decrease 
of trabecular separation and BM spacing (Lajeunesse et al., 2003; Burr and Gallant, 
2012). Hypomineralisation of subchondral bone succeeding as a consequence of 
abnormal local high bone turnover and densification of the subchondral plate associated 
with a complete loss of cartilage (Bettica et al., 2002; Burr and Gallant, 2012). Other 
histopathological changes that have been reported in the subchondral bone, include 
microdamage, vascularisation of osteochondral junction and bone marrow lesions 
(BMLs) (Burr and Radin, 2003; Walsh et al., 2010; Campbell et al., 2016). 
1.1.7.2 Bone marrow lesions 
Bone marrow lesions have been consistently documented to play a fundamental role in 
development of OA and are considered to represent an important risk factor for structural 
deterioration (Felson et al., 2003; Kazakia et al., 2013). BMLs were first described as an 
ill-defined high signal on magnetic resonance imaging (MRI) with increased signal 
intensity using fluid sensitive magnetic resonance sequences (Wilson et al., 1988). 
Histological evaluation at these sites revealed the presence of fat cell necrosis and 
localized marrow fibrosis associated with microfractures of the trabecular bone at various 
stages of healing (Leydet-Quilici et al., 2010). The lesions lack well defined margins, 
may fluctuate in size within a short time and are associated with the progression of 
increased vascularity, articular cartilage loss and fluctuation of pain in knee OA (Xu et 
al., 2012). 
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The BMLs have received increased attention lately due to their ‘almost exclusive’ 
association with cartilage degradation and alteration of the articular surface in OA (Bowes 
et al., 2016). BMLs were also shown to be associated with abnormal trabeculae on 
histopathology (Zanetti et al., 2000), subchondral bone cysts (Carrino et al., 2006) 
possibly developed in pre-existing BML regions. The presence of BMLs in OA correlates 
overall with the severity of joint pain and with progression of OA cartilage and bone 
changes (Taljanovic et al., 2008). Their association with pain has been recently evidenced 
by an elegant study by Kuttapitiya et al. using extensive histological and gene expression 
analysis of bone areas with BMLs (Kuttapitiya et al., 2017). In this study it was 
demonstrated that BMLs areas are characterised by a high metabolic activity and their 
transcriptional profile showed increased expression of  multiple genes associated with 
pain sensitivity as well as genes associated with bone remodelling activity (Kuttapitiya et 
al., 2017). 
Furthermore, work by the Leeds group showed that in hip OA, BML areas were 
associated with topographic and numerical disturbances of bone resident mesenchymal 
stem cells (MSCs) (Campbell et al., 2016). This study also reported functional in vitro 
alterations of these cells which may point to a role of MSCs in the abnormal bone 
phenotype in OA.  
1.1.7.3 Bone sclerosis 
There is agreement in the findings of most studies that the subchondral bone thickness 
and trabecular bone volume in OA increases (Fazzalari and Parkinson, 1997; 
Lajeunesse et al., 1999) and this may be accounted by the subchondral bone sclerosis 
observed in the late stages of the disease. Subchondral bone sclerosis is defined as an 
increase in bone mass and density, and is a common radiographical feature of advanced 
disease stages (Burr and Gallant, 2012). A marked characteristic of subchondral bone 
sclerosis is the formation of new bone tissue that has lower mineralization (L.G. Cox et 
al., 2012) and consequently alterations in the strength and stiffness of the bone tissue. 
1.1.7.4 Subchondral bone cysts 
The cavitary lesions in the subchondral bone, commonly described as ‘intra-osseous 
lesions’, ‘pseudo-cysts’ or ‘geodes’, are a common feature of advanced OA, especially at 
sites of great cartilage loss (Li et al., 2013). Subchondral bone cysts are composed of 
fibroconnective tissue that may initially contain fluid but ossify in later disease stages.   
Despite a continuous focus on these OA lesions over many decades, the exact aetiology 
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and pathogenesis of subchondral bone cysts are still not clear (Li et al., 2013). Some 
observations suggested that bone cysts in OA tend to develop at sites of pre-existing 
BMLs (Carrino et al., 2006) which have led to the concept that they are generated directly 
within the subchondral bone (Martel-Pelletier et al., 2016). It was proposed that bone 
damage and necrosis initiate the process of osteoclast-mediated bone resorption that leads 
to cyst formation (Crema et al., 2010). Evidence also showed that patients with 
subchondral bone cysts had greater disease severity and pain, and a higher risk of joint 
replacement than donors with BML alone (Tanamas et al., 2010). More studies showed 
that areas of subchondral bone cysts in OA are also accompanied by activated osteoblasts 
and osteoclasts (Havdrup et al., 1976; Sabokbar et al., 2000). This indicates an association 
of these bone cells with a high bone turnover, however the exact cellular mechanisms 
involved are still unclear. 
1.1.7.5 Osteophytes 
Similar to subchondral bone cysts, osteophytes are also very common alterations in OA 
described as “fibrocartilage-capped bony outgrowths” (van der Kraan and van den Berg, 
2007). Osteophyte formation is an integral component of OA pathogenesis and are 
usually observed at the joint margins (Martel-Pelletier et al., 2016). 
Osteophytes can form early in the development of OA and can be observed prior to joint 
space narrowing, potentially arising as an attempt to stabilize the joint rather than 
contribute to the progression of joint pathology (van der Kraan and van den Berg, 2007). 
In support to this idea, studies shown that osteophytes removal increased joint instability 
in some OA animal models (Pottenger et al., 1990) and no association was found between 
osteophyte size and OA progression in humans (Felson et al., 2005). While marginal 
osteophytes are common in patients with OA, the appearance of osteophytic outgrowths 
in the central portions of the articular space of both hip and knee OA have also been 
documented (Varich et al., 1993; McCauley et al., 2001). While less common, these 
central osteophytes were found to be in a temporal relationship with the marginal 
outgrowths and furthermore, associated with the severity of cartilage damage (Varich et 
al., 1993; McCauley et al., 2001). 
Although the histological features of this tissue pathology has been thoroughly 
investigated and its importance clearly stated (Lajeunesse et al., 2003), there is a lack of 
information pertinent to the cellular mechanisms behind these tissue alterations. 
Histological appearance of damaged tissue is a mere reflection of skewed cellular and 
molecular mechanisms and evidence pertaining these drivers is still insufficient. 
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1.1.8 Hip OA 
The hip joint is the second most common site for OA (after knee) with around 11% (2.46 
million) of people in England affected (Aresti et al., 2016). It carries a heavy burden of 
disease having a high prevalence amongst elderly population with an estimated 25% of 
lifetime risk of symptomatic OA in people who live to the age of 85 (Murphy et al., 2010). 
However, research in hip OA is fairly scant compared to knee OA focused research, 
possibly owing to the reported higher prevalence of knee OA (Neogi and Zhang, 2013) 
as well as ease of imaging and accessibility for various clinical interventions (Gold et al., 
2015). 
As for OA in general, there is no single cause for hip OA.  Several risk factors are linked 
to the development of hip OA including age, gender, genetics, obesity, and local joint risk 
factors, such as cartilage matrix composition and structure, and mechanical stress 
(Martel-Pelletier et al., 2016). However, the aetiology of primary hip OA remains 
unknown. In addition to these generic risk factors, it was shown that long-term exposure 
to sports among men, especially when combined with heavy workloads, increased the 
risk of hip OA (Vingård et al., 1993). Furthermore, some studies provided more evidence 
that heavy workloads and musculoskeletal injuries were specifically associated with an 
increased predilection for hip OA (Juhakoski et al., 2008) while others indicated obesity 
as another influencing factor (Lievense et al., 2002), body weight having been shown to 
be a predictor of OA incidence not only in hand and knee, but also in the hip (Oliveria et 
al., 1999). 
The arcOGEN GWAS study provided clear evidence that hip OA at the molecular genetic 
level is different than knee OA and it that the risk of OA is not uniform between these 
two skeletal sites (arcOGEN Consortium et al., 2012). This may confirm that hip OA has 
a different pathophysiology than knee OA, having been shown that some of the hip OA 
associated polymorphisms were not necessarily associated with knee OA and vice-versa. 
For example, results from arcOGEN study revealed that single nucleotide polymorphisms 
(SNPs) specifically associated with hip OA were located on ASTN2 the CHST11 genes 
as well as in between the FILIP1 and SENP6 genes and between the KLHDC5 and 
PTHLH genes respectively (arcOGEN Consortium et al., 2012; Warner et al., 2016). 
Some of these genes, including PTHLH are known to be linked to bone development and 
osteogenesis (Minina et al., 2002). 
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1.1.9 Pathogenesis of hip OA 
The cellular and molecular changes in hip OA may be a result of altered biomechanical 
loading on the hip joint and share common features with all other OA-affected joints 
(Aresti et al., 2016). It is commonly believed that biomechanical alterations caused by 
risk factors acting at the person level and/or joint level, initiate the driving force of OA 
pathogenesis. This imply an acceleration of the subchondral bone turnover and hence, an 
increase in subchondral bone remodelling (Burr and Gallant, 2012). Simultaneously, 
cartilage microdamage occurs in the form of microcracks, which span across the 
osteochondral unit to subchondral bone. These microcracks facilitate later increased 
vascularization and the bidirectional passage of important cytokines and growth factors 
throughout the osteochondral junction, thus connecting the cartilage and subchondral 
bone biochemically as well as mechanically (Sharma et al., 2013; Li et al., 2013). 
However, the precise signalling molecules and cellular sources involved in the 
biochemical cross talk between articular cartilage and subchondral bone have not yet been 
fully elucidated. 
As mentioned in Section 1.1.4, the current literature presents different routes of OA 
progression, driven primarily by the commonly observed cartilage damage or 
subchondral bone OA-associated changes. Some authors describe OA progression to start 
in the articular cartilage where extracellular matrix is remodelled by the resident under 
the influence of inflammation. Alterations of extracellular matrix lead to changes in the 
biomechanical environment of chondrocytes, which further drives the progression of the 
disease (Maldonado and Nam, 2013). Conversely, others place the initiation of the disease 
below the cartilage, driven by abnormal biomechanics which enhance subchondral 
remodelling activities, potentially as a response to repair bone damage, and that these 
bone alterations could primarily affect cartilage degeneration (Burr and Gallant, 2012). 
However, current evidence is unclear with respect to which of these routes contribute 
more to OA development. Irrespective of the site of initiation, the alterations on either 
side merge together in the osteochondral junction, leading to a common feature of hip 
OA represented by an osteochondral breach. In addition to the multiple osteochondral 
alterations described extensively by the literature (Suri and Walsh, 2012), patients with 
severe degenerative OA of the hip reportedly have impaired venous drainage from the 
juxta-chondral trabecular bone across the cortex and hypoxia of the subchondral bone 
(Findlay, 2007). 
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Some MRI studies indicated that hip OA accompanied with joint pain has bone alterations 
and radiographic OA can progress to more advanced stage OA over a short time period 
(Kamimura et al., 2014). This rapid progressive form of hip OA was first reported by 
Forestier in 1950s  and subsequent case series and reports emphasized the clinical, 
radiographic and pathologic findings of this unusual condition, defined as joint space loss 
at a rate greater than 2 mm per year or if more than 50% of joint space is lost in 1 year 
(Batra et al., 2008; Flemming and Gustas-French, 2017). In the early stages, radiographic 
appearance showed either normal appearance or mild OA changes however within a few 
months of the onset of symptoms, the destruction of the femoral head and acetabulum 
with sclerosis, subchondral cysts, and minimal or no osteophytes were observed (Batra et 
al., 2008). While these authors noted that it can be easily mistaken for other conditions, 
all the pathologic findings, however, were consistent with OA (Batra et al., 2008) and 
may be associated with enhanced bone remodelling activities. 
The pivotal importance of bone involvement in rapidly progressive hip OA is strongly 
suspected in humans. Some studies suggested that rapidly destructive hip OA may result 
from subchondral bone insufficiency fractures, documented as non-traumatic fractures 
immediately below the articular cartilage and commonly associated with the presence of 
BMLs and reduced bone mineral density (Yamamoto and Bullough, 2000). Furthermore, 
severe subchondral alterations were later documented in an MRI study on 12 patients 
diagnosed with  rapidly progressive OA (Boutry et al., 2002). The alterations were mainly 
represented by subchondral bone sclerosis, abnormal trabeculae and cyst-like 
subchondral defects (Boutry et al., 2002). 
1.1.9.1 Diagnosis and clinical features 
It is often possible to diagnose hip OA on the basis of clinical presentation alone, but 
radiographic investigation is useful to confirm the diagnosis and to monitor disease 
progression (Murphy et al., 2016). However, it is important to note that patients with 
evident radiographic changes may not necessarily show correlating clinical symptoms 
and vice versa, some patients with severe radiographic hip OA may be asymptomatic 
(Pereira et al., 2011). Using pelvic radiographs data from the Framingham Osteoarthritis 
Study a community based study of OA, and Osteoarthritis Initiative, a multicentre 
longitudinal cohort study of OA, it was shown that 15.6% of patients with frequent hip 
pain had radiographic evidence of OA, while only 20.7% of patients with radiographic 
hip OA had frequent pain (Kim et al., 2015). 
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Therefore, diagnostic criteria of hip OA according to American College of Rheumatology 
uses a combination of clinical and radiographical assessment. This involves a 
combination of hip pain and either femoral and/or acetabular osteophytes on radiograph 
or erythrocyte sedimentation rate (ESR) £ 20mm/hour together with axial joint space 
narrowing on radiograph (Altman et al., 1991). Patients with hip OA typically develop 
pain over months to years rather than acutely, however as mentioned some patients can 
progress with rapidly-developing form of the disease. During clinical investigation, 
patients describe pain and stiffness that is worse in the morning or after sitting or resting, 
usually in the groin or thigh regions that radiates into the buttocks or knee (Woolhead et 
al., 2010). Stiffness in the hip joint makes it difficult to walk or bend and upon 
examination, muscle weakness can also be observed. “Locking” or “sticking” of the joint 
and a grinding noise (crepitus) during movement caused by loose cartilage fragments and 
other tissues interfering with smooth hip motion are also reported. Internal rotation is the 
most sensitive single indicator of hip OA, with decreased range of motion in the hip 
commonly affecting the ability to walk (Birrell et al., 2001). 
The Kellgren-Lawrence (KL) scale is often used to classify the degree of deterioration of 
the joint using radiologic assessment of OA (Kellgren and Lawrence, 1957); The KL 
grading system uses a scale between 0-4, as follows: Grade 0: normal; Grade 1: doubtful 
joint space narrowing (JSN) and possible osteophytic lipping; Grade 2: definite 
osteophytes and possible JSN on anteroposterior weight-bearing radiograph; Grade 3: 
multiple osteophytes, definite JSN, sclerosis, possible bony deformity; Grade 4: large 
osteophytes, marked JSN, severe sclerosis and definite bony deformity. However, this 
scale is not specific for hip OA grading. Therefore in 1963, Kellgren used the knee 
classification to describe similarly four grades of hip OA, based on the degree of joint 
space narrowing, osteophyte formation, arthritic changes affecting the bone margins, and 
gross deformity. This grading has been recently updated by Altman et al. (Altman and 
Gold, 2007) and relies on the radiological evaluation of the typical radiographic features 
of hip OA, illustrated in Figure 1.6. These include joint space narrowing, marginal 
osteophytes and other alterations that can be observed radiologically, such as subchondral 
bone cysts in the acetabulum or femoral head, flattening of the femoral head or thickening 
of the medial femoral calcar (Aresti et al., 2016). 
Radiological investigation can provide information on joint space narrowing, presence of 
cysts and in later stages of disease, sclerosis of the subchondral bone and osteophyte 
formation. Radiography is widely available, cost effective and interpretation is relatively 
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simple when compared to more sophisticated imaging modalities such as MRI, which in 
turn is more sensitive in detecting early structural changes (Guermazi et al., 2012). 
MRI has many advantages over radiography and allows the assessment of more joint 
tissues and their morphological changes in three dimensions, with more types of available 
contrast. Abnormalities that can be observed using MRI include joint space narrowing, 
alterations in the subchondral bone including BMLs and presence of osteophytes. Unlike 
radiography, MRI can directly visualize articular cartilage and other joint tissues, such as 
meniscus (knee), tendon, muscle, or effusion. This led to OARSI to recommend MRI for 
the assessment of cartilage morphology (Conaghan et al., 2011). However, MRI 
assessment of the hip is more challenging than in the knee for several reasons. The hip 
joint is deep within the body and it is not in the isocentre of the magnet while the cartilage 
is very thin making very difficult to differentiate between the acetabular and femoral 
cartilage. Furthermore, the hip is a spherical joint and therefore partial volume effects are 
stronger than in the knee joint. Surface coils need to be used which allow high signal and 
high resolution imaging, but there are no dedicated hip coils (Gold et al., 2015). 
 
Figure 1.6. Typical plain radiograph of bilateral hip osteoarthritis. Notice the loss of 
joint space (1), osteophytes (2), subchondral sclerosis (3), and subchondral cysts (4). In 
this advanced case, there is also evidence of deformity of the femoral head (5). Joint 
space narrowing is the best diagnostic criterion (Croft et al., 1990). Figure adapted from 
(Aresti et al., 2016) 
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1.2 Bone remodelling 
Recognising that bone is a living organ rather than simply a hard carcass was a major 
advance in bone biology, thereby establishing the fundamental idea that bone is 
metabolically active and that cell dynamics facilitate the duality of bone construction and 
deconstruction by processes commonly referred to as bone modelling and remodelling. 
Both processes involve formation of bone by osteoblasts and its degradation by 
osteoclasts (Kenkre and Bassett, 2018). Osteoclasts are of haematopoietic origin and their 
main role is to resorb bone while osteoblasts are the main bone forming cells, with a 
mesenchymal origin. Both cell types are discussed in more detail in Section1.2.3. 
In bone modelling bone resorption and formation occur at distinct skeletal sites to 
accomplish the major changes in bone shape and mass, such as during skeletal growth 
and development of long bones with large diameter. By contrast, in remodelling, these 
two processes are tightly coupled both spatially and temporally so that the overall bone 
volume and structure remain unchanged (Allen and Burr, 2014). 
1.2.1 Bone remodelling process 
Bone remodelling is a continuous and co-ordinated process that results in both formation 
and degradation of bone in order to maintain bone homeostasis. This active and dynamic 
process depends on the tightly regulated balance between bone formation and bone 
resorption as well as a complex interaction between different cell types which is regulated 
by a variety of biochemical and mechanical factors (Rucci, 2008). Particularly for 
trabecular bone which is mainly affected by OA, bone remodelling occurs as a cycle of 
cellular events at the bone surfaces and can be divided into five phases: activation, 
resorption, reversal, formation, and quiescence (Allen and Burr, 2014).  
Anatomically, these processes in health take place within defined areas, described as basic 
multicellular units (BMU), which contain the main cellular players, osteoblasts and 
osteoclasts, as well as a capillary blood supply (Frost, 1990).  As described in Figure 1.7, 
the bone remodelling process starts with the recruitment of osteoclasts precursors at the 
site of bone remodelling and their differentiation into mature, active osteoclasts. Once 
mature osteoclasts are present, bone lining cells retract from the surface of the bone by 
yet unknown mechanisms and form a raised canopy over the site to be resorbed (Hauge 
et al., 2001). Osteoclasts adhere to the exposed mineralised matrix and create a sealing 
zone allowing to dramatically increase cell surface and providing an ideal secretory 
environment to start dissolving the bone (Figure 1.7).  
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Soluble factors are released in the microenvironment during bone matrix degradation and 
the cells present at the bone surface are thought to be involved in the coupling of bone 
resorption and bone formation processes (Kenkre and Bassett, 2018). The exact transition 
signals that mediate the coupling mechanisms are still not elucidated, but evidence so far 
point to an important, but incompletely understood role for bone lining cells. These 
soluble factors, including bone morphogenetic proteins (BMPs), fibroblast growth factors 
(FGFs) and transforming growth factor β (TGF β), are likely responsible for the formation 
and accumulation of the osteoblasts in the reabsorbed area (Rucci, 2008). Bone formation 
is achieved by osteoblast and takes approximately 4 months in humans (Eriksen, 2010) 
The termination of the bone remodelling cascade is marked by the complete 
mineralisation of the newly formed osteoid. At this stage, osteoblasts end their life cycle 
by either apoptosis, become flattened as bone lining cells while some embed into their 
own matrix and differentiate into the terminal stage of maturation, becoming osteocytes 
(Figure 1.7). Osteocytes play a key role at this stage by releasing bone formation 
inhibitors, such as sclerostin (SOST) (Bonewald, 2011), and will be discussed in detail as 
part of Chapter 4. 
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Figure 1.7. Bone remodelling cycle in health. Bone turnover follows a sequence of 
events that includes activation, recruitment of osteoclasts to begin resorption, 
degradation and removal of bone, reversal stage and clearance of bone surface preparing 
it for formation of new bone by osteoblasts. After this phase a quiescent or resting period 
occurs. 
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1.2.2 Cellular mechanisms of bone remodelling 
Osteoarthritis is characterized by marked alterations in the composition, structure and 
functional properties of periarticular bone. These changes are mediated by the cells that 
remodel and model bone under physiological conditions and hence they may hold the key 
to understanding the pathophysiological processes associated with the skeletal changes in 
OA. This section provides a basic description of the cells involved. 
1.2.2.1 Osteoclasts and bone resorption 
Osteoclasts are large, multinucleated cells that form through fusion of mononuclear 
precursors of the hematopoietic lineage that also give rise to macrophages. Osteoclasts 
formation, activation and their unique functional property to resorb bone is regulated by 
the soluble molecules macrophage colony stimulating factor (M-CSF), receptor activator 
of NF-κB ligand (RANKL), osteoprotegerin (OPG), and signaling through the cell 
surface receptor activator of NF-κB (RANK) (Brendan F Boyce and Xing, 2007). 
Resident cells at the site of bone remodelling initiation, including BM stromal cells and 
osteoblasts, are known to produce the main regulators of osteoclasts formation M-CSF 
and RANKL (Lacey et al., 1998). Mononuclear precursor cells undergo proliferation in 
response to stimulation by M-CSF and upon RANKL ligation to its receptor RANK, the 
osteoclasts form by cytoplasmic, but not nuclear, fusion of their mononuclear precursors 
(Wada et al., 2006) (Figure 1.8). In most circumstances, the number of nuclei correlates 
positively with the bone-resorbing activity of osteoclasts (Brendan F. Boyce and Xing, 
2007). Inhibition of osteoclasts formation is achieved by OPG, which acts as a ‘decoy’ 
receptor by competing with RANKL for its receptor RANK, consequently preventing 
osteoclast differentiation and the survival of pre-existing osteoclasts (Figure 1.8) (Hsu et 
al., 1999). 
The unique functional property of osteoclasts is the resorption of bone. As discussed in 
section 1.2.1, bone resorption is a process of bone matrix destruction accomplished by 
osteoclasts through a series of orchestrated molecular and physical changes.  
In the early stages, osteoclasts bind to collagen, fibronectin, and laminin via β1 family of 
integrin receptors, especially the αvβ3 which binds to osteopontin and bone sialoprotein 
(Ross and Teitelbaum, 2005). Upon contact with bone matrix the osteoclast forms a 
ruffled border by transforming its fibrillar actin cytoskeleton into an actin ring, thereby 
allowing the formation of a sealing zone around the periphery of osteoclast attachment to 
the matrix, commonly referred to as Howship’s lacuna (Väänänen et al., 2000) (Figure 
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1.8). The Howship’s lacunae seal and isolate the acidified resorption compartment from 
the surrounding bone surface and facilitates the dissolution of the inorganic component. 
Osteoclasts pump protons through H+-ATPase, generated by Carbonic Anhydrase II into 
the sealing zone to dissolve the bone mineral, causing the ambient pH within the 
resorptive lacuna to fall to less than 4 (Silver et al., 1988; Tolar et al., 2004). This allows 
the release of acid-optimal lysosomal enzymes, such as cathepsin K (CTSK) activated by 
tartrate resistant-acid phosphatase (TRAP) and matrix metalloproteinases, which degrade 
the collagen-rich matrix by cleaving the helical and telopeptide regions of collagen 
(Delaissé et al., 2003). This results in the release of peptides that are endocytosed, 
transported through the cell and extruded through a functional secretory domain at the 
dorsolateral surface (Väänänen et al., 2000). These peptides can be used clinically to 
determine the rates of bone resorption (Greenblatt et al., 2017) while histochemical TRAP 
staining is widely used to identify osteoclasts in vivo and in vitro. The resorption process 
is terminated by osteoclasts apoptosis, ensuring no excess resorption occurs. 
1.2.2.2 Osteoblasts and bone formation 
Osteoblasts are responsible for the production of the organic constituents of the bone 
matrix. Osteoblasts do not function individually, but are found in clusters along the bone 
surface, lining on the layer of bone matrix that they are producing. However, how the 
osteoblasts emergence from their mesenchymal progenitors and the molecular 
mechanisms controlling their differentiation are still unclear. 
Once the osteogenically-committed MSCs stop proliferating, they change shape from 
spindle-shape to large cuboidal differentiated osteoblasts. The morphological 
characteristics of osteoblasts indicate their main function as protein synthesizing cells, 
including the large cuboidal shape, abundant rough endoplasmic reticulum and prominent 
Golgi apparatus, as well as various secretory vesicles (Florencio-Silva et al., 2015). 
Following their short cycle as bone matrix synthesisers, the majority of osteoblasts have 
one of the three fates: most of the osteoblasts (90%) die through apoptosis and are 
replaced by new osteoblasts for as long as the formation process is necessary and 
undergoing; another fraction of osteoblasts are incorporated in the osteoid matrix as living 
cells and become osteocytes while others return to a quiescent state lining the bone 
surface as bone lining cells (Franz-Odendaal et al., 2006). 
Bone formation takes approximately 4 to 6 months to complete (Eriksen, 2010) and 
occurs in two main steps: deposition of organic matrix and its subsequent mineralization. 
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Osteoblasts contribute to bone matrix formation by synthesis and directional secretion of 
type I collagen, which makes up over 90% of bone matrix protein (Morgan et al., 2008). 
Together with other types of collagen, proteoglycans, fibronectin and specific bone 
proteins, such as osteopontin, bone sialoprotein and osteocalcin, osteoblasts give shape 
to the unmineralised osteoid. This flexible hydrated protein matrix is further mineralised, 
providing the stiffness and rigidity specific to bone, as opposed to other collagenous 
matrices. Osteoblasts contribute to osteoid mineralization by releasing small, membrane-
bound matrix vesicles that concentrate calcium and phosphate and enzymatically destroy 
mineralization inhibitors such as pyrophosphate or proteoglycans, these events resulting 
in nucleation and growth of crystals of hydroxyapatite [Ca10(PO4)6(OH)2] among the 
collagen cross-links (Anderson, 2003). 
Molecular communication between all the bone cells in the BM compartment is a 
fundamental mechanism that regulates bone formation and resorption with remarkable 
precision. However, the research focus has traditionally been on the cells directly 
involved in removing and depositing bone, the osteoclasts and osteoblasts. The other cells 
along the osteogenic axis, namely MSCs and osteocytes, indirectly involved in the 
remodelling process, have been largely disregarded in OA studies. Given their active 
involvement in these processes, this gap in knowledge must be addressed for a full 
understanding of cellular mechanisms underlying bone associated pathologies in OA. 
There is a stark absence of knowledge on the roles of MSCs and osteocytes in OA. 
Therefore, work in this thesis aim to shed more light on the place occupied by both MSCs 
and osteocytes in the bone remodelling series of events, how they contribute to the 




Figure 1.8. Osteoclasts differentiation and activation. In the presence of RANKL 
released by stromal cells, RANK presenting monocytic precursors of osteoclasts 
differentiate and fuse together to form the osteoclasts which become active in contact 
with the bone matrix as they start resorbing the bone. Osteoclastogenesis is inhibited by 
the actions of OPG, which act as a ‘decoy’ receptor preventing the RANKL binding on 
the surface of osteoclasts precursors, preventing their differentiation and survival while 
allowing bone to form. 
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1.2.3 Bone remodelling in OA 
The imbalance between bone formation and bone resorption reflects an inappropriate 
bone remodelling activity (Rucci, 2008), which may lead to disturbances in bone mass, a 
characteristic often associated with various pathological conditions, such as OA (Li and 
Aspden, 1997). 
Under homeostatic conditions, bone remodelling is tightly coupled playing an essential 
role in bone health and is a prerequisite for the maintenance of microdamaged bone that 
occurs as a result of normal terrestrial impact. As previously mentioned, coupling in this 
context refers to the temporal succession of events during the bone remodelling processes 
where the molecular signals that regulate the activities of osteoclasts and osteoblasts 
activity in a co-ordinated way. This equilibrium however is known to be altered in OA. 
Subchondral bone changes described in Section 1.1.7, as well as increased bone turnover 
in OA (Burr and Radin, 2003), are all results of alterations of bone remodelling processes 
and have been detected early in OA progression (Day et al., 2001; Hochberg et al., 2009). 
The joint degeneration process in OA is therefore thought to be characterized by a spatial 
and temporal separation of the bone remodelling cycles (Burr and Gallant, 2012). 
Specifically, an increased remodelling was shown to dominate the early stages of the 
disease, marked by subchondral bone loss, and was considered as a determinant of OA 
progression (Bettica et al., 2002). As the disease progresses the remodelling rate reduces, 
shifting the balance towards an increase in bone formation (Burr and Gallant, 2012). This 
alteration results in increased bone volume, which can be associated with an apparent 
sclerosis, however the tissue is not well mineralised and may not be very stiff (L.G. Cox 
et al., 2012). While this may be partly attributed to an impaired mineralisation on behalf 
of osteoblasts (Sanchez et al., 2008), little is known about the roles of other osteogenic 
lineage cells in this process. On both sides of the osteoblasts stage of differentiation, the 
MSCs and the terminally differentiated osteocytes, may also be involved in the impaired 
bone remodelling activity, especially in the uncoupled mechanisms that seem to be 
skewed during the sequential phases of the bone remodelling cycle in OA (Burr and 
Gallant, 2012). However, there is very limited knowledge about how these various 
mesenchymal lineage cells achieve this in vivo. 
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1.3 Mesenchymal Stromal/Stem Cells 
1.3.1 History and nomenclature of MSCs 
In seminal studies during the 1960s and 1970s, pioneering work of Alexander 
Friedenstein, later working with Maureen Owen, provided evidence for an inherent 
osteogenic potential of a cell population in BM, distinguishable from the majority of 
hematopoietic cells (Friedenstein et al., 1968). They found that seeding BM cell 
suspensions at clonal density results in the establishment of a rapidly adherent fibroblastic 
cell originating from the BM stroma that can establish a colony in a density-independent 
manner, now known as colony forming unit fibroblasts (CFU-Fs) (Friedenstein et al., 
1970). When the progeny (i.e. BM stromal cells) of these CFU-Fs were transplanted in 
vivo in a diffusion chamber (i.e. a closed system), cartilage formed in the relatively 
anaerobic interior and bone on the relatively aerobic exterior of the diffusion chamber. 
When transplanted in vivo using an appropriate scaffold (i.e. an open system), the colonies 
recreated a bone/marrow organ composed of bone, osteocytes, osteoblasts, 
haematopoiesis-supportive stroma and marrow adipocytes of donor origin, and 
haematopoiesis of recipient origin (Owen and Friedenstein, 1988). These observations 
were extended in 1980 and 1990 by other experiments demonstrating that these cells were 
multipotential and could give rise to osteoblasts, chondrocytes and adipocytes (Pittenger 
et al., 1999) and together with others that followed who demonstrated self-renewal 
(Sacchetti et al., 2007), clearly indicated that BM stroma contains a bona fide skeletal 
stem cell capable of reforming skeletal tissues (Bianco et al., 2008).  
Adult stem cells, also known as somatic stem cells, possess the fundamental properties 
of stem cells, that is, self-renewal capacity and multipotency, although their 
differentiation capacity is restricted to the tissue where they reside (Kfoury and Scadden, 
2015). The mechanisms controlling the fate of stem cells are not fully understood, but 
they are thought to depend on the interaction with other cells as well as with their 
microenvironment or niche (Ferraro et al., 2010). Niches are composed of other cells, 
extracellular matrix, and signalling factors, which, in combination with the inherent 
characteristics of stem cells, define their properties and potential (Fuchs et al., 2004). In 
vivo, adult stem cells are thought to divide asymmetrically to produce two kinds of 
daughter cells. Whereas one remains in the niche as a self-renewing stem cell, the other 
one becomes a precursor or progenitor cell, exits the niche, and enters a pathway of 
proliferation and differentiation, which leads to the formation of a mature cell type. 
Stemness refers to the biological pathways and mechanisms that preserve the cell in its 
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undifferentiated stem state, their ability to reconstruct the tissue of origin in vivo while 
also contributing to its maintenance and repair, thus demonstrating both multipotency and 
the ability to self-renew (Kolf et al., 2007). 
Whether these cells should be considered true stem cells at all or as multipotent 
progenitors of mesenchymal lineages has been the focus of intense debate (Sipp et al., 
2018). Since their initial description, these multipotent BM cells have been given different 
names. Friedenstein, who is generally credited for the discovery of MSCs, used the term 
osteogenic stem cells (Friedenstein et al., 1987), while Maureen Owen called them 
marrow stromal stem cells to underline that they generate stromal cells in long-term 
cultures (Owen et al., 1987). Based on their supposed capacity for self-renewal and 
differentiation capacities, Arnold Caplan was the first to introduce the term 
‘mesenchymal stem cells’ (Caplan, 1991), which has become popular in the literature. 
Others have suggested an alternative term ‘skeletal stem cell’ to emphasise their potential 
to generate the cellular constituents of the skeleton (Bianco et al., 2008). In the absence 
of in vivo test for their self-renewal, the International Society for Cellular Therapy has 
therefore proposed the term ‘multipotent mesenchymal stromal cell’ (Horwitz et al., 
2005). 
1.3.2 Defining the MSCs 
Decades of studies following their discovery have offered significant in-depth 
understanding of the biological features of MSCs, however much of the information has 
been obtained from in vitro studies on culture-expanded cells. 
There are two main concepts by which the MSCs can be found in the current state of the 
art in MSC literature worldwide. Firstly, MSCs were defined as a heterogeneous 
population of cells that proliferate in vitro as plastic-adherent cells, have fibroblast-like 
morphology, form colonies in vitro and can differentiate into bone, cartilage and fat cells 
(Horwitz et al., 2005). However, some claim that stromal cells that apparently fulfil these 
criteria for an MSC have been isolated from almost every type of connective tissue (da 
Silva Meirelles et al., 2006) and therefore these features represent a common stromal cell 
adaptation to in vitro culture, and therefore do not reflect physiological functions of 
culture-initiating cells in vivo.  
Secondly, others tried to not distort the initial concept of MSCs since its discovery by 
Friedenstein et al., recommending to define MSCs functionally, by experimentally 
demonstrate both self-renewal and multipotency in vivo, i.e. the MSCs would be able  to 
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generate fully differentiated tissues in vivo and have the ability to reconstitute in vivo cells 
identical in phenotype and potency to those explanted (Bianco et al., 2013). Culture-
expanded cells from the bone cavities (i.e. bone marrow) fulfil both these definitions, 
form adherent cultures and show self-renewal in vivo, which cannot be said for similar 
cells expanded from other tissues (Sacchetti et al., 2016). 
There is currently no clear distinction between cultured and native cells when referred to 
MSCs and therefore this confusion is noteworthy. Knowledge of the natural identity of 
MSCs and how these cells are different from their culture-expanded counterparts 
represents a fundamental aspect, especially when handling MSCs experimentally to 
studying diseases, such as OA. Work in this thesis will tackle such issue in order to 
address important questions in the MSC field and more importantly, in their use to study 
OA pathogenesis. 
1.3.2.1 Culture-expanded MSCs 
The notion that all MSCs are equal is a common misconception (Phinney and Sensebé, 
2013). Significant differences have been found between multipotentiality and function of 
MSCs derived from different tissues (Winter et al., 2003; Li et al., 2015), and even within 
the same type of tissues sourced from different anatomical sites (Lopa et al., 2014). It has 
been demonstrated that the cellular and functional properties can be affected in MSCs 
from different origins even when cultured under the same conditions. For example, 
Sakaguchi et al. showed that human MSCs isolated from the BM exhibited the strongest 
osteogenic potential whereas those isolated from synovium were predominant in 
chondrogenesis and adipogenesis (Sakaguchi et al., 2005).  
As a consequence, the International Society for Cellular Therapy (ISCT) issued a position 
statement to establish a consensus over minimal criteria for designation of multipotent 
mesenchymal stromal cells, thereby also proposing the term "stromal" to be used instead 
of "stem" (Horwitz et al., 2005; Dominici et al., 2006). According to ISCT, the cells must 
adhere to plastic under standard culture conditions. Secondly, the cells should have a 
distinct and homogenous phenotype, with ≥95% of the population expressing the cell 
surface markers CD105 (endoglin), CD73 (ecto5’nucleotidase) and CD90 (Thy-19). 
Additionally, the cells should be negative or with ≤2% of the cells presenting CD45 (a 
pan-leukocyte marker), CD34 (the endothelial and haematopoietic marker), CD14 or 
CD11 (both monocyte/macrophage markers), CD79 or CD19 (both B-cell markers) or 
HLA-DR (a marker of professional antigen-presenting cells, only expressed on MSCs if 
stimulated by IFN-γ). Finally, the cells should have trilineage potentiality, with the ability 
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to differentiate into the osteogenic, the chondrogenic and the adipogenic lineages in vitro 
as assessed with standard staining methods (Dominici et al., 2006). 
The defining function of in vitro MSCs for multipotentiality was described in the late 
1990s by Pittenger et al. providing evidence of MSC commitment and differentiation 
towards osteogenic, adipogenic and chondrogenic lineages (Figure 1.9) (Pittenger et al., 
1999). By using specific culture conditions, this differentiation capacity has been 
exploited in vitro to generate cells of the mesenchymal lineage, including bone, fat and 
cartilage which can be assessed by evaluating the formation of mineralized matrices, 
production of fat droplets and expression of type II collagen respectively (Pittenger et al., 
1999). 
The lineage commitment and differentiation of MSCs is driven by a tightly orchestrated 
cascade of transcription factors and signalling cascades. Osteogenic differentiation can 
be achieved by culturing the cells with ascorbic acid, β-glyceralphosphate and 
dexamethasone for 3 weeks in specialised osteogenic media (Pittenger et al., 1999). 
Osteogenic induction is marked by increased alkaline phosphatase activity at final week 
of differentiation, calcium deposition (positive for Alizarin Red) and mineral aggregation 
(positive for von Kossa staining). Gene expression analysis of differentiating cells 
normally confirms osteogenesis by elevation of osteogenesis-related master transcription 
factors runt-related transcription factor 2 (RUNX2) and osterix (SP7) expression at early 
time points and a later up-regulation of bone-matrix proteins, such as osteocalcin, 
encoded by BGLAP (Pittenger et al., 1999).  
Adipogenesis, the process by which MSCs differentiate into adipocytes, is equally 
regulated by a complex and highly orchestrated gene expression program. The critical 
transcription factor documented to promote MSC adipogenesis while repressing 
osteogenesis is the peroxisome proliferator-activated receptor γ (PPARγ) while the fatty 
acid binding protein 4 (FABP4) and adiponectin are involved in the formation of mature 
adipocytes (Rosen and MacDougald, 2006). The expression of these molecules confirms 
adipogenic differentiation and can be used in combination with measuring the lipid 
droplets by Oil red and Nile red staining (Rosen and MacDougald, 2006).  
The aim of the chondrogenic differentiation of MSCs in vitro is to mimic the natural 
process of cartilage development that occurs in vivo. Studies have documented 
benchmark genes associated with MSCs-derived chondrocytes, such as the transcription 
factor SOX9, responsible for driving the chondrogenic commitment (Bi et al., 1999) and 
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genes associated with cartilage extracellular matrix formation, including collagen type II, 
aggrecan or biglycan (Pittenger et al., 1999). 
 
Figure 1.9. MSCs differentiation. The MSCs have the potential to self-renew and 
differentiate towards the three mesodermal lineages (cartilage, bone and fat) driven by 
the actions of master transcription factors and microenvironmental cues. 
Noteworthy is that the ISCT criteria does not include the assessment of MSC’s stemness, 
an important characteristic of adult stem cells. The common criteria established by the 
ISCT is used for identifying MSCs in vitro (Dominici et al., 2006), the surface markers 
having broad cell reactivity and are therefore not suitable alone for the detection of MSCs 
in vivo (Boxall et al., 2012). However, MSCs can be isolated and expanded with high 
efficiency (Pittenger et al., 1999). More recently it has been shown that placenta and 
umbilical cord blood/cord contain higher levels of MSCs than bone marrow, and these 
tissues are typically considered as biological waste and discarded after childbirth 
(Spitkovsky and Hescheler, 2008). Adipose tissue has also been shown to contain a much 
higher frequency of MSCs than bone marrow; with a study carried out finding 2% of 
nucleated cells in lipoaspirate after a low invasive subcutaneous lipoaspiration procedure 
were MSCs (Strem et al., 2005). It has been shown that MSCs from alternative areas other 
than the bone marrow may be more predisposed to differentiate into certain lineages, for 
example, MSCs isolated from the cartilaginous areas of the knee demonstrated increased 
levels of chondrogenesis when compared to bone marrow MSCs, but reduced levels of 
adipogenesis (English et al., 2007).  
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While culture-expanded MSCs are indeed capable of differentiating into bone, cartilage 
and fat cells and are readily available to be isolated from many adult tissue types, there 
are several limitations which hamper the understanding of their in vivo biology and 
particularly, their role in OA pathogenesis. These limitations mainly stem from the 
discrepancies between cultured and native MSCs, especially with regards to the changes 
induced by culture manipulations. More than one decade from the initial statement 
(Dominici et al., 2006), the ISCT criteria have not fully resolved the complexity of MSCs, 
moreover it can be misleading given the continuous waves of evidence marking the 
differences between native and culture expanded MSCs (Harichandan et al., 2012; 
Churchman et al., 2012), which will be further addressed in this thesis (Chapter 3). 
1.3.2.2 Native MSCs  
Since their first discovery in the BM, the MSCs were also demonstrated to be resident in 
both trabecular (Jones et al., 2010) and cortical bone (G. Cox et al., 2012). The BM 
represents a niche of intense activities with regards to haematopoiesis and bone 
remodelling. Bone marrow MSCs are critical to the bone microenvironment by virtue of 
their roles in providing a pool of progenitors for maintaining local tissue homeostasis and 
supporting haematopoiesis (Greenbaum et al., 2013). As mentioned, OA subchondral 
bone is marked by alterations in bone remodelling processes (Section 1.2.2), however the 
roles of local resident MSCs in these activities in OA have so far eluded scrutiny. One of 
the reasons for the scarcity of studies in native MSCs is the lack of specific surface 
markers, MSCs isolated by plastic adherence representing a heterogeneous mixture of 
cells with varying proliferation and differentiation potentials. 
Currently, the purified human BM MSCs are characterized by a combination of markers, 
detailed in Table 1.2. These markers include and are not limited to, STRO-1, CD146, 
CD271 (LNGFR), MSCA-1, CD49a, CD73, CD105, CD106 (VCAM-1) and CD140b 
(Quirici et al., 2002; Jones et al., 2002; Gronthos et al., 2003; Aslan et al., 2006; Bühring 
et al., 2007; Sacchetti et al., 2007; Battula et al., 2009). However, some of the surface 
markers, such as CD49a, CD73, CD140b, and CD146 are widely expressed in other 
stromal cells (e.g., pericytes and reticular cells) and thus are not unique to MSCs. With 
this in mind, some negative markers are also used in combination with the aforementioned 
positive markers, including endothelial and haematopoietic cell markers, such as CD45 
and CD31 (Pittenger et al., 1999; Jacobs et al., 2013). 
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Table 1.2. Positive markers used for native BM MSC identification  
Marker Name Function Reference 
STRO-1 - Unknown 
(Simmons and Torok-







(Quirici et al., 2002; 
Jones et al., 2002; Jones 
et al., 2010) 
CD105 Endoglin Receptor for TGF-βI and III (Barry et al., 1999) 
CD106 VCAM-1 Mediates adhesion to leukocytes expressing alpha 4 integrins 
(Gronthos et al., 2003; 
Mabuchi et al., 2013) 
CD146 MCAM, MUC-18 
Cell adhesion, highly expressed 
on endothelial cells, receptor for 
laminin alpha 4 and netrin-1. 
(Shi and Gronthos, 
2003; Sacchetti et al., 
2007) 
CD56 NCAM Cell-cell or cell-matrix adhesion; (Battula et al., 2009) 
CD73 5’nucleotidase 
Ectoenzyme, catalysis of purine 
5’ mononucleotides to 
nucleosides 
(Barry et al., 2001) 
CD90 Thy-1 Cell adhesion, highly expressed at sites of inflammation 
(Jones et al., 2002; 
Mabuchi et al., 2013) 
SSEA-4 - Laminin binding; also hES marker (Gang et al., 2007) 
CD140b PDGFR-b MSC proliferation and migration (Bühring et al., 2007) 
MSCA-1 TNAP Phosphate ectoenzyme 
(Battula et al., 2009; 
Cuthbert et al., 2015; 
Busser et al., 2015) 
CD49a VLA-1 Receptor for collagen and laminin 
(Deschaseaux et al., 
2003) 
CD140a PDGFR-α 
Mesoderm formation and 
connective tissue development 
during the embryogenesis 
(Li et al., 2014) 
GD2 - Neural ganglioside (Martinez et al., 2007) 
CD10 Neprilysin Metalloprotease (Campioni et al., 2003) 
SUSD2 - Cell adhesion and migration 
(Battula et al., 2009; 
Cuthbert et al., 2015; 
Busser et al., 2015) 
CD166 ALCAM Cell-cell adhesion (Stewart et al., 2003) 




Whereas for haematopoietic stem cells there is a gold standard to assess their self-renewal 
and multipotency as a single-cell level in vivo by reconstituting the haematopoietic niche 
in myeloablated recipients (Osawa et al., 1996), such an assay has not yet been universally 
established for MSCs to test their identity in vivo. As such, one group harnessed their 
capacity to form bone and heterotopic BM formation and identified a population of self-
renewing MSCs covering the BM micro-vessels as recognized by the CD146 surface 
marker expression (Sacchetti et al., 2007) which was later found to also express CD271 
(Tormin et al., 2011). The self-renewal capacity of these MSCs was demonstrated in an 
elegant mouse study by using the neural stem cell marker Nestin (Méndez-Ferrer et al., 
2010). This was the first study to prove that MSCs in the BM represent the common pool 
for osteochondro-progenitors and that they can be serially transplanted following non-
adherent culture conditions (Méndez-Ferrer et al., 2010).  
The in vivo identity of BM MSCs is now firmly established as CD271+ cells (Boxall et 
al., 2012). CD271 (also named as low-affinity nerve growth factor receptor) is a receptor 
for neurotrophins, which stimulate neuronal cells to survive and differentiate (Tomellini 
et al., 2014). It was first suggested as an MSC marker for BM resident MSCs by Quirici 
et al. (Quirici et al., 2002) and further advanced by work in our laboratory and others 
(Jones et al., 2002; Bühring et al., 2007; Jones et al., 2010; Busser et al., 2015; H. Li et 
al., 2016).  
The topography of CD271 positive MSCs in the BM placed them in the stromal reticular 
net, the perivascular region of the BM compartment as well as the endosteal region, lining 
the bone surface (Jones and McGonagle, 2008; Tormin et al., 2011; Sivasubramaniyan et 
al., 2018). It was further demonstrated that CD271 MSCs enriched more than 40-fold for 
CFU-Fs in the human BM alone or in combination with other cell surface markers, such 
as CD45 for negative selection of haematopoietic lineage cells (Quirici et al., 2002; Jones 
et al., 2002; Cuthbert et al., 2012). The removal of the haematopoietic lineage is 
commonly required as CD271 alone may not be sufficient to obtain a pure MSC 
population (Boxall et al., 2012) since CD271 was found to be expressed, although on low 
levels, on hematopoietic progenitor cells of the erythroid lineage (Cuthbert et al., 2012).  
Cell population having the CD45-CD271+ phenotype has been extensively demonstrated 
by work in our laboratory and others to exhibit all the classical characteristics of MSCs, 
including the uniform expression of other MSC markers such as CD73, CD105 and CD90 
(Jones et al., 2002; G. Cox et al., 2012; Churchman et al., 2013).  
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Using the CD146 marker, it was shown by work of Tormin et al. that the CD271+ MSC 
population exists within two different niches in vivo: endosteal and perivascular, MSCs 
being reported in both the CD271+CD146- and CD271+CD146+ fractions (Tormin et al., 
2011). While these subsets have distinct cell-surface phenotypes based on CD146 
expression, this was suggested to be related with their distinct BM topographies and 
consequently the access to different gradients of oxygen that exist between the endosteal 
surface and in the proximity of blood vessels where CD146+ cells reside. Both subsets 
demonstrated the lineage commonality of CD271+ cells and were evidenced to generate 
haematopoietic stroma in vivo, a key property which demonstrated the MSC nature of 
CD271+ cells (Tormin et al., 2011). This observation might be critical to understanding 
the link between MSCs and bone lining cells. 
1.3.3 MSCs and bone formation 
As previously discussed (Section 1.1.8), bone sclerosis in OA is characterised by an 
increase in the bone volume due to an increase in tissue density that is hypomineralised 
(Lajeunesse et al., 2003). This indicates an increase in the indices of bone formation in 
OA patients which may be explained by an aberrant MSC differentiation activity, which 
will be addressed by work in this thesis. However, the molecular mechanisms occurring 
in MSCs leading to bone formation must be defined first. 
The differentiation process is believed to occur in two steps: the commitment of MSCs 
towards the specific lineage progenitor cells, and the subsequent maturation from 
progenitors to the specific cell type. The transcription factors involved in MSC 
commitment to osteogenesis that are commonly used for in vitro tests have been already 
outlines in Section 1.3.2. Whilst in vitro MSC differentiation is induced biochemically, 
osteogenic differentiation of MSCs in vivo relies on the concerted activation of a complex 
network of pathways controlled both locally and systemically during bone formation 
process. Wnt (a portmanteau of Wingless and integration 1) family and bone 
morphogenetic proteins (BMPs) are the main drivers of the early events in osteogenesis, 
while the helix-loop-helix Twist family of proteins maintain MSCs proliferation (Zaidi, 
2007).  
Wnt proteins are a family of 19 highly conserved Wnt secreted glycoproteins that play 
essential roles during development and tissue homeostasis and is a critical pathway for 
both skeletogenesis and skeletal remodelling (Baron and Kneissel, 2013). Some Wnt 
proteins, such as Wnt3a and Wnt10b, bind to Frizzled receptors, and recruit the LRP5/6 
co-receptors to activate the canonical signalling pathway, leading to β-catenin 
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stabilization and translocation into the nucleus, enhancing the transcriptional activity of 
the downstream Wnt/b-catenin mediator, T-cell factor/lymphoid enhancer factor 
(TCF/LEF) (Cadigan and Waterman, 2012; Fakhry et al., 2013). Binding of Wnt proteins 
to LRP5/6 is inhibited by osteocyte-secreted factors, such as Dickkopf-related protein 1 
(Dkk1) and SOST, both molecules produced by and therefore attributing critical roles to 
osteocytes in regulating bone remodelling (Tian et al., 2003; Li et al., 2005).  
BMPs are considered to be a diverse group of phylogenetically conserved growth factors 
belonging to the TGF-b superfamily of signal molecules with 20 members identified so 
far. In the adult, BMP-2 acts as a potent stimulator of ectopic bone formation (Chen et 
al., 1997) and it is used clinically along with BMP-7 to enhance bone formation, for 
example, for the treatment of long bone open-fractures treated with intramedullary 
fixation, non-union fractures (Govender et al., 2002). BMP signalling through the 
recruitment and activation of heterodimeric Smad proteins controls the expression of 
Runt-related transcription factor 2 (RUNX2), also known as core binding factor alpha1 
(CBFA1) (Ducy et al., 1997).  
Indispensable for osteoblast differentiation, RUNX2 transcription factor drives the early 
steps of MSC commitment towards the pre-osteoblast phenotype and no other lineages. 
This dominant effect was demonstrated by the fact that RUNX2-null mice are devoid of 
osteoblasts and lack bone formation (Komori et al., 1997; Ducy et al., 1997). 
Furthermore, RUNX2 was also shown to upregulate osteoblast-related genes associated 
with bone formation, such as collagen type 1A1 (COL1A1), alkaline phosphatase (ALP), 
osteopontin (SPP1) and osteocalcin (BGLAP) (Fakhry et al., 2013). Osteopontin, encoded 
by SPP1 gene (also known as bone sialopotein-1), is a polar linking protein in the 
extracellular matrix (Denhardt and Guo, 1993; Denhardt and Noda, 1998). Factors known 
to promote RUNX2 activation include BMPs, TGF-β, parathyroid hormone (PTH) and 
FGFs, while the transcription factors TWIST1 and TWIST2 act as a negative regulator 
(Kaneki et al., 2006).  
The transition from pre-osteoblasts to osteoblasts is facilitated by the second transcription 
factor unequivocally required for osteoblast differentiation, Osterix (also known as SP7). 
Osterix is a zinc finger-containing transcription factor belonging to the SP family of 
transcription factors, specifically expressed in osteoblasts, and required for bone 
formation (Komori, 2006). Similar to RUNX2, the activation of osterix in MSCs is 
achieved by anabolic signals, such as BMP-2 and insulin growth factor 1 (IGF-1) (Celil 
and Campbell, 2005). Its fundamental role in bone formation was demonstrated by studies 
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showing that osterix deficient mice lack bone formation, however they have normal levels 
of RUNX2, indicating osterix location downstream of RUNX2 (Nakashima et al., 2002). 
At this stage, the osteoprogenitor cells stop proliferating, increase their expression of 
ALP, and begin to secrete type 1 collagen and other non-collagenous matrix proteins 
while anchoring to the newly formed osteoid by cadherin-11 (CDH11) and N-cadherin 
(Ferrari et al., 2010) exhibiting secretory functions resembling the osteoblasts (Section 
1.2.3.2) 
1.3.4 Native MSCs in OA 
The transcriptional profile of healthy BM CD271+ MSCs has been previously 
characterised (Churchman et al., 2012; H. Li et al., 2016) and the expression of genes 
associated with bone, fat and cartilage were documented, indicating their multipotency. 
Furthermore, recent in vitro studies showed that some of the osteogenic molecules, 
including SPARC (osteonectin), ALP (alkaline phosphatase) and TNFRSF11B 
(osteoprotegerin) increased significantly following standard in vitro osteogenic 
differentiation (Churchman et al., 2017). Thus, the potential contribution of BM CD271+ 
MSCs to bone formation activities has been indicated by their gene expression profile in 
health. While aberrant bone remodelling activities and bone sclerosis are well-established 
features of OA (Burr and Gallant, 2012), the nature of MSCs in this disease has not been 
established yet. Furthermore, their roles in bone remodelling in humans are so far limited, 
but recent studies point to a potential involvement of native MSCs in OA 
pathophysiology. 
While studies investigating the nature and the roles of native MSCs in OA are currently 
scarce, in one specific mouse model of OA, it was shown that the number of MSCs are 
increased in the subchondral BM of OA mice, attracted by an increase in TGF-b 
concentrations resulted following bone resorption (Zhen et al., 2013). This study 
suggested that the increase in MSCs is possibly due to changes in their topography, 
migrating from their perivascular location towards the surface of the bone where they 
participate in bone remodelling activities.  
Some studies investigating the MSCs in human OA showed contrasting results to mouse 
work, with no differences observed in their numbers in comparison to healthy bone (Jones 
et al., 2010). However, emerging evidence documented aberrant MSCs activities in hip 
OA bone. The recent study of Campbell et al. showed an accumulation of MSCs in the 
damaged areas of hip OA marked by the presence of BMLs (Campbell et al., 2016) 
possibly as a repair attempt mechanism. While these MSCs exhibited functional and 
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transcriptional alterations in vitro, especially with regards to their mineralisation 
potential, their native state was not investigated. Furthermore, as mentioned 
(Section1.3.2) more recent evidence showed that MSCs isolated from OA bone exhibit 
phenotypical and transcriptional alterations in vitro (Barry and Murphy, 2013; Campbell 
et al., 2016), while their native profile in OA has not been explored yet. Together with 
their documented accumulation in altered areas of OA both in human (Campbell et al., 
2016) and OA animal models (Zhen et al., 2013) is indicative that their native profile may 




For a long period of time, osteocytes have been regarded as dormant cells ‘entombed’ 
within the mineralized bone matrix. While the other bone cells, such as osteoblasts and 
osteoclasts, were mainly defined by their functional role, the osteocytes were primarily 
defined by their morphology and location embedded in the bone. This was mainly due to 
their inaccessible location and the lack of tools to deepen the study of these cells. 
However, with the recent technological advances of high-resolution microscopic 
technologies and high-throughput molecular screening, as well as the development of 
cell- and tissue-specific transgenic animals, the research field involving osteocytes has 
experienced an increased growth over the last decades unravelling their biological 
properties and the important functions they have in the skeleton. 
Osteocytes are the most abundant bone cells, making up more than 90% of all the cellular 
component of bone, with an estimated ~42 billion osteocytes in the adult human skeleton 
(Buenzli and Sims, 2015). As stated above, the osteocytes have been mainly defined by 
their morphology and represent the terminally differentiated stage of the osteogenic 
lineage cells, however the exact mechanisms that regulate how and why and osteoblast is 
destined to become embedded into the bone matrix and start a new life as an osteocyte 
are still not fully understood.  
In humans, osteocytes were postulated to live long, with an estimated average half-life of 
a human osteocyte as long as 25 years (Frost, 1960). However, considering an overall 
bone-remodelling rate between 4 to 10% per year (Manolagas, 2000), the life of some 
osteocytes may be shorter and likely difficult to establish, especially given the differences 
between cortical and trabecular bone. Cortical bone has a higher density, organised in 
osteons (Harversian system) where the osteocytes are arranged in concentric layers 
around the central canal (Harversian canal) may have an increased life span due to large 
variations in the rate of cortical remodelling (Bach-Gansmo et al., 2015). In contrast, 
trabecular bone comprises a meshwork of thin trabeculae where the resident osteocytes 
are exposed to a higher remodelling activity, i.e. they are replaced at a higher rate. What 
is quite clear is that the lifespan of osteocytes greatly exceeds that of active osteoblasts, 
which is estimated to be only three months in human bones (Manolagas, 2000). 
1.4.1 Osteocytogenesis and osteocyte morphology 
Under normal conditions, the transition from osteoblast to osteocyte follows closely 
regulated steps that correlate intimately to the changes of the cell surroundings. The 
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incremental formation of osteoid and its subsequent mineralization would result in the 
temporal and spatial changes in matrix composition, oxygen tension, and mechanical 
stress, which consequently contribute to the physical transformation of these cells and 
changes in osteocyte morphology (Chen et al., 2018).  
The research literature describes various stages of transition from osteoblasts to 
osteocytes, (Figure 1.10) as reviewed by Franz-Odendaal et al. (Franz-Odendaal et al., 
2006). According to this scheme a subpopulation of osteoblasts on the bone surface slows 
down their matrix production as relative to neighboring cells and progressively immerse 
themselves in this newly formed osteoid. These cells gradually undergo radical 
morphological changes from large, cuboidal to a ramified, stellate shape. It was estimated 
that during the transition to nascent osteocytes, the cell shrinks its size by 30% and 
reaching a total reduction by 70% once the osteocyte is fully differentiated (Palumbo, 
1986). Along their transition, the volume of the large cuboidal osteoblasts and the number 
of cytoplasmic organelles gradually decrease, including the rough endoplasmic reticulum, 
Golgi apparatus, and mitochondria (Florencio-Silva et al., 2015) while the nucleus-to-
cytoplasm ratio increases (Schaffler et al., 2014) and cytoplasmic projections radiate 
away from the cell body towards the mineralizing front. Overall, this metamorphosis 
implies a change in their function, away from their role in extracellular matrix synthesis 
and more towards mediators in cellular communication and mechanosensory roles.  
Accompanying all the physical transformations are changes in their molecular construct. 
During osteocyte development and maturation, a multitude of molecules are 
downregulated or switched off while others gradually start being expressed. These 
molecules include molecular markers specific to osteoblasts that decline in their 
expression, such as ALP, osteocalcin (BGLAP) and collagen type 1 (Paic et al., 2009) or 
osteocyte specific molecules, such as E11 (podoplanin) or SOST which start being 
expressed at different stages of maturation (Dallas et al., 2013). A more thorough 
discussion of the molecular mechanisms behind osteocyte development and maturation 
is presented in Chapter 4, Section 4.1.3. 
In humans, mature osteocyte cell bodies measure ~9 µm in the short axis by 20 µm in the 
long axis (Mullender et al., 1996) with a gap present between the cell and the lacuna wall. 
Mature osteocytes are regularly dispersed throughout the bone matrix residing in ~15-20 
µm lacunae (Bonewald, 2011). Originating from the lacunae, cytoplasmic extensions 
(dendritic processes) travel through the matrix via ~200-300 nm thick passageways called 
canaliculi, connecting the osteocytes between each other as well as with other bone cells 
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residing at the bone surface (You et al., 2004). The dendritic processes are approximately 
half the diameter of the canaliculi leaving a gap sufficient for two processes to lie side by 
side at points of gap junctional communication between two osteocytes. While the cell 
body orientation is aligned to the collagen fibres in the bone matrix, these dendritic 
processes are polarised towards the vasculature and the mineralised front and range in 
between 30-80 projections for each individual cell (Palumbo et al., 1990). Furthermore, 
the canalicular wall is wave-like with periodic conical protrusions in the form of collagen 
fibrils acting as anchoring points (hooks) for  osteocyte attachment of the dendritic 
processes via integrins (McNamara et al., 2009). 
Distinctive osteocyte morphologies were observed depending on the different types of 
bone as well as its stage of maturation. For example, in load-bearing long bones where 
the load is predominantly aligned with the longitudinal orientation of the bones, 
osteocytes were found to have mostly an elongated shape (Vatsa et al., 2008). On the 
other hand, round osteocytes were found in flat bones, such as calvariae, where the 
mechanical load has a lower amplitude and different directionality (Vatsa et al., 2008). 
Osteocyte morphology and orientation thus seem to also be affected by the mechanical 
loading direction. 
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Figure 1.10. Osteocyte differentiation and maturation. Active osteoblasts originating 
from MSC osteoprogenitors are gradually embedding into the collagenous matrix of the 
osteoid as young osteocytes which subsequently mature as the matrix mineralises. During 
this transformation process (white arrows), the embedding osteoblasts transform by 
extending dendritic processes and reducing cell body volume. Gap junctions are present 
between all cells for direct communication. The square panel shows gap junction between 
the cell processes, red arrow indicating the traffic of soluble molecules and nutrients. 
Diagram modified from (Franz-Odendaal et al., 2006). 
1.4.2 Lacuno-canalicular network 
Due to their location buried in the mineral matrix, osteocytes have no space to proliferate 
and are also presented with challenges regarding intercellular communication and access 
to nutrients and oxygen. However, these cells have adapted exquisitely to these adverse 
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conditions by interconnecting into a complex network commonly referred to as the 
lacuno-canalicular network (LCN).  
The LCN enable intercellular communication through gap junctions allowing the 
osteocytes to act as a functional syncytial network (Noble, 2008) and thus retaining 
connections with the surface layer of osteoblasts and bone lining cells. Furthermore, the 
LCN is also in the vicinity of vascular supply therefore allowing the cells to be supplied 
with oxygen and nutrients (Dallas et al., 2013).  
The gap junctions connecting the dendritic processes between osteocytes as well as the 
hemichannels on the cell surface allow the exchange of nutrients and facilitate the 
transport of small signalling molecules among these cells. The osteocyte gap junctions at 
the tip of their dendritic projections is mainly composed by the most abundant member 
of the connexins family, Connexin 43, which plays an important role in the maintenance 
of intercellular communication and response (Civitelli, 2008). The LCN represents an 
ideal milieu for the transfer of exogenous and endogenous signals via mechanical and 
biochemical mechanisms (Knothe Tate, 2003). 
1.4.3 Osteocyte functions 
While osteocytes have been historically regarded as inactive placeholders in the bone 
matrix, recent data indicate that they are metabolically active and multifunctional cells 
(Noble, 2008).  
Studies showed that osteocytes are necessary to maintain bone mass in response to normal 
load, but in the absence of load, they send signals that enhance bone resorption (Tatsumi 
et al., 2007). For example, during exercising or lifting heavy weights, the bone mass 
increases. Conversely, unloading, as occurs with space flight i.e. microgravity or 
immobilization, results in bone loss (Tatsumi et al., 2007). Bone tissue health depends on 
the ability of bone cells to recognize and respond to mechanical and biochemical stimuli, 
a process called mechanotransduction. The mechanotransduction biological process 
implies the transduction of a load-induced biophysical signal, such as fluid flow, substrate 
deformation, or electro-kinetic effects, to a cell and ultimately throughout a cellular 
network (Donahue, 2000).  
Considering their unique location distributed throughout the bone matrix with extensive 
interconnectivity, osteocytes are the best candidates for detecting and coordinating 
responsiveness to mechanical signals (Klein-Nulend et al., 2013). Since osteocyte 
dendritic processes are in contact with osteoblasts on the bone surface and with adjacent 
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osteocytes, it is believed that osteocyte communicate mechanical signals to osteoblasts 
and perhaps other skeletal cells to affect their function (Klein-Nulend et al., 2013).  
The exact mechanisms by which osteocytes sense and respond to mechanical signals are 
still unclear. It is believed that the mechanical signals are transmitted to the osteocyte 
cytoskeleton via cell surface receptors directly, through the compact bone matrix 
structure, or indirectly via fluid pressure and shear stress conveyed by fluid moving 
through the canaliculi due to load-induced fluid flow (Knothe Tate, 2003). The 
extracellular fluid in the lacunar-canalicular space is believed to be the coupling medium 
through which the osteocytes are stimulated and able to translate the mechanical loading-
induced fluid flow shear-stress into biochemical effects at cellular level (Weinbaum et 
al., 1994). Deformation of the bone matrix surrounding osteocytes during mechanical 
strain imposes a shear stress by the movement of fluid along the canaliculi and is believed 
to produce perturbations in the osteocyte cell body or dendritic processes. In vitro studies 
using osteocytes cell lines demonstrated the importance of actin cytoskeleton along with 
the other filament networks and focal adhesion molecules in mechanotransduction by 
osteocytes (Alenghat and Ingber, 2002; Ponik et al., 2007; Santos et al., 2010). 
Furthermore, other studies suggested that crucial in sensing the changes in surroundings 
are a mechanosensory protein complex formed by a cilium and its associated proteins 
PolyCystins 1 and 2 (Xiao et al., 2006).  
Several biologic effects in response to mechanical forces or lack of them have been 
described. Upon mechanical stimulation, osteocytes immediately respond by producing 
several secondary messengers, such as adenosine triphosphate (ATP), nitric oxide (NO), 
Ca2+, and prostaglandins (PGE2 and PGI2,) which influence bone physiology (Klein-
Nulend et al., 1995; Genetos et al., 2007). Conversely, targeted deletion of osteocytes 
leads to bone loss and unresponsiveness to loading (Tatsumi et al., 2007). This was 
attributed to the osteocyte specific protein sclerostin, the product of the SOST gene (van 
Bezooijen et al., 2004). Sclerostin was shown to inhibit bone formation, both in vitro and 
in vivo, by its effects on Wnt pathway in osteoblast lineage cells (Li et al., 2005). 
Furthermore, it was demonstrated that SOST is elevated during reduced loading and it is 
reduced during increased loading (Robling et al., 2008).  
Osteocytes have been lately recognised to have critical regulatory roles in bone 
homeostasis, orchestrating the functions of osteoblasts and osteoclasts, thus acting as a 
master regulator of bone remodelling (Prideaux, Findlay, et al., 2016). Their control on 
bone formation is achieved through the aforementioned molecule SOST, which is 
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mechanically dependent and is a very potent bone formation inhibitor with demonstrated 
implications in OA pathology (Poole et al., 2005; Jia et al., 2018). Osteocytes have also 
regulatory roles in bone resorption by activating osteoclastogenesis. Recent evidence 
demonstrated that osteocytes are the main producer of RANKL and directly modulate 
bone resorption by promoting osteoclasts formation (Nakashima et al., 2011; Xiong et 
al., 2015). Furthermore, apoptosis or injury-induced necrosis of osteocytes defines the 
spatial domains in which bone remodelling occurs. It was observed that osteocyte 
apoptosis can occur at sites of microdamage, and it is proposed that dying osteocytes are 
targeted for removal by osteoclasts (Verborgt et al., 2002), possibly due to the release of 
RANKL along the canaliculi from the dying osteocytes. 
Osteocytes also have endocrine functions, regulating mineral and phosphate metabolism 
at a local and systemic levels. Systemically, osteocytes play an important role in bone-
kidney axis through the production of the phosphaturic factor, fibroblast growth factor 23 
(FGF23) (Riminucci et al., 2003). Additionally, as cells embedded in the bone matrix, 
osteocytes also contribute to the maintenance of that matrix. As reviewed by Plotkin et 
al., osteocytes produce phosphoproteins like dentin matrix protein 1 (DMP1), matrix 
extracellular phosphoglycoprotein (MEPE) and phosphate-regulating neutral 
endopeptidase, X-linked (PHEX) regulating mineral deposition, signalling with other 
bone cells in addition to regulating FGF23 production (Plotkin and Bellido, 2016).  
The molecular mechanisms through which osteocytes exert their control on bone 
formation and bone resorption as well as their secretory profile that contributes to mineral 
and phosphate homeostasis are discussed further in Chapter 4.   
Independently of the mechanisms involved, it is important to note that the regulatory and 
mechanosensory role of osteocytes are mainly possible due to their extensive LCN. The 
dendritic processes radiate in different directions and cover a vast bone area, allowing the 
communication with other bone cells as well as the transduction of cellular signals in 
response to biomechanics. Given their function as transducers of mechanical strains, it is 
likely that osteocytes might undergo enormous changes during biomechanical associated 
conditions, such as OA. Together with their regulatory roles in bone remodelling and 
mineral homeostasis, these changes may affect osteocytes not only morphologically but 




1.5 Hypothesis and aims 
It was hypothesised that subchondral bone sclerosis as well as other bone abnormalities 
in hip OA result from alterations in the bone remodelling activities. The MSCs and 
osteocytes play a profound role in driving these alterations and therefore contributing to 
OA pathology. 
The aims of this thesis are: 
1. To investigate the transcriptional and topographical changes in native MSCs of hip OA 
bone using healthy iliac crest as control bone (Chapter 3).  
2. To develop a method to study native osteocytes transcriptional profile in both OA and 
healthy bone and to study their transcriptional and topographical changes in hip OA 
compared to healthy bone (Chapter 4).  




Chapter 2 General methods 
The basic methods described in this chapter have been used throughout the whole project, 
with more specific methods described in the Materials and Methods sections of individual 
chapters. The complete list of reagents, solutions and buffers used in this project is listed 
in Appendix 1 while plastics, consumables and equipment in Appendix 2. All illustrations 
were created in Adobe Illustrator by the author of this thesis unless otherwise stated. 
2.1 Patient samples  
In total, 63 donors were recruited following written informed consent. This research was 
undertaken after approval from the Leeds East and Leeds West Research Ethic 
Committees as well as local National Health Service Research and Development 
(Appendix 3).  
All the samples in the OA group used across this project were harvested from 42 donors 
with end-stage OA (18 males and 24 females) undergoing total hip arthroplasty (median 
age 71 years old, range 40-89). Control bone was from iliac crest (IC) samples collected 
from 18 patients (9 males and 9 females) undergoing orthopaedic surgery for metal 
removal following previous fracture, who were otherwise healthy (median age 51 years 
old, range 24-87). The choice of healthy IC as control bone was due to the limited 
availability of healthy femoral heads. However, recent published data provided 
compelling evidence with regards to the validity of this type of bone is studying both 
osteocytes and MSCs (Ilas et al., 2019) and the cellular identity of MSCs has been 
previously documented to be similar between the two sites with regards to their surface 
markers phenotype and functional properties (Jones et al., 2010). Furthermore, in addition 
to IC, for histological analyses n=3 femoral heads were included from non-OA donors 
undergoing total hip arthroplasty for neck of femur fracture (all females, 54, 88 and 93 
years old respectively). All samples were collected and processed on the day of the 
surgery and basic patient demographics were recorded and included in Appendix 4.  
2.2 Tissue harvest, processing and overall study design 
Whole femoral heads excised following total hip arthroplasty or iliac crest bone samples 
were collected in saline solution and transported in sealed sterile containers. Figure 2.1 
illustrates the overall experimental design used in this thesis while the detailed description 
of each procedure is included in the Materials and Methods section of each chapter. The 
bone samples were used either for histological assessment (Chapter 4 and Chapter 5) or 
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enzymatically digested to obtain the MSCs (Chapter 3 and Chapter 5) and osteocytes 
(Chapter 4). To avoid culture manipulations, the bone treatment procedure was developed 
to simultaneously obtain pure osteocyte-enriched fragments and matched native MSCs. 
The MSCs were isolated by fluorescence activated cell sorting (FACS) from the 
enzymatically extracted cell suspension and used for gene expression analysis and 
functional assays, described in detail in Chapter 3 and Chapter 5. From the same cell 
suspension, MSCs were also isolated by plastic adherence and culture expanded to be 
used for CFU-F assays and gene expression analysis, detailed in Chapter 3. The remaining 
bone fragments following enzymatic treatment were further processed for complete tissue 
denudation in order to obtain pure native osteocytes which were also assessed for gene 
expression, described in detail in Chapter 4.  
2.2.1 Bone mechanical processing and enzymatic treatment 
Tissue processing was performed under strict aseptic conditions in the cell culture facility. 
From all bone samples, bone resident MSCs were extracted by enzymatic digestion as 
described previously (Jones et al., 2010) and followed by either cell sorting or culture 
expansion, using well established protocols by work in our laboratory (Jones et al., 2010; 
Churchman et al., 2012; Campbell et al., 2016). First, the cartilage was carefully removed 
from the femoral heads using a No. 24 blade scalpel (Swan-Morton) and 19 cm Stille-
Liston bone cutting forceps (Sklar). Iliac crest bone fragments were processed intact due 
to their smaller size and weight (<1g). Bone samples from femoral heads were broken 
down into small fragments (<1 g) using a 22 cm Stille-Luer bone rongeur (Sklar) and 
washed repeatedly with phosphate buffered saline (PBS, Sigma) to remove fat, 
haematopoietic cells and clots. After weighing the bone fragments, they were subjected 
to 4 hours’ incubation at 37º C with collagenase solution (Appendix 1) containing 
Collagenase I (Worthington Biochemical) in 20% Foetal Calf Serum (FCS, Biosera) and 
80% Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher) (corresponding to 
3000U/g of bone). The samples were kept in a water bath with regular shaking every 20 
minutes to remove all adherent cells from the bone surfaces and disperse the bone pieces 
evenly in the collagenase solution. 
Following digestion, the collagenase solution containing the released cells was separated 
from the bone chips by filtering it through a 70 µm cell strainer, while the bone fragments 
were further washed in large volumes of PBS to remove any residual cells, fat or clots. 
The PBS washes were filtered and pooled with the original collagenase solution, 
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centrifuged at 100xg for 10 minutes) and resuspended in DMEM (commonly 15-30 ml), 
containing 10% FCS and 1% penicillin/streptomycin (P/S, Thermo Fisher).  
The remaining digested bone fragments were kept in PBS (no more than 1 hour) for 
further processing and RNA extraction from native osteocytes, described in detail in the 




Figure 2.1. The overall design of experimental procedures. Trabecular bone samples 
(OA and controls) were used for histological assessment or cell extraction. To obtain the 
stromal cell suspension and denuded osteocyte-enriched bone, the bone samples were 
mechanically broken down into small fragments and enzymatically digested. From the 
obtained cell suspension, the MSCs were isolated by FACS or by plastic adherence and 
used for subsequent gene expression analysis and functional in vitro assays. The 
remaining bone fragments were used for RNA isolation and gene expression analysis. 
For histological assessment bone samples were EDTA-decalcified and embedded in 
paraffin before the staining procedures. 
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2.3 Cell culture  
2.3.1 Determination of cell number and viability  
The number of viable nucleated cells released by enzymatic digestion was determined 
using the trypan blue exclusion method using a haemocytometer with a Neubauer 
counting chamber and an inverted light microscope. 
The cell suspension to be counted was prepared at the appropriate dilution in DMEM and 
subsequently diluted 1:1 in Trypan blue solution (Sigma) for counting. Approximately 10 
µl of the mixture was transferred by capillary action to the haemocytometer and viewed 
under a bright field microscope at 10x magnification. The method is described in Figure 
2.2 and is based on the observation that viable cells exclude the dye and non-viable cells 
stain blue due to a breakdown in cell membrane integrity. Viable cells were counted on 
four 1mm2 squares which were then averaged. In order to maintain accuracy, a minimum 
number of 100 cells were counted. Where the cell number was difficult to count, the 
procedure was repeated following appropriate dilution of cell suspension.  
The number of viable cells/ml in the cell suspension were determined using the formula 
below. In brief, the average cell count of the four large squares was multiplied by 104 and 
then multiplied again by the dilution factor (e.g. multiplied by two if cell : dye ratio is 
1:1). The total number of viable cells represents the value of cells/ml in the original cell 
suspension multiplied by total volume.  
𝑁𝑜. 𝑜𝑓	𝑛𝑢𝑐𝑙𝑒𝑎𝑡𝑒𝑑𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 = 𝑁𝑜. 𝑜𝑓	𝑐𝑒𝑙𝑙𝑠	𝑐𝑜𝑢𝑛𝑡𝑒𝑑	𝑥	106𝑥	𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛	𝑓𝑎𝑐𝑡𝑜𝑟	 
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Figure 2.2. Manual cell counting using trypan blue exclusion method. The cells were 
diluted 1:1 using trypan blue and placed in the counting chamber. Live cells with intact 
membrane exclude the dye (empty symbols) while dead cells stain blue (blue symbols). 




2.3.2 MSCs Isolation by plastic adherence and culture expansion 
Cultures were initiated by plating a known number of nucleated cells from the 
enzymatically released cell suspension. Specifically, 106 cells as manually counted by 
Trypan Blue exclusion method were plated directly in 7 ml of Stem MACS MSC 
expansion media (Miltenyi Biotec) in T25 flasks and incubated at 37º C, 5% CO2. Cells 
were allowed to attach for 48 hours and at this time-point non-adherent cells were 
removed by washing with 5 ml PBS and replacing the medium. These cells were 
expanded until sub-confluence, i.e.  the cells just started to touch each other (~70% 
confluence), denoted as passage 0 (P0) and then passaged.  
Passaging the MSCs was performed by removing the media and washing the cells with 
PBS before detaching them from the plastic surface using Trypsin solution (Appendix 1). 
Trypsin is a proteolytic enzyme of serine protease family with optimum activity at 37º C. 
The exact mechanism involves cutting away the focal adhesions, which anchor the cells 
onto the culture dish, at the C-termini side of Lysine or Arginine. Cell detachment was 
assessed under an inverted phase-contrast microscope following 2-3-minute incubation 
with 1 ml of Trypsin solution. The trypsin containing the detached cells along with any 
residual cells from the flask were collected with 8 ml of DMEM and centrifuged at room 
temperature for 5 minutes at 300xg. The supernatant was discarded and the cell pellet 
disrupted and resuspended in 1 ml of DMEM. The number of cells at each passage were 
determined by Trypan Blue exclusion method and an appropriate cell solution volume 
was transferred in T25 flasks corresponding to a cell density of 104 cells/cm2 (i.e. 2.5x105 
cells/flask) for all subsequent passages up to passage 4 (P4). At this point they were lysed 
for RNA isolation from each flask while the remaining cells were frozen for future use as 
described in Section 2.3.3. 
2.3.3 Cryopreservation and thawing cells 
Cryopreservation of cells following tissue processing is a common technique used for 
long term storage. The solution of mixed, uncultured cells released following enzymatic 
treatment of bone was centrifuged at 300xg for 5 minutes and resuspended in an 
appropriate amount of freezing media containing 45% DMEM/1% P/S, 45% FCS and 
10% Dimethyl sulfoxide (DMSO, Sigma) at 107 cells/ml. Cell suspension was then 
transferred in 1 ml aliquots into each 1.8ml labelled cryovials and then rapidly placed into 
an isopropanol based freezing container (Mr. Frosty, Nalgene) and kept at -80° C 
overnight for slow freezing (rate of approximately 1º C per minute). The vials were 
subsequently transferred to liquid nitrogen for long term storage.  
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The culture-expanded MSCs (cMSCs) remaining following passaging and at the end of 
culture-expansion experiments were also frozen and stored for further use. The 
cryopreservation of cMSCs was performed following the same method and freezing 
media using 106 cells/ml aliquots or less per cryovial.  
Frozen and thawed enzymatically-released cells were used during the project in some 
experiments for cell sorting (Section 2.4), MSC culture expansion (Section 2.3) or CFU-
F assays (Chapter 3, Section 3.3.3). Frozen cryovials were thawed at 37° C in a water 
bath until no ice-crystals were visible. The cells were then transferred using a sterile 
pastette to a 15 ml tube and resuspended in DMEM/10% FCS/1% P/S which was added 
to the cells drop-wise up to a total volume of 10 ml with gentle mixing every time. To 
reduce cell clumping, especially for the vials containing uncultured cells, the 
DMEM/10% FCS/1% P/S was prior supplemented with DNase I (20 U/ml, Sigma). In 
order to remove the DMSO used for cryopreservation, the cells were centrifuged at 300xg 
for 10 minutes at room temperature and resuspended in an appropriate amount of 
DMEM/10% FCS/1% P/S. After counting, the cells were seeded in T25 culture flasks, 
placed in a humidified incubator at 37º C and 5% CO2 at cell densities specified in 
corresponding sections and grown in Stem MACS media until the cells reached 
confluence. 
2.4 Native MSCs purification by FACS 
Fluorescence activated cell sorting (FACS) was used in experiments presented in Chapter 
3 to enumerate the native MSCs frequency in the enzymatically released cells from 
healthy and OA bone and to isolate pure MSC populations for gene expression analysis. 
For experiments described in Chapter 5 FACS was employed to enumerate and isolate 
pure native MSCs subpopulations for culture-expansion (Chapter 5, Section 5.3.5) and 
gene expression analysis (Chapter 5, Section 5.3.6). Specifically, in Chapter 3 the MSCs 
were selected based on the CD45-CD271+ phenotype (Jones et al., 2010) (Chapter 1, 
Section 1.3.2) while in Chapter 5 the CD45-CD271+ MSC population was segregated 
into distinct subsets based on the expression of CD146 (Tormin et al., 2011) and CD56 
(Battula et al., 2009; Sivasubramaniyan et al., 2018) (Chapter 1.3.2). Details of each of 
these experiments are provided in the Materials and Methods section of each chapter. 
By using FACS various cell properties are simultaneously analysed, such as cell size 
(forward scatter, FSC) and granularity (side scatter, SSC). This can be combined with the 
detection of surface markers labelled with different fluorescent dyes which emit at certain 
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wavelengths. When light from a laser interrogates a cell, that cell scatters light in all 
directions (Figure 2.3A). The light that is diffracted in the forward direction (i.e. along 
the same axis the laser is travelling) is detected in the Forward Scatter Chanel. The 
intensity of this signal has been attributed to cell size. Laser light that is scattered at 90º 
to the axis of the laser path is detected in the Side Scatter Channel when there is a change 
in the refractive index. The intensity of this signal is proportional to the amount of 
cytosolic structure in the cell, such as granularity. As the fluorescent molecule present in 
or on the antibody bound to the cell is interrogated by the laser light, it will absorb energy 
from the laser light and release the absorbed energy at a longer wave length. The emitted 
light passes through the optical filters and is detected by photodetectors, converted to 
electrical impulses which are then digitalised and quantified.  
The BD Influx 6 flow cytometer (BD Bioscience) used in this project is equipped with 
four lasers at 355 nm (ultra-violet), 405 nm (violet), 488 nm (blue), 561 nm 
(green/yellow) and 633 nm (red) complemented by fluorescence detectors that can detect 
a total of 19 colour parameters from all lasers. Therefore, the fluorochromes chosen for 
the four antibodies in this project (CD271-APC, CD45-FITC, CD56-BV421 and CD146-
PE) spanned across the spectrum and minimised the cross-over, as depicted in Figure 
2.3B. Any spill-over (e.g. from FITC to PE) was corrected as detailed in Section 2.4.2. 
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Figure 2.3. Light scattering and fluorochromes spectrum in flow cytometry. (A) 
Determination of cell size and granularity by using the Forward Side Scatter (FCS) and 
Side Scatter (SSC). (B) Spectrum chart indicating the four fluorochrome for the 
antibodies used in sorting experiments as well as the filters (coloured rectangles) used 
for their detection in the corresponding channel. Dotted lines represent the excitation 
wave length while their emission is in full colour. 
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2.4.1 Staining cells for cell sorting 
Data in Chapter 3 include MSCs purification using the CD45-CD271+ phenotype (Jones 
et al., 2010) while in Chapter 5, this population was further divided by using antibodies 
for CD56 (Battula et al., 2009; Sivasubramaniyan et al., 2018) and CD146 (Tormin et al., 
2011). As previously discussed in Chapter 1, Section 1.3 and detailed in Chapter 3, 
CD271 is the most common surface marker used for native MSCs isolation from the BM 
(Quirici et al., 2002; Bühring et al., 2009; Jones et al., 2010). Within this population of 
MSCs previous studies revealed the existence of distinct subsets based on the surface 
marker expression of CD146 (Tormin et al., 2011) and CD56 (Battula et al., 2009), as 
described in Chapter 1, Section 1.3 and Chapter 5, Section 5.1.3. In this thesis, the MSCs 
were isolated by using antibody for CD271 while the haematopoietic lineage cells (HLCs) 
were identified by using antibody for CD45, the most commonly used haematopoietic 
lineage marker (Shivtiel et al., 2008). A standard experimental arrangement and 
distribution of staining tubes for cell sorting calibration, the isotype controls as well as 
the antibody cocktails used in this thesis are detailed in Table 2.1. 
Fluorescence compensation settings were optimised by using anti-mouse Ig κ/negative 
control CompBeads (BD Biosciences). The set contains both positive and negative 
microparticles which were mixed with the same conjugated antibodies used in the 
experiment providing an accurate compensation correction for spectral overlap for any 
combination of fluorochrome-labelled antibodies. The positive beads population binds to 
all isotypes conjugates of the specific immunoglobulin while the negative beads have no 
binding capacity. For example, as shown in Figure 2.3B, an antibody conjugated with 
FITC may emit light which crosses over with the light emitted by another antibody 
conjugated with PE, therefore light from FITC spills over into the channel for PE and 
vice-versa. This crossover can be compensated by using single colours compensation 
beads. Therefore, each conjugate needs to be tested in every channel and the spill-over 
subtracted from the channels other than its own. This was performed by flow cytometry 
staff members as part of instrument calibration prior to each sorting experiment. 
Unstained cells and IgG1 isotype controls (Table 2.1) were used in each experiment to 
determine cells auto-fluorescence and non-specific background staining as described in 
each chapter and position the gate for each cell population investigated.  
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CD271 APC 595 nm/660 nm ME20.4-1.H4 Miltenyi Biotec 
CD45 FITC 488 nm/530 nm T29/33 DAKO 
CD56 BV-421 405 nm/421 nm HCD56 Biolegend 
CD146 PE 488 nm/580 nm P1H12 Miltenyi Biotec 
Isotype control APC 595 nm/660 nm X40 Miltenyi Biotec 
Isotype control FITC 488 nm/530 nm MCA928F BioRad 
Isotype control BV-421 405 nm/421 nm MOPC-21 Biolegend 
Isotype control PE 488 nm/580 nm MCA1210 BioRad 
2.4.1.1 Sample staining 
Depending on the cellularity of each sample, form the enzymatically released cell 
suspension, approximately 1.5-3x106 cells were resuspended in each staining tube in 100 
µl of FACS buffer (Appendix 1) and incubated in a 10% Fc receptor blocking solution 
(Appendix 1) for 10 minutes at room temperature before the fluorophore-conjugated 
antibodies were added. Blocking step is required to inhibit non-specific binding and 
reduce background fluorescence. The cells were incubated with the conjugated antibodies 
for 20 minutes at room temperature, washed in FACS buffer and centrifuged for 5 minutes 
at 300xg. Cells were re-suspended in 500 µl FACS buffer, filtered through a 72 µm cell 
strainer cap (Corning Falcon) into a fresh tube to remove any remaining bone debris or 
cell clumps. To exclude the dead cells, 10 µl 7-amino-actinomycin (7-AAD) (Miltenyi 
Biotec) was added before the cell sorting procedure. Similar to trypan blue, 7-AAD only 
penetrates the disrupted membrane then binds to DNA and can be fluorescently detected 
in dead cells. 
2.4.1.2 Controls and compensation beads staining 
Compensation beads and isotype controls were stained simultaneously with the sample 
sorting tube. Approximately 200,000 cells were used in the isotype control tubes which 
were stained using 10 µl of each isotype control of the same species as the conjugated 
antibodies (all IgG1) and the corresponding fluorochrome. The unstained tubes contained 
the same number of cells as the isotype controls and were subjected to the same 
treatments, without the addition of antibodies. The compensation beads were first 
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vortexed and one drop of each was added to 100 µl FACS buffer in separate FACS tubes 
corresponding to each antibody. Then the conjugated antibodies (10 µl each) were added 
to the beads, one antibody in each tube, and incubated for 15 minutes at room temperature 
in the dark. The stained beads together with the sample and controls were then washed 
with 1 ml of FACS buffer, centrifuged at 300xg for 5 minutes and resuspended in 500 µl 
of FACS buffer before being analysed. 
Table 2.2. Standard list of tubes used for FACS experiments 


































Comp Beads 10 µl CD45 





Comp Beads 10 µl CD146* 
Comp Beads (no cells) 1 
Drop each 
6 CD271 Comp Beads 10 µl CD271 
Comp Beads (no cells) 1 
Drop each 
7 CD56 
Comp Beads 10 µl CD56* 
Comp Beads (no cells) 1 
Drop each 
* only used for FACS experiments in Chapter 5 
 
2.4.2 Data acquisition and analysis of MSC frequencies 
The acquisition of all tubes, compensation and instrument settings were performed by 
staff members of flow cytometry facility. The voltages for FSC and SSC were kept the 
same for every experiment, as changing the voltages would result in altered profiles 
making consistent gating more difficult. Data was acquired on the BD Influx flow 
cytometer and the raw data files were analysed using the FlowJo Software (Tree Star).  
Several steps were taken in order to guarantee a pure MSC population and accurate 
selection of the positive cells. The stained beads were run first and compensation was 
altered for each channel prior to sorting of cells from the samples. Hence, spectral 
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compensation was first performed by using the CompBeads as described above, by 
recording 10,000 events form each positive controls of the conjugated antibody. 
Similarly, 10,000 events from the isotype controls were then acquired for each antibody 
using cells from the sample under investigation in order to set the correct gates for the 
desired populations.  Next, the FSC and SSC voltages were set up by using unstained 
cells from the sample to be analysed. This would allow separation of contaminating small 
bone debris and other impurities, such as collagen or DNA, following the digestion 
procedure (Figure 2.1). To the unstained cells was then added 10 µl 7-AAD in order to 
separate the dead cells from viable cells on the red channel (Figure 2.4). In all experiments 
the cells were gated sequentially, first by using the FSC and SSC to eliminate debris and 
then the negative 7-AAD fraction was excluded to keep live cells only (Figure 2.4). As 
shown in Figure 2.4 physical gates were then created by selecting cells positive for 
CD271, comprising the MSC population, while the CD45 was used for HLCs selection, 
serving as control population for MSCs in subsequent gene expression experiments. In 
general, an average of 4x104 MSC events (range 1x104-2.8x105 events) and 4x105 HLC 
events (range 1.6x104-2.3x106 events) were collected after sorting. The cell sorting 
procedure, including calibration was usually performed within 2-4 hours, depending on 
the number of samples analysed for the experiment. 
The analysis of MSC frequencies was performed by calculating the percentage of gated 
CD271 positive cells from the total of the gated live cells based on the total number of 
events acquired (Figure 2.4). Similarly, the subsequent MSC subsets were calculated as 
percentage of CD56, CD146- positive as well as the double negative cells of the gated 
CD271+ fraction, as depicted in Figure 2.4. 
The purified sorted MSCs populations and control HLCs were collected directly into 100 
µl of RNA lysis buffer (Norgen Biotek) and stored at -80º C for subsequent RNA isolation 
as detailed in Chapter 3 while the CD271+ MSC subsets where collected for both gene 
expression and culture-expansion, as detailed in Chapter 5, Section 5.3.5. 
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Figure 2.4. Gating strategy for MSCs enumeration and sorting. Viable cells were 
identified using FSC and SSC then the live cells were selected using 7AAD. Isotype 
controls for each antibody conjugate were used to select positive populations while HLCs 
were defined using CD45. For further purification within the CD45-CD271+ gate, cells 
were selected for CD56+ and CD146+.  
 68 
2.5 Gene Expression 
2.5.1 RNA isolation 
Before RNA isolation the working surface and pipettes were wiped with RNase Away 
(Fisher Scientific) to remove any traces of RNase’s. RNase free pipette tips and 
microcentrifuge tubes were used for all the steps during the isolation procedures in order 
to avoid RNA degradation or contamination. 
The RNA isolation from osteocyte-enriched bone fragments is described in detail in 
Chapter 4, Section 4.3.3. In brief, the RNA was isolated using an adaptation of the 
methods of Chomczynski and Sacchi (Chomczynski and Sacchi, 1987) using chloroform 
extraction and isopropanol precipitation of RNA. For RNA isolation from culture-
expanded cells or cell isolated by FACS, a column-based method was employed by using 
RNA isolation kits (all from Norgen Biotek) and following the manufacturer’s protocol. 
The procedure is based on a column resin as the separation matrix for the RNA and a 
high-salt buffer system with guanidine salt which allows the RNA to be preferentially 
purified from other cellular components and contaminants based on its electrical charge 
within a spin column. Firstly, the cells were lysed with the lysis buffer provided by the 
kit supplemented fresh before each procedure with 1% b-mercaptoethanol (Sigma). This 
ensured the denaturation of RNases by reducing disulphide bonds and destroying the 
native conformation required for enzyme functionality. In combination with the strong, 
but temporary denaturing effects of guanidinium salts in lysis buffer any RNases present 
in the material to be extracted from will be completely inactivated, thus extending the life 
of the stored RNA. 
As stated in Section 2.4, the cells isolated by FACS were sorted straight into 100 µl of 
RNA lysis buffer and vortexed for homogenisation before the RNA isolation procedure, 
while the cultured MSCs were lysed directly into the flask. For this, the culture media 
was removed and the cells were thoroughly washed with PBS (3 times), which was 
carefully removed using a pipette to prevent RNA lysis buffer dilution. Then 500 µl RNA 
lysis buffer was applied to the cell layer and collected by aspiration with a pipette 
following scraping the flask bottom using a sterile cell scraper (Corning). The collected 
lysate was stored at -80º C for subsequent RNA isolation.  
The lysate was mixed with an equal volume of 95% ethanol (diluted in DEPC water) and 
then up to 600 µl of the mixture was applied to the column, in several steps if necessary. 
The samples were all treated with DNase-1 solution (Norgen Biotek) for 15 minutes at 
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room temperature, before the washing steps. Following 1-minute centrifugation at 
13000xg, the RNA was retained onto the column while the remaining impurities were 
washed twice with 400 µl of the provided washing buffer. Purified RNA was then eluted 
in an appropriate volume of nuclease free water or elution solution provided by the kit.  
The concentration and purity of RNA was assessed using the Nanodrop ND-1000 
spectrophotometer and 2 µl of RNA per reading. Spectrophotometric analysis is based on 
the principles that nucleic acids absorb ultraviolet light in a specific pattern. In the case 
of DNA and RNA, a sample is exposed to ultraviolet light at a wavelength of 260 nm and 
a photo-detector measures the light that passes through the sample. Some of the ultraviolet 
light will pass through and some will be absorbed by the DNA/RNA. An optical density 
(OD) 260:280 ratio between 1.9 and 2.2 were used as a measure of pure RNA to be used 
for the gene expression experiments described in this project. 
2.5.2 cDNA synthesis 
The RNA was converted into cDNA by using a High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). To synthesize the cDNA, a reaction mix was 
made up as described in Table 3. The reaction mix comprising the appropriate amount of 
10X Random primers, 100 mM dNTP mix, 10X RT buffer, MultiScribe reverse 
transcriptase and RNase inhibitor was then mixed with the appropriate amount of total 
RNA depending on the requirements for the downstream applications (e.g. qPCR). In 
order to have an equal starting material for qPCR reactions and therefore judge accurately 
the gene expression levels investigated, the RNA volume was normalised for every 
reaction depending on the amount of cDNA product required.  
Table 2.3. Reaction components for cDNA synthesis 
Component Volume for 1 reaction 
10X Random primers 2 µl 
100 mM dNTP mix 0.8µl 
10X RT buffer 2 µl 
MultiScribe reverse transcriptase 1 µl 
RNase inhibitor 1 µl 
Total reaction master mix 10 µl 
+  
Total RNA 10 µl 
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The volume was adjusted to 20 µl with nuclease-free water (Nalgene) in clean 0.2 ml 
tubes and PCR reaction performed by incubation of the samples in a Techne TC512 
thermal cycler (Geneflow) using the following cycling conditions (Table 4): 25° C for 10 
minutes to initiate the reaction then hold for 2 hours at 37°C; the reaction was terminated 
by incubation at 85° C for 5 minutes. Samples were kept frozen until use at -20° C. 
Table 2.4. Thermal cycling conditions for cDNA synthesis 
Settings Step 1 Step 2 Step 3 Step 4 
Temperature 25° C 37°C 85° C 4º C 
Time 10 minutes 120 minutes 5 minutes ¥ (up to 5 hours) 
 
2.5.3 qPCR reactions 
Quantitative real-time polymerase chain reaction (qPCR) was performed using TaqMan 
reagents to evaluate the gene expression profiles of osteocytes and MSCs in this thesis. 
The TaqMan assays for the genes of interest are detailed in Appendix 5, all from Thermo 
Fisher and specified in the Methods section of each chapter.  
This technique has a high degree of sensitivity and specificity, being commonly used for 
gene expression evaluation experiments. The detection system used by TaqMan involves 
dual labelled probe, with a fluorophore attached at the 5’ of the oligonucleotide and a 
quencher at the 3’ end (Figure 2.5). The juxtaposition of the fluorophore and quencher 
inhibits the fluorescence under the light excitation during cycling and therefore its 
detection. During the exponential stages of PCR, each target sequence is amplified by the 
Taq polymerase resulting in probe displacement and therefore the fluorescent signal can 
be detected and quantified in real time. The emitted fluorescence correlates with the 
cDNA template in the reaction and therefore can be quantified.  
The qPCR was performed in 10 µl reactions on a 384 plate all in triplicate during each 
experiment. The reactions mix was prepared by adding 5µl of TaqMan gene expression 
master mix (Applied Biosystems), 0.5µl of TaqMan gene expression assay (Thermo 
Fisher) and a total of 4.5 µl mix of cDNA in nuclease free water resulted from the cDNA 
reaction. Additionally, a number of controls were also used, as follows: no template 
control was also used to assess the presence of any contamination or false positive results 
by omitting the cDNA in the reaction mix and no reverse transcription control was used 
to confirm the absence of genomic DNA contamination by simply omitting the reverse 
transcriptase during cDNA preparation.  
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Figure 2.5. Schematic diagram of the TaqMan mechanisms in qPCR. 1. At the start of 
qPCR, the temperature is raised to denature the double-stranded cDNA. During this step, 
the signal from the fluorescent dye on the 5' end of the TaqMan probe is quenched on the 
3' end. 2. The reaction temperature is lowered to allow the primers and probe to anneal 
to their specific target sequences. 3. Taq DNA polymerase synthesizes new strands using 
the unlabelled primers and the template. When the polymerase reaches a TaqMan probe, 
its endogenous 5' nuclease activity cleaves the probe, separating the dye from the 
quencher. Adapted from Thermo Fisher. 
Table 2.5. Reaction components for qPCR  
Component Volume for 1 
reaction 
Volume for 1 
port 
TaqMan Gene Expression Master Mix (2X) 5 µl N/A 
TaqMan Gene Expression Assay (20X) 0.5 µl 50 µl 
cDNA template + H2O 4.5 µl 50 µl 





Some of the gene expression analysis in Chapter 3 and Chapter 5 was performed using a 
TaqMan Low Density Array (TLDA) card in a 96a format (Figure 2.6). The TaqMan 
probes for TLDA as well as for all the other experiments were designed to cover most of 
the isoforms commonly expressed and also using exon spanning wherever possible in 
order to avoid gDNA amplification, the full list of transcripts presented in Appendix 5. 
This micro fluidic technology utilizes eight sample-loading ports, each connected to 48 
reaction chambers pre-loaded by the manufacturer with the specified probes. The reaction 
mix for each port contained 50 µl of cDNA and nuclease free water mix, containing a 
total amount of 200 ng of cDNA, and 50 µl of TaqMan Gene expression Master Mix, 
hence a 100 µl reaction mix per port. Following loading all the ports the card was 
centrifuged to dispense the cDNA samples to the reaction wells and then sealed and the 
ports trimmed using a scissors (Figure 2.6). The card was then loaded and data acquisition 
was similar to regular qPCR on the QuantStudio™ 7 Flex Real-Time PCR System 
(Applied Biosystems) using the same cycling conditions as used for all the experiments 
but with a block specifically designed for TLDA cards.  
Data for normal qPCR and TLDA cards was acquired using ABI PRISM 7900HT SDS 
or QuantStudio™ 7 Flex Real-Time PCR System and SDS Software. Thermal cycling 
conditions (Table 8) used for qPCR comprised of initial steps of 2 minutes at 50º C and 
then 10 minutes at 95º C followed by 40 amplification cycles of 10 secs at 95º C and 1 
min at 60º C. The fluorescence of the double stranded products was recorded in real time 
and the results obtained using the SDS Software (Applied Biosystems). A standard curve 
was previously constructed with serial dilutions of cDNA from a few samples.  









Temperature 50° C 95°C 95° C 60º C 




Figure 2.6. Experimental setup for gene expression analysis using TLDA. The ports 
were first loaded with 100 µl of cDNA and TaqMan Master Mix then centrifuged to 
dispense the mix into each well. The wells were sealed using a sealer and the ports were 
trimmed off. qPCR was performed on a QuantStudio™ 7 Flex system. 
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2.5.4 qPCR data analysis 
The qPCR analysis relies on the Ct values (threshold cycle) values resulted following the 
qPCR run. These values were determined by the cycle number where the fluorescence 
produced by the amplified product accumulating exponentially over a defined threshold. 
The increase in the Ct value is inversely proportional to the amount of starting cDNA 
material, i.e. the lower the Ct value the higher the initial amount of cDNA.  
In order to present the qPCR data as individual data points it was recommended to be 
presented as 2-DCt rather than the raw Ct values (Livak and Schmittgen, 2001). When 
presenting the data from gene expression experiments, it is also recommended to 
normalize the values to an internal control to exclude variations arising from different 
inputs of total mRNA to the reaction (Schmittgen and Livak, 2008). Data in this project 
was therefore normalised to the reference gene hypoxanthine phosphoribosyltransferase 
1 (HPRT1). The choice of reference gene had been previously determined and optimised 
by Dr. Sarah Churchman from previous published work (Churchman et al., 2012) 
following a screening of approximately 30 endogenous control genes, establishing 
therefore HPRT1 as the most reliable transcript to use in MSCs related work. While 
GAPDH for example may be an excellent gene stably expressed at much higher levels 
across most of the cell types in comparison to HPRT1, the majority of the genes 
investigated in this project have a general low expression level (Ct values above 25), 
similar to HPRT1 (Churchman et al., 2012). Together with the presumably low amount 
of starting genetic material obtained from sorted cells, HPRT1 has been shown to be an 
appropriate endogenous control.  
Therefore, to determine the relative expression of the genes of interest, following 
normalisation to HPRT1, data analysis was carried out and presented by the well-
established 2-∆Ct method (Schmittgen and Livak, 2008). Since all the reactions for all 
samples were performed in triplicate, the resulted values obtained from each reaction 
were averaged and used for subsequent calculations. Then normalisation (ΔCt) was 
calculated as: ΔCt = (Ct	gene	of	interest	 − 	Ct	endogenous	control) 




2.6.1 Tissue preparation for histological analysis 
2.6.1.1 Fixation 
Prior de-calcification it is particularly important to thoroughly fix the specimens in order 
to stop autolysis and thereby preserving tissue integrity, poorly-fixed bone specimens 
become macerated during decalcification affecting the downstream histological analysis 
(Skinner et al., 1997; Callis and Sterchi, 1998). Bone fragments and whole femoral heads 
were processed for histologic analysis before and after collagenase digest. All bone 
samples were washed twice with PBS and immediately fixed in 10% neutral buffered 
formalin (Sigma). Some samples were cut in smaller pieces and agitated daily for better 
penetration of the fixative agent. Depending on sample size, the fixation was performed 
at room temperature between 24 hours for <1g iliac crest samples and up to 2 weeks for 
whole femoral heads in at least 20X volume of the tissue (Figure 2.8). Following fixation, 
the fixative was removed and disposed safely using the appropriate paraformaldehyde 
disposal bottles in the fume hood. All bone samples were washed three times with PBS 
before starting the decalcification procedure.  
2.6.1.2 Decalcification 
As mineralized bone is such a hard material, decalcification of the samples was performed 
to remove the mineral content so that good-quality paraffin sections can be prepared that 
will preserve all the microscopic elements, i.e. the highly cellular BM and complex 
trabecular structure. In order to protect the cellular and fibrous elements of bone from 
damage caused by the acids used in common decalcifying agents, such as formic acid, 
slow de-calcification with ethylenediaminetetracetic acid (EDTA) was used. The 
decalcification process is slow but gentle, causing little tissue damage (Callis and Sterchi, 
1998) as compared to other methods for which stronger acids are required. Conventional 
stains are largely unaffected by EDTA calcification. Decalcification by using EDTA is 
pH dependent and is achieved by chelating calcium from the bone mineral i.e. dissolution 
of the bone hydroxyapatite complex, and can be represented by the following equation: 
Ca10(PO4)6(OH)2 + 8H Û 10 Ca++ + 6PO4-- + 2H2O (Skinner et al., 1997). 	 
Following fixation, the samples were washed twice in PBS and then placed in 14% EDTA 
solution (pH 7.4, Appendix 1) for decalcification. Since EDTA progressively dissolves 
and moves calcium from the organic matrix into the surrounding liquid, the solution was 
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changed every week until decalcification was complete as confirmed by radiographic 
analysis.  
Where whole femoral heads were used for histology, after 2-3 months when the 
decalcification process has penetrated more than half of the femoral head, the tissue was 
cut in half or quarters by using a general used histopathology knife in order to allow full 
penetration of EDTA (Figure 2.7). 
It is important to determine the point at which all the calcium has been removed, because, 
from this point on, tissue damage seems to occur at an increasing rate. Over-
decalcification may cause maceration of the softer tissue elements. On the other hand, 
specimens that are incompletely decalcified may be difficult or impossible to section. The 
method chosen for this study was to X-ray the specimens wherein transparency suggested 
complete decalcification. Bone specimens were scanned weekly to verify the stage of 
decalcification and decide whether further treatment was required (Figure 2.8). The x-ray 
machine used for this purpose was CS2200 (Carestream Health) with an exposure time 
of 0.113s at 70kV. The images were captured on standard dental films which were read 
on the automated unit with its corresponding installed software.  
2.6.1.3 Paraffin embedding and Sectioning 
Following decalcification, the samples were embedded in paraffin wax to offer support 
to the tissue for sectioning. Decalcified bone tissues were placed in plastic cassettes 
(Figure 2.9A) and processed for paraffin embedding using an overnight programme from 
neutral buffered formalin (10 % for 30 minutes) through graded ethanol (70% for 1 hour; 
90% for 1 hour; 95%, for 1 hour; 100%, for 1 hour; 100%, for 2 hours; 100% for 2.5 
hours) to xylene (3 buckets; 1 hour, 1 hour, 1.5 hour) to molten paraffin wax (2 buckets; 
4 hours and 5 hours). Embedding in paraffin blocks took place in a Leica embedding 
centre using a hot paraffin dispenser and hot plate (Leica) (Figure 2.9B). Molten wax was 
poured into the plastic cassettes containing the tissue which were orientated to provide a 
transversal section of the whole femoral head. Wax then hardens within the plastic 
cassettes and makes up the finished block (Figure 2.9C), allowing blocks to be easily cut.  
Tissue blocks were sectioned using a Leica RM2235 microtome (Leica Microsystems) 
fitted with a S+ type blade (CellPath). The blocks were initially trimmed by cutting serial 
10 µm sections until tissue was fully exposed. Sections of 5 µm thickness were then cut, 
producing a string of serial slices joined together (Figure 2.9D). The strings, also called 
“ribbons”, were allowed to stretch and smooth out creases in a 45º C water bath and then 
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lifted out onto SuperFrost Plus glass slides. Residual water was dried from the slides in a 
37º C incubator overnight.  
  
Figure 2.7. Sample preparation for fixation, decalcification and embedding. Whole 
femoral head was fixed in PFA and partially decalcified. Then the femoral head was cut 
in half for complete EDTA penetration and decalcified completely.  
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Figure 2.8. X-ray images showing gradual mineral removal by EDTA. The images were 
captured monthly on standard dental films and read on the automated unit. Gradual loss 




Figure 2.9. Paraffin embedding and sectioning of bone tissue for histology. The bone 
tissue was placed in a cassette (A) and processed overnight for paraffin embedding. Using 
a Leica hot plate dispenser, liquid hot paraffin was poured onto the tissue (B) and placed 
on a cold plate until the block solidified (C). Tissue sections were cut using a Leica 
microtome for histological analysis (D). 
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2.6.2 Haematoxylin and Eosin staining  
Slides were deparaffinised by allowing to stand on a hot plate at 70º C for 20 minutes and 
then cleared in Xylene in a fume hood. The tissue was then rehydrated by placing the 
slides through graded ethanol, from high to low concentrations: absolute ethanol (3x3 
minutes), 75% ethanol (1x3 minutes), 50% ethanol (1x3 minutes) and then into tap water 
for 2 minutes. Slides were then taken out of the fume hood and transferred to Harris 
Haematoxylin (Sigma) for 2 minutes after which they were cleared with tap water for 1 
minute. To perform the ‘blueing’ of the nuclei the slides were placed in Scott’s tap water 
(Appendix 1) for 2 minutes and washed in running tap water then immediately immersed 
in Eosin-Y (Appendix 1) solution for another 2 minutes. After washing in tap water for 1 
minute the slides were dehydrated by immersing in absolute ethanol four times for 2 
minutes each and then cleared in Xylene. The slides were then mounted with DPX 
medium (Sigma) and dried at room temperature before visualizing under light 
microscope.  
2.6.3 Immunohistochemistry 
For immunohistochemistry staining the Dako Envision Detection System 
(Peroxidase/DAB, Rabbit/Mouse) (Dako) kit was used according to the manufacturer 
instructions. The slides were first dewaxed and rehydrated similarly to H&E method. 
Next, hydrophobic round circles were drawn around the tissue using a PAP pen (Abcam) 
in order to designate the staining area and preventing reagents spill. The endogenous 
peroxidase activity was blocked by 5 minutes incubation with dual enzyme blocking 
solution (Dako kit) and the slides were then washed in tris buffered saline (TBS, 
Appendix 1) twice, for 1 minute and 5 minutes respectively. The non-specific binding 
was blocked using Antibody diluent (Dako) during 30 minutes incubation at room 
temperature in a humidified chamber. After washing the slides twice in TBS as before, 
the primary antibody was applied. The primary antibody had been previously diluted in 
Antibody diluent (Dako) at the appropriate dilution as described in each chapter and as 
previously determined by performing an antibody titre. Approximately 200 µl (enough to 
cover the tissue) was applied on the slide and incubated at room temperature for 1 hour. 
Slides were then washed twice in TBS to remove residual antibodies and incubated with 
the secondary reagent, Labelled polymer-HRP (Dako kit) for 30 minutes at room 
temperature. After washing in TBS, the slides were incubated with DAB reagent for 10 
minutes at room temperature. Counterstaining was performed using Harris haematoxylin 
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(Sigma) with 2 minutes incubation followed by 1 minute in Scott’s tap water until blue 
developed. Slides were washed in tap water and then dehydrated and cleared in Xylene.  
2.6.4 Acquisition and initial image analysis 
Slides were scanned on Leica Aperio AT2 up to an original magnification of ×20 and 
images were captured using Aperio Imagescope software (Leica). For OA femoral heads, 
antibody staining was also analysed using Nuance Multispectral Imaging System (Caliper 
Life Sciences) in selected regions differing in a degree of OA pathology based on the 
gross appearance of bone and cartilage as detailed in Chapter 4, Section 4.3.6 and Chapter 
5, Section 5.3.2.  
The digital images were acquired under a Nikon Eclipse bright-field microscope equipped 
with CRi multispectral camera. The regions of interests (ROIs) in the IHC images with 
characteristic sclerotic and non-sclerotic bone were selected using the ×20 magnification. 
Each ROI containing the trabecular space and positive DAB staining was captured at x20. 
To minimize selection bias, 10 images per slide were randomly selected from the ROI. 
For each IHC staining section, a total of six spectral cubes containing the complete 
spectral information at 20 nm wavelength intervals from 420 to 720 nm were randomly 
obtained from different areas of the section by CRi Nuance multispectral imaging 
systems. As a result, 20 bright-field IHC images were captured including identical 720p 
RGB images and 720p MS images, and all saved in Tagged Image File Format (TIFF) 
with consistent resolution of 1360 × 1024 pixels for analysis. 
2.6.5 Quantitative image analysis 
After imaging acquisition, the software package within CRi Nuance multispectral 
imaging system was used for quantification of IHC-positive areas using standard spectral 
unmixing and processing methods. CRi Nuance multispectral imaging system is 
comprising the Nikon Eclipse microscope, an attached CRi multispectral camera for 
image acquisition and the software Nuance 2.8 which was used to build the spectral 
libraries.  
Spectral libraries contain spectral information which was extracted in both bright-field 
multispectral and red, green and blue (RGB), using images with a cube format (RGB 
images converted to Nuance specific cube format). Each chromogen has its unique 
spectral characteristics (curve), which is the basis for building the spectral library. The 
spectral characteristics (curve) for two chromogens (DAB and haematoxylin) in 
multispectral and RGB images were obtained by spectral unmixing. This spectral library 
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was built from the control slides, which was used to unmix the positive signals (DAB and 
haematoxylin) on each test slide by recognizing its unique spectral curves for 
quantification. Specific steps of CRi Nuance software have been previously described 
and briefed as the following: 1. Selection of targets for the specific antibodies used and 
background with different spectra; 2. Image un-mixing and elimination of background 
crosstalk: the target images with different spectra were automatically unmixed into DAB 
(molecular status) and haematoxylin component images by the software based on spectral 
library; and 3. Quantification of unmixed DAB component images. 
Antibody expression levels stained on IHC slide were best quantitated as total optical 
density (OD) values per unit of positive area in one view field. The final quantitative 
results of each marker were the average values of the 10 cube images. 
2.7 Statistics 
The statistical analyses were performed using Mann-Whitney test for comparisons 
between two groups while Wilcoxon test was used for comparison between 
paired/matched samples. For the intergroup differences, Kruskal-Wallis analysis was 
used corrected with the Bonferroni-Dunn for multiple-group comparison and Friedman 
test for the donor matched samples. The normality test could not be used in all cases given 
the low sample numbers and the values were assumed to come from a non-Gaussian 
distribution. Specific details of the statistical tests carried out for each data set are 
provided in each chapter. 
Results are presented as scatter dots plots with median lines or box and whisker plots, 
with boxes representing the upper and lower quartiles of the median, and whiskers 
representing the maximum and minimum values, calculated using GraphPad Prism 
version 7 software. Results were considered significantly different at p < 0.05 (with 
significance level denoted as *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.001). 
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Chapter 3 Native CD45-CD271+ MSCs in OA bone 
3.1 Introduction 
As a chronic, progressive and irreversible degenerative joint disease, OA affects millions 
of people in the UK and worldwide. Biomechanically abnormal joint loading resulting 
from obesity, joint instability, or trauma can affect the bone via progressive cartilage 
deterioration and subchondral bone remodelling (Martel-Pelletier et al., 2016). Although 
multiple risk factors including age, sex, obesity, genetics and joint trauma can likely 
contribute to the onset of OA, the cellular mechanism(s) underlying the disease are not 
clearly delineated. Given their high proliferative rates and ability for repair both bone and 
cartilage, mesenchymal stem cells have emerged as a theoretical therapy for OA in recent 
years. However, their roles in the pathology of human OA in vivo is still incompletely 
understood. Growing evidence indicate that MSCs may be implicated in OA, possibly by 
endogenous repair mechanisms or even in aberrant repair attempts such as the formation 
of osteophytes. 
3.1.1 Joint resident MSCs  
While knowledge of the BM resident MSCs has advanced significantly over the years in 
regards to their phenotypical characteristics and functional properties (Chapter 1, Section 
1.3.2), the same cannot be said about the MSCs in other joint tissues. The up-to-date body 
of evidence indicate the presence of heterogeneous cell populations in joint tissues that 
display MSC-like characteristics, although their specific phenotype has yet to be 
established  (McGonagle et al., 2017).  
3.1.1.1 Synovium MSCs 
The synovium consists of the synovial membrane which encapsulates the joint providing 
structural support and the synovial fluid for appropriate lubrication and nutrients essential 
for normal joint function (Smith, 2011).  
Topographically, synovium MSCs were shown to be residing in the synovial membrane 
that lines the spaces of diarthrodial joints as well as in the synovial fluid (De Bari et al., 
2001; Jones et al., 2004). Normal synovial fluid has been demonstrated to contain a 
resident MSC population (Jones et al., 2004) which was later demonstrated to increase 
during OA (Jones et al., 2008). Further investigation revealed that in comparison to 
normal joints, i.e. no obvious cartilage damage, the synovial membranes from OA 
patients also contained increased numbers of cells presenting an MSC phenotype, judged 
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by the expression of CD271, CD44 and CD90 (Hermida-Gómez et al., 2011). Evidence 
pertaining OA synovial MSCs documented the presence of different phenotypes of MSCs 
based on their topography, where CD55+ MSCs were found in the surface region, 
CD271-CD55- MSCs in the stromal region, and CD271+ MSCs in the perivascular region 
(Mizuno et al., 2018). However, these results need to be confirmed in healthy synovium 
but are in agreement with respect to the perivascular location of CD271+ MSCs in the 
BM (Tormin et al., 2011).  
3.1.1.2 Cartilage MSCs 
Studies reported the presence of a small population of MSC-like resident progenitors in 
the mature articular cartilage that are capable of differentiating into mature chondrocytes 
(Dowthwaite et al., 2004; Williams et al., 2010). Furthermore, it was shown that resident 
MSC-like progenitors had an increased frequency in OA cartilage (Fickert et al., 2004; 
Su et al., 2015) and diverged into two subpopulations, one of which exhibited an early 
senescent phenotype, which possibly reflects a replicative exhaustion following repeated 
but failed attempts at cartilage repair (Fellows et al., 2017). Recent evidence also 
implicate cartilage resident MSCs in cell clustering in OA cartilage, some of the clusters 
consisting entirely of cartilage resident MSC progenitors (Jayasuriya et al., 2018). This 
evidence confirms the presence of cartilage resident MSC progenitors and indicate their 
putative involvement in OA. Of note, since articular cartilage is an avascular tissue this 
evidence suggests that not all MSCs are perivascular.  
Recently OA has been accepted as a disease of the whole joint, eventually affecting every 
tissue component. With plenty of evidence to indicate that MSCs resident in other joint 
tissues are also affected (McGonagle et al., 2017), this knowledge would facilitate a better 
understanding of how the bone-resident MSCs are affected by OA. 
3.1.2 The current state-of-the art on native bone-resident MSCs in health 
and OA 
As stated previously, MSCs have been documented in almost all vascular postnatal organs 
(Crisan et al., 2008), but there are tissues which contain a higher frequency of MSCs than 
others. Typically, MSCs are isolated from BM taken from the iliac crest or the hip, but 
MSCs represent only a very small fraction of nucleated cells in the BM, between 0.001- 
0.01% (Jones and McGonagle, 2008). However, previous work in our laboratory 
demonstrated that cells extracted by enzymatic digestion of the bone fragments contained 
65-fold more CD271+ MSCs than BM aspirate, having the same cellular identity (Jones 
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et al., 2010). This indicated that not all bone resident MSCs can be released by BM 
aspirate and furthermore, it challenged the concept that MSCs were a rare population 
(McGonagle et al., 2017). In the enzymatically released fraction from OA femoral heads, 
the MSCs showed ageing-related loss of proliferation in vitro, but no gross osteogenic 
abnormalities (Jones et al., 2010). In a recent study, the MSC numbers were shown to be 
increased in areas of BML (Campbell et al., 2016) indicating a repair attempt of the bone 
resident MSC population, however the biology of native joint resident MSCs in vivo in 
OA is still incompletely understood. 
Using different extraction methods have also recently revealed more information 
regarding the CD271+ MSC population. It was shown that in comparison to aspiration, 
MSCs isolated by rasping the femoral shaft of OA donors released more CD271+CD56+ 
MSCs, these cells having an increased chondrogenic potential in vitro in comparison to 
CD271+CD56- MSCs (Sivasubramaniyan et al., 2018). This recent study further supports 
the idea of multiple distinct MSC subsets within the CD271 fraction as well as the 
importance of isolation method with respect to their downstream use and site of 
extraction. It further indicated that some MSCs may be preferentially located onto the 
bone surface in OA, however this was not yet tested using functional assays. 
As mentioned in Chapter 1, Section 1.3.2 the bone resident MSCs may play critical roles 
in mediating the coupling of bone resorption and formation. In an animal study it was 
shown that in response to osteoclastic bone resorption, MSCs migrate to the local site of 
repair, which is essential for coordinating bone remodelling (Zhang et al., 2009). 
However, in OA the bone remodelling process appears to be uncoupled. In a more recent 
OA animal study, in which anterior cruciate ligament transection was used to induce OA, 
nestin was employed as a surface marker to identify and track the MSCs. It was shown 
that MSCs accumulated and exhibited functional alterations in the joints affected by OA 
(Zhen et al., 2013). The high concentrations of TGF-β had been released from the 
subchondral bone during osteoclast-mediated bone resorption, facilitating MSCs 
recruitment and proliferation (Zhang et al., 2009).  
As mentioned in Chapter 1, Section 1.3.4, numerical and topographic alterations have 
been recently reported in hip OA resident MSCs, specifically in the lesioned areas of OA 
femoral head bone (Campbell et al., 2016). In this study Campbell et.al. showed that the 
CD271+ MSCs resident in OA femoral heads accumulate in higher numbers in the areas 
of BML in comparison to non-lesioned areas. Furthermore, the MSCs isolated from the 
BML areas exhibited functional and transcriptional alterations in vitro. The BML MSCs 
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showed a decreased proliferation and mineralisation capacity as well as altered 
transcriptional expression of RANKL and C-X-C chemokine receptor type 4 (CXCR4), 
encoding the receptor for C-X-C motif chemokine 12 (CXCL12) (Campbell et al., 2016). 
The CXCL12/CXCR4 signalling axis (Kitaori et al., 2009) has been regarded as a master 
regulator of stem cell migration and is essential in adult BM to maintain haematopoiesis 
(Sugiyama et al., 2006). It was shown to be expressed at high levels by CD271+ MSCs 
isolated from the BM (Churchman et al., 2012) and have important roles in stromal 
support of haematopoiesis (Greenbaum et al., 2013) and MSC migration to sites of injury 
(Kitaori et al., 2009). 
Overall, these studies so far provided evidence which point to a global increase in the 
numbers of MSCs in all OA-affected joint tissues, possibly as a repair attempt on behalf 
of the tissue-resident MSCs population. Furthermore, these data indicate potential 
functional alterations of MSCs in OA in addition to their increased numbers. 
3.1.3 Culture-expanded MSCs 
Over the past two decades the research in the field of MSCs has grown exponentially, 
with a substantial focus on culture expanded MSCs (Schäfer et al., 2016). This is due not 
only to their ease of isolation, manipulation and maintenance but also because of their 
rapid proliferation in culture which can provide a known number of cells for delivery in 
musculoskeletal regenerative therapies. However, compelling evidence showed that this 
results in functional deficits as well as immuno-phenotypical and transcriptional changes 
(Harichandan et al., 2012; Churchman et al., 2012). Using the CD271 phenotype to 
identify native BM MSCs, recent studies showed that culture-expanded BM MSCs are 
not functionally and transcriptionally equivalent to their in vivo counterparts, notably with 
regard to bone related signalling pathways (Churchman et al., 2012), adhesion receptors 
and signalling molecules (Qian et al., 2012), and homing capacity (Morikawa et al., 
2009). The “in vitro age” of MSC cultures was shown to detrimentally affect the 
proliferative and differentiation potential of the MSCs, eventually leading to culture 
senescence (Wagner et al., 2008).  
Culture-expanded BM MSCs are also characterised by a poor haematopoietic-support 
(Qian et al., 2012; Churchman et al., 2012) and were shown to lose their ability to migrate 
to the BM having been in culture (Rombouts and Ploemacher, 2003). In addition, 
expanded MSCs have a decreased multilineage differentiation potential (Pevsner-Fischer 
et al., 2011) and lose their self-renewal capacity. Cultured primary cells do not grow 
infinitely, but undergo only a limited number of cell division leading to cellular 
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senescence (Hayflick, 1965) and as somatic stem cells, MSCs are no exceptions 
(Digirolamo et al., 1999). Moreover, MSCs isolated from trabecular bone samples from 
patients with OA showed an in vitro ageing-related loss of proliferation (Jones et al., 
2010). 
Since their identification, native MSCs have been classified as a heterogeneous 
population when considering morphology and surface marker expression. However, 
ISCT criteria suggested that culture expanded MSCs are homogeneous (Dominici et al., 
2006) which emphasises the differences between native MSCs and culture-expanded cells 
defined by the ISCT. Adhesion molecules, extracellular matrix molecules, cytokines, 
growth factor receptors and antigens associated with numerous cell types are all 
associated with MSC cell interactions and functions (Bobis et al., 2006). For example, a 
variety of surface markers, such as CD44, are highly expressed on cultured cells, but not 
on native MSCs (Battula et al., 2009; Qian et al., 2012) and the expression of the native 
MSC marker CD271 is rapidly lost in culture (Tormin et al., 2011).  
Altogether, these changes have been so far shown using BM MSCs, and no other types 
of MSCs including MSCs enzymatically extracted from bone. While in vitro MSCs have 
been extensively characterised, the current state of affairs with regards to their native 
counterparts is still growing and more work is need to advance the knowledge in order to 
fully understand the natural properties of these cells. The majority of OA related 
alterations were observed in MSCs under cultured conditions. Therefore, to understand 
their role in OA-associated pathology it is important to investigate their native state in 
both OA and under normal, healthy conditions.  
Evidence pertaining the nature of bone-resident MSCs in vivo is currently scarce, 
however these studies provide some indication of changes that may occur in MSCs from 
OA affected bone. These may include loss of proliferation and changes in their 
mineralisation capacity (Campbell et al., 2016), but this has not been comprehensively 
investigated.  
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3.2 Chapter aims 
1. To compare the number of native MSCs in OA femoral heads bone and control bone. 
2. To compare the gene expression profile of native MSCs in OA and control bone. 
3. To investigate whether any putative gene expression alterations are maintained in 






3.3.1 Patient samples 
For all the experiments in this chapter a total number of n=30 OA donors (12 males and 
18 females) with age range between 40-90 years (median=72) and n=19 healthy donors 
(10 males and 9 females) with age ranging between 17-78 years (median=55) were 
recruited.  
3.3.2 Experimental overview 
Following the enzymatic digestion of the bone fragments (Chapter 2, Section 2.2) 
heterogeneous cell suspensions were obtained containing all the cellular component in 
the trabecular BM compartment from both healthy and OA donors. As shown in Figure 
3.1, several experiments were performed at this stage. From this cell suspension the MSCs 
were enumerated and purified by FACS using the CD45-CD271+ phenotype in parallel 
with CFU-F assay. From the same cell suspension, the MSCs were also isolated by plastic 
adherence and culture-expanded for four passages. The freshly sorted cell populations 
along with donor-matched (in most cases) culture-expanded MSCs were subsequently 




Figure 3.1. Experimental plan used to enumerate and analyse the native and cultured 
MSCs phenotype in healthy and OA bone. From the pool of enzymatically extracted cell 
suspension MSCs were purified by FACS using the CD45-CD271+ phenotype or culture 
expanded up to four passages. MSCs obtained from both experiments along with control 
HLCs were used for gene expression analysis by qPCR. From the same pool of 
enzymatically released cells, CFU-F assays were set at three seeding densities in 
duplicate. 
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3.3.3 MSC enumeration using CFU-F assay 
The CFU-F assay is a well-established method for the quantification of native MSCs from 
the BM or other tissues (Chapter 1, Section 1.3.2). Due to previously-described high 
donor variation (Kuznetsov et al., 2009) the assay was performed using gradient seeding 
densities and set up with a defined cell concentration following optimisation.  
The CFU-F assay was performed by plating the released cells at different densities, 
directly in standard MSC media (StemMACS, Miltenyi Biotec).  Media was pre-warmed 
to 37º C in a water bath while the nucleated cells released from the bone fragments were 
re-suspended in DMEM/10%FCS/1%P/S and counted using the Trypan Blue exclusion 
method as described in Chapter 2 Section 2.3.1. The cells were then transferred to 60 mm 
culture dishes containing 3 ml of pre-warmed StemMACS at three different seeding 
densities of 1x104, 2x104 and 5x104 cells/dish respectively, all in duplicate. After 48 
hours, the non-adherent haematopoietic cells and debris were removed by one PBS wash 
and a full media change. The cells were cultured for 14 days at 37º C, 5% CO2 with half 
media change twice per week.  
Following 14 days in culture the media was removed and the dishes were washed twice 
with PBS. The colonies were fixed with 3.7% PFA (3 ml) at room temperature for 20 
minutes. After removing the PFA, 3 ml of 1% methylene blue solution (in 10 mM borate 
buffer, pH 8.8, Appendix 1) was added and incubated for another 20 minutes to stain the 
colonies. After washing with tap water, the plates were left overnight to dry before 
counting the colonies. A colony was considered a group of 50 cells or more that were 
close to each other and distant from other groups of cells as visualised via low power 
microscopy (Gronthos et al., 2003). The colonies were manually counted and CFU-F 
frequency was established as percentage of cells seeded initially. The stained colonies 
were scanned at 360 dpi using a generic Epson scanner.  
3.3.4 FACS 
Since CD271 has been described as the most reliable marker for bone resident MSCs in 
vivo as discussed in Chapter 1, Section 1.3.2, the MSCs were purified using the CD45-
CD271+ phenotype. Cell sorting was additionally employed to determine and compare 
the frequency of CD45-CD271+ bone resident MSCs between health and OA samples. 
In addition, the purified cell populations were used for gene expression analysis in order 
to investigate the differences in the transcriptional profile of native MSCs between health 
and OA while HLCs were also selected as negative control.  
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Staining and cell sorting were performed as described in Chapter 2, Section 2.4.1. The 
cells were sorted into MSCs (CD45-CD271+) and negative control HLCs 
(CD45+CD271-) fractions. For frequency analysis, a minimum of 100,000 events were 
acquired and analysed using a BD Influx system (BD Biosciences) as described in 
Chapter 2, Section 2.4.2. The MSCs fraction was gated as CD45-CD271+ and their 
proportion was then calculated as relative to total live cells. For gene expression analysis, 
the cells from the MSC (CD45-CD271+) and HLC (CD45+CD271- ) fractions were sorted 
directly into 100 µl of RL RNA lysis buffer (Norgen Biotek) containing 1 µl of b-
mercaptoethanol and immediately stored at -80º C for downstream RNA isolation and 
gene expression analysis (Section 3.3.6).  
3.3.5 Cell culture 
For culture expansion experiments, the nucleated cells from enzymatically-released cell 
suspensions were counted using Trypan blue and then seeded at a density of 1x106 
cells/flask in T25 tissue culture flasks (Corning) in 7 ml of StemMACS media and 
incubated at 37° C and 5% CO2 as described in Chapter 2, Section 2.3. The majority of 
experiments were performed using fresh digest obtained on the day of processing, 
however in some instances, the cells were recovered following freezing in liquid nitrogen 
and culture-expanded after thawing as described in Chapter 2, Section 2.3.2. 
After two days, the media was removed and the cells washed twice with 5 ml PBS to 
remove non-adherent cells. The media was replenished and expansion continued until 
cells achieved approximately 70-80% confluence which was assigned as passage 0 (P0); 
at this point cells were washed with 5 ml of PBS then the cells were detached using 1ml 
of trypsin solution (Invitrogen, Appendix 1) at 37° C for 2-5 minutes. The cells were then 
centrifuged at 600xg for 5 minutes, counted and re-seeded in StemMACS media at a 
density of 5x103 cells/cm2 in T25 tissue culture flasks and returned to incubation in the 
same conditions.  
Cells were passaged when ~80% confluent, trypsinised and counted manually by trypan 
blue then reseeded at the same cell density. This was repeated from P0 onwards until P4 
was achieved. Culture growth rates were then established by dividing the number of days 
between passages by the number of population doublings (PDs). The PDs before P0 were 
calculated using the CFU-F data and the following formula:  




where Ni represents the cell numbers at the first trypsinisation and CFU-F represents the 
colony-forming number of seeded cells. For the following passages, the PDs were 
calculated as follows: 
𝑃𝐷 = 𝐿𝑜𝑔2	 P
𝑁𝑡
𝑁𝑖T	
where Nt and Ni are the terminal and initial cell counts, respectively. 
3.3.6 Gene expression analysis 
Between 2x103-7x103 cells from each fraction, CD45-CD271+ (MSCs) and 
CD45+CD271- (HLCs) respectively, were collected in 100 µl RNA lysis buffer. Total 
RNA was then extracted as described in Chapter 2, Section 2.5.1 using the Single Cell 
RNA isolation kit (Norgen Biotek) following the manufacturer instructions. Culture 
expanded MSCs were lysed at P4 and the RNA isolated using Total RNA extraction kit 
(Norgen Biotek) following the manufacturer instructions and as described in Chapter 2, 
Section 2.5.1. Briefly, the lysate was thawed on ice and an equal volume of 95% ethanol 
was added to precipitate the RNA. The mixture was loaded onto the spin column and 
centrifuged at 13000xg for 1 minute to bind the RNA. At this stage the flow-through was 
discarded and DNase digestion was performed. Following gDNA removal the RNA was 
washed twice using the kit washing buffer prior to be eluted using RNase free water in a 
small volume of 13 µl for sorted cells and 25 µl for cMSCs. The concentration and purity 
of RNA was assessed by Nanodrop and cDNA synthesised using the High Capacity 
Reverse Transcription kit (Applied Biosystems) as described in Chapter 2, Section 2.5.2 
using a total amount of 200 ng RNA per sample.  
The transcriptional profile of MSCs and HLCs purified by FACS from healthy (n=6) and 
OA (n=12) bone fragments was analysed using TaqMan probes and TLDA cards, while 
the cMSCs were analysed using TaqMan probes only (all from Thermo Fisher). The 
complete list of transcripts and assay IDs are detailed in Appendix 5. The genes of interest 
were selected based on previously published work by Dr. Sarah Churchman (Churchman 
et al., 2012). The genes selected for experiments in this chapter covered molecules 
specific to MSCs functional properties, especially associated with their multipotentiality, 
bone remodelling activities and stromal support. The reactions for qPCR were performed 
in triplicate as described in Chapter 2, Section 2.5. All gene expression levels were 
normalised to the house keeping gene HPRT1 and analysed using the 2-∆Ct method 
(Chapter 2, Section 2.5.4).  
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3.3.7 Statistics 
The statistical analyses for gene expression experiments were performed using Mann-
Whitney test for comparisons between two groups and Wilcoxon for matched paired data 
between two groups. The comparison between healthy and OA groups from FACS 
analysis and CFU-F assays included the Mann-Whitney test. Results were presented on a 
log scale as scattered dot plots with bars representing medians, connected dots plots for 
paired data or box and whisker plots, with boxes representing interquartile range, and 
whiskers representing the maximum and minimum values, calculated using GraphPad 
Prism version 7 software. Results were considered significantly different at p < 0.05 (with 




The first aim of this chapter was to investigate the number of native MSCs in OA femoral 
heads compared to control trabecular bone. In order to enumerate the MSCs and establish 
potential differences in their frequency in healthy and OA bone, two different techniques 
were used: the classic CFU-F assay (Jones et al., 2010) and the quantification of CD45-
CD271+ cells using FACS (Jones et al., 2010). Without having access to healthy femoral 
heads, the cells extracted from healthy iliac crest bone were used as control instead. It 
was demonstrated previously in our laboratory that cells isolated using the CD45-
CD271+ phenotype from BM aspirate from iliac crest and enzymatically digested iliac 
crest, and femoral head bone have the same MSC identity with regards to their 
phenotypical and functional characteristics (Jones et al., 2010).   
3.4.1 Investigation of MSCs frequency in OA bone by CFU-F assay 
To evaluate the frequency of MSCs in the enzymatically released cells from the bone 
fragments, the CFU-F assay was used and the resulted colonies following 14 days in 
culture were counted.  
Following enzymatic digestion of bone fragments from healthy (n=10) and OA (n=13) 
donors, the total number of nucleated cells extracted was manually counted using trypan 
blue exclusion method. To account for the donor-to-donor variation the cells were seeded 
at three different densities and MSC frequency was calculated as a percentage of colonies 
in relation to total seeded cells based on the lowest seeding density which could be 
counted accurately. Representative CFU-F photographs are presented in Figure 3.2 
showing the overall gradual increase of colonies in the dishes proportional to the increase 
in seeding density. 
When counting colonies from dishes with a similar seeding density of 1x103 cells, the 
number of colonies varied greatly between different donors of the same group (Figure 
3.3A). The colonies resulted from CFU-Fs also showed a wide heterogeneity in size, 
which possibly reflects a different capacity to proliferate, a different stage of commitment 
of the initiating cells, or it may be due to different migration potentials (D’Ippolito et al., 
1999; Gothard et al., 2013). Based on the median values of the CFU-Fs assay it was 
determined that the MSCs frequency as proportion of total nucleated cells was 2-fold 
higher (p=0.0191) in OA compared to the healthy bone-derived cells, with median values 
of 0.25% for healthy cells and 0.45% for OA (Figure 3.3B). This suggested that the 
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number of MSCs in OA bone is higher and will be further verified by cytometric 
quantification. 
 
Figure 3.2. Cell seeding densities optimisation for CFU-F assays. Representative CFU-
F assays in 60mm culture dishes seeded with cells enzymatically released from bone of 
one healthy and one OA aged matched donors. Images show proportional increase of the 





Figure 3.3. Examples of CFU-F dishes from healthy and OA donor cells and MSCs 
frequency. A. CFU-Fs generated using equivalent seeding densities of cells 
enzymatically released from healthy and OA bone; col: colony. B. Graph showing the 
comparison between the CFU-F assays of the enzymatically released cells from healthy 
(n=10) and OA (n=13) bone calculated as percentage of the number of seeded cells; 
Mann-Whitney test.  
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3.4.2 Enumeration and purification of MSCs from OA bone  
To further validate the increased MSC frequency observed in OA as determined by the 
CFU-F assay, MSC enumeration was performed by FACS using the CD45-CD271+ 
phenotype on the cells released from bone immediately following the enzymatic digestion 
without any in vitro manipulation.  
The analysis was performed using the acquisition and gating strategy described in Section 
3.3.4 and Chapter 2, Section 2.4.2 on the enzymatically released cells from healthy (n=11) 
and OA (n=22) bone fragments. A minimum of 1x105 events were acquired from all 
samples in order to obtain accurate statistical representations of the obtained cell 
populations. The resulting plots from the representative experiments are illustrated in 
Figure 3.4, noting an obvious variation between the donors.  
The proportion of CD45-CD271+ MSCs as a percentage of total live cells was 3.4-fold 
higher in OA (p=0.0231) compared to cells from healthy iliac crest bone (medians 1.26% 
and 4.33%, Figure 3.5A). These results are contrasting previous studies where no 
difference was found when comparison was made between healthy and OA MSCs using 
the same cell phenotype (Jones et al., 2010). A close linear relationship (R=0.7416, 
p=0.0180) was found between the frequencies of MSCs as assessed by CFU-F and the 
proportion of CD45-CD271+ cells extracted from OA and healthy bone (Figure 3.5B), 
consistent with previous studies performed on BM aspirated MSCs (Cuthbert et al., 
2012). Not all the CFU-F assays were matched with the FACS experiments therefore 
correlation was only calculated based on only donor matched samples from n=2 healthy 
and n=8 OA cells. It is important to note that while the fold difference in CFU-Fs between 
healthy and OA was only 2-fold, the differences in the proportion of CD45-CD271+ cells 
enumerated by FACS were higher (3.4-fold). However, this correlation indicated that the 
percentage of CD45-CD271+ cells was consistent with the CFU-F data, showing a higher 
proportion of MSCs in OA bone compared to healthy iliac crest.  
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Figure 3.4. MSC enumeration by FACS. Representative cell sorting plots illustrating 
FACS analysis of native, uncultured cells released from bone of three healthy and OA 
donors which were subsequently stained with CD45-FITC and CD271-APC following 
enzymatic treatment. 
 100 
                
Figure 3.5. MSC frequency by FACS and correlation with CFU-F assay. (A) Graph 
showing higher proportion of CD45-CD271+ cells as percentage of total live cells in OA 
(n=22, grey box) compared to healthy cells (n=11, white box); Mann-Whitney test. (B) 
Correlation of CFU-Fs and CD45-CD271+ cells from donor-matched samples of healthy 
(n=2, green dots) and OA (n=8, black dots); Spearman correlation.  
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3.4.3 Molecular profile of native MSCs in OA femoral heads 
Having determined a higher frequency of MSCs in OA femoral heads compared to IC 
bone, both by CFU-F assay and by cytometric analysis, the molecular profile of the CD45-
CD271+ cells from both healthy IC (n=6) and OA bone (n=11) was next investigated by 
qPCR.   
In order to validate the MSC identity of the CD45-CD271+ cells, the gene expression 
levels of transcripts specific to MSCs (Churchman et al., 2012) were analysed in the 
sorted fractions from both healthy and OA samples. The donor-matched HLC sorted 
fractions, selected as CD45+CD271- by FACS, were used as a negative control cell 
population for confirmation of MSC molecular markers in the CD45-CD271+ cell 
population. A set of nine markers were selected to confirm MSC identity. These 
mesenchymal lineage genes, associated with stromal-support potential as well as 
multipotentiality, were previously shown to be specific to native BM MSCs released by 
aspiration (Tormin et al., 2011; Churchman et al., 2012).  
Gene expression analysis showed that all the tested transcripts were significantly higher 
in the CD45-CD271+ cells compared to donor matched HLCs isolated from healthy iliac 
crest (Figure 3.6). The highest level of expression in the CD45-CD271+ cells was 
observed for CXCL12 (1748-fold, p<0.05), a molecule associated with haematopoietic 
support (Greenbaum et al., 2013). Also, detected at higher levels were the transcripts 
associated with MSC osteogenic potential, such as SPARC, SPP1 as well as SP7 which 
was not expressed in any of the HLCs but was found in all tested CD45-CD271+ cells. 
The MSC/early osteoblasts markers CDH11 (2361-fold, p<0.05), ALPL (349-fold, 
p<0.05) and COL1A1 (91-fold, p<0.05) (Kawaguchi et al., 2001; Ghazanfari et al., 2017) 
were found at higher levels in the CD45-CD271+ cells compared to HLCs along with the 
MSC-specific adipogenic transcript FABP4 (119-fold, p<0.05). MCAM, which is a 
surface marker for perivascular MSCs (Tormin et al., 2011) was also confirmed at higher 
levels in CD45-CD271+ cells compared to HLCs (12-fold, p<0.05). 
In the cells isolated from OA bone, all transcripts showed similar trends of expression 
(Figure 3.7). They all showed significantly higher level of expression in CD271+ cells 
compared to HLCs, although the differential expression for some genes differed from 
their healthy counterparts which may indicate an alteration in their transcriptional profile 
in OA.  
All the MSC-specific transcripts tested were therefore significantly higher in CD45-
CD271+ cells compared to HLCs and the fold change differences are detailed in Table 
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3.1. A similar study from our laboratory evaluated the same transcripts in healthy BM 
MSCs (Churchman et al., 2012) but this is the first study to investigate the gene 
expression profile of these cells enzymatically-released from bone. The results were 
consistent with the previous published study (Churchman et al., 2012) in regard to all the 
analysed transcripts, the gene expression profile of healthy BM MSCs being similar to 
the healthy enzymatically-released MSCs. Data in this chapter also introduced CDH11 as 
a new molecule that showed higher expression levels in MSCs.  
The bone remodelling associated genes encoding for RANKL and OPG (TNFSF11 and 
TNFRSF11B, respectively) were also tested as they were previously shown to be 
expressed by MSCs (Churchman et al., 2012; Campbell et al., 2016) and are important 
modulators of bone remodelling processes. The mRNA levels of TNFSF11 (encoding 
RANKL) were significantly higher in both healthy (15.6-fold, p=0.0312) and OA (10.8-
fold, p=0.0156) CD45-CD271+ cells compared to donor-matched HLCs (Figure 3.8). 
Similarly, TNFRSF11B (encoding OPG) was also shown to be specific to CD45-CD271+ 
cells, being 76.6-fold higher in healthy CD45-CD271+ cells compared to HLCs 
(p=0.0312) while in OA cells the mRNA levels for OPG were also higher in CD45-
CD271+ cells compared to HLCs (13.1-fold, p=0.0195) (Figure 3.8). So far, both 
molecules showed high specificity for MSCs in both healthy and OA samples indicating 





Figure 3.6. Comparative gene expression between healthy MSCs and HLCs. Relative 
expression of genes associated with MSC multipotentiality and stromal support in donor 
matched MSCs and HLCs from healthy IC (n=6) bone fragments. Gene expression levels 
presented on a log scale and relative to HPRT1; Wilcoxon test for paired data. Missing 
dots represent values below detection in the respective data set. 
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Figure 3.7. Comparative gene expression between OA MSCs and HLCs. Relative 
expression of genes associated with MSC multipotentiality and stromal support in donor-
matched MSCs and HLCs from OA (n=11) bone fragments. Gene expression levels are 
presented on a log scale and relative to HPRT1; Wilcoxon test for paired data. Missing 
dots represent values below detection in the respective data set. 
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Figure 3.8. Bone remodelling genes in healthy and OA MSCs and HLCs. Gene 
expression levels comparison of genes associated with bone remodelling in donor-
matched MSC and HLC sorted from healthy (n=6) and OA (n=11) bone fragments. Gene 
expression levels are presented on a log scale and relative to HPRT1; Wilcoxon test for 
paired data. 
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Table 3.1. Fold differences in gene expression based on median values of MSCs and 
HLCs sorted as CD45-CD271+ and CD45+CD271- respectively, from healthy and OA 
bone. 








SP7 BD in HLC NT LD in HLC NT 
CDH11 2360.8 * 0.0313 390.8 *** 0.0010 
CXCL12 1747.6 * 0.0313 298.7 *** 0.0010 
ALPL 348.6 * 0.0313 126.5 ** 0.0020 
SPP1 155.2 * 0.0313 20.6 NS 0.2061 
SPARC 118.5 * 0.0313 224.6 ** 0.0039 
FABP4 117.1 * 0.0313 18.9 ** 0.0020 
COL1A1 91.4 * 0.0313 94.6 * 0.0391 
TNFRSF11B 76.6 * 0.0312 13.1 * 0.0195 
TNFSF11 15.6 * 0.0312 10.8 * 0.0156 
MCAM 11.9 * 0.0313 10.6 NS 0.4131 
BD – below detection 
LD – low detection 
NS – not significant 




Altogether, this data confirmed the molecular identity of CD45-CD271+ cells as MSCs 
based on the significantly high expression of multiple MSC markers in comparison to 
matched HLCs. Next a 96-gene TaqMan Low Density Array was used to investigate, in 
greater depth, the transcriptional profile of native MSCs and how OA may alter their 
RNA expression levels. The panel of 96 gene transcripts are detailed in Appendix 5 and 
included molecules associated with the Wnt pathway, MSC stromal support, 
osteogenesis, chondrogenesis, migration and stimulation of angiogenesis. The qPCR raw 
data generated by this array was obtained from Dr. Sarah Churchman using the CD45-
CD271+ sorted cells (n=6 healthy and n=7 OA) processed as part of the experiments 
described in this chapter. Expression levels were calculated based on the 2-∆∆Ct method 
and normalised to HPRT1. These expression levels were pooled with the values from the 
MSCs molecular identity described in the above experiments and analysed together. The 
data generated by the 96-gene array as well as the panel used for MSC molecular identity 
used the same TaqMan assay and the same samples were used for both experiments.  
Comparison was made between the CD45-CD271+ sorted cells from IC and OA bone. 
The fold differences for each group was calculated and the genes with expression levels 
higher than 2-fold were selected for further analysis. This revealed significant differences 
in MSCs’ osteogenesis-related genes, most of these genes found to be higher in OA MSCs 
compared to healthy IC bone control (Figure 3.9). A significant increase in the levels of 
RUNX2, the master transcription factor involved in osteogenic differentiation 
(Nakashima et al., 2002) was detected in OA MSCs (7-fold, p=0.0177). Other osteogenic 
transcripts that were found to be elevated OA MSCs compared to healthy IC bone controls 
included SPARC (5-fold, p=0.0034), ALPL (3-fold, p=0.0477) and CDH11 (3-fold, 
p=0.0249) (Figure 3.9). No significant difference was noted in the levels of other 
osteoblast-associated molecules (SP7, SPP1, COL1A1 and COL1A2), although a trend 
for higher expression was noted for SP7 and COL1A2 (Figure 3.9). This data potentially 
indicated an early osteogenic commitment of the MSCs extracted from OA femoral 
heads. 
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Figure 3.9. Comparative gene expression of osteogenesis molecules between healthy 
and OA MSCs. The mRNA levels of genes associated with osteogenesis and bone 
formation in native MSCs sorted from healthy (n=6, empty boxes) and OA (n=11, grey 
boxes) bone fragments. Gene expression levels presented as relative to HPRT1 and 
Mann-Whitney test was used for statistical analysis. 
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As major players in bone remodelling and expressed at considerably higher levels in 
MSCs compared to HLCs as shown in Figure 3.10, the mRNA levels for RANKL and 
OPG were also tested (Brendan F Boyce and Xing, 2007). Based on median values, the 
levels of TNFRSF11B were found at higher levels in OA MSCs (3.4-fold, p=0.0202) 
while TNFSF11 expression was similar between both groups (Figure 3.10). In addition to 
the enhanced osteogenic commitment judged by the transcriptional analysis described 




Figure 3.10. Comparative gene expression of bone remodelling molecules between 
healthy and OA MSCs. The mRNA levels of bone remodelling associated genes encoding 
for OPG (TNFRSF11B) and RANKL (TNFSF11) in native MSCs sorted from healthy 
(n=6, empty boxes) and OA (n=11, grey boxes) bone fragments. Gene expression levels 
presented as relative to HPRT1 and Mann-Whitney test was used for statistical analysis. 
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As shown in Figure 3.11, the expression level of genes associated with chondrogenesis 
and cartilage formation showed an overall decrease in OA. The major chondrogenic 
transcription factor SOX9 (Bi et al., 1999) was significantly reduced in OA MSCs (5-fold, 
p=0.0082) as well as the levels of CHAD (chondroadherin), encoding a protein involved 
in chondrocytes adhesion (Camper et al., 1997), which was only expressed at lower levels 
in 2 out of 6 tested samples compared to healthy MSCs (Figure 3.11). Decreased gene 
expression levels were also observed for UGDH (14-fold, p=0.0140) and PAPSS (6-fold, 
p=0.0260), both encoding enzymes involved proteoglycan synthesis and cartilage 
formation (Haque et al., 1998; Wen et al., 2014). Although not statistically significant, a 
6-fold increase in the levels of ACAN (p=0.0519) and 4-fold in PRELP (p=0.1797) was 
noted in OA MSCs. This is intriguing since both genes encode extracellular matrix 
proteins that play an important part in the structural integrity of the cartilaginous tissue 
and contrasts the significant decrease of other chondrogenesis-related genes in native OA 
MSCs. 
No difference was observed in the genes associated with adipogenesis. The main 
adipogenic transcription factor PPARG as well as the mature adipogenic protein 
transcript; FABP4, showed similar levels in the MSCs isolated from both healthy and OA 
bone (Figure 3.12).  
The α-smooth muscle actin gene, ACTA2 was observed to be 9-fold increased (p=0.0411) 
in OA MSCs while the levels of MCAM, a gene encoding the CD146 antigen, were also 
higher in OA MSCs (2.4-fold, p=0.0365) compared to healthy MSCs. Noteworthy, both 
genes were shown to be expressed in BM CD271+ MSCs (Churchman et al., 2012), 
however since the CD146 marks an MSC subset associated with a perivascular location 
(Tormin et al., 2011), these differences between healthy and OA may be associated with 
an increased presence of perivascular MSCs subsets in OA. Furthermore, no differences 
were noted in the expression levels of the stromal support molecule, CXCL12 between 
healthy and OA native MSCs (Figure 3.13), these results may indeed point to a potential 
implication of a perivascular subset of MSCs in OA bone. This would be further 
investigated by FACS to determine both the protein expression levels as well as the 
proportion of this MSC subset in OA bone.  
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Figure 3.11. Comparative gene expression of chondrogenesis molecules between 
healthy and OA MSCs. The mRNA levels of chondrogenic transcripts in native MSCs 
sorted from healthy (n=6, empty boxes) and OA (n=11, grey boxes) bone fragments. Gene 




Figure 3.12. Comparative gene expression of adipogenesis molecules between healthy 
and OA MSCs. The mRNA levels of adipogenic transcripts in native MSCs sorted from 
healthy (n=6, empty boxes) and OA (n=11, grey boxes) bone fragments. Gene expression 
levels presented as relative to HPRT1 and Mann-Whitney test used for statistical analysis 




Figure 3.13. Comparative gene expression of vascular and stromal support molecules 
between healthy and OA MSCs. The mRNA levels of angiogenic-related transcripts in 
native MSCs sorted from healthy (n=6, empty boxes) and OA (n=11, grey boxes) bone 
fragments. Gene expression levels presented as relative to HPRT1 and Mann-Whitney 
test was used for statistical analysis.  
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Table 3.2. Fold changes based on median values in the expression levels between 




Fold change p Value 
 Healthy OA 
Osteogenesis 
RUNX2 3.036 21.04 6.9 * 0.0177 
SPARC 22.14 101.9 4.6 ** 0.0034 
CDH11 6.358 17.05 2.7 * 0.0249 
ALPL 5.577 17.01 3.1 * 0.0477 
SP7 0.3101 0.5323 1.8 NS 0.4923 
SPP1 47.96 49.15 1.0 NS 0.8836 
COL1A1 1.416 3.121 2.2 NS 0.2115 
COL1A2 16.54 161.7 9.8 NS 0.0734 
Bone 
remodelling 
TNFRSF11B 0.1531 0.5225 3.4 * 0.0202 
TNFSF11 0.2494 0.2801 1.1 NS 0.2677 
Chondrogenesis 
SOX9 17.15 3.456 5.0 **0.0082 
CHAD 0.5644 BD NT NT 
UGDH 29.00 2.080 13.9 * 0.0140 
PAPSS2 7.849 1.222 6.4 * 0.0260 
ACAN 0.4522 2.717 6.0 NS 0.0519 
PRELP 3.118 13.35 4.3 NS 0.1797 
Adipogenesis 
FABP4 1.464 1.945 1.3 NS 0.5908 




ACTA2 0.2617 1.249 4.8 * 0.0411 
MCAM 1.908 4.501 2.4 * 0.0365 
CXCL12 233.2 164.6 0.7 NS 0.8075 
BD – below detection 
NT – not tested 
NS – not significant 
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3.4.4 Cultured MSCs 
To determine whether the observed differences in gene expression are maintained in 
culture, the MSCs isolated from bone of healthy and OA donors were culture-expanded 
in StemMACS media up to P4 and then gene expression analysed. First, the morphology 
and growth kinetics of the culture expanded cells were investigated.  
Following the enzymatic digestion, approximately one million cells from the obtained 
cell suspension were seeded in a T25 flask. Morphological features of MSCs were 
examined by phase-contrast microscopy. Within hours after seeding, the cells attached to 
the culture surface and exhibited a typical fibroblastic-like spindle-shaped appearance 
(Figure 3.14A and B). When observed under the inverted microscope, the cells released 
from both healthy and OA bones contained a heterogeneous pool of cells, including a 
high number of plastic-adherent and proliferative stem-like adherent cells (Figure 3.14). 
During the first week in culture, the MSC showed increased proliferation, which 
gradually resulted in maintaining a homogeneous fibroblastic morphology (Figure 3.14C 
and D). 
The majority of non-adherent cells were subsequently removed during the media 
exchanges throughout passages. Visual assessment of cultures from both healthy and OA 
groups showed indistinguishable morphology, with no differences in cell size and shape, 
which was maintained between passages. Of importance, the cells maintained their 
proliferative and plastic-adherent properties after freezing down and recovering from 
liquid nitrogen. When the cells reached confluence, they were trypsinised, counted and 
seeded back at a cell density of 104cells/cm2 representing 2x105 cells per T25 flask. 
During the four passages the cells showed no differences in morphology, both healthy 
and OA cells maintaining their elongated MSC-like shape (Figure 3.15).  
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Figure 3.14. Culture expanded cells from healthy and OA bone prior to first passage. 
MSCs early in culture isolated from healthy (A) and OA (B) bone have started to attach 
to the surface and proliferate as soon as 24 hours following extraction and seeding. After 
approximately 7 days the cells from both healthy (C) and OA (D) bone were confluent 
with no distinguishable differences in morphology. Some bone debris could be observed 




Figure 3.15. Late-passage culture expanded cells from healthy and OA bone. Culture 
expanded cells from healthy (A) and OA (B) bone at the start of passage 4 (24 hours after 
seeding) showed signs of proliferation. Following 2-3 days in culture both healthy (C) 
and OA (D) bone MSCs have reached confluence, less debris present and a more 
homogenous cell population with cells that look similar in size and shape.  
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For each passage the cell number was evaluated after trypsinization when 70–80% of cell 
confluence was achieved. The culture expansion experiment was performed with cells 
extracted from n=10 healthy and n=12 OA bone. The initiating cultures needed on 
average 6 days to reach sub-confluence and only 2-3 days were required between each 
passage. The cultures were stopped after four passages and the population doublings as 
well as cell counts between the passages were calculated based on seeded CFU-Fs as 
described in Materials and Methods (Section 3.3.3). While no statistically significant 
differences were found in the growth rates measured as days/PD, across the four passages 
between healthy and OA derived MSC cultures (median values of 2.03 and 2.59, 
respectively, Figure 3.16), a trend for higher PDs was observed for OA MSCs.  
Interestingly this suggest that the higher CFU-Fs observed in the OA group compared to 
healthy IC may be associated with slower proliferation as the doubling times of MSCs 
released from OA bone were longer than healthy IC MSCs. However, another explanation 
may be the increased frequency of MSCs in the extracted cells from OA bone as assessed 
by FACS. Also noteworthy is the OA donor variability in comparison to healthy cMSCs. 
While the age spread on healthy donors was higher than in OA (Appendix 3), the results 
were opposite, which may indicate that the higher variability in OA may be associated 
with the disease.   
Figure 3.16. Comparative growth rate between healthy and OA bone cMSCs. Graphs 
showing the growth rate of cultured MSCs derived from healthy (n=10, white box) and 
OA (n=12, grey box) bone measured as days/PD. A trend for higher growth rate and 
increased variability was observed in OA MSC cultures. However, the PD rates showed 
no significant differences between healthy and OA donors calculated as days/PD based 
on Mann-Whitney test. 
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3.4.5 Gene expression comparison between native and cultured MSCs from 
OA bone 
As mentioned in the introduction of this chapter (Section 3.1.3), healthy IC BM MSCs 
lose their native gene expression following passaging in culture. However, the molecular 
profile of culture-expanded MSCs from other sources, i.e. healthy iliac crest and OA 
femoral heads have not been investigated yet. Therefore, analysis in this chapter aimed at 
establishing the differences of cMSCs in comparison to their in vivo counterparts in both 
healthy and OA bone-derived MSCs. Furthermore, comparison between healthy and OA 
cMSCs were also performed to establish whether the differences observed in native MSCs 
were maintained in culture.  
Once the cells have reached four passages, the culture was stopped and gene expression 
was analysed in OA cMSCs while healthy IC cMSCs were used as control. These 
comparisons were made between native CD45-CD271+ MSCs isolated by FACS from 
healthy (n=6) and OA (n=11) bone previously described above in Section 3.4.3 and 
culture-expanded MSCs seeded from the pool of cells extracted from healthy (n=9) and 
OA (n=11) bone, out of which n=4 were donor matched.  
As expected, a drastic difference in the gene expression cMSCs from healthy bone 
occurred when the cells were culture expanded. The levels of many of the tested 
molecules were lower in cMSCs compared to native CD45-CD271+ MSCs. The MSCs 
markers associated with their osteogenic and adipogenic potentials showed the highest 
differences, the level of osteogenic transcription factor SP7 were found to be 470-fold 
(p=0.0043) lower in cMSCs as well as the adipogenic protein FABP4, which was 236-
fold (0.0004) lower in cMSCs (Figure 3.17). Furthermore, the other osteogenic related 
genes were also significantly lower in cMSCs compared to native cells, including SPP1 
(85-fold, p=0.0004) and ALPL (17-fold, p=0.0360) (Figure 3.17) along with the stromal 
support molecule, CXCL12 which was 11-fold (p=0.0004) lower in healthy cMSCs 
compared to native cells. Two other molecules associated with osteogenesis, SPARC and 
COL1A1 were both significantly higher in cMSCs compared to native MSCs (Figure 
3.17). The only genes that did not show any changes while in culture were adhesion 
molecules CDH11 and MCAM (Figure 3.17). Taken together this data indicated that the 
trends for lower expression in cMSCs compared to native CD271+ MSCs were consistent 
with those found for MSC from IC aspirates (Churchman et al., 2012; Ghazanfari et al., 
2017). Furthermore, these results indicate that osteogenic pathway genes may be affected 
by the culture conditions. 
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Next, the same panel of genes was investigated in native and cultured MSCs extracted 
from OA femoral heads as OA MSCs were also susceptible to these changes. Results 
showed that the same trends observed in healthy MSCs were present in OA MSCs. All 
the transcripts that were found to be lower in healthy cMSCs, SP7, CXCL12, ALPL, SPP1 
and FABP4 (Figure 3.18) were as well significantly decreased in the cultured MSCs 
isolated from OA bone. All the fold changes are listed in Table 3.3 and it was notable that 
some fold changes were different in the OA group as compared to the healthy MSCs. For 
example, while the MCAM levels were unchanged when comparing the healthy MSCs, 
there was a significant decrease observed in the cells expanded from the OA bone (5-fold, 
p=0.0006). This may be due to the perturbations observed in native MSCs and 
documented in Section 3.4.3 above, or it may indicate that these differences caution 
against using cMSCs to understand OA since they fail to reflect their native phenotype. 
When comparing the levels of the molecules responsible for bone remodelling regulation 
in healthy and OA derived MSCs, alterations were also found in both mRNA levels for 
RANKL (TNFSF11) and OPG (TNFRSF11B) (Figure 3.19).  
In both healthy and OA cMSCs a significant decrease was observed in RANKL mRNA 
levels, being 121-fold (p=0.0016) and 35-fold (p=0.0001) decreased in healthy and OA 
cMSCs respectively compared to native MSCs. Opposite trends were observed in the 
levels of OPG, which was shown to be significantly up-regulated in both healthy (5-fold, 
p=0.0048) and OA group (3-fold, p=0.0032).  
The changes observed in the levels of OPG however were not as distinct as the ones 
observed for RANKL. This may be explained by the increased levels of OPG in native 
OA MSCs compared to healthy MSCs (Figure 3.10). However, regardless of the 
expression levels in native MSCs, the similar pattern was observed for both molecules, 




Figure 3.17. Comparative gene expression between native and cMSCs derived from 
healthy bone. Graphs showing the comparison in mRNA levels between native (CD45-
CD271+, n=6) MSCs and culture-expanded MSCs (cMSCs, n=9) isolated from healthy 
iliac crest bone. Gene expression levels presented as relative to HPRT1 and Mann-
Whitney test was used for statistical analysis. 
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Figure 3.18. Comparative gene expression between native and cMSCs derived from OA 
bone. Graphs showing the comparison in gene expression levels between native (CD45-
CD271+, n=11) MSCs and culture-expanded MSCs (cMSCs, n=11) isolated from OA 
femoral head bone. Gene expression levels presented as relative to HPRT1 and Mann-
Whitney test was used for statistical analysis. 
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Figure 3.19. Comparative gene expression of bone remodelling molecules between 
native and cMSCs derived from healthy and OA bone. The mRNA levels of bone 
remodelling associated genes in native and culture-expanded MSCs extracted from 
healthy and OA bone. Gene expression levels presented as relative to HPRT1 and Mann-
Whitney test was used for statistical analysis. 
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Table 3.3. Table summarising the median fold differences in gene expression levels 
between native and culture-expanded MSCs extracted from healthy and OA bone. 
  
 












SP7 443 0.0043 470 <0.0001 
CXCL12 11.25 0.0004 5.81 0.0006 
ALPL 17.36 0.0360 16.90 0.0003 
CDH11 1.07 NS 1.42 NS 
SPP1 85.03 0.0004 215.78 <0.0001 
FABP4 236.07 0.0004 106.61 <0.0001 
MCAM 1.44 NS 5.11 0.0006 
TNFSF11 121.66 0.0016 35.01 0.0001 
Higher in cMSCs 
COL1A1 43.71 0.0048 3.79 NS 
SPARC 13.50 0.0004 2.43 0.0041 
TNFRSF11B 4.97 0.0048 2.91 0.0032 
BD – below detection 
NS – not significant 
NT – not tested 
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In summary, the gene expression differences observed between healthy and OA native 
MSCs were not found to be maintained following culture-expansion. The only difference 
observed between healthy and OA cMSCs was in the bone remodelling associated 
molecules, particularly the mRNA levels of RANKL. In comparison to healthy cMSCs 
the levels of RANKL mRNA were 4-fold higher (p=0.0043) in the OA cMSCs (Figure 
3.20). The mRNA levels for the resorption inhibitor OPG (TNFRSF11B) also indicated a 
trend for higher expression in the OA cMSCs, however it failed to reach statistical 
significance (Figure 3.20). Noteworthy are the opposite trends observed for RANKL and 
OPG when the cells were exposed to culture, particularly the increased expression of 
RANKL in OA cMSCs.  
None of the other transcripts tested in relation to MSC identity or their multipotential 
nature showed any differences between the healthy and OA-derived cultures (Figure 
3.21). Although the fold differences observed in native cells were not notably high, a 
similar trend would still be expected to be observed in the cultures. 
Considering these overall changes in gene expression observed between native and 
cMSCs, especially with regards to the two main mediators of bone resorption, it 




Figure 3.20. Comparison of bone remodelling associated gene ex between healthy and 
OA cMSCs. The mRNA levels of bone remodelling associated genes in culture-expanded 
MSCs extracted from healthy (n=9, white boxes) and OA (n=11, grey boxes) bone. Gene 




Figure 3.21. Comparative gene expression between healthy and OA cMSCs. 
Comparison of mRNA levels of genes associated with MSC phenotype in culture-
expanded MSCs from healthy (n=9, white boxes) and OA (n=11, grey boxes) bone. All 
the transcripts showed no significant differences between healthy and OA extracted cells. 
Gene expression levels presented as relative to HPRT1 and Mann-Whitney test was used 




The main aim of this chapter was to test whether MSC numbers and their gene expression 
profile are altered in OA affected bone. The current understanding of the contribution of 
MSCs to the mechanisms underlying  OA pathology and endogenous repair mechanisms 
is limited, however, their importance may be reasonably assumed given their wide 
distribution in all of the joint tissues (Barry and Murphy, 2013; McGonagle et al., 2017). 
Furthermore, recent OA studies in both animal models (Zhen et al., 2013) and humans 
(Campbell et al., 2016) point to an involvement of bone resident MSCs in OA pathology. 
Therefore, this chapter focused on investigating the MSC numbers in OA femoral heads 
by means of enumeration and purification to establish their presence in OA affected bone. 
In order to ascertain how the OA pathological environment may affect their gene 
expression, the transcriptional profile was also analysed in their native state and was 
further verified if it is faithfully preserved following culture expansion. 
3.5.1 Investigation of MSCs numbers in OA 
In order to obtain an accurate quantification of the MSCs numbers in OA bone, their 
enumeration was performed using two different assays, CFU-F and cell sorting using 
surface marker selection. Data in this chapter obtained from the CFU-F assays showed 
that the frequency of MSC among the cells extracted from OA bone was significantly 
higher compared to the cells from healthy iliac crest. This result is in contrast to a previous 
study in our laboratory, where no alterations in the CFU-Fs were found in cells from OA 
in comparison to healthy bone (Jones et al., 2010). The 2-fold increase described in the 
current chapter may be attributable to the technical improvement in the MSC extraction 
protocol. The bone fragments were subjected to more stringent washing following the 
enzymatic treatment (Chapter 2, Section 2.2.1) as well as an additional low speed 
centrifugation step, which all contributed to the release and capture of more cells, possibly 
some that were tightly attached to the bone surface. This may point to bone lining cells 
as a strong candidate responsible for the observed differences and moreover, a potentially 
increased presence of these cells in OA. 
Variations were observed in the CFU-Fs among donors from the same group and were 
further found similarly variable among the CD45-CD271+ population of cells enumerated 
from healthy and OA samples by FACS. This may be indeed attributed to patient 
variability, but given the limited supply of human tissue, especially healthy iliac crest 
bone, an analysis between age- and sex-matched donors of healthy and OA bone was not 
always possible. However, efforts have been made to narrow the age gap by selecting 
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older IC and younger OA donors. Additionally, to account for the inter-donor variability 
and optimise for a feasible colony count, the CFU-F assays were performed by plating 
the cells at different seeding densities. To obtain an accurate quantification of the native 
MSC frequencies, optimal density was chosen based on the number of cells that were 
seeded initially in order to generate the most reliable number of colonies that could be 
counted accurately. 
The CFU-F assay is a very common, robust and straight forward technique for 
enumeration of native MSCs (Kuznetsov et al., 2009). However, it is also time consuming 
and retrospective, being reflective of many variables that may affect the end-point result, 
such as initial cell seeding density, subjectivity in scoring the colonies or merged 
colonies, all leading to a high degree of variability. Meanwhile, flow cytometry, which is 
rapid, reliable, and reproducible, could provide a useful alternative to CFU-F assay, but 
the prerequisite to using this method is a clear understanding of the phenotype of native 
MSCs. 
Thus far the low-affinity nerve growth factor receptor; CD271, has been considered one 
of the most specific and reliable markers for native MSCs (Quirici et al., 2002; Jones et 
al., 2002; Bühring et al., 2007; Bühring et al., 2009; H. Li et al., 2016) while CD45 is 
commonly employed as a negative selection marker to identify the haematopoietic 
lineage cells. This phenotype has been used in previous studies to purify MSCs from cells 
isolated from many joint tissues, including trabecular (Jones et al., 2010) and cortical (G. 
Cox et al., 2012) bone and BM (Quirici et al., 2002; Jones et al., 2002; Bühring et al., 
2007) and described as functionally and phenotypically similar. 
The enumeration of MSCs extracted from both healthy and OA bone was therefore 
performed utilising the CD45-CD271+ phenotype in parallel to CFU-F assays. Enzymatic 
digestion of trabecular bone fragments from OA femoral heads released an abundance of 
CD45-CD271+ cells. This is in accordance with previous studies in our laboratory that 
showed a high number of CD45-CD271+ MSCs in the trabecular bone from OA femoral 
heads expressing the common MSC surface markers CD105, CD73 and CD90 (Jones et 
al., 2010). Data in this chapter showed that the proportion of CD45-CD271+ MSCs 
extracted from the OA femoral heads was 3.4-fold higher than in healthy iliac crest bone. 
This finding corroborates the CFU-F data and may be similar attributed to technical 
improvement of MSC extraction. However, there was only a 2-fold difference observed 
in the MSC frequency based on the CFU-F assay, which may be explained by the fact 
that not all CD271+MSCs form CFU-F, as previously reported (Cuthbert et al., 2012).  
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The differences between health and OA as well as inter-donor variability could be 
attributable to variations in the extent of damage of OA femoral heads. The heterogeneity 
of OA and the variable extent of associated bone damage has been well documented (Suri 
and Walsh, 2012; Burr and Gallant, 2012). Previous studies assessing the presence of 
MSCs in OA bone indicated no differences in comparison to healthy bone (Jones et al., 
2010) although their numbers were later shown to increase with pathology (Campbell et 
al., 2016). However, the lack of repair observed in OA joints is not due to a decrease in 
MSCs population, which may explain the common addition of exogenous MSCs in cell-
based therapies. Hence this evidence led to the assumption that MSCs presence in OA 
femoral heads were not altered. Data presented here showed that MSCs are present in 
higher in numbers in OA bone, which may be due to a pathological repair attempt. 
Previous work in our laboratory showed that MSCs were increased in areas of OA 
damage, specifically more MSCs were shown to inhabit areas affected by BM lesions in 
comparison to non-lesioned areas (Campbell et al., 2016). 
3.5.2 Transcriptional profiling of native bone resident CD45-CD271+ MSCs 
in OA bone 
While showing that OA trabecular bone harbours a higher concentration of MSCs relative 
to healthy bone, the questions still remain on how these MSCs participate in the attempted 
repair or contribute to the disease process and whether they inhibit or trigger the 
abnormalities associated with OA. To address this, the CD45-CD271+ MSCs purified by 
FACS were investigated at a transcriptional level for a more comprehensive 
characterisation of their native phenotype in both health and OA.  
In addition to their surface phenotype that has been previously evidenced in several 
studies (Quirici et al., 2002; Jones et al., 2002; Bühring et al., 2007; Jones et al., 2010; 
Churchman et al., 2012), the transcriptional profile of the CD45-CD271+ cells and their 
MSC identity has also been previously described (Qian et al., 2012; Churchman et al., 
2012; Ghazanfari et al., 2017), but in cells aspirated from healthy BM. In contrast, in this 
chapter the identity of MSCs extracted from the bone of healthy and OA donors was 
established by means of gene expression. In comparison to donor-matched HLCs, the 
MSCs extracted from healthy and OA bone and purified using the CD45-CD271+ 
phenotype showed a distinct gene expression signature specific to mesenchymal lineage 
and similar to BM MSCs (Churchman et al., 2012). Among the most specific MSC 
marker observed in this chapter, was SP7, also known as osterix. As a bone-specific 
transcription factor, SP7 is required for osteoblast differentiation and is therefore critical 
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for bone formation (Nakashima et al., 2002; Kaback et al., 2008). In both healthy and OA 
samples SP7 was found to be expressed in CD45-CD271+ MSCs while in HLCs was 
completely absent in the healthy samples and at very low levels on only two out of 11 
OA tested samples. Another robust marker was identified as CXCL12. Consistent with 
previous findings using BM MSCs (Churchman et al., 2012), the expression of CXCL12, 
a highly-expressed molecule characteristic of MSC stromal support activity (Greenbaum 
et al., 2013), was also significantly higher in MSCs compared to HLCs. All the other 
MSC markers were expressed in a distinct manner at significantly higher levels in MSCs 
compared to matched haematopoietic cells, confirming simultaneous osteogenic, 
adipogenic and haematopoiesis supporting transcriptional activity in bone resident CD45-
CD271+ cells, thus confirming, at the molecular level, their multipotential stromal nature. 
A plethora of studies have been carried out on culture expanded MSCs isolated from 
various sources, although their native profile is still unexplored. Gene expression of 
native MSCs analysed in this chapter revealed an increased osteogenic commitment of 
MSCs from OA bone. This can be evidenced by the increased expression of several genes 
associated with osteogenesis and bone formation, including RUNX2, ALPL, SPARC and 
CDH11. This finding may provide a mechanistic explanation to the global increase in 
bone formation and sclerosis observed at the late stages of this disease (Burr and Gallant, 
2012) considering the samples used here were from later-stage OA. 
The first step in MSC lineage commitment and formation of osteoprogenitors is regulated 
by key transcription factors, such as RUNX2 and SP7 (osterix) (Nakashima et al., 2002) 
(Chapter 1, Section 1.3.2). This step involves expression of lineage inducing factors as 
well as inhibition of factors that maintain lineage plasticity. The initial progenitor are still 
bi-potential and can commit to either osteo- or chondro-lineage depending upon the 
threshold of SOX9 and RUNX2/SP7 (Nishimura et al., 2008). Compared to healthy MSCs, 
OA MSCs had significantly lower levels of SOX9 (5-fold) while the levels of RUNX2 and 
SP7 were both elevated (8-fold and 2-fold, respectively). This indicated that the 
osteogenic commitment of OA MSCs was also supported by the higher  levels of bone 
matrix markers and early osteoblasts, such as CDH11 and ALPL (Anh et al., 1998; Ferrari 
et al., 2010) as well as COL1A1, SPP1, SPARC (osteonectin), which were also at higher 
levels to different degrees in OA MSCs compared to healthy IC bone controls. Therefore, 
a relatively higher expression of these genes in OA MSCS suggest a fairly appreciable 
bone anabolic activity supported by their osteogenic commitment. Histological studies 
would be needed to confirm at a protein level the association of abnormal bone formation 
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with the CD45-CD271+ MSCs investigated in this chapter. Further, immunohistological 
studies are needed to investigate the presence of MSCs in relation to new bone formation 
in OA femoral heads.  
Age-related decreases in proliferation and osteoblast differentiation in human MSCs have 
been described (Zhou et al., 2008) therefore the increased osteogenic potential observed 
in MSCs in OA are unlikely to be influenced solely by the age of the patients, but more 
likely by the active and strenuous environment they reside in. Dominant aberrations 
within the MSC microenvironment may alter their gene expression and consequently the 
way MSCs modulate bone homeostasis and repair. MSCs reside in a highly 
interconnected niche (Isern and Méndez-Ferrer, 2011), interacting with all the other cells 
around them which are all subjected to the same physical stress exerted by a 
biomechanical disease like OA. In a mouse model of OA, Cao et al. described an increase 
in MSC numbers following OA induction which were recruited by the increase in TGF-
b activated by bone resorption (Zhen et al., 2013) and led to aberrant bone formation. 
Data presented here revealed a similar increase in MSC numbers in OA bone and taken 
together with their osteogenic bias may suggest a similar mechanism in human OA, thus 
confirming the findings observed in the mouse models, although more work is needed in 
order to determine the triggers of these changes and how can the balance be re-
established. 
During skeletal development and throughout life, the cells in the bone compartment 
synthesize and secrete molecules that in turn initiate and control osteoclast differentiation 
(Teitelbaum, 2007). As described in Chapter 1, Section 1.2.3, OPG acts as a decoy 
receptor that binds to RANKL and prevents it from interacting with its receptor RANK, 
inhibiting osteoclastogenesis (Brendan F Boyce and Xing, 2007). Higher levels of OPG 
observed in OA MSCs in comparisons to their healthy counterparts described in this 
chapter suggest an MSC involvement in bone resorption inhibition in addition to their 
enhanced osteogenic commitment and anabolic activity. Although this finding comes as 
a supportive evidence of an exacerbated bone phenotype in OA, a more thorough 
investigation is needed, including an assessment of bone resorption activity in OA bone 
to assess the osteoclasts presence as well as more confirmatory experimental procedures 
that may directly implicate MSCs in bone resorption inhibition. Studies investigating the 
RANKL/OPG pathway in OA also suggested an altered expression of these molecules in 
OA subchondral osteoblasts (Kwan Tat et al., 2008), indicating an osteoblast lineage 
specific aberration in the expression of these molecules. It would be interesting to 
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investigate the levels of these molecules on the remaining line of MSC differentiation, 
the bone embedded osteocytes, as they have been described to be the main producers of 
RANKL (Xiong et al., 2015). 
Another interesting finding in native OA MSCs was the low expression levels of SOX9, 
the major transcription factor inducible of chondrogenesis (Bi et al., 1999). Similarly, 
other molecules involved in cartilage formation were also lower, such as UGDH and 
PAPSS. Interestingly, an early study carried out by Murphy et al. reported that OA MSCs, 
even in locations remote from sites of damage, had reduced chondrogenic and adipogenic 
potential in vitro (Murphy et al., 2002). 
These findings together with the reduced levels of many chondrogenesis molecules 
presented in this chapter point to an alteration in the commitment of MSCs in OA, with 
the switch locked into forming bone, rather than replacing the damaged cartilage. But 
very intriguing was the high level of aggrecan transcript (ACAN) observed in the OA 
MSCs, which encodes the proteoglycan, an integral part of cartilage tissue. This contrasts 
previous studies showing lower expression of ACAN in OA MSCs (Campbell et al., 
2016), however this study was performed using cultured MSCs. In another in vitro study 
it was shown that ACAN expression can be induced by elevated TGF-b levels (Tuli et al., 
2003). It is possible therefore to assume that this increase in ACAN observed in native 
OA MSCs may be due to an increase in the levels of TGF-b previously described by Cao 
et al. in the subchondral bone in OA mouse models (Zhen et al., 2013). As shown here 
and in other studies (Churchman et al., 2012; Ghazanfari et al., 2017) there are 
considerable differences in the gene expression levels between native and in vitro 
expanded MSCs, discussed in more detail in the next section. 
Differences in the transcriptional profile between healthy and OA native MSCs described 
here may be due to the existence of a subpopulation within the CD45-CD271+ fraction 
which is increased in OA. It is already known that native CD45-CD271+ MSCs in the BM 
stroma reside in both endosteal and perivascular niches (Chapter 1, Section 1.3.2), the 
latter around the blood vessels, marked by the CD271+CD146+ MSC phenotype (Tormin 
et al., 2011). The increased levels of MCAM, which encodes the surface MSC marker 
CD146 (Tormin et al., 2011), observed in the OA native MSCs may indicate an increase 
in this particular MSC subset. This could be verified by FACS or flow cytometry by 
selecting for this population from the CD45-CD271+ MSC pool. Additionally, the 
expression levels of ACTA2 was shown to be elevated in OA MSCs, a gene encoding the 
α-smooth muscle actin, known to be expressed by pericytes (Schmitt-Gräff et al., 1989; 
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da Silva Meirelles et al., 2008) as well as BM MSCs (Churchman et al., 2012) and the 
marrow sinusoidal pericytes that also express CD271 in situ (Cattoretti et al., 1993; 
Tormin et al., 2011). Given the increased angiogenesis and vascular invasion that has 
been described in OA bone (Findlay, 2007), an increase of a perivascular population of 
MSCs would not be surprising. More intriguing is their osteogenic commitment described 
here which still remain to be deciphered with regards to the causative mechanism behind 
it. 
3.5.3 Culture-expanded MSCs 
Using FACS directly after the enzymatic extraction of cells from the bone tissue allowed 
a pure population of MSCs to be obtained in comparison to the plastic adhesion method, 
where the waiting time to obtain comparable homogeneity was considerably high. Culture 
expanded MSCs provide heterogeneous progeny which do not faithfully reflect the 
properties of their native counterparts, alterations in the transcriptional and functional 
profile having been previously documented on BM MSCs (Churchman et al., 2012; 
Ghazanfari et al., 2017). These changes that occur between native and cultured cells may 
be due to the biochemical changes in the MSCs consequently to their adaption to in vitro 
culture conditions. While the cMSCs investigated in this chapter were not subjected to 
immunophenotyping using standard ISCT criteria (Dominici et al., 2006), the 
experimental methods were used in accordance with previous published literature. 
Multiple studies using culture-expanded cells showed that by using this isolation method 
(Chapter 2, Section 2.3.2) the cMSCs maintain their phenotype and multipotency as stated 
by the ISCT for more than four passages (Churchman et al., 2012; H. Li et al., 2016; 
Ghazanfari et al., 2017). 
Previous published data documented transcriptional and phenotypic alterations following 
culture expansion in MSCs derived from healthy BM aspirate (Qian et al., 2012; 
Churchman et al., 2012; Ghazanfari et al., 2017). Results presented here are consistent 
and showed for the first time similar alterations in bone-resident MSCs, providing more 
evidence concerning the differences between native cells and their in vitro counterparts. 
The markers tested in relation to their osteogenic and adipogenic potential as well as 
stromal support, were all altered in culture in the same pattern, in MSCs from both healthy 
and OA bone. Comparison of culture-expanded cells between healthy and OA showed no 
differences with regards to the transcripts associated with MSC multipotential and 
stromal support activity, contrasting the distinct alterations observed in native cells. These 
alterations documented similarly in cultured MSCs isolated from healthy BM 
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(Churchman et al., 2012) showed the same transcripts changed under cultured conditions. 
Furthermore, the transcripts associated with bone remodelling encoding for RANKL and 
OPG have also been previously documented. Elevated levels of RANKL mRNA (Wagner 
et al., 2008) as well as decreased OPG (Churchman et al., 2017) showed similar changes 
following culture expansion of MSCs from healthy BM MSCs as documented in this 
chapter using bone-resident MSCs.  
Irrespective of the site of extraction (bone or BM) or pathological state of the bone 
(healthy or OA), these MSCs suffer changes in vitro that should be taken into 
consideration in future studies and are not a good tool to study disease pathophysiology. 
Conversely, these changes may also be reversible as cMSCs can differentiate and 
upregulate these molecules following differentiation induction. 
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Chapter 4 Osteocytes in OA bone 
4.1 Introduction 
In the previous chapter, investigations were performed to uncover any potential 
abnormalities in MSCs resident in OA bone. The presented data showed that OA MSCs 
were proportionally increased, and that they had gene expression bias towards bone 
formation and inhibition of bone resorption. Furthermore, upon culture-expansion, 
important gene expression patterns were lost, emphasizing the drawbacks of culture-
expansion methodologies in the study of mesenchymal-lineage cells. This chapter will 
investigate if MSC abnormalities have an impact on their most differentiated osteogenic 
– lineage progeny – osteocytes, and whether osteocyte pathology can also contribute to 
pathogenesis of OA. 
4.1.1 Subchondral bone changes in OA and the role of osteocytes 
As mentioned in Chapter 1, OA has a multifactorial anatomical (McGonagle et al., 2010) 
and pathogenetic basis (Martel-Pelletier et al., 2016). It is recognised as a disease of the 
whole joint and is characterised by pathological changes to cartilage, subchondral bone 
and the synovium (Lories and Luyten, 2011; Goldring and Goldring, 2016a). Irrespective 
of the site of initiation, subchondral bone sclerosis is an important feature in OA 
pathophysiology (Henrotin et al., 2012). Other changes in OA bone include alterations in 
overall shape, mineral density and bone remodelling rates, osteophyte formation, 
development of subchondral bone cysts and advancement of the tidemark with vascular 
invasion into the calcified cartilage (Goldring, 2008; Goldring, 2009; Burr and Gallant, 
2012). Altered bone architecture and other signs of ongoing, or recent, bone remodelling 
activity were proposed as an early and very important events in OA  (Lajeunesse and 
Reboul, 2003) particularly evident in BMLs (Zanetti et al., 2000), which are predictive 
of OA progression (Bowes et al., 2016). .  
It is still not clear whether the bone abnormalities observed in OA are a consequence of 
the disease or a trigger. However, the interface between subchondral bone and the outer 
surface of the joint- including cartilage- is disrupted, which may allow the exchange of 
molecular signals that could influence the progression of the disease in both directions. It 
is also possible that abnormal mechanical loading on the joint is a critical factor affecting 
both subchondral bone and cartilage tissues simultaneously. This may lead to a combined 
effort of the bone derived cells to engage an endogenous repair mechanism which in OA 
seems to be unsuccessful. 
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The alterations in the subchondral bone that characterise the osteoarthritic process 
represent adaptations to local biomechanical and biological signals. These changes are 
mediated by bone cells that modify the architecture and properties of the bone through 
active cellular processes of modelling and remodelling (Goldring, 2009). Remodelling of 
microdamaged bone in both health and OA is essential for the maintenance of bone 
strength. The majority of studies into bone remodelling in OA have focused on osteoblasts 
(Couchourel et al., 2009), their parent: MSCs (Zhen et al., 2013; Campbell et al., 2016), 
and osteoclasts (Durand et al., 2013).  However, there is a paucity of data on osteocytes 
in OA, which is surprising given that osteocytes are the most abundant and longest living 
bone cells (Boskey and Coleman, 2010).  
Osteocytes play a cardinal role in bone mechano-transduction (Klein-Nulend et al., 2013) 
and are increasingly viewed as master regulators of the bone remodelling cascade 
(Prideaux, Findlay, et al., 2016). In an elegant study by Zhen et al. in a murine model of 
OA it was shown an increase of MSCs in the osteochondral areas in response to abnormal 
mechanical loading due to OA and furthermore, the inhibition of TGF-b in these MSCs 
attenuated the disease (Zhen et al., 2013). In this study it was hypothesised that the altered 
microenvironment induced by abnormal mechanical loading in OA may lead to “in situ” 
commitment of osteoprogenitors in the BM cavities (Zhen et al., 2013). Given the 
osteocytes function as mechano-sensors and master regulators of bone formation and 
resorption (Prideaux, Findlay, et al., 2016), these findings indicated that osteocytes may 
be acting as triggers of OA bone pathology and rises the awareness of the importance of 
the whole mesenchymal lineage in OA bone. Another study reported increased osteocytes 
death in OA (Jaiprakash et al., 2012) suggesting an altered OA osteocyte phenotype 
which may be a consequence of the disease progression and relates to an altered MSC 
phenotype described in Chapter 3 of this project and by others (Zhen et al., 2013; 
Campbell et al., 2016) which may influence their downstream progenies and vice-versa. 
However, the role of osteocytes in OA pathophysiology is still unexplored and more work 
is needed to understand the cellular mechanisms behind OA bone pathology.  
4.1.2 Current methodologies for studying osteocyte biology in health and 
disease 
While bone MSCs are easily accessible for direct study following enzymatic extraction 
and cell sorting as shown in the previous chapter, the study of osteocytes in vivo has 
proved challenging due to their location, embedded in the mineralized matrix. This makes 
them difficult to isolate and therefore other experimental approaches for their study have 
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been undertaken. Prior to the discovery of genetic markers specific to osteocytes, these 
cells were identified by their morphology and spatial relationships within bone. 
Osteocytes were defined by their location, which may translate into a lack of knowledge 
regarding their function.  
Further on, the ‘gold-standard’ for the study of osteocytes nowadays is the use of in vitro 
cell lines, such as MLO-Y4 (Kato et al., 1997) or generation of in vitro surrogate cells 
(Thompson et al., 2015) and more recently, 3D cultures using differentiating osteoblastic 
cells into gel matrices (Sun et al., 2015) or the co-culture of osteoblasts on top of MLO-
Y4 osteocyte cell line cultured in three dimensional collagen gels (Vazquez et al., 2014). 
Although these cultures likely give a better approximation of the natural environment of 
the osteocyte, they still require the use of cell lines or isolated cells, with all their 
limitations. In addition, gels do not exactly mimic the biochemical make-up of the matrix. 
These methods may be effective in generating a morphologically similar cell type, but it 
is unlikely that they resemble the in vivo phenotype of osteocytes, as the conditions where 
they exert their functions are largely different. As opposed to culture conditions, in vivo 
osteocytes reside encased in a mineralised matrix forming an interconnected osteocyte-
canalicular cell network  with a central and multi-functional role in regulating skeletal 
homeostasis (Bonewald, 2011). Mechanosensing is widely accepted as one of the 
principal function of osteocytes.  This functionality places these cells as transducers of 
mechanical strains that are translated into biochemical signals with influence over the 
communication among osteocytes and between osteocytes and other bone cells, including 
the MSCs. Their location is a determinant of their three-dimensional shape, and thereby 
likely affecting their ability to sense mechanical signals and the communication within 
the lacuno-canalicular network as well.  
Attempts to isolate osteocytes from mouse (Stern et al., 2012) and human bone (Prideaux, 
Schutz, et al., 2016) have been performed previously but the cell population remained 
impure.  Without a specific cell marker, the population would contain other cell types 
from the surrounding microenvironment. Also, as native osteocytes are no longer able to 
divide, osteocytes cultures may quickly be overgrown by other cell types, limiting the 
useful life span of the culture. It remains to be shown to what extent osteocytes cultured 
in two dimensions on tissue culture plastic retain their complete osteocyte-like phenotype.  
4.1.3 Osteocyte molecular markers 
To assess the osteocyte purity and stage of maturation, a panel of genes has been proposed 
comprising classical osteocyte markers (Dallas et al., 2013) summarised in Figure 4.1. 
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The molecular signature of osteocytes comprises genes and proteins that control dendritic 
morphology and canaliculi formation, phosphate metabolism and matrix mineralization, 
bone formation and bone resorption (Plotkin and Bellido, 2016). Knowledge of this 
signature of osteocytes in their native state would allow a more direct and thorough 
examination of the molecular and cellular biology of these cells in the context of OA 
pathology.  
 
Figure 4.1. Osteocyte molecular signature during differentiation process. As the 
osteoblast differentiate into embedding osteocytes a decrease expression of ALP 
concomitant with an increase expression of proteins associated with canalicular 
formation (E11, MMP14) is maintained in early osteocytes and decreases as they 
terminally differentiate. During the maturation process osteocytes secrete Wnt pathway 
inhibition (DKK1, SOST) and paracrine phosphate regulation (FGF23). Cytokines 
responsible for bone resorption activation (RANKL) or inhibition (OPG) are also 
secreted at all stages of differentiation. MEPE, PHEX and DMP1 are proteins 
responsible for mineralisation process and are expressed at more mature stages. SOST 
is exclusively expressed by mature osteocytes. Adapted from (Compton and Lee, 2014). 
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Osteocyte’s osteoblastic origins are well recognised (Aubin and Turksen, 1996), however 
while in their mature stage of differentiation the nature of the relationship between 
osteocytes and their mesenchymal ancestry, the MSCs is still unclear. Osteocyte-specific 
molecules start being expressed once the osteoblasts stop actively producing bone matrix 
and they become entrapped within the formed osteoid where they differentiate into 
osteocytes (Dallas et al., 2013). As discussed in Chapter 1, Section 1.4.1, approximately 
10-20% of the osteoblasts continue their differentiation process to osteocytes, while some 
are cleared by apoptosis or become quiescent bone lining cells (Miller et al., 1989; Aubin 
and Turksen, 1996), however the determinant behind osteoblasts’ fate it is still unknown.  
Osteocytogenesis is not a passive process, on the contrary, is invasive and requiring the 
cleavage of collagen and potentially other matrix molecules (Karsdal et al., 2004). 
Holmbeck et al. showed that the dramatic morphological changes during the initial 
embedding are facilitated by MMP14, also known as MT1-MMP. This membrane bound 
matrix metalloproteinase is required for the development of the dendritic processes as 
they protrude in the newly forming osteoid (Holmbeck et al., 2005). One of the earliest 
molecules also demonstrated to be responsible for the cytoskeletal changes during 
osteocytic differentiation is E11, also known as podoplanin. This transmembrane 
glycoprotein was shown to be responsible for dendrite elongation in response to 
mechanical strain (Zhang et al., 2006). E11 has been proven by various studies to play an 
essential important role in osteocyte formation. E11 is highly expressed during the 
transition from osteoblast to the nascent osteocyte concomitant with matrix 
mineralisation and the formation of dendritic processes (Staines et al., 2016). E11 
expression was demonstrated by an in vitro study using the MLO-Y4 osteocytic cell line 
to be intimately modulated by the extent of mineralisation of the extra cellular matrix, 
revealing the importance of the interaction between the cells and the matrix they reside 
in (Prideaux et al., 2012).  The mineralization of the extracellular matrix proved therefore 
essential for terminal osteoblast differentiation to the osteocyte phenotype. Studies in 
mice also showed that conditional deletion of this protein in bone leads to a disrupted 
osteocyte network and shorter dendritic processes (Staines et al., 2017). 
Osteocytes express molecules with important roles in mineralisation and phosphate 
metabolism, such as dentin matrix protein 1 (DMP1), phosphate-regulating neutral 
endopeptidase on chromosome X (PHEX) and matrix extracellular phosphoglycoprotein 
(MEPE). DMP1 is required for osteocytes maturation and bone mineralisation (Rios et 
al., 2005; Feng et al., 2006). DMP1-null mice displayed a defective bone mineralisation 
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accompanied by an altered osteocyte phenotype, with increased expression of osteoblastic 
and early osteocyte genes in mature osteocytes as well as lack of sclerostin expression 
(Rios et al., 2005). Although the exact function of PHEX has not yet been elucidate, 
mutations in either DMP1 or PHEX were associated hypophosphatemic rickets and 
elevated levels of fibroblast growth factor 23 (FGF23) (Feng et al., 2006). Osteocytes 
have also been described as exerting endocrine functions through the actions of FGF23 
(Dallas et al., 2013), mainly expressed by osteocytes (Yoshiko et al., 2007). Factors 
secreted by osteocytes act in concert not only to regulate skeletal mineral homeostasis 
locally, but also to control serum phosphate levels systemically by actions on the kidney. 
The most direct link between osteocytes and the kidney is provided by FGF23, a 
phosphaturic hormone produced by osteocytes that acts on kidney tubule cells to suppress 
tubular phosphate reabsorption (Riminucci et al., 2003).  
4.1.4 Osteocytes roles in bone resorption and formation 
Osteocytes play a central role in bone remodelling (Prideaux, Findlay, et al., 2016). Their 
contribution to bone resorption has been documented by numerous studies. One of the 
means by which osteocytes modulate bone resorption is through their death. Osteocyte 
apoptosis can occur at sites of microdamage and it was proposed that dying osteocytes 
are targeted for removal by osteoclasts (Verborgt et al., 2002). Apoptotic osteocytes 
release signals to stimulate the remodelling of the bone at specific sites and time points 
(Manolagas, 2006). Such signals include the osteoclastogenesis activator, RANKL that 
binds to precursor and mature osteoclasts, which stimulates their differentiation, function 
and survival (Nakashima et al., 2011), as discussed in Chapter 1, Section 1.2.3. 
Osteocytes also produce the main inhibitor of RANKL; OPG, and the ratio of RANKL to 
OPG at a particular location determines the magnitude of bone resorption at that site 
(O’Brien et al., 2013).  
Emerging evidence also supports the idea that osteocytes actively participate in bone 
resorption by remodelling the lacunae in which they reside (Wysolmerski, 2012), a 
process known as osteocytic osteolysis. Osteocytes lacunae of lactating mice were shown 
to be larger during lactation and it comes back to normal after lactation in both cortical 
bone and trabecular bone (Qing et al., 2012). It was also shown that osteocytes express 
genes that osteoclasts use for resorption, including Acid Phosphatase 5, Tartrate Resistant 
(ACP5, commonly known as TRAP) and cathepsin K (CTSK) and these genes are 
significantly increased during lactation and decrease after (Qing et al., 2012). Enlarged 
perilacunar matrix was also found increased and shown to be remodelled by osteocytes 
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during stress, such as glucocorticoid treatment (Fowler et al., 2017). By perilacunar 
remodelling osteocytes dynamically resorb and replace the surrounding perilacunar bone 
matrix to maintain mineral homeostasis (Fowler et al., 2017) although this process in OA 
have not been investigated yet. Osteocyte-mediated bone resorption may represent an 
attractive therapeutic target to delay or prevent the development of OA as well as other 
associated bone conditions.   
At the same time, osteocytes have also been recognised for their role in controlling bone 
formation by their production of SOST (van Bezooijen et al., 2004) and DKK1, another 
Wnt inhibitor, which was also reported to contribute to osteophyte formation in OA 
(Diarra et al., 2007; Weng et al., 2010). When sclerostin binds to the LRP5/6 and Frizzled 
co-receptors on the cell surface of osteoblasts, Wnt/β-catenin signalling is inhibited (Li 
et al., 2005), thereby inhibiting osteoblast differentiation, proliferation, and activity, 
resulting in reduced osteoblastic bone formation (Li et al., 2008). Both SOST and DKK1 
have been recently shown to be implicated in OA subchondral bone changes (Weng et 
al., 2010; Zarei et al., 2017; Jia et al., 2018) and limited data also suggests their important 
role in osteocyte survival or apoptosis in human OA bone pathology (Jaiprakash et al., 
2012). A recent study showed that the low levels of sclerostin induced by mechanical 
loading in severe late-stage OA in mice as well as the elevation of bone formation in the 
subchondral plate are the major mechanisms characterizing subchondral bone phenotypes 
observed in this murine model of OA (Jia et al., 2018). 
Emerging evidence from animal models and in vitro studies revealed critical functions of 
osteocytes in bone homeostasis and consequently there are indications of their potential 
involvement in bone associated pathologies. However, the biology of human osteocytes 
and especially their implication in OA is currently unexplored. More work is needed for 




4.2 Chapter aims 
1. To establish robust gene markers for human native osteocytes and to test their 
specificity by comparing their expression with donor-matched MSCs.  
2. To investigate the gene expression signature of osteocytes in OA bone in 
comparison to healthy IC control bone  
3. To document the topographic relationships between MSCs and osteocytes in OA 
femoral head bone, and in relation to disease associated pathology. 
  
 142 
4.3 Methods  
To avoid culture manipulations, the bone treatment procedure was developed to 
simultaneously obtain pure osteocyte-enriched fragments and matched native CD45-
CD271+ MSCs (Chapter 2, Section 2.2). The enzymatic extraction of MSCs was 
described in Chapter 2, Section 2.2.1. The remaining bone fragments following this 
procedure were further used for RNA isolation from native osteocytes and to confirm 
their purity by gene expression and histology. 
4.3.1 Patient samples  
The bone samples obtained following the MSC extraction procedure described in Chapter 
3 were used in parallel for osteocyte-enrichment during this study. For all the experiments 
in this chapter a total number of n=30 OA donors (12 males and 18 females) with age 
range between 40-90 years (median=72) and n=19 healthy donors (10 males and 9 
females) with age range between 17-78 years (median=55) were recruited. The 
osteocytes-enriched bone fragments were obtained from control IC bone biopsies of n=11 
healthy donors and from n=9 OA femoral heads and used for gene expression analysis. 
In addition, healthy (n=6) and OA (n=11) sorted MSCs and HLCs which were obtained 
following MSC isolation described in Chapter 3 were used here as controls for gene 
expression analysis along with the osteocytes-enriched bone fragments. Amongst these 
samples, total number of 5 samples were donor matched for MSCs, HLCs and osteocytes 
(n=2 IC and n=3 OA). While IC bone was used as healthy control for experiments in this 
chapter, recent published literature (Ilas et al., 2019) provided supportive evidence of its 
suitability and comparable gene expression for both osteocytes and MSCs. 
For histological studies a total of n=4 OA femoral head samples were used while n=3 
healthy IC were used as control bone. The samples used for histology in some cases were 
different from the ones used for MSC extraction and osteocyte-enrichment. The healthy 
IC bone specimens obtained from surgery were not sufficient to perform both experiments 
while some femoral heads were used as whole only to have a global (macroscopic) view 
of hip OA pathology.  
4.3.2 Sample processing to produce osteocyte-enriched bone fragments  
As described in Chapter 2, Section 2.2, the enzymatic treatment during MSC extraction 
procedure was first optimised to remove most of the cellular material from the bone 
surfaces while the osteocytes remained embedded in the bone. For this, the denuded bone 
fragments were washed repeatedly with sterile PBS to remove any contaminant tissue. 
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The bone fragments were distributed equally in conical tubes (approximately 5g in each 
tube) with 15ml of sterile PBS and shaken rigorously to dislodge any remaining soft tissue 
in the trabecular cavities. After every wash, organic residue consisting of fat, blood clots 
and other stromal tissue was cleared away leaving the PBS of clear appearance. At this 
stage the bone fragments were visibly clean of any residual tissue and they were clear 
white in appearance (Figure 4.2). Some of the bone fragments were used for RNA 
isolation (approximately 1g for each RNA isolation procedure) while the rest were placed 
in 3.7% PFA for overnight fixation and used for histological validation of this method. 
 
Figure 4.2. Bone processing for osteocytes enrichment. The remaining bone fragments 
following enzymatic treatment were further depleted of all soft tissue by extensive PBS 
washes. After each wash the residual tissue cleared away until the bone was white in 
appearance. The bone fragments were lysed in situ for RNA extraction from osteocytes. 
 144 
4.3.3 Osteocytes-enriched bone RNA isolation and gene expression  
As described in Chapter 2, Section 2.2 and 2.5, osteocyte-enriched bone obtained 
following collagenase digestion and osteocyte enrichment procedure from healthy IC and 
OA femoral heads were used for RNA isolation and subsequent gene expression analysis. 
To extract pure native osteocyte RNA, the tissue-denuded bone fragments were 
homogenised in Guanidine isothiocyanate (GITC) lysis buffer (GITC solution containing 
0.4% sodium citrate, 1% N-lauryl sarcosine and 0.5% β-mercaptoethanol, Appendix 1). 
The bone fragments were homogenised by using a pipette tip or scalpel with a number 10 
blade to break the fragments into the smallest sizes and allow the lysis buffer to penetrate 
the bone chips and lyse the osteocytes in situ. The lysate was immediately transferred to 
1.5ml centrifuge tubes and kept at -80 ºC until RNA isolation was performed.  
Total RNA was extracted as outlined in Chapter 2, Section 2.5.1 using an adaptation of 
the previously described method by Chomczynski and Sacchi (Chomczynski and Sacchi, 
1987) and summarised in Figure 4.3. After homogenisation, the samples were mixed with 
an equal volume of acid phenol (pH 5, Sigma), 0.1 volume of 2M sodium acetate (Sigma) 
and 0.2 volume of chloroform : isoamyl alcohol (24:1, Sigma) and let to settle on ice for 
10 minutes. The tubes were then centrifuged at 4 ºC and 15000 g for 30 minutes. The 
aqueous phase formed (Figure 4.3) was carefully retained without disrupting the 
interphase and transferred into a new tube. The RNA was precipitated by adding an equal 
volume of isopropanol and incubated at -80 ºC for 2 hours or at -20 ºC overnight, followed 
by DNase (Invitrogen) treatment as described in Section 2.2.1. Total RNA was pelleted 
down with 5 minutes centrifugation at 15000 g at 4 ºC and resuspended in 50 µl of RNase 
free water. After quantification with Nanodrop the RNA was stored at -80 ºC.  
The isolated RNA was used to synthesize first-strand cDNA using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) described in Chapter 2, Section 
2.5.2. qPCR was performed on a QuantStudio™ 7 Flex Real-Time PCR System (Applied 
Biosystems) as described in Chapter 2, Section 2.5.3 using the same cycling conditions. 
The gene expression levels were normalised relative to housekeeping gene HPRT1 and 
calculated using the 2-∆Ct method similarly to all experiments in this study. The TaqMan 
probes for the genes of interest used for these experiments are detailed in Appendix 4, all 




Figure 4.3. Schematic representation of the RNA isolation from osteocytes-enriched 
bone. The tissue lysate was mixed with phenol:chloroform:isoamyl alcohol (25:24:1 
ratio) and allowed to settle. After 30 minutes’ centrifugation, the mixture separated into 
different layers (phases) based on density gradient. The upper aqueous phase containing 
the RNA was carefully removed and mixed with an equal volume of isopropanol for RNA 
precipitation. 
4.3.4 In vitro method validation 
Since the principal function of osteocytes is to sense and respond to mechanical forces it 
was hypothesised that the mechanical processing of the bone prior to collagenase 
treatment may affect the gene expression of these cells. To assess whether the mechanical 
stimulation of the bone fragments affected the gene expression levels of the embedded 
osteocytes, an in vitro assay was developed (Figure 4.4). The principle of this experiment 
was to allow the bone fragments to rest in culture and then mechanical stimulation would 
be applied by means of breaking down the bone in a similar manner as per the processing 
protocol described above. Bone fragments from different time points and with or no 
mechanical stimulation were homogenised for RNA extraction and gene expression 
analysis.  
Following enzymatic digestion and osteocytes-enrichment as described above, bone 
fragments from three donors were placed in 60 mm culture dishes with 3 ml of DMEM 
supplemented with 10% FCS and 1% P/S. After one day in culture, bone fragments were 
considered at rest. Approximately 100 mg of bone fragments were washed thoroughly 
with PBS and lysed for RNA isolation with no manipulation, straight from culture. Same 
weight of bone was then mechanically broken down to smaller fragments and then 
homogenised and lysed for RNA extraction. Similarly, RNA was isolated at Day 7 before 
and after mechanical stimulation and samples were all further analysed for gene 
expression using the osteocyte-specific gene markers.  
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Bone fragments from each time point were also tested for cell viability using a live/dead 
staining kit (Thermo Fisher) and viewed with a confocal microscope (Nikon A1R). 
Intracellular esterase activity and an intact plasma membrane are distinguishing 
characteristics of live cells. This kit was used to discriminate live from dead cells by 
simultaneously staining with green-fluorescent calcein to indicate intracellular esterase 
activity and red-fluorescent ethidium homodimer-1 to indicate loss of plasma membrane 
integrity. The bone fragments (100 mg or less) were washed with PBS and incubated for 
1 hour with 4 µM calcein (Thermo Fisher) and 8 µM ethidium homodimer-1 (Thermo 
Fisher) in 1ml of sterile PBS in the dark at room temperature. After a brief wash in PBS 
the bone fragments were examined with a confocal microscope Nikon A1R by using the 
488 nm laser line to detect calcein (green) and the 647 nm laser line for ethidium 
homodimer-1 (red). The background levels were negligible or completely absent because 
both stains fluoresce only in contact with the cells. The images were captured and 
generated using the integrated software, Nikon Elements (Nikon).  
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Figure 4.4. Schematic illustration of experimental setup for in vitro culture of 
osteocyte-enriched bone fragments. Bone fragments from n=3 OA donors were split into 
fractions at two different time-points following culture, at Day 1 and Day 7 respectively. 
At each time point bone fragments from one fraction were homogenised in RNA lysis, 
second fraction was broken down (mechanically stimulated) and then homogenised in 
RNA lysis and the third fraction was stained with live/dead stain which was further 
visualised using a confocal microscope. Both first and second fractions were processed 
for gene expression analysis by qPCR. 
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4.3.5 Histology  
Osteoarthritic femoral heads (n=4) and IC bone fragments (n=3) were fixed in PFA and 
decalcified in EDTA as described in Chapter 2 Section 2.6.1. Decalcified bone sections 
(5 µm thick) were used for immunohistochemistry or stained with HE, Safranin O and 
fast green, and TRAP.  
4.3.5.1 Haematoxylin and Eosin 
Tissue samples from bone fragments used in MSC extraction and osteocyte-enrichment 
were used for HE staining to assess the complete soft tissue removal from the bone 
fragments. Bone samples were collected before any enzymatic treatment and after the 
osteocyte-enrichment procedure. All the collected bone fragments were fixed and 
decalcified as described in Chapter 2, Section 2.6.1. Additionally, whole femoral heads 
were decalcified and embedded in large cassettes in order to provide a global view of hip 
OA, as described in Chapter 2, Figure 2.8. Slides with 5 µm tissue sections were 
deparaffinised and rehydrated as described in Chapter 2, Section 2.6.2. The slides were 
then transferred to Harris Haematoxylin (Sigma) for 2 minutes after which they were 
cleared with tap water for 1 minute. To perform the ‘blueing’ of the nuclei the slides were 
placed in Scott’s tap water for 2 minutes and washed in running tap water then 
immediately immersed in Eosin-Y solution for another 2min. After washing in tap water 
for 1 minute the slides were dehydrated and cleared in Xylene. The samples were then 
mounted with DPX medium (Sigma) and dried at room temperature before visualizing 
under light microscope. 
4.3.5.2 Safranin O 
Safranin 'O' was used for the detection of articular cartilage and its distinct separation 
from the bone tissue, as well as to evaluate any pathological changes in relation to disease. 
The intensity of safranin 'O' staining is directly proportional to the proteoglycan content 
in the cartilage while Fast green provides a clear contrast to the Safranin O staining. For 
this method Safranin O solution was prepared at 1% in distilled water by dissolving 2.5g 
of Safranin O powder (Sigma) in 250ml dH2O. Following deparaffinisation and 
rehydration, the slides were incubated in Weigert’s Iron Hematoxylin solution (Sigma) 
for 5 minutes followed by immersion for 2 seconds in 1% Acid Alcohol (1% HCl in 80% 
ethanol) to remove excess stain and define the nuclei. Slides were then counterstained in 
0.02% Fast Green for 1 minute and cleared in 1% Acetic acid for 30 seconds. The slides 
were then incubated for 10 minutes at room temperature in Safranin O solution and rinsed 
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briefly in absolute ethanol. Slides were dehydrated and cleared in xylene then mounted 
with DPX.  
4.3.5.3 Tartrate resistant acid phosphatase staining 
To detect osteoclast activity, TRAP staining was performed histochemically. The enzyme 
TRAP is expressed by osteoclasts during the process of bone resorption. The stain utilises 
Fast Red (Sigma) as a chromogenic substrate and tartrate with an acidic pH (pH 4.7-5) 
which relies on the chemical interaction between the cells expressing the enzyme and 
tartrate combined with a chromogenic substrate. The TRAP staining solution mix was 
prepared fresh, before every staining procedure, by dissolving 0.06% Fast Red Violet LB 
salt (Sigma) and 0.01% Naphthol AS-MX Phosphate in 200ml of already made TRAP 
basic incubation media (0.2 M sodium acetate and 50 mM L (+) tartaric acid in dH2O, 
pH 5.0). Paraffin sections of 5 μm thickness were deparaffinised in three changes of 
xylene (3 min each) and rehydrated (3 changes 95% ethanol, 3 min each; 1 change 75% 
and 50% ethanol each 3 min, dH2O for 2 min). After rehydration, samples were placed 
in pre-warmed TRAP staining solution mix for 30 min at 37ºC or until osteoclasts 
appeared bright red. Subsequently sections were rinsed with dH2O and counterstained 
with 0.02% Fast Green. Fast Red salt is soluble in ethanol therefore common graded 
ethanol dehydration was avoided and the slides were air dried overnight instead and 
mounted with aqueous Leica CV Ultra mounting media (Leica) the next day. Slides were 
scanned as described in Chapter 2 Section 2.6.4 and staining analysed in regions of bone 
sclerosis compared to non-sclerotic regions. 
4.3.6 Immunohistochemistry 
Immunohistochemistry staining was performed using the EnVision+ Dual Link System-
HRP (DAB+) (DAKO) as described in Chapter 2, Section 2.6.3. The antibodies used for 
this study were against CD271 (1:100, clone NGFR5, Abcam), E11 (1:200, clone NZ1, 
Merck Millipore), OPG (1:500, polyclonal, Abcam), RANKL (1:500, polyclonal, 
Abcam) and CTSK (1:300, Proteintech). Endogenous peroxidase activity was blocked for 
10 minutes by enzyme blocking solution (DAKO kit) and non-specific binding was 
blocked for 30 minutes using antibody diluent (DAKO). Tissue slides were then 
incubated with primary antibodies for 1 hour and secondary antibody for 30 minutes. The 
secondary antibody consisted of a labelled-polymer horse radish peroxidase (HRP) which 
was applied first for 30 minutes followed by 10 minutes incubation with 3,3'-
diaminobenzidine tetra hydrochloride (DAB) (both included in the DAKO kit). DAB 
reacts with HRP forming an insoluble brown-coloured precipitate at locations where 
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labelled-polymer HRP is bound to primary antibodies. The slides were then 
counterstained with haematoxylin for 2 minutes and mounted using DPX media. The 
optimal concentration of primary antibody was determined in dilution series on test tissue 
sections. No primary antibody was used as negative control; these slides were incubated 
with antibody diluent alone.  
Slides were scanned on Leica Aperio AT2 up to an original magnification of ×20 and 
images were captured using Aperio Imagescope (Leica) as described in Chapter 2 Section 
2.6.4. Semi-automatic counting of E11-positive osteocytes was performed within a 
defined bone area and region of interest from OA femoral head sections from n=3 donors, 
using a minimum of 10 regions per patient. Percentage of positive osteocytes from total 
number of osteocytes per region analysed was calculated to determine the number of 
early/immature osteocytes in sclerotic and non-sclerotic areas of hip OA. The abundance 
of CD271-positive MSCs was assessed as percentage of positively stained area within a 
defined trabecular bone cavity area and region of interest, using a minimum of 10 regions 
per patient as described in Chapter 2, Section 2.6.5. This quantification was performed to 
ascertain the abundance of CD271-positive MSCs in sclerotic and non-sclerotic regions 
of hip OA, similarly to E11. No quantification was performed for OPG, RANKL and 
CTSK, the expression of these proteins was analysed qualitatively in regions of bone 
sclerosis and compared to non-sclerotic regions and healthy IC. 
4.3.7 Statistics 
The statistical analyses for gene expression experiments were performed using Mann-
Whitney test for comparisons between two groups and Wilcoxon for matched paired data 
between two groups. Kruskal-Wallis analysis was employed for intergroup differences, 
corrected with the Bonferroni-Dunn multiple-group comparison. For the 
immunohistochemistry experiments, the statistical analysis for area quantifications 
included Mann-Whitney test for comparisons between the sclerotic and non-sclerotic 
areas for each patient. 
Results are presented as scatter dots plots with medians or box and whisker plots; with 
boxes representing interquartile range, and whiskers representing the maximum and 
minimum values, calculated using GraphPad Prism version 7 software. Results were 
considered significantly different at p < 0.05 (with significance level denoted as 




4.4.1 Preparation of osteocyte-enriched bone fragments 
In order to investigate the gene expression profiles of native human osteocytes a protocol 
was first optimised to extract RNA from pure native osteocytes, depleted of any 
contaminating cells present on the bone surfaces and BM cavities. To test its purity, the 
gene expression was analysed and compared to their MSC progenitors. Therefore, a 
protocol for the simultaneous preparation of osteocyte-enriched bone and donor-matched, 
pure uncultured MSCs from that same bone was first optimised derived from the already 
established method used for MSC extraction described in Chapter 3, Section 3.3.2. 
Histological examination of the bone fragments following osteocyte enrichment was 
employed to visually assess the complete removal of cellular material from the bone 
surface. The aim was to keep the osteocytes embedded in the bone as the only cellular 
material in the denuded bone fragments. 
Haematoxylin-eosin stained trabecular bone before enzymatic treatment showed a 
delicate meshwork of bony trabeculae covered by bone-lining cells in which the highly 
cellular BM tissue resided (Figure 4.5A). Following collagenase treatment and extensive 
PBS washes, the stromal tissue and bone lining cells were completely removed from the 
trabecular cavities, with only occasional cells remaining attached to the bone surface in 
small deep pores (Figure 4.5B). These bone fragments were further washed with PBS to 
ensure complete removal of bone lining cells leaving only embedded osteocytes as the 
remaining cellular material (Figure 4.5C, D). This osteocyte-enriched bone was 
subsequently used for gene expression analysis.  
To obtain a better view over the osteocyte’s phenotype, their gene expression was 
compared to the MSCs and HLCs extracted from the stromal compartment following the 
collagenase digestion and purified by FACS, as described in Chapter 2, Section 2.4. The 
analysis was therefore performed using the osteocytes-enriched bone in comparison with 
the donor matched MSCs (CD45-CD271+ cells), while HLCs (CD45+CD271- cells) 
were used as a control non-mesenchymal lineage population. 
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Figure 4.5. Haematoxylin and Eosin staining of trabecular bone illustrating the 
generation of osteocyte-enriched bone fragments. (A) Histological appearance of the 
bone trabeculae and BM tissue before processing. (B) After collagenase digestion, most 
of the marrow tissue, containing the MSCs, was removed by the enzymatic digestion, with 
minimal cells remaining in the deep pores of the bone. (C) Bone trabeculae showing the 
complete removal of residual bone lining cells by the extensive washes. (D) Higher 
magnification photomicrograph showing osteocytes embedded in the bone matrix as the 
only visible cellular material left following enzymatic digestion and extensive wash. 







4.4.2 Expression of osteocyte-specific genes in osteocyte-enriched bone and 
MSCs  
To assess osteocyte enrichment following the above procedure, gene expression analysis 
was first conducted on healthy IC bone followed by OA femoral head bone. The first aim 
of the gene expression analysis performed in osteocytes and MSCs was to verify 
osteocytes identity based on specific osteocyte markers as described in Section 4.1.3 and 
secondly to assess the potential alterations that occur in OA bone. The HLCs fraction was 
used as negative control population for the mesenchymal lineage cells.  
In addition to the selected osteocytes markers, three MSCs markers used previously in 
Chapter 3, CXCL12, ALPL and SP7, were also selected as specific for MSCs and to serve 
therefore as negative markers for osteocytes.  
In the RNA from IC bone, as expected, the expression of classical late osteocytes markers 
SOST, DMP1, MEPE and PHEX was higher in osteocyte-enriched bone compared to 
purified MSCs (Figure 4.6A). SOST and PHEX were particularly low in MSCs (detectable 
only in 1 out of 6 tested samples) and could therefore be considered the most 
differentially-expressed molecules between osteocytes and MSCs. DMP1 and MEPE 
were also confirmed to be osteocyte specific, being 60-fold (p=0.002) and 18-fold 
(p=0.013) higher, respectively, in osteocytes compared to MSCs. Apart from PHEX, all 
other tested osteocyte-specific transcripts were expressed at considerably lower levels in 
HLCs, confirming their mesenchymal lineage specificity (Figure 4.6A). The expression 
of FGF23, E11 and DKK1 in osteocytes compared to MSCs failed to reach statistical 
significance, although a trend for lower expression in MSCs was observed (Figure 4.6A). 
In respect to the selected native MSC specific molecules, these were tested here for the 
first time in native osteocytes. Compared to MSCs, osteocytes expressed lower levels of 
all three MSCs specific transcripts CXCL12, ALPL and SP7, in line with their more 
mature differentiation stage (Figure 4.6B). However, these differences were not as large 
as those between MSCs and HLCs, consistent with anticipated differences between cells 
of different lineages (MSCs and HLCs) and cells representing different maturation stages 
within the same lineage (MSCs and osteocytes).  
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Figure 4.6. Comparative gene expression of osteocytes and MSC markers in healthy 
bone. Comparison of (A) osteocyte-, (B) MSC -specific gene expression in osteocyte-
enriched fragments (OCY) (n=11), CD45-CD271+ mesenchymal stem cells (MSC) (n=6) 
and CD45+CD271- haematopoietic lineage cells (HLC) (n=6) from healthy bone. 
Results are expressed relative to HPRT1. Absence of dots indicate that values were below 
detection thus precluding full statistical analysis of the respective data set. 
 155 
Similar trends were observed between MSCs and osteocytes following analysis of 
femoral head bone samples from OA patients (Figure 4.7A). The greatest differences 
between osteocytes and MSCs were found for late osteocyte markers SOST, DMP1, 
PHEX, MEPE and FGF23. The genes for SOST, DMP1 and PHEX were expressed in all 
osteocytes group while these transcripts were detected in only some of the either MSCs 
or HLCs fractions, similarly to the healthy group described above. In the cases where 
transcripts could be detected on more than half of the tested samples statistical analysis 
confirmed the increased levels in osteocytes compared to MSCs and HLCs. The levels of 
E11 and DKK1 showed a trend for lower expression in MSCs compared to osteocytes 
(Figure 4.7A), similar to the ones observed in the cells derived from healthy bone (Figure 
4.6A) although they failed to reach statistical significance. All the three MSC markers 
were consistently higher in MSCs as compared to osteocytes and HLCs (Figure 4.7B), 
consistent with the levels observed in the healthy group.  
Gene expression analysis described here confirmed the specificity of the selected 
molecules to verify osteocyte identity. Furthermore, this data taken together with the 
histological assessment of the enrichment-procedure serve as evidence that the protocol 
optimised to study the gene expression profiles of native osteocytes was successful. 
Although all the tested molecules showed specificity to the cells that were selected to be 
tested for, several differences were noted. Some molecules analysed in both MSCs and 
osteocytes were expressed at different levels between healthy and OA groups and were 
further investigated in the following sections.  
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Figure 4.7. Comparative gene expression of osteocytes and MSC markers in OA bone. 
Comparison of osteocyte- (A), MSC and early osteoblast-specific (B) gene expression in 
osteocyte-enriched fragments (OCY) (n=9), CD45-CD271+ mesenchymal stem cells 
(MSC) (n=11) and CD45+CD271- haematopoietic lineage cells (HLC) (n=11) from OA 
bone. Results are expressed relative to the values of HPRT1. Missing dots indicate that 
values were below detection thus precluding full statistical analysis of the respective data 
set.  
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4.4.3 In vitro assessment of osteocyte-enriched bone fragments 
Since osteocytes are mechano-sensory cells it was hypothesised that the mechanical 
processing of the bone fragments may affect gene expression levels in osteocytes. To 
investigate this the fragments were mechanically broken down at several intervals while 
being in culture at rest. The RNA was isolated from osteocytes before and after 
mechanical processing, at day 1 and day 7.   
To confirm the viability of osteocytes under culture conditions, the bone fragments were 
incubated with a live/dead stain comprising of calcein and ethidium homodimer-1. Before 
incubation however, the bone fragments were observed under an inverted microscope to 
identify any potential cell outgrowths from the denuded bone fragments. As shown in 
Figure 4.8A there were no visible cells in the culture dish or surrounding the bone chips 
after a week under tissue culture conditions, suggesting successful depletion of any 
remaining stroma or bone lining cells. Using confocal microscopy, the samples after one 
week in culture medium had a considerable number of live cells present (Figure 4.8B). It 
is difficult to discriminate osteocytes from any other cells that may have grown on the 
bone surface, however these cells may originate from a rather low number of 
contaminating cells at the start of the experiment.   
The gene expression levels of the main osteocyte markers assessed in samples from the 
three donors showed no specific pattern either before or after mechanical processing 
(Figure 4.9). However, the results confirmed the expression of all osteocyte-specific 
molecules. Without any specific expression pattern, this data may also indicate that the 
gene expression levels are more likely affected by the culture conditions rather than 
mechanical stimulation. Considering data obtained from fresh osteocytes (Figure 4.7), an 
overall reduction in gene expression was observed in Day 7 as compared to Day 1. 
Especially noticeable is the reduced expression of FGF23 under culture conditions, both 
at Day 1 and Day 7. 
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Figure 4.8. Viability of osteocyte-enriched bone fragments culture. (A) shows the 
absence of cells in the culture dishes and around the bone fragments following one week 
in culture. (B) shows the live (green) and dead (red) staining of osteocyte-enriched bone 
fragments in culture conditions after 1 week. Scale bar, 200 µm 
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Figure 4.9. Gene expression of osteocyte transcripts and molecules associated with 
bone remodelling in cultured enriched-bone fragments. Graphs show relative gene 
expression levels of osteocyte specific molecules under culture conditions and 
mechanical stimulation after one day and one week. Dots with connecting lines represent 
expression levels on a log scale between rest and mechanical stimulation while 
unconnected dots denote levels below detection of the corresponding data points. 




4.4.4 Gene expression in osteocytes from OA bone 
Having established a reliable method to study gene expression in native osteocytes and 
MSCs from the same bone, the next aim was to analyse potential differences between 
healthy and OA osteocytes in their native state. The gene expression analysis was 
performed on fresh samples using native osteocytes RNA obtained from n=9 OA and 
n=11 healthy donors. 
4.4.4.1 Osteocyte-specific markers 
No significant differences in the expression of classical osteocyte transcripts (SOST, 
DMP1, MEPE, PHEX, FGF23 and DKK1) were noted between healthy and OA bone 
osteocytes, apart from the early osteocyte markers E11 and MMP14 (Figure 4.10).  
Both molecules are specifically expressed by osteocytes at their early stage of 
differentiation facilitating their embedding in the newly formed osteoid (Holmbeck et al., 
2005; Zhang et al., 2006). E11 was 9-fold higher in OA femoral head osteocytes 
compared to IC osteocytes (p=0.0028, Figure 4.10) whereas the level of MMP14, 
involved in the maintenance of osteocytic dendritic processes (Holmbeck et al., 2005), 
was 4-fold higher in OA compared to IC osteocytes (p=0.0097, Figure 4.10).  
These elevated levels observed in the early osteocyte marker E11 and the osteocyte 
specific MMP14 indicate an immature osteocyte phenotype with an active embedding 
activity. In support to this idea, all the other markers tested are mainly expressed by more 
mature osteocytes (Dallas et al., 2013) and no significant differences between healthy and 
OA groups was noted (Figure 4.10). .  
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Figure 4.10. Comparative gene expression of osteocyte-specific molecules between 
healthy and OA osteocytes. Gene expression levels in osteocytes from healthy (empty 
boxes, n=11) and OA bone (grey boxes, n=9) revealed that only the molecules that are 
expressed on early osteocytes showed significant differences (E11 and MMP14). No 
significant differences were observed in the levels of the late osteocyte markers; Results 
are expressed relative to the values of HPRT1. 
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4.4.4.2 Bone resorption molecules 
To investigate whether the OA environment modulated molecules involved in bone 
remodelling, the expression of RANKL (encoded by TNFSF11), OPG (encoded by 
TNFRSF11B), and resorption molecules cathepsin K (encoded by CTSK) and TRAP 
(encoded by ACP5) also implicated in osteocyte osteolysis pathways (Qing et al., 2012; 
Wysolmerski, 2013; Dole et al., 2017) were analysed in parallel to the classical osteocyte 
transcripts described above. 
Interesting differences were observed in expression of the selected genes associated with 
bone or bone matrix remodelling (Figure 4.11). While the mRNA levels for RANKL 
showed no significant difference between healthy and OA osteocytes, mRNA expression 
levels for OPG were 5-fold higher in osteocytes from OA bone (p=0.0185). The 
molecular balance between the osteoclastogenesis activator RANKL and its antagonists, 
OPG, dictates the rate of osteoclastogenesis (Brendan F Boyce and Xing, 2007) and 
hence, bone resorption. The ratio between these two molecules was calculated and it was 
determined that the OPG/RANKL mRNA ratio in OA osteocytes was 7-fold increased 
(p=0.0083, Figure 4.11) compared to healthy osteocytes, suggesting a bias towards bone 
resorption inhibition modulated by the osteocytes. Interestingly, similar trends were 
found on OA MSCs (Chapter 3, Section 3.4.3). 
The other molecules involved in the activity of bone resorption process, CTSK and TRAP, 
were also analysed alongside RANKL and OPG but with no significant differences 
between the healthy and OA osteocytes was observed, although a trend to increase 
expression in OA was noted in both genes (Figure 4.11). To validate this data, the 
expression of all resorption associated molecules will be further investigated at a protein 
level by immunohistochemistry.  
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Figure 4.11. Comparative gene expression of bone remodelling molecules between 
healthy and OA osteocytes. Comparison of gene expression levels between osteocytes 
from healthy bone (empty boxes, n=11) and OA bone (grey boxes, n=9) of the main 
molecules associated with bone resorption: osteoprotegerin (OPG), receptor activator of 
nuclear factor kappa-Β ligand (RANKL), cathepsin k (CTSK) and tartrate resistant acid 
phosphatase (TRAP). Results are expressed relative to the values of HPRT1. Mean ratio 




Taken together, these patterns of gene expression suggested higher early osteocyte 
activity and a potential bias for inhibition of bone resorption by osteocytes in OA femoral 
head bone. This data points to an underestimated role of osteocytes in OA bone pathology 
with implications to their early progenitors, the MSCs, which were shown to have a 
similar profile as described in Chapter 3.  
No age-dependent trends were observed for differentially expressed genes (E11, MMP14, 
OPG and RANKL) neither in IC nor OA osteocytes (Figure 4.12) indicating that the 
observed differences in the genes between healthy and OA osteocytes were likely to be 
characteristic of OA bone pathology rather than a result of systemic changes in bone 
homeostasis related to donor age.   
 
Figure 4.12. Donor age correlations of differentially expressed genes in healthy and 
OA osteocytes. Correlation between the gene expression levels of differentially expressed 
molecules from healthy (green dots) and OA (red dots) osteocytes and the donor age 
(years). Trend lines are shown in each graph with correlation coefficients and p values 
calculated using non-parametric Spearman correlation test. 
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4.4.5 Histological assessment of molecules of interest 
Gene expression analysis in osteocytes as well as MSCs (Chapter 3) showed an altered 
expression of genes involved in bone formation and remodelling. The differentially 
expressed genes were further assessed at protein level by using immunohistochemistry 
and in addition, their tissue distribution in relation to OA pathology was investigated. Of 
specific interest, this whole tissue distribution would also indicate potential topographical 
relationships between osteocytes and MSCs, the main cells under investigation as 
specified in the aims of this thesis. 
Based on the visual appearance of the articular cartilage and the underlining subchondral 
bone, it was observed that within the same femoral head, the degree of tissue damage was 
heterogeneous. To identify areas of bone and cartilage pathology, Safranin O staining was 
first performed on whole OA femoral heads (Figure 4.13A). Safranin O is a basic stain 
which binds with proteoglycans (acids) in cartilage with a strong affinity forming a red 
complex. The intensity of the staining depends on proteoglycan’s quantity contained in 
cartilage. This stain allowed for a distinctive separation of bone and cartilage making it 
possible to measure the bone areas in regions of visible damage and compare it to areas 
with a normal appearance. The areas of bone sclerosis commonly associated with 
increased bone volume (L.G. Cox et al., 2012) were identified below the regions of severe 
osteochondral damage, cartilage loss as well as fibrovascular tissue invasion beyond the 
tidemark (Figure 4.13B). Non-sclerotic regions (NS) (Figure 4.13B) representing 
minimally affected trabecular bone areas were localised distal from the diseased 
osteochondral regions or to the areas with the least osteochondral damage.  
Bone area measurements associated with these regions were performed to assess the 
validity of S and NS regions selection and showed a significant increase in the areas 
occupied by bone in S regions. Using ImageScope software (Leica) the cartilage was 
excluded from the selected regions for analysis, and bone area calculated as percentage 
of total tissue area, comprised thereof bone and stromal cavity. In S regions, the area 
covered by bone was between 54.08%-90.38% (median of 61.72%) while in the NS 
regions the bone was significantly reduced (p<0.0001) being in the range of 8.72% - 




Figure 4.13. Representative histology images of the whole femoral head stained with 
Safranin O. (A) Global picture of OA associated pathologies in a whole OA femoral 
head, noting the association between cartilage denudation and increased bone area. (B) 
Distinct bone and cartilage abnormalities characteristic to hip OA with the squares 
indicating the sclerotic (S) and non-sclerotic (NS) regions which were used for 
subsequent analysis and shown at higher magnification; arrow: tidemark, *: 
fibrovascular tissue. Sample ID: DIFHOA018 
5 mm























Figure 4.14. Comparison of bone area measurements between non-sclerotic (empty 
boxes) and sclerotic (grey boxes) areas of hip OA from three different donors. A 
minimum of 10 regions each in three femoral heads (FH) from all donors were used for 
area measurements and represented as percentage of bone out of total tissue area from 
the region of interest selected for analysis.  
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4.4.6 Bone resorption associated molecules 
To investigate the expression of the bone remodelling molecules as well as their tissue 
distribution in relation to the areas of OA bone pathology, IHC was employed using 
antibodies against OPG, RANKL and CTSK. The expression of TRAP was assessed 
histochemically by staining for the acid phosphatase enzymatic activity using a TRAP 
assay. This would facilitate the investigation of active osteoclasts but would also help to 
determine whether the TRAP enzymatic activity is present in osteocytes, having had 
shown its expression at a gene level. The immunohistological staining for RANKL and 
OPG was analysed in S and NS regions of n=2 OA femoral heads, selected based on the 
measurements described above as well as in n=1 healthy iliac crest. 
In the severe sclerotic regions of OA femoral head, strong OPG staining was observed, 
most obvious being in the fibrovascular tissue that had replaced the BM and breached the 
tidemark into the cartilage (Figure 4.15, upper panels); osteoblasts and some osteocytes 
were also strongly OPG-positive (Figure 4.15, bottom panels). In contrast, RANKL was 
absent or very low expressed (Figure 4.15, bottom panels). No obvious OPG or RANKL 
staining was found in the articular cartilage of this particular sample with a severe degree 
of osteochondral damage (Figure 4.15, upper panels).  
In the subchondral areas of the same femoral head, but distant from the osteochondral 
damage, the cartilage in this area was thicker and of normal appearance but with no 
positivity for either of the proteins (Figure 4.16).  This area was characterised by no 
visible alteration in bone or stromal tissue and no expression of RANKL and OPG was 
observed in either stromal cells or osteocytes (Figure 4.16, bottom panels).  
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Figure 4.15. Immunohistochemical staining of OA femoral head showing the 
topography of OPG and RANKL positive cells in subchondral S regions. Square areas 
magnified from upper panels showing the proximity of OPG positive osteocytes (arrow 
heads) to bone lining osteoblasts and the abundance of OPG in the dense fibrovascular 
tissue. In contrast RANKL is not expressed in any of the osteocytes from the same area 
while its expression in the fibrovascular tissue is notably lower. Scale bars: 300 µm upper 
panels, 100 µm bottom panels. Sample ID: DIFHOA018 
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Figure 4.16. Immunohistochemical staining of OA femoral head bone showing the 
topography of OPG and RANKL positive cells in subchondral NS regions. Square areas 
magnified from upper panels confirming the absence of OPG and RANKL positivity in 




Due to the heterogonous nature of OA bone alterations (Burr and Gallant, 2012), a second 
femoral head was analysed. It was noted that in this sample with less cartilage damage, 
the extent of bone sclerosis and fibrovascular tissue invasion was not as evident, 
suggesting a different stage of progression of the disease. In those samples, the expression 
of OPG was located similarly to previous sample, in the subchondral regions (Figure 4.17 
upper panels). However, in contrast to the regions with more severe bone sclerosis and 
general OA associated pathology documented in previous sample (Figure 4.15), RANKL 
was also found to be expressed here at similar levels and locations to OPG (Figure 4.17, 
bottom panels). Furthermore, in this sample the osteocytes and chondrocytes also showed 
positivity for both RANKL and OPG, suggesting a general remodelling modulation in 
this patient at a tissue level (Figure 4.17, magnified areas, left panels). In this sample, a 
notable number of bone remodelling sites was observed in the subchondral area, defined 
as an increased presence of osteo/chondroclasts and osteoblasts. This may be a 
consequence of the general RANKL expression which facilitated osteoclastogenesis 
while the presence of osteoblasts may indicate a high number of MSCs in that area in 
response to the high remodelling activity. 
In both samples analysed, osteocytes from the trabecular bone, that was non-sclerotic and 
distant from the subchondral area, were weakly positive for both RANKL and OPG, while 
expression in stromal tissue was not as evident as in the subchondral sclerotic areas 





Figure 4.17. Staining of OPG and RANKL in S regions of hip OA from second patient 
marked by severe osteochondral damage. Magnified rectangular areas show that there 
is evident staining of both molecules in the cells from areas of bone remodelling. Arrows: 
osteoblasts; arrow heads: osteo/chondroclasts; empty arrow heads: osteocytes. Scale 
bars: 200 µm left panels, 50 µm right panels. Sample ID: DIFHOA012  
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Figure 4.18. Staining of OPG and RANKL in non-sclerotic areas of hip OA from the 
second patient, located distant from subchondral area. Magnified rectangular areas 
show that expression in the stromal tissue is not as evident, although some osteocytes are 
positive, for both RANKL and OPG (arrow heads). Scale bars: 200 µm left panels, 50 µm 
right panels. Sample ID: DIFHOA012  
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Following the analysis of OPG and RANKL in these two samples of apparent different 
stages of degree progression, the expression of the two resorption modulation molecules 
was found to be heterogeneous between these patients. However, in both patients the 
expression of OPG and RANKL was predominantly found in the osteochondral regions 
while the distal regions were similar in appearance in both patients. In the second patient, 
the expression of RANKL was found strongly positive in bone remodelling areas. The 
positivity was detected on osteo/chondroclasts, as expected probably due to its membrane 
binding during their differentiation, as well as on the other cells, including the osteoblasts, 
bone lining cells and osteocytes. Further assessment using TRAP staining will be used to 
determine osteo/chondroclasts clasts activity in those regions of interest. In contrast, in 
the first patient there were no osteoclasts visible and the RANKL expression was absent.  
The expression of both molecules was found on osteocytes and corroborates the gene 
expression data. Both OPG and RANKL were found in osteocytes from regions of bone 
sclerosis as well as regions with no sclerosis or distal from the osteochondral area. 
Although no visible difference of expression was observed in the osteocytes between the 
different regions, their expression would be further investigated in the healthy IC in order 
to confirm the gene expression findings while the expression in MSCs will be investigated 
subsequently. 
While RANKL and OPG are molecules regulating the osteoclastogenesis and have 
mainly a regulatory role over the osteoclast differentiation, CTSK and TRAP are both 
enzymes with joined roles in the resorption activity itself. To investigate these molecules, 
antibody staining was performed using antibodies against CTSK while TRAP was 
assessed cytochemically using an acid phosphatase chromogenic based assay. Both 
stainings were performed on whole femoral head tissue sections from n=3 OA donors. 
Safranin O was also employed to allow the visual separation between bone and cartilage, 
making it possible to identify the nature of the tissue where the resorption takes place and 
hence differentiate between chondroclasts and osteoclasts, based on their tissue location.  
Numerous resorption pits could be observed in the subchondral areas of hip OA. 
Osteoclasts with ≥3 nuclei were frequently seen in those areas and were usually localized 
in resorbing bays, often in apposition to bone tissue as confirmed by Safranin O (Figure 
4.19). CTSK staining revealed the enzyme expression in the subchondral areas with high 
specificity only to osteoclasts. The osteoclasts activity was confirmed by the presence of 
TRAP as revealed in Figure 4.19, bottom panels.  TRAP-positive cells adjacent to bone 
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surface in the same location with the CTSK positive cells indicate the presence of active 
osteoclasts in those areas and inherently, bone remodelling activity.  
Osteocytes in those areas were found to be negative for CTSK as well as TRAP, both 
molecules showing specificity to osteoclasts only.  
             
Figure 4.19. Cartilage replacement by bone in subchondral regions of hip OA. OA 
femoral heads stained with Safranin O (upper panels), anti-Cathepsin K (CTSK, middle 
panels) and tartrate resistant acid phosphatase (TRAP, bottom panels). Safranin O 
indicates new bone formation breaching the cartilage. Increased bone remodelling 
activity is marked by CTSK- and TRAP-positive osteoclasts (arrow heads) within the 
same site with osteoblasts (arrows) and osteocytes (empty arrow heads) which are both 
negative. Scale bars: 200 µm, left panels; 50 µm, right panels. Sample ID: DIFHOA018 
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Assessing the expression of these resorption molecules in relation to osteocytes as well 
as MSCs was important to be evidenced here and served as part of the aims of this chapter. 
To correlate with the data obtained by gene expression, bone resorption associated 
molecules were investigated by immunohistochemistry in healthy IC.  
In healthy control IC bone, OPG staining was confined to stromal cells (Figure 4.20), 
with no expression observed in osteocytes. Similarly, RANKL was not expressed in 
healthy IC osteocytes or stromal tissue. CTSK was found on very low levels in IC, being 
restricted to osteoclasts only, which were limited to occasional bone remodelling sites 
(Figure 4.20, upper panels). This is expected because in IC the bone remodelling has 
minimal activity (Clarke, 2008). 
Since osteoclasts presence is minimal in healthy IC, but elevated in OA subchondral areas 
concomitant with tissue remodelling sites (Figure 4.20), the gene expression levels 
observed in the resorption molecules in OA osteocytes (CTSK and TRAP, Figure 4.11) 
could be in theory, attributed to osteoclasts contamination. However, histological 
evidence in Section 4.4.1 clearly shows complete soft tissue denudation. Moreover, as 
shown so far in the histological images, osteoclasts are rare cells with a short life-span, 
only present in the tissue remodelling areas and of orders of magnitude lower numbers 
compared to osteocytes. This suggests that the detected signal can only come from 
osteocytes. The absence of TRAP and CTSK expression at protein level may be due to 
an inability of these molecules to be translated from mRNA in osteocytes. Moreover, 
TRAP enzymatic activity is detected under a low pH (4.7-5), which may not be the case 
in the lacunar environment where osteocytes reside in.  
In summary, the expression of OPG was found elevated in all mesenchymal lineage cells, 
with an overall increased expression in the S areas of OA femoral heads. Meanwhile, the 
levels of RANKL were only noted in areas of active tissue remodelling, in both osteocytes 
and MSCs. These active areas were also associated with the presence of osteoclasts, 
which absence was corroborated with the increase expression of OPG, hence inhibiting 
their differentiation and survival. All together, these results confirm the involvement of 




Figure 4.20. Representative images from healthy IC in comparison to OA femoral head 
bone. OPG and RANKL are not expressed in healthy IC although OPG is present in the 
stromal compartment. Cathepsin K (CTSK) specificity for osteoclasts (arrow heads) was 
evident and no osteocytes were found positive. No osteoclasts were found in healthy IC 




4.4.7 Osteocyte and MSC distribution in relation to bone pathology in OA  
Osteocytes gene expression analysed previously showed elevated levels of the early 
osteocyte marker E11 (Figure 4.7 and 4.10). To confirm this at a protein level and to 
investigate the topography of MSCs in relation to osteocytes, the distribution of E11-
positive osteocytes and CD271-positive MSCs were next analysed on large sections of 
OA femoral heads from three patients in relation to OA bone pathology and in one control 
IC bone.  
Similar to analysis of OPG and RANKL, some variation in the degree of pathology was 
evident between femoral heads. The antibody staining was compared between evidently 
sclerotic regions and the regions with no evidence of bone sclerosis as described in Figure 
4.13.   
In sclerotic regions, intense E11-positive staining was found in all the osteocytes which 
were mostly concentrated near the outer edges of thick trabeculae of OA femoral head, 
with the highest density proximal to cuboidal osteoblasts (Figure 4.21). Their presence in 
the proximity of osteoblasts is consistent with them being newly embedded in bone, also 
suggested by their morphology. In contrast, the osteocytes in non-sclerotic regions of the 
osteochondral area (Figure 4.21) showed noticeable differences, both in their distribution 
and morphology. The frequency of E11-positive osteocytes is visibly reduced compared 
to the sclerotic regions while the cells appeared smaller in size and with less dendritic 






Figure 4.21. Immunohistochemical staining of OA femoral head showing the 
topography of E11 positive cells. Global view of E11 positive osteocytes in sclerotic 
regions (left panels) and non-sclerotic regions (right panels) of the osteochondral region. 
Square areas magnified from upper panels showing the abundance of E11 positive 
osteocytes in the sclerotic areas (left panel) with increased presence in proximity to the 
bone lining osteoblasts (arrows). In non-sclerotic areas (right panels) E11 positivity was 
not as evident, with only some positive osteocytes and of distinctive morphology, with 
smaller, more elongated cell body and less dendritic processes compared to the ones from 
sclerotic areas.  Arrow heads: E11 positive osteocytes; arrows: osteoblast. Scale bar: 
200 µm (upper panels) and 50 µm (bottom panels). Sample ID: DIFHOA018 
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Having observed the noticeable difference in morphology of the osteocytes between the 
two distinct areas of OA pathology, the E11-positive osteocytes were examined at a 
higher magnification in both sclerotic and non-sclerotic regions, but also in healthy IC 
bone (Figure 4.22).  
The E11-positive osteocytes from healthy IC resemble a morphology consistent with 
previous published work (Zhang et al., 2006; Prideaux et al., 2012; Staines et al., 2017). 
They were characterised by an elongated morphology with a small cell body and 
organised dendritic processes aligned towards the surface of the bone. The E11-positive 
osteocytes from the non-sclerotic regions of femoral heads had an indistinguishable 
morphology to IC ones, with the osteocytes having a similar elongated body and aligned 
dendritic processes. Also, their size seems to decrease proportionally with their 
embedding distantly from the bone surface (non-sclerotic, Figure 4.22). In contrast, the 
osteocytes from the sclerotic areas had numerous and disorganised dendritic processes 
radiating chaotically from their body, with no specific orientation. Their cell body was 
visibly larger and more circular compared to osteocytes from non-sclerotic areas and 
healthy IC and they seem to be present at a higher density in the vicinity of the bone lining 
cells (Figure 4.22).  
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Figure 4.22. Morphology of E11 positive osteocytes in IC and OA bone. Representative 
images showing immunostaining for E11 in healthy iliac crest bone (upper panel) and 
non-sclerotic (middle panel) and sclerotic (bottom panel) regions of OA femoral heads. 
High magnification images show the similar morphologies of E11 positive osteocytes 
between iliac crest and non-sclerotic regions of OA femoral head as opposed to the 
distinct morphologies of osteocytes from the sclerotic regions. Scale bar: 100 µm (left 
panels) and 50 µm (right panels). Sample IDs: IC: DIHIC03; OA: DIFHOA018 
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E11 positivity was next analysed semi-quantitatively and compared between sclerotic 
(Figure 4.23A) and non-sclerotic (Figure 4.23B) regions of the femoral heads from three 
different donors. To avoid any bias in counting the positive osteocytes, the signal for E11-
positivity was measured by using the computer software Nuance with the threshold set 
on negative control DAB-only positive slide. All the osteocytes were then counted in a 
minimum of 10 regions for each patient and the percentage of positive osteocytes out of 
total osteocytes in the bone area of a selected region of interest was calculated and 
presented as average for each S and NS region.  
As shown in Figure 4.23C, the E11-positive osteocytes in the non-sclerotic areas were 
significantly less numerous (average 5-fold, p<0.0001) than in sclerotic areas. In all three 
donors, the percentage of E11-positive osteocytes in the non-sclerotic areas ranged 
between 6% and 49% with a median of 15% across all patients while in the sclerotic areas 
the majority were E11 positive. In the sclerotic areas, the percentages of E11-positive 
osteocytes ranged between 40% and 96% with a median of 76% across all three donors. 
Statistically significant distinction in the presence of E11-positive osteocytes was 
observed in the samples from all three patients.  
The significant increase of the E11-positive osteocytes in the sclerotic regions of the OA 
femoral heads allows an explanation for the differences observed in the gene expression 
analysis. The osteocytes from OA bone had a higher level of E11 gene expression, 
however this comparison was performed between global osteocytes from OA and healthy 
bone, irrespective of the site of damage. Here, the elevated numbers of E11-positive 
osteocytes indicate that the difference observed in gene expression may be due to their 




Figure 4.23. Quantification of E11 positive osteocytes in S and NS regions of OA bone. 
Representative images showing immunostaining for E11 in sclerotic (A) and non-
sclerotic (B) regions of OA femoral heads. Right panels A and B show the selection of 
regions of interest (within the dashed lines) in the bone area for semi-automatic counting 
of E11 positive osteocytes. Red colour indicates positive staining based on the negative 
control threshold set on DAB-only slide. (C) The proportions of E11-positive osteocytes 
in these regions was quantified in a minimum of 10 regions each in three femoral heads 
(FH) from three donors (empty boxes – non-sclerotic regions, grey boxes – sclerotic 
regions). Scale bars: 100 µm. Sample ID: DIFHOA018 
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In Chapter 3, several alterations in the gene expression of native MSCs were observed 
between healthy and OA bone-derived cells. These included an increased expression of 
osteogenic molecules, such as RUNX2, SPARC, ALPL, CDH11 and OPG. In the present 
chapter, so far it has been demonstrated that the OA osteocytes were also affected by the 
disease process, confirmed at both the gene expression level and protein level. 
Specifically, E11-positive osteocytes were shown to be accumulated in the sclerotic areas 
of the femoral heads of hip OA characterised by an increased bone area. Since the MSCs 
have been previously shown to be accumulated at sites of OA associated bone alterations 
(Campbell et al., 2016), this emphasises the value in investigating MSCs topography in 
relation to the E11-positive osteocytes in the sclerotic areas of hip OA. 
In the sclerotic regions of OA femoral heads, CD271-positive MSCs were highly 
abundant in the fibrovascular tissue, that had replaced the BM, with the highest density 
of positive cells present around blood vessels and near bone surfaces lined with cuboidal 
osteoblasts (Figure 4.24, left panels). In non-sclerotic regions, especially in the 
subchondral area, CD271-positive cells were less numerous and had predominantly bone-
lining topography (Figure 4.24, right panels). A dense fibrovascular tissue of yet 
unknown cellular origin, inhabits the sclerotic bone cavity which breached into the 
cartilage layer. Although other cells were present, such as osteoblasts and the dense 
fibrovascular tissue, the majority of them were CD271-positive cells with a high 
abundance around the blood vessels and in proximity to the bone surface. In the 
subchondral area of minimal osteochondral damage, the fibrovascular tissue was absent 
and the CD271-positive cells were restricted to a bone lining location (Figure 4.24, right 
panels). 
The non-sclerotic trabecular bone that was distant from the subchondral areas was also 
lined with CD271-positive cells which were similar in localisation to healthy IC bone 
(Figure 4.25). Within non-sclerotic regions CD271 positivity was also detected in the 
stromal tissue cells with no visible distinction between the healthy IC and the non-
sclerotic trabecular bone from OA femoral heads (Figure 4.25). The trabecular bone along 





Figure 4.24. Immunohistochemical staining of OA femoral head showing the 
topography of CD271 positive cells in S regions (left panels) and NS regions (right 
panels) of the subchondral bone. Square areas magnified from upper panels showing 
the abundance of CD271 positive cells in the dense fibrovascular tissue of sclerotic areas 
(left panel) with increased presence around blood vessels and adjacent to bone lining 
osteoblasts shown by long arrows. In non-sclerotic areas (right panels) CD271 positivity 
was less prominent, with only some bone lining cells positive. Arrow heads: CD271+ 
cells; arrows: osteoblasts. Scale bar: 200 µm (upper panels) and 50 µm (bottom panels). 
Sample ID: DIFHOA018 
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Figure 4.25. Topographical comparison of CD271 positive cells between healthy iliac 
crest and NS regions of OA bone. Similarity in the topography of CD271+ cells from the 
trabecular bone distant from subchondral bone, in the non-sclerotic areas of OA femoral 
heads (left panels) and healthy iliac crest bone (right panels). Arrow heads point to 
CD271+ cells lining the bone in both regions as well as the scattered presence in the 
stromal tissue. Scale bar: 200µm (upper panels) and 50µm (bottom panels). Sample IDs: 
IC: DIHIC03; OA: DIFHOA018 
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To quantify the presence of MSCs in regions of bone sclerosis (S) and compare it to 
regions of less damage (non-sclerotic, NS), the CD271 positivity was then measured 
within the trabecular space of S (Figure 4.26A) and NS (Figure 4.26B) regions of OA 
femoral heads (n=3). The quantification was done by using a computer software (Nuance) 
with the threshold set on a control DAB-only positive slide and calculation was performed 
as percentage of positive area in relation to total bone cavity area.  
The density of CD271-positive cells in the S regions populated by the aforementioned 
dense fibrovascular tissue in all three patients was significantly higher than the donor-
matched non-sclerotic areas. In the S regions, the area of CD271 positivity was 9-fold 
higher (p<0.0001) than in the non-sclerotic regions from the same femoral head (Figure 
4.26C) based on the medians between the three donors analysed in this experiment. The 
differences between the two regions were statistically significant, consistently across all 
three donors (Figure 4.26 C). 
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Figure 4.26. Quantification of CD271 staining in OA femoral head from sclerotic (A) 
and non-sclerotic (B) bone areas. Left panels in A and B show representative DAB+ 
cells (brown) in the regions selected for analysis. Right panels show the selection of 
regions of interest (within the dashed lines) in the bone cavity area for CD271 
quantification. Red colour indicates positive staining based on the negative control 
threshold set on DAB-only slide. (C) Quantification of CD271+ area of non-sclerotic 
(empty boxes) and sclerotic (grey boxes) regions from n=3 femoral heads (FH); Arrow 





Altogether, this staining pattern revealed that, similar to E11-positive osteocytes, in 
sclerotic regions the CD271-positive MSCs also accumulated in sclerotic areas and that 
they were located near the bone surface as well as within the fibrovascular tissue, 
particularly around blood vessels as shown in Figures 4.24 and 4.26.  
Next, the co-localisation of CD271+ MSCs and the early E11-positive osteocytes within 
the same area was analysed using adjacent sections from the same tissue samples (Figure 
4.27). Many CD271+ MSCs can be seen concentrated in the vicinity of osteoblasts 
(Figure 4.27, right panel), in proximity to the bone. This suggests the possibility that 
MSCs located near the bone surface rather than perivascular MSCs may be specifically 
responsible for osteoblasts and subsequently, for osteocyte deposition. The left panel in 
Figure 4.27 shows the distinct morphologies of osteocytes strongly positive for E11 and 
situated near the bone surface, some in direct contact with these bone lining cells, which 
in the absence of osteoblasts are CD271+ as shown previously (Figures 4.25 and 4.26). 
Since E11 expression marks a new stage along the osteogenic progression, it would be 
interesting to investigate bone-lining MSC subset is more detail, particularly in relation 
to bone pathology in OA. 
     
Figure 4.27. MSC and early-osteocyte co-localisation in S areas of hip OA. Left panel: 
increased MSC presence is marked by abundance of CD271+ cells (brown) near bone 
surface and in the fibrovascular tissue, adjacent to bone lining cells and osteoblasts 
(arrows). Right panel: E11-positive osteocytes (brown) embedded in newly formed 
osteoid. A demarcation line separates the bone rich in E11-positive osteocytes from the 
more mineralised bone, inhabited by more mature and less E11-positive osteocytes with 
different morphology. Scale bar: 50 µm. Sample ID: DIFHOA018 
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4.5 Discussion 
The unexplored functional characteristics of osteocytes and MSCs during OA 
pathogenesis and progression, and the possibility of detecting novel molecular candidates 
responsible for their interaction under normal and pathological conditions holds great 
interest. Although the communication between osteocytes and other bone cells such as 
osteoblasts has been well documented (Kamioka et al., 2004; Paic et al., 2009; Dallas and 
Bonewald, 2010) their interactions with the MSCs are still unexplored. In the present 
work, it was hypothesised that abnormally committed MSCs would directly impact on 
their terminally differentiated osteocyte descendants with numerical and functional 
perturbations in OA bone.  
4.5.1 The simultaneous analysis of osteocytes and MSC from human bone 
Firstly, to address this, methodologies were optimised to investigate the gene expression 
signature of native osteocytes in osteocyte-enriched bone fragments and compare it to 
native uncultured MSCs from the same bone. The MSCs were isolated by enzymatic 
extraction as previously described (Jones et al., 2010), followed by cell sorting using the 
CD45-CD271+ cell surface phenotype and gene expression analysis as described in 
Chapter 3 Section x. The enzymatic removal of all the soft tissue from the bone surface 
was possible during the MSC extraction stage, leaving the bone-embedded osteocytes to 
be the only remaining cellular material. The approach was then to lyse the osteocytes in 
situ and extract the RNA from native osteocytes without any in vitro manipulation. 
The first aim of this chapter was to establish robust gene markers for native human 
osteocytes and test their specificity by comparing them to native MSCs. The selected 
panel of genes have been previously documented and established as osteocytes markers 
based on extensive animal work and on cell lines as reviewed by Dallas et al. (Dallas et 
al., 2013), but their specificity to native human osteocytes has not yet been investigated.  
The study of osteocytes in their native environment is complicated by their entrapment in 
a mineralised bone matrix (Prideaux, Findlay, et al., 2016) hence the biochemical data 
characterizing their precise role in bone associated pathologies have thus far been limited. 
Several in vivo models have been developed to study their function, however the studies 
on human osteocytes is scarce. Native gene expression of osteocytes has been 
documented in a mouse model for load induced adaptation of the vertebras (Wasserman 
et al., 2013) and similarly on osteocytes isolated by gene fractionation and FACS, also 
from mouse bones. Pertaining human studies, some focused on the analysis of their 
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viability and molecular responses following short-term culture of the osteocyte-enriched 
bone chips (Shah et al., 2016; Pathak et al., 2016). However, in these two studies, 
osteocytes were studied in vitro, their purity was not confirmed histologically and no 
comparisons were made with other bone-lineage cells such as MSCs.  
Data in this chapter showed that markers of mature osteocytes, such as  the bone 
formation inhibitor SOST and the mineral and phosphate regulating molecules, DMP1, 
MEPE and PHEX (Martin et al., 2011) were the most specific markers for human 
osteocytes when compared to MSCs. Although SOST is commonly known as a classical 
osteocyte molecule (van Bezooijen et al., 2004),  and its specificity was confirmed in this 
chapter, the variable expression levels found here suggest more caution in the use of this 
molecule as a positive marker on its own for osteocytes studies.  
On the other hand, the expression of DMP1, PHEX and MEPE were reliably expressed 
in all osteocytes samples at higher levels than the MSCs from the same bone. MEPE, 
originally identified as a substrate for PHEX, is primarily expressed by osteocytes 
(Nampei et al., 2004). Evidence for a direct role of MEPE in bone mineralisation came 
from the increased mRNA expression levels of MEPE seen during osteoblast matrix 
mineralisation (Petersen et al., 2000). DMP1 and PHEX  are both expressed by osteocytes 
and were also shown to regulate the expression of FGF23 (Martin et al., 2011). The key 
regulator of phosphate homeostasis, FGF23, is expressed predominantly by osteocytes 
(Yoshiko et al., 2007; Ubaidus et al., 2009) and data presented here showed higher levels 
of expression in osteocytes compared to MSCs in both health and disease. As expected, 
the early osteocyte marker E11 was the least differentially expressed between osteocytes 
and MSCs.   
The expression of these markers in osteocytes in vitro however, requires further 
investigation. While most of the markers showed stability in culture (for 7 days), the 
expression of FGF23 was clearly affected (Figure 4.9). Moreover, the expression of 
RANKL and OPG also showed dysregulated expression while subjected to mechanical 
stimulation and while in culture conditions. Current studies using osteocytes culture 
methods should take into consideration the effect of culture conditions on the phenotype 
of these cells. An in vitro study by Pathak et al. investigated the effect of RA-serum or 
inflammatory cytokines on expression of human osteocyte-specific proteins and 
cytokines (Pathak et al., 2016). While osteocytes are viable after one week in culture as 
shown in this chapter and by this study as well (Pathak et al., 2016), and still express their 
specific markers as described in Section 4.4.3, the osteocyte phenotype is likely to be 
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different than its native counterpart. Data obtained from these cultures should consider 
potential differences induced by culture conditions to the factors secreted by osteocytes 
and more work is needed to determine the extent of these changes. This may include 
analysis of gene expression and measurement of osteocytes-secreted soluble factors 
during a lengthier time course with multiple and closer time points. Furthermore, 
osteocyte-specific mechanical stimulation methods could also be employed, such as fluid 
flow, hydrostatic pressure, mechanical stretching or low-magnitude, high-frequency 
vibration (Lau et al., 2010). 
Altogether, this differential gene expression pattern observed in native osteocytes by the 
methodology described in this chapter confirmed that the optimised bone processing 
protocol produced osteocyte-enriched bone and could be used to compare osteocyte gene 
expression between healthy and OA bone. 
4.5.2 Osteocytes in hip OA 
The second aim was therefore to investigate the gene expression profiles of native 
osteocytes in OA as compared to their healthy counterparts. It was shown that native 
osteocytes in OA resemble an early phenotype marked by increased expression of E11 
and MMP14 and may be involved in bone resorption inhibition indicated by elevated 
levels of OPG. 
Osteocytes sense biomechanical signals through a highly interconnected network of 
dendritic processes (Bonewald, 2011). The formation of these dendritic processes occurs 
at the early stages of osteocytes development during their entrapment in the bone matrix. 
While the elongation of dendritic processes is facilitated by E11, also known as 
podoplanin (Zhang et al., 2006) the embedding of osteocytes in the collagenous osteoid 
has been described to involve the expression of MMP14 (Holmbeck et al., 2005). Data in 
this chapter showed high levels of E11 transcripts in native OA osteocytes which 
indicated a young and immature profile of these cells in OA. The increased expression of 
MMP14 observed here is therefore more owing to these elevated early-osteocytes, 
actively embedding into the osteoid. In response to changes in bone biomechanics, 
osteocytes adapt by modulating the local and global environment (Rubin et al., 2002), by 
recruiting osteoclasts to resorb bone and osteoblast to form bone, maintaining normal 
tissue homeostasis. However, this adaptation may be also possible by means of their own 
ability to resorb bone and modulate its matrix attachment. The elevated levels of MMP14 
found in OA osteocytes may also indicate an active osteocytic osteolysis during the early 
stages of osteocytes maturation. Indeed, two animal model studies have shown that peri-
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canalicular osteopenia is a feature of osteocyte remodelling (Fowler et al., 2017; Dole et 
al., 2017). 
The RANKL/OPG system is a pathway of important clinical implications with potential 
therapeutic role in skeletal diseases such as osteoporosis (Cummings et al., 2009), 
rheumatoid arthritis (Haynes et al., 2008), juvenile Paget’s disease (Whyte et al., 2002) 
and a range of bone tumours (Mundy, 2002). When the mRNA expression levels of 
RANKL and OPG were compared between OA osteocytes, it was observed that a trend 
exists for increased OPG expression in OA bone however, RANKL levels were unaltered. 
As mentioned before, several lines of evidence have now established a key role for 
osteocytes in the regulation of bone resorption by its expression of RANKL, showing that 
deletion of RANKL in osteocytes leads to increased bone mass (Nakashima et al., 2011; 
Xiong et al., 2015). However, equally important is its main inhibitor, OPG, and little is 
known about the role of OPG in osteocytes. Data presented in this chapter with regards 
to OPG suggest that osteocytes may act together with MSCs for a global enhancement of 
bone formation and inhibition of bone resorption. MSCs were documented in Chapter 3 
as having a committed osteogenic profile while here data suggest that osteocytes may 
play a role in supporting that osteogenic activity by inhibition of bone resorption. 
However, confirmation of these mechanisms requires further work. 
In addition, the mRNA levels for the other two molecules with active roles in bone 
resorption, cathepsin K and TRAP, showed trends for increased expression at a gene level 
in OA osteocytes, but not statistically significant. However, using histology and IHC 
osteocytes in OA showed no positivity for either TRAP or CTSK, indicating they are not 
involved directly in resorption activities. This comes in contradiction with other studies 
reporting TRAP positive osteocytes and a potential contribution to OA subchondral bone 
pathogenesis (Jaiprakash et al., 2012), however that study was performed in knee OA. 
Hip and knee OA have distinct clinical presentations (Le Marshall et al., 2013) which 
may indicate different progression rates and, biochemical and cellular responses due to 
the different anatomical sites with distinct biomechanical properties of the joints. 
Sclerostin is a known potent inhibitor of bone formation which was confirmed to be 
secreted mostly by mature, late osteocytes (Poole et al., 2005). The variable low levels of 
SOST observed in OA osteocytes in this study as well as by others (Jaiprakash et al., 
2012) may represent their response to the magnitude of altered biomechanics of the OA 
joint (Jia et al., 2018). Furthermore, a more viable explanation may be the variable rates 
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of early-osteocyte formation from MSCs, these immature cells being unlikely to produce 
SOST as suggested by data in this chapter. 
4.5.3 Topographic relationships between osteocytes and MSCs in OA 
femoral head bone 
The final aim of this chapter was to map the topographical relationships between 
osteocytes and MSCs in relation to OA associated bone alterations. With the use of 
antibodies against E11 for early osteocytes and CD271 for MSCs, active osteocytogenesis 
was documented in osteoarthritic femoral heads in the vicinity of MSCs, in sclerotic areas 
associated with severe osteochondral damage. This provided an indication of the cellular 
mechanism for pathological subchondral bone changes including subchondral bone 
sclerosis in hip OA.  
High densities of E11-positive osteocytes were found in the outer edges of thick bone 
trabeculae in areas of bone sclerosis and cartilage loss and in proximity to CD271-positive 
MSCs and osteoblasts confirming an ongoing osteocyte formation process in OA femoral 
heads at the protein level. These early osteocytes were also characterised by disorganised 
dendritic processes which may translate into poor mechanosensing capabilities (Burra et 
al., 2010). In healthy bone, osteocytes are well connected, and the dendritic processes are 
oriented in the direction of the blood supply and along the pressure lines induced by 
mechanical forces (Palumbo, 1986; Petrtýl et al., 1996; You et al., 2004). In osteoarthritic 
bone, there is a notable distortion of the dendritic processes, which may indicate a 
decreased connectivity. All the molecules secreted by osteocytes reach their target 
through the interconnected canalicular network (Schaffler et al., 2014). Changes in 
osteocyte connectivity could have a dramatic effect not only on osteocyte function and 
viability, but also on the mechanical properties of bone. Although IHC and histological 
assessment in this chapter provided an indication of a disrupted osteocyte network, this 
could be further investigated by means of 3D visualisation of the whole lacuno-
canalicular network in the sclerotic areas associated with OA. 
Immunohistochemical staining showed strong OPG protein positivity in the whole of the 
fibrovascular tissue which invaded into the articular cartilage in non-weight bearing areas 
where it could be a forerunner to a central osteophyte. Previous studies proposed 
fibrovascular tissue, which also carries nerves, as a contributor to OA joint pain (Suri and 
Walsh, 2012). The present data indicated its potential contribution to central 
osteophytosis in hip OA.  
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It would be interesting to establish whether the reported subchondral bone softening in 
OA bone (L.G. Cox et al., 2012; Burr and Gallant, 2012) is attributable to an inability of 
the newly formed osteocytes to mineralise their surrounding tissue or it is the 
hypomineralisation that prevents the maturation of these cells. Studies on animal models 
suggest the latter. It was shown that the maturation of osteocytes was halted by inhibiting 
matrix mineralisation, suggesting that mineralization of the matrix surrounding the 
osteocyte is the trigger for their differentiation from an immature osteoblastic-like form 
to a mature osteocyte (Irie et al., 2008). This was later confirmed by Prideaux et al. in a 
in vitro study using MLO-Y4 cell line demonstrating that the mineralisation of the 
extracellular matrix drives the osteocytes maturation and moreover, it induces the 
expression of E11 (Prideaux et al., 2012). Data presented in this chapter provides 
evidence of increased human early osteocytes presence in areas of bone sclerosis in hip 
OA, in the vicinity of MSCs however further work is needed to establish the degree of 
tissue mineralisation in these areas of interest. This can be done by micro-CT in the first 
instance followed by tissue decalcification and Mason Trichrome staining to observe the 
newly formed bone (osteoid) and immunohistochemistry using antibodies against E11 to 
confirm the presence of early osteocytes in these regions. 
The present findings demonstrated for the first time, the high specificity of the selected 
genes for discriminating between native human osteocytes and MSCs, and a pattern of 
differences reflective of osteocyte maturation stage from the earliest markers such as E11 
to the late markers, DMP1 and SOST. The results in this chapter have implicated 
subchondral bone MSCs as a key population driving subchondral bone abnormalities in 
hip OA with direct consequences in their descendants, the osteocytes. No previous study 
has documented early osteocytes in OA, in regions of active bone formation where their 
immature progenitors, the MSCs, accumulate in high numbers. Highly heterogeneous 
MSC topographies prevented accurate quantification of individual MSCs in situ, however 
surface area measurements indicated their significant accumulation in sclerotic areas. The 
cellular origin of the fibrovascular tissue formation is intriguing, but its fibroblast and 
bone lineage cellular elements are likely to be derived from MSCs. Furthermore, given 
the heterogeneous nature of MSCs and the increased expression of MCAM in the OA-
resident CD271+ MSCs it is possible that a certain perivascular subset may be the driver 
of this osteogenic bias and if true, may be harnessed for therapy interventions. 
The present findings documenting an exaggerated MSC-early osteocyte maturation axis 
in hip OA (Figure 4.28) provide a cellular mechanism for pathological subchondral bone 
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sclerosis in this condition and implicate aberrant differentiation of local bone-resident 
MSCs in human OA pathogenesis. The dynamics of osteocytes in respect to morphology, 
gene expression and implicitly, their function, depend upon the cell’s prior differentiation 
history as well as its living environment within the tissue. Exploiting this method to 
extract biochemical information from osteocytes will greatly facilitate a more complete 
understanding of their biology in vivo both in health and disease. 
                     
 
Figure 4.28. Cellular mechanisms of bone sclerosis in OA: The schematic illustrating 
the spatial cellular relationships along the “MSC – Osteocyte axis”. Sclerotic regions 
in the OA subchondral bone are characterised by thickened trabeculae. Resident 
osteocytes are morphologically distinct, with a rounded cell body and high number of 
dendritic projections. They are E11-positive and densely distributed in the vicinity of 
bone lining osteoblasts and adjacent MSCs. The fibrovascular tissue replacing the BM in 
the sclerotic regions is populated by a high number of bone lining and perivascular 
MSCs. In non-sclerotic regions, the trabeculae are much thinner with a significantly 
lower density of E11-positive osteocytes and MSCs. Osteoblasts are absent from the 
surface of the bone due to lower bone remodelling activity while MSCs are lining the 




Chapter 5 The roles of a novel CD45-CD271+CD56+ MSC subset in OA 
bone 
5.1 Introduction 
Skeletal tissue undergoes constant remodelling throughout adult life in order to maintain 
bone strength and tissue homeostasis. As described in previous chapters, bone 
remodelling is an active and dynamic process involving the participation of multiple cell 
types as well as the secretion and uptake of numerous growth factors and cytokines by 
these cells during different stages of this process (Rucci, 2008). Osteoprogenitor lineage 
differentiation is one of the key processes involved in bone formation and remodelling. 
During this process, a subpopulation of mesenchymal progenitors undergoes osteoblast 
lineage commitment and matures through a series of differentiation steps. In response to 
appropriate signals the progenitor cells first proliferate, then secrete extracellular matrix 
that will then mineralize, embedding the cells within the matrix (Aubin, 1998). The 
osteocytes, engulfed in this mineralized matrix, represent the terminal differentiation 
stage of osteoblast lineage. While the osteocytes and MSCs were discussed in previous 
chapters, little is known about the intermediate stage of differentiation which is 
commonly represented by a still poorly defined subpopulation of osteoprogenitors. 
Furthermore, data presented in Chapter 3 and Chapter 4 indicate that it is this 
osteogenically-committed MSC subsets that may be increased in OA. This chapter 
follows with the aims to identify the surface phenotype of these osteoprogenitor cells in 
health and disease and investigate their gene expression profile, with reference to their 
effectors, the osteoblasts and terminally differentiated osteocytes as well as their 
progenitors, the MSCs. Progress in this area may provide new insights into how these 
cells may be harnessed to prevent damage and re-establish bone homeostasis in OA. 
5.1.1 Osteogenic commitment of MSCs 
So far data presented in this project indicated an increased osteogenic activity in OA bone, 
with evidence implicating both MSCs and osteocytes in the abnormal bone phenotype 
observed in OA. The MSCs present in OA femoral heads were shown to accumulate in 
areas of bone sclerosis while gene expression analysis suggested an altered phenotype 
with a predilection for bone formation. Furthermore, an increased density of young and 
immature osteocytes inhabiting the sclerotic bone areas where MSCs and osteoblasts 
were found to accumulate (Figure 4.28) may indicate a result of a skewed differentiation 
balance in the resident MSCs population. Along the osteogenic differentiation axis 
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however, there are other cellular stages that are still not clearly defined yet, such as the 
committed osteoprogenitor MSCs which subsequently give rise to the bone forming 
osteoblasts.  
The specific differentiation pathways of MSC are guided by a complex multigenic 
process under the control of key regulatory and  transcriptional  factors, such as RUNX2 
and osterix (SP7) (Komori, 2006), as described in detail in Chapter 1, Section 1.3.3.  
RUNX2 is well known as an early osteogenic marker (Komori et al., 1997) regulating, 
amongst other genes, the expression of BGLAP (osteocalcin) (Sierra et al., 2003), a 
protein involved in matrix mineralization and calcium ion homeostasis (Wei and 
Karsenty, 2015) also widely used as a marker for new bone formation (Chapurlat and 
Confavreux, 2016). Other molecules known to be commonly attributed to the osteogenic 
MSC lineage are SPP1 (osteopontin), type I collagen and ALP. Bone specific ALP, 
encoded in MSCs by ALPL gene, is necessary to supply phosphate for bone mineral and 
is a good indicator of bone synthesis (Garnero and Delmas, 1998) while type I collagen 
represents the major protein component of bone (Tamma et al., 2014). Both molecules 
were shown to be expressed by native MSCs (Churchman et al., 2012). Along the 
osteogenic differentiation process, the cells also express osteomodulin (OMD), also 
known as osteoadherin (Rehn et al., 2008). OMD is an extracellular matrix keratan 
sulphate proteoglycan member of the small leucine-rich repeat protein family (Sommarin 
et al., 1998) secreted into the matrix at the time of mineralization (Lucchini et al., 2004; 
Rehn et al., 2008) and is proposed to be a reliable marker for mature osteoblasts. Its 
overexpression was shown to enhance the differentiation and maturation of osteoblasts in 
vitro (Rehn et al., 2008) and may be implicated in mineralization processes, regulating 
osteoblast metabolism by binding alpha (V) beta (3)-integrin (Lucchini et al., 2004; Rehn 
et al., 2008). The expression of many genes associated with osteoblasts on 
undifferentiated MSCs is intriguing. The simultaneous expression of mature fat 
molecules may indicate they are present in a poised state ready for differentiation 
(Nombela-Arrieta et al., 2011). It was therefore hypothesised that the osteogenic 
committed MSCs subset is likely to have upregulated bone associated genes while the fat 
transcripts would be downregulated. 
5.1.2 Bone lining cells: the candidate subset and novel players in bone 
remodelling 
The topographical localisation of native CD45-CD271+ MSCs in the BM stroma places 
these cells in both endosteal and perivascular niches (Chapter 1, Section 1.3.2), the latter 
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marked by the CD271+CD146+ MSC phenotype (Tormin et al., 2011). The results in 
Chapter 3 revealed that OA native MSCs were characterised by an increased 
transcriptional level of the surface perivascular MSC marker CD146 (Tormin et al., 2011) 
together with high expression of multiple osteogenesis-related transcripts. Considering 
the increased vascular presence in the OA affected bone (Walsh et al., 2010), this 
prompted the idea that in OA there was an increase in this particular MSC subset and may 
represent a good candidate for the osteogenic aberrations observed in OA bone. However, 
the cells lining the bone surface, including the already documented bone-lining 
CD271+CD146- MSCs (Tormin et al., 2011), may represent a runner-up candidate. 
As stated in Chapter 1, the proportion of osteoblasts and osteoclasts in the skeleton 
represents a relatively small fraction in the pool of all bone cells. With regards to bone 
surface cells in particular, nearly 75% of cancellous bone surfaces and about 95% of 
intracortical surfaces is covered by a lining layer of flat cells (Miller et al., 1989). Bone 
lining cells (BLCs) much as their name suggests, are found lining the endosteal surfaces 
considered "inactive" or “resting” in terms of remodelling or modelling activities (neither 
resorption nor formation takes place), hence the commonly attributed name of quiescent 
bone lining cells (Matic et al., 2016).  
These cells have long been observed histologically, primarily characterised based on their 
flat, elongated bone lining morphology and so far, their physiological functions in normal 
bone homeostasis has remained elusive. One of their roles proposed due to their location 
is that of a functional cellular barrier between bone and BM, separating the bone 
interstitial fluid from the general extracellular fluid (Wein, 2017). In addition, their 
location may also favour a direct contact with bone matrix embedded osteocytes, acting 
as a cellular link in calcium exchange and other substrates released by osteocytes (Wein, 
2017). As such, these cells are best positioned to be the cells mediating MSC-osteocyte 
axis in OA. 
To date, no markers have been described specific to BLCs or effective techniques to 
selectively isolate these cells, although they are thought to constitute part of the osteoblast 
lineage due to the expression of various bone related molecules (Miller et al., 1989; 
Andersen et al., 2009; Matic et al., 2016). Recent evidence in mouse models showed that 
BLCs represent a major source of osteoblasts during adulthood using cell tracing of 
osterix expressing bone lining cells. It was demonstrated that following osteoblasts 
ablation, the BLCs were proliferative and contributed significantly to new bone 
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formation, with little input from the nearby mesenchymal progenitors, identified by 
Gremlin marker (Matic et al., 2016). 
More compelling evidence has recently emerged to support the idea that BLCs represent 
an osteoblastic progenitor pool. As discussed in both Chapter 1, Section 1.4 and Chapter 
4, Section 4.1, SOST is a potent bone formation inhibitor secreted exclusively by 
osteocytes (van Bezooijen et al., 2004). Studies demonstrated the activation of bone 
formation following administration of antibodies against SOST in animal models (Li et 
al., 2009) and humans (McClung et al., 2014). Of importance is that the antibodies 
blocking SOST induced conversion of BLCs into active osteoblasts by their direct 
reactivation, contributing to increased osteoblast numbers following treatment in mice 
(Kim et al., 2017). Therefore, SOST neutralization caused BLCs to reacquire an 
osteoblastic phenotype. This followed a previous study in which it was demonstrated that 
BLCs reactivation was induced by intermittent parathyroid hormone treatment which 
additionally lowered SOST levels in bone (Keller and Kneissel, 2005). Altogether this 
indicated that BLCs reactivation could occur via reducing SOST production by 
osteocytes. 
In addition to providing a source of osteoblasts (Matic et al., 2016), BLCs were shown to 
be critical in more bone remodelling processes. As discussed in Chapter 1, Section 1.2, 
the first phase of the bone remodelling process is activation of the endosteal surface. This 
implied that resorption was initiated at inactive sites, still coated by BLCs. The activation 
phase involves the recruitment of osteoclasts precursors at these sites moving on to the 
next stage of bone resorption by osteoclasts following their attachment to the bone surface 
(Allen and Burr, 2014). More evidence implicating BLCs in bone remodelling processes, 
indicate their role in coupling these phases of bone formation and bone resorption. As 
discussed in Chapter 1, Section 1.2, coupling requires the input of the cells present in the 
BMU following bone resorption, also known as reversal cells. These cells have been 
described to be present at the convergence of osteoclasts and osteoblasts and identified as 
BLCs (Andersen et al., 2013). Furthermore, some authors studying these events suggested 
their contribution to the progenitor pool of cells present in the BMU canopy (Kristensen 
et al., 2014). Furthermore, BLCs are thought to clean the surface of Howship’s lacunae 
following osteoclastic bone resorption (Everts et al., 2002). Specifically, BLCs were 
shown to digest the remnant of collagen fibrils following bone resorption by osteoclasts. 
More interestingly, it was revealed that following the clean-up of the resorption pit, the 
BLCs deposited a thin layer of a collagenous matrix along the Howship's lacuna, in close 
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association with an osteopontin-rich cement line, thus preparing the grounds for the bone 
forming osteoblasts. Their catabolic functions were also demonstrated by their increased 
expression of matrix metalloproteinases (Dierkes et al., 2009). Given that CD271 was 
found expressed on BLCs (Figure 4.25), particularly in areas of bone remodelling and on 
canopies (Figure 4.26) in OA bone, it represents a good candidate for the osteogenic 
committed subset of MSCs. 
At the endosteal level of the trabecular bone, a flat spindle-shaped cell layer was 
previously documented to express CD56, also known as neural adhesion molecule 
(Andersen et al., 2009). This molecule was also shown to be strongly expressed in most 
osteoblasts along bone trabeculae that coincide with the presence of collagen I and 
alkaline phosphatase activity (Lee and Chuong, 2009). Further histological studies 
showed that the CD56 expressing cells lining the surface of the bone (Andersen et al., 
2009) were also expressing osterix (SP7) (Kristensen et al., 2013), indicating cells of 
osteoblastic lineage. On the bone surfaces, canopies have also been described as 
structures separating remodelling sites from the BM, consisting of CD56-positive 
osteoblasts at an early differentiation stage (Kristensen et al., 2013; Kristensen et al., 
2014). Altogether this evidence indicates that CD56 represents a good candidate marker 
for the osteogenic committed MSCs subset. 
5.1.3 Current state of the art in CD271 MSCs subsets 
As mentioned in Chapter 1, Section 1.3.2, the topography of MSCs resident in the BM 
places them in a perivascular and bone lining location as well as in the stromal reticular 
niche, known as adventitial reticular cells where they are anchoring the other cells 
providing structural support of the stromal tissue (McGonagle et al., 2017). While the 
perivascular localisation would give MSCs easy access to most tissues for repair if needed 
(François et al., 2006), MSCs are also thought to be lining the bone surface (Tormin et 
al., 2011), as confirmed in this study (Figure 4.25 and 4.26). This endosteal localisation 
may provide them an ideal advantage to be involved in the bone remodelling activities.   
As discussed in previous chapters, CD271 is accepted as the most specific marker for 
native BM MSCs (Quirici et al., 2002; Bühring et al., 2007; Jones et al., 2010).  However, 
this population is heterogenous with studies indicating multiple subsets that form part of 
the same CD271+ phenotype (Battula et al., 2009; Tormin et al., 2011). The availability 
of appropriate molecular and cell surface markers that can be used to isolate and 
characterize these cell populations may lead to isolation of homogeneous cell samples. 
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Cluster of differentiation 146 (CD146), also known as melanoma cell adhesion molecule 
(MCAM) or cell surface glycoprotein Muc18, was originally identified as an endothelial 
cell marker with a role in cell-matrix interaction and angiogenesis (Lehmann et al., 1989; 
Bardin et al., 2001). CD146 defines the self-renewing MSC population located in the 
perivascular space of the BM (Sacchetti et al., 2007) which was also later introduced as 
an MSC surface marker in combination with CD271 (Tormin et al., 2011). Both the 
CD271+CD146- and CD271+CD146+ cells were later shown to have self-renewal 
properties as well as enriched CFU-Fs. Although they display a similar phenotype, the 
CD271+CD146+ population was associated with a perivascular location in the BM cavity 
where they have access to elevated oxygen levels close to the blood vessels as opposed 
to the more hypoxic conditions in the proximity of the bone surface (Tormin et al., 2011). 
Both CD271 and CD146 have been described to identify uncultured multipotent MSCs 
(Sacchetti et al., 2007; Tormin et al., 2011; Mabuchi et al., 2013) and are altered when 
the cells are expanded in culture. CD271 expression is lost during culture expansion 
(Quirici et al., 2002; Churchman et al., 2012) while CD146 surface marker expression is 
upregulated once the cells are cultured but is downregulated when cultured under hypoxic 
conditions (Tormin et al., 2011). Furthermore, data in Chapter 3 suggested an increased 
presence of a perivascular MSCs subset in OA based on overall higher proportion of 
CD271+ MSCs in OA bone determined by FACS as well as the increased mRNA 
expression of MCAM (encoding CD146) in OA CD271+ MSCs. 
Another surface marker used in conjunction with CD271 is CD56, also known as neural 
cell adhesion molecule. As a known marker for natural killer, neural, and more recently 
for muscle cells (Van Acker et al., 2017) it was additionally shown to be expressed on a 
small subset of BM CD271+ cells (Bühring et al., 2007) and having a particular 
chondrogenic bias (Battula et al., 2009). In a more recent study, Sivasubramaniyan et al. 
isolated MSCs based on this phenotype from sites distant from the affected bone of OA 
patients and confirmed the enhanced chondrogenic potential of the CD271+CD56+ cells 
but moreover, demonstrated the distinct topographical location of this subset in the 
endosteal region (Sivasubramaniyan et al., 2018).  
All the evidence presented above indicates the existence of at least two topographical 
subsets within the CD271+ MSC fraction, and that either of them may contain 
osteoprogenitors increased in number in OA. However, CD56+ BLCs may represent a 
stronger candidate for such cells based on their proximity to osteoblasts and osteoclasts 
as shown in the previous chapter (Figure 4.28). Based on this, the focus of this chapter 
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was the isolation of osteoprogenitor MSCs and their enumeration and characterisation 
from healthy and OA bone using CD56 and CD146 surface markers, used for the first 
time in combination with CD271.  
5.2 Chapter aims 
1. To document the topography of CD56+ cells in OA and control bone and establish 
the existence of CD271+CD56+ bone lining MSC subset. 
2. To enumerate the CD271+CD56+ and CD271+CD146+ MSC subsets in OA and 
healthy bone. 
3. To explore the native CD271+CD56+ and CD271+CD146+ MSC subsets in OA 
by investigating their osteogenic commitment using gene expression analysis and 




5.3.1 Patient samples 
For all the experiments in this chapter a total number of n=18 OA donors (8 males and 
10 females) with age range between 40-90 years (median=72) and n=11 healthy donors 
(5 males and 6 females) with age range between 17-78 years (median=55) were recruited. 
The MSC subsets were enumerated and isolated using FACS from the cell suspensions 
obtained following bone digestion procedures described in Chapter 2, Section 2.2.1.  
For histological studies a total of n=4 OA femoral head samples were used while n=3 
healthy IC and n=3 non-OA neck of femur fractures femoral heads were used as control 
bone. As described in Chapter 4, the samples used for histology in some cases were 
different from the ones used for MSC extraction.  
5.3.2 Immunohistochemistry  
Sequential sections (5 µm) of decalcified trabecular bone (Chapter 2, Section 2.6.1) were 
deparaffinized in xylene and rehydrated through graded ethanol series to water. EnVision 
+ Dual Link System-HRP (DAB+) (DAKO, UK) was used for the staining procedure as 
described in Chapter 2, Section 2.6.3. The primary antibody used for CD271 has been 
described in Chapter 4, Section 4.3.6 while for CD56 a rabbit monoclonal antibody (clone 
EPR2566, Abcam, UK) was used at a 1:300 dilution. The staining procedure was similar 
as described in Chapter 4, Section 4.3.6. The optimal concentration of primary antibody 
had been determined in dilution series on test tissue sections similar to CD271 in Chapter 
4.  
5.3.3 Immunofluorescence 
Immunofluorescence was chosen to investigate the co-localisation of the two markers, 
CD271 and CD56 in OA femoral heads. Tissue sections were dewaxed and rehydrated as 
described in Chapter 2, Section 2.6.2. The tissue was then permeabilised to allow 
intracellular staining with 0.25% Triton-X-100 (Sigma) for 15 minutes at room 
temperature and washed several times in TBS. Antigen sites were blocked using 5% 
Casein solution (Appenix 3) for 30 minutes at room temperature before subsequent 
addition of the same primary antibodies used for IHC (Section 5.3.2). After 1-hour 
incubation at room temperature, the primary antibody was washed in TBS for 5 minutes 
and the appropriate conjugated secondary antibody was added to the tissue sections for 1 
hour at room temperature. The CD271 antibody was raised in mouse and therefore a goat 
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anti-mouse antibody was used conjugated with Alexa Fluor 488 (1:200, Thermo Fisher). 
The CD56 antibody was raised in rabbit and therefore a donkey anti-rabbit was used 
conjugated with Alexa Fluor 647 (1:200, Abcam). After washing, the slides were 
mounted with a coverslip using VectaShield with DAPI (Vector Laboratories). 
Fluorescence was analysed using a Nikon A1 confocal laser microscope (Nikon) and 
multiple fluorescent images were acquired and presented using NIS Elements software 
(Nikon). The maximum excitation wavelength for Alexa Fluor 488 is 495 nm and 
emission peaks at 519 nm, therefore the blue 488 nm laser line was used to detect cells 
positive for CD271. To detect the CD56 cells, the excitation wavelength for Alexa Fluor 
647 is 650 nm and emission peaks at 665 nm, therefore the red 647 nm laser line was 
used. No primary antibody slide was used as control with both secondary antibodies in 
order to set the threshold and normalise for background signal.  
5.3.4 Picrosirius Red staining 
Picrosirius red (PSR) was employed to stain and visualise the collagen fibres in OA 
femoral heads (n=4) in order to determine areas of new bone formation. The staining 
procedure was performed following dewaxing and rehydration as described in Chapter 2, 
Section 2.6.2. The slides were then incubated for 1 hour at room temperature in 0.1% 
PSR solution (Appendix 1). Next, the slides were briefly washed for 1-2 seconds in 0.5% 
acetic acid before being mounted with DPX (Leica). 
The slides were visualised using brightfield (Nikon) as well as polarized light (Nikon) 
microscopes in order to evaluate the size and organization of collagen fibrils of 
subchondral bone in parallel with adjacent slides stained for CD56 by IHC. 
5.3.5 Cell sorting 
Based on topography, the CD271+ MSCs were shown to reside in a perivascular location, 
marked by the expression of CD146 (Tormin et al., 2011) as well as lining the bone, 
marked by the expression of CD56 (Battula et al., 2009). Therefore, FACS was employed 
to enumerate and isolate these distinct subsets within the CD271+ MSCs fraction in order 
to investigate their presence in healthy and OA bone in addition to gene expression 
comparison between these subsets. 
Staining and cell sorting experiments were performed similar to MSCs enumeration and 
sorting described in Chapter 3, Section 3.3.4, with the addition of the two antibodies 
(CD56 and CD146) for further segregation of the CD271 fraction. All antibodies used in 
this study as well as the gating strategy used for the identification and sorting of CD45-
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CD271+ population and its sub-fractioning in the CD271+CD56+CD146- (designated as 
CD56+), CD271+CD56-CD146+ (CD146+) and CD271+CD56-CD146- (double 
negative, DN) subsets was described in Chapter 2, Section 2.4. 
5.3.5.1 FACS analysis and sorting for gene expression analysis 
Bone fragments from healthy IC and OA femoral heads were mechanically processed as 
described in Chapter 2, Section 2.2 and enzymatically treated. Following enzymatic 
extraction of all cellular material from the bone fragments, the cells were filtered and 
manually counting using Trypan blue exclusion method as described in Chapter 2, 
Section 2.3.1. Depending on cellularity, approximately 3x106 cells were centrifuged at 
300xg for 5 minutes and resuspended in 100 µl of FACS buffer. Following 10 minutes 
incubation with Fc block, the four antibodies (CD271, CD45, CD56 and CD146) were 
added at the dilution described in Chapter 2, Section x and incubated for 15 minutes in 
the dark, at room temperature. After staining, cells were washed and processed for cell 
sorting and FACS analysis using the gating strategy described in Chapter 2, Section 2.4.1. 
The percentages of the MSC subsets was calculated as percentage of number of events in 
the gated live CD271+ MSCs population, as described in Chapter 2, Section 2.4.2. 
Additionally, together with the CD271+CD146+ and CD271+CD56+ fractions, the 
double negative subset (designated as DN) was also selected for analysis as described in 
Chapter 2, Section 2.4.2. On average, 6x104 events were acquired to gate the CD271+ 
fraction across all OA experiments, ranging between 0.8x104 -2.8x105 while from healthy 
bone an average of 2.5x104 events, ranging between 2.3x104 -9.9x104 events. The MSC 
subsets were sorted from this CD271+ population for downstream processing for in vitro 
functional assays (Section 5.3.5.2 and 5.3.7) or gene expression analysis by qPCR 
(Section 5.3.5.3). 
5.3.5.2 Cell sorting for functional assays 
Following FACS analysis the MSC subsets from n=3 OA donors were collected for in 
vitro functional assays in 500 µl of StemMACS media. Immediately following cell 
sorting, cells from each MSC subset were seeded in 6-well culture plates at similar cell 
densities, while the CD45+ subset was seeded at a higher cell density due to less likely 
chance to have adherent cells (Tormin et al., 2011) and served as control population. The 
number of cells required for differentiation assay of MSC subset was not sufficient 
following cell sorting, therefore all sorted fractions were minimally expanded up to P1 as 
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described in Chapter 2, Section 2.3.2 and used for each assay as described in Section 
5.3.7.   
5.3.6 Gene expression of the sorted MSC subsets 
Following the cell sorting experiments, the selected subsets (CD56+, CD146+ and DN) 
were collected for gene expression analysis in 100 µl or RNA lyses buffer (Norgen 
Biotek). Due to the different cell proportions within the selected subsets, an average 
number of 5x103 cells were collected for the CD146+ (range 0.5x102- 1.3x104 cells) and 
7.6 x104 for DN subsets (range 1.2x104-1.5x105), however due to low and variable 
numbers of the CD56+ subset, only an average of 3x103 cells (range 0.5x103-1.5 x104 
cells) were collected. Additionally, 1x105 cells from the CD45+ fraction were collected 
as control. The RNA was then isolated from all collected cells using a Single Cell RNA 
extraction kit (Norgen Biotek) and cDNA synthesised from all volume of extracted RNA 
using High Capacity Reverse Transcription kit (Applied Biosystems) as described in 
Chapter 2 and based on manufacturer instructions. 
For gene expression analysis a custom pre-designed TLDA card (format 96a; Applied 
Biosystems) was used as described in Chapter 2, Section 2.5.3 and manufacturer 
instructions. Exon-spanning TaqMan assays were selected for the array when possible, 
generally comprising genes associated with MSCs multipotentiality and stromal support, 
similar to the panel used in Chapter 3. The complete list of transcripts is detailed in 
Appendix 5. The cDNA (50 µl for each sample in nuclease free water) and TaqMan 
master mix (50 µl) (Applied Biosystems) were prepared as a single mix and 100 µl was 
used per port, allocating 2 ports/sample corresponding to a total of 96 assays (48 
genes/port), as described in Chapter 2, Section 2.5.3. Data analysis was carried out using 
2-DCt method, with results normalized to the values for the reference gene HPRT1. The 
hierarchical cluster analysis was performed using the Cluster 3.0 open source software as 
described previously (Churchman et al., 2012). Using this software, the gene expression 
values were first transformed to a logarithmic scale and then hierarchical clustering was 
performed for genes and samples arrays using Spearman rank correlation and complete 
linkage. This method clusters the genes with similar levels of expression between the 
subsets, the results being visualised as a dendrogram using the Tree View software. 
5.3.7 Differentiation assay 
Trilineage differentiation of MSCs is a defining property of MSCs and was used to 
compare the potential of the sorted MSCs subtypes to undergo osteogenic, adipogenic 
 208 
and chondrogenic differentiation in vitro using standard techniques. In particular, these 
functional assays were aimed at confirming the gene expression results and therefore to 
verify the reflection of the osteogenic commitment of subsets under investigation. 
All differentiation assays were performed for the three MSC subsets isolated by FACS 
from n=3 OA donors and culture expanded up to P1. Exemplified in Figure 5.1 are the 
details of cells distribution for functional assays together with the number of cells seeded 
and replicates for each MSC subset from each donor, hence a total number of n=9 samples 
(n=3 donors and n=3 MSC subsets).  
                          
Figure 5.1. The flowchart of differentiation assays experimental plan. The MSC subsets 
were induced towards osteogenic, adipogenic and chondrogenic lineages. The functional 
assays were performed for each of the three MSC subsets (CD56+, CD146+ and DN) 
isolated by FACS from n=3 OA donors.  
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5.3.7.1 Osteogenic differentiation  
Following isolation by FACS and subsequent culture expansion of all three cell types 
from OA patients (n=3) (Section 5.3.5.2), the MSCs were seeded in duplicate into 6-well 
tissue culture plates (Corning) at a seeding density of 1x104 cells/well and incubated at 
37° C, 5% CO2 (Figure 5.1). Osteogenesis was induced with ready-made osteogenic 
differentiation media OsteoDiff from Miltenyi Biotec. Half of the media was changed 
twice weekly and cultures were maintained for 14 or 21 days when they were stopped 
depending on the assay performed: the level of osteogenic differentiation was determined 
by assessing the alkaline phosphatase (ALP) activity, measuring the accumulated calcium 
using a calcium liquid colorimetric assay and staining the deposited calcium with Alizarin 
Red. For ALP and Alizarin Red assays, cells were seeded in a 6-well plate in duplicate at 
a cell density of 3x104 cells/well. For calcium detection, the cells were seeded similarly 
in 6-well plate at the same cellular density, in triplicate. Additionally, qPCR was also 
performed to analyse the expression of osteogenic specific molecules, RUNX2 and 
BGLAP using TaqMan assays (Thermo Fisher), detailed in Appendix 5. 
5.3.7.2 Detection of alkaline phosphatase activity  
For determination of ALP activity, osteogenic cultures were terminated on day 14 post-
induction (Pittenger et al., 1999). The media was removed from the adherent cells, which 
were washed gently with 1 ml PBS and subsequently fixed with the addition of 2 ml of 
citrate fixative solution (Appendix 1) for 30 seconds at room temperature. The fixative 
was then removed, and wells were washed twice with dH2O. The assessment of ALP 
activity was performed by adding 1 ml fast blue salt solution (Appendix 1) to each well 
and incubated in the dark at room temperature for 30 minutes to allow colour 
development. Following incubation, the wells were washed gently with 1 ml dH2O until 
clear and allowed to air dry. Dishes were subsequently scanned using an Epson digital 
scanner and high magnification images acquired using an inverted microscope with an 
Olympus camera attached. 
5.3.7.3 Alizarin Red staining 
This assay was performed to assess the in vitro osteogenesis by determination of the 
accumulated calcium in the extracellular matrix of the cultured cells. Alizarin Red 
staining solution was prepared fresh prior to performing the assay (Appendix 1). The cells 
were first fixed by incubation on ice for 1 hour with cooled (at -20º C) absolute ethanol. 
After fixation, the cells were gently washed several times with dH2O and incubated with 
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Alizarin Red staining solution for 10 minutes at room temperature. Following staining 
the cells were washed twice with dH2O and air-dried over-night. Dishes were 
subsequently scanned using an Epson digital scanner and high magnification images 
acquired using an inverted microscope with an Olympus camera attached. 
5.3.7.4 Determination of total calcium accumulation  
Colorimetric assay was used for quantification of calcium content produced by and 
accumulated in the osteogenically differentiated MSCs. At the culture end-point (21 days 
post induction) the cells were washed gently with sterile calcium-free PBS (Invitrogen) 
and subsequently incubated at room temperature for 5 minutes with 0.5 M hydrochloric 
acid (HCl) to extract calcium from the mineralized extracellular matrix. Using a 
disposable cell scraper (Fisher Scientific) cells were mobilised from each well and along 
with the HCl were transferred using a sterile pastette into 1.5 ml microcentrifuge tubes. 
Calcium was extracted by 4 hours’ agitation at 4° C in a rotator and subsequently stored 
at -20º C. Prior to calcium production assay, samples were equilibrated to room 
temperature and centrifuged at 5000xg for 5 minutes to remove any remaining cellular 
debris (Jaiswal et al., 1997). 
For determination of calcium content, the Sentinel Calcium kit (Sentinel Diagnostics) was 
used following the producer instructions. First, standards were prepared ranging from 0 
to 800 ng calcium/well using the calcium standard solution provided. Flat bottomed 96-
well plates were loaded with 6 µl of standards and 6 µl of samples’ supernatant in 
triplicate to which 200 µl of the ‘working dye’ solution (0.3 mM o-cresolphthalein-
complexone, provided in the kit) was added for each corresponding MSC sample (n=3 
donors, n=3 MSC subtype each, i.e. 9 samples). The mixture was incubated in the dark 
for 10 minutes at room temperature and the calcium content was measured using a 
microplate reader with a 570 nm wave length filter. Cresolphtalein-complexone reacts 
with calcium ions at pH>10 to form a purple coloured complex and the colour intensity 
is directly proportional to the concentration of calcium; this was quantified by measuring 
the absorbance at 570 nm. When samples did not fall within the standard curve, a 1:1 
dilution was performed for those samples only and the plate was read again. Once 
measured, the absorbance can be converted to concentration of calcium by comparing the 




5.3.7.5 Adipogenic differentiation  
Following culture expansion to obtain the required cell number for differentiation, cells 
were induced towards the adipogenic lineage using the commercially available 
adipogenic media (AdipoDiff, Miltenyi Biotec). Quantitative measurement of 
adipogenesis was performed by Oil red and Nile red staining in parallel with gene 
expression analysis using established adipogenic markers, PPARg and FABP4 (both from 
Thermo Fisher) (Aldridge et al., 2013) detailed in Appendix 5. 
For Oil red staining 5x104 MSCs/well were seeded in triplicate into 24-well tissue culture 
plates (Corning) containing 1ml adipogenic media and incubated at 37° C, 5% CO2. For 
Nile red staining the cells were seeded in triplicate in a 48-well plate at a seeding density 
of 4x104 MSCs per well in 500 µl of adipogenic media. For both assays, half of the culture 
media was replaced twice every week and cultures were terminated on day 21 (Aldridge 
et al., 2013).  
5.3.7.6 Detection of lipid vacuoles by uptake of Oil Red  
On day 21, seeded cells were washed twice with PBS and fixed with 500 µl of 3.7% PFA 
at room temperature for 15 minutes. Oil Red solution was prepared fresh before the 
staining procedure.  
After fixation, the Oil red staining solution was applied at 1 ml/well and incubated for 20 
minutes at room temperature before washing twice with 1 ml PBS. For qualitative 
assessment of oil red uptake, a brightfield microscope was used and images captured 
using a digital camera (Olympus).  
5.3.7.7 Quantification of adipogenesis by Nile Red fluorescence measurement  
Nile red assay was performed similar to the Oil red staining up to the post-fixation stage. 
After the fixative was removed and the cells washed gently, the PBS was fully aspirated 
from the wells and replaced with an exact volume of 200 µl in each well. This was used 
as a background reading to be used for an accurate quantification of the fluorescent dyes, 
Nile red (excitation at 450-500 nm and emission at >528 nm) and DAPI (excitation at 
358 nm and emission at 461 nm) (both from Sigma). The wells containing PBS were used 
therefore to measure emission at 460 nm and 535 nm following excitation at 355 nm and 
485 nm respectively. The PBS was then replaced with 200 µl of a solution mix containing 
0.2% saponin (Sigma), 1μg/ml DAPI and 1μg/ml Nile red in PBS (Aldridge et al., 2013). 
Additionally, DMSO only wells were also used as baseline controls. Saponin was used to 
facilitate the penetration of Nile red into the cells which becomes fluorescent in contact 
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with lipids, while DAPI was used to stain for nuclei. The plate was incubated in the dark, 
wrapped in foil, for 15 minutes at room temperature. After staining the cells were washed 
twice, then 200 µl PBS was added to each well and the plate was read again as before.  
To quantify adipogenic induction, the Nile red to DAPI ratio was calculated. But first, the 
background from the first readings was subtracted from the second readings. Then the 
mean emission value for each triplicate for both Nile red and DAPI were calculated and 
this value divided by the mean value from control readings containing DMSO only to 
obtain the fold changes in adipogenic differentiation. 
5.3.7.8 Chondrogenic differentiation 
For chondrogenic differentiation the cells were cultured in the form of a 3D pellet (Jones 
et al., 2002). To form each pellet, 2.5x105 MSCs were suspended in 0.5 ml of 
chondrogenic media (ChondroDiff, Miltenyi Biotec) and centrifuged for 5 minutes in 
screw top 1.5 ml microcentrifuge tubes at 400xg. Screw caps were fastened loosely in 
order to allow gas exchange and incubated at 37º C, 5% CO2; half the media was replaced 
every 3 days for a total culture period of 21 days. From each sample, a total of n=6 pellets 
were generated and investigated, as follows: n=2 pellets were snap-frozen in optimal 
cutting temperature (OCT) compound (Fisher Scientific) using the vapour phase of liquid 
nitrogen prior to cryo-sectioning and staining with toluidine blue; n=3 pellets were 
prepared for papain digestion followed by glycosaminoglycan (GAG) assay while n=1 
pellet was lysed for RNA extraction using standard RNA lysis buffer from a kit (Norgen 
Biotek) and qPCR using chondrogenic transcripts for SOX9 and COL2A1 detailed in 
Appendix 5. 
5.3.7.9 Papain digestion 
The chondrogenic pellets (n=3 for each subset) were degraded using a papain-based 
digestion in order to be able to quantify the content of GAGs in the samples. The activated 
papain enzyme digestion solution was prepared as described in Appendix 1. The 
chondrogenic pellets were incubated overnight with 200 µl of this solution in a 60º C 
water-bath. Following incubation, the digested pellets were mixed thoroughly and 
centrifuged at 15,000xg for 10 minutes at room temperature and immediately stored at -




5.3.7.10 Glycosaminoglycan assay 
This assay was performed using the commercially available kit Blyscan (Biocolor) by 
using the papain digest from n=3 pellets for each MSC subset from the n=3 donors. This 
kit relies on the interaction between the sulphated polymers and 1.9 dimethylmethylene 
blue (DMMB) dye. Similar to the calcium assay, a standard curve for GAG content was 
prepared using the standard reagents provided in the kit, ranging between 0-5 µg/well. 
Samples assessment was performed by mixing 1 ml of DMMB with 200 µl of the papain 
digest sample, vortexed and mixed by constant agitation in a circular rotator for 30 
minutes at room temperature. The mixture was then centrifuged at 15,000xg for 10 
minutes so that the dye bounded to the GAG content in the samples was pelleted on the 
bottom of the tubes. The excess dye was gently removed without disrupting the coloured 
pellet, then 1 ml of dye dissociation agent was added to the sample and mixed similarly 
in a circular rotator for 30 minutes at room temperature. In a clear round-bottom 96-well 
plate 200 µl of each standard and samples were plated in triplicate and absorbance was 
read on a Berthold plate reader (Appendix 1) using a 656 nm wave length filter. The 
quantification was performed based on the GAG standard curve and the absorbance which 
was converted to concentration of GAGs/pellet by comparing the absorbance of the 
known GAG standards to the sample absorbance. 
5.3.7.11 Toluidine blue staining  
For toluidine blue staining, 7 µm thick sections were prepared from snap-frozen pellets 
(n=2 for each subset) using a CM3050S cryostat (Leica) and adhered to SuperFrost 
histology slides (Fisher Scientific). Slides were allowed to air-dry overnight then 
incubated with cooled methanol (Sigma) for 20 minutes at -20° C. Subsequently, slides 
were removed from methanol and allowed to air dry for 30 minutes. Once dry, slides were 
incubated in pre-warmed toluidine blue solution (Appendix 1) at 37° C for 30 minutes 
then briefly washed in isopropanol (Sigma Aldrich) to remove excess toluidine blue. 
Slides were incubated in xylene (Sigma Aldrich) for 5 minutes at room temperature and 
mounted using coverslips and DPX mounting media (Sigma Aldrich). Slides were 





The statistical analyses for gene expression experiments were performed using Kruskal-
Wallis for intergroup differences, corrected with the Bonferroni-Dunn for multiple-group 
comparison. Mann-Whitney analysis was employed for comparisons between two groups 
and Wilcoxon for matched paired data between two groups. Results were presented on a 
log scale as scattered dot plots with bars representing medians, connected dots plots for 
paired data or box and whisker plots, with boxes representing interquartile range, and 
whiskers representing the maximum and minimum values, calculated using GraphPad 
Prism version 7 software. Results were considered significantly different at p < 0.05 (with 




In previous chapter an increased presence of young immature osteocytes was detected in 
areas of bone sclerosis in OA femoral heads using staining for the expression of the early-
osteocyte marker E11. Within the stromal compartment of the same areas an increased 
presence of MSCs marked by the CD271 expression was also observed by IHC. The 
BLCs that were located interposed between these young osteocytes and the stromal 
compartment showed positivity for CD271 (i.e. flat cells on the endosteal surface) (Figure 
4.25 and 4.26), while osteoblasts were CD271 negative (Figure 4.27). Previous studies 
described cells lining the bone surface to be positive for the adhesion molecule CD56 
(Kristensen et al., 2013) and since they localised within the same location with the 
endosteal CD271 cells, it was hypothesised that some of the BLCs may represent an 
osteogenic subset of CD271+ MSCs. Another subset - CD146+ - was also analysed as 
CD271+ OA MSCs showed an increased expression of MCAM, encoding CD146 
(Chapter 3, Section 3.4.3) pointing to an involvement of this perivascular subset in OA 
bone.  
5.4.1 Identification of CD56+ cells in OA bone by IHC 
Given the altered MSCs phenotype in late stages of OA, CD56 was first employed as a 
candidate marker to investigate the osteogenic lineage cells in OA femoral heads. Based 
on the literature, the CD56 positivity would be present on cells in both sclerotic and non-
sclerotic areas (Kristensen et al., 2013; Kristensen et al., 2014). Therefore, to confirm the 
presence and determine the topographical location of these cells in relation to sclerotic 
areas, the investigation was performed first by using CD56 and CD271 alone, followed 
by the study of double-positive cells.  
Upon examination, it was observed that CD56 was indeed expressed on all cells present 
on the bone surface, in both S and NS areas (Figure 5.2). The expression of CD56 in S 
areas was not limited to BLCs (Figure 5.2A black arrow), but was also expressed by the 
mature bone forming osteoblasts (Figure 5.2A black arrow head) and bone resorbing 
osteoclasts (Figure 5.2A white arrow), although their presence was scarce, only present 
at bone remodelling sites. In contrast to the CD271 expression documented in Chapter 4, 
the expression of CD56 was negative in the stromal tissue. Active osteoblasts could be 
detected visually based on their morphology as large cuboid cells, while BLCs are much 
flatter in relation to the bone surface and osteoclasts have the defining multinucleated 
characteristic as described in Chapter 4, Section 4.4.5.  
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In NS areas the expression of CD56 was also found to be expressed in the cells covering 
the bone surface. However, the NS areas, as mentioned in Chapter 4, Section 4.4.7, were 
characterised by decreased trabecular bone area which was covered by bone lining cells 
only. No bone remodelling compartments were observed in these regions and therefore 
the osteoblasts and osteoclasts were absent.  
The expression of CD56 in both S and NS areas was consistent with the initial hypothesis 
and with the published research (Kristensen et al., 2014), indicating that only the cells on 
the bone surface showed positivity for this marker. 
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Figure 5.2. Representative IHC images showing CD56 positive cells in OA femoral 
heads from S areas (A) and NS areas (B). S areas are characterised by fibrovascular 
cones invading the articular cartilage dominated by bone remodelling units where all 
bone surface cells showed positivity for CD56, including the single thick layer of BLCs 
(black arrow), osteoblasts (black arrow head) and osteoclasts (white arrow). In NS areas 
a continuous single layer of bone lining cells was present and shown positivity for CD56 
(black arrow). Scale bar: 100µm. Sample ID: DIFHOA010 
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The positivity of CD56 staining was next assessed in large sections of bone from four OA 
femoral heads in order to quantify the distribution of CD56+ cells in relation to OA bone 
pathology. The analysis was performed in sclerotic (S) (Figure 5.3A) and non-sclerotic 
(NS) (Figure 5.3B) areas of OA bone, using the same samples and similar approach 
described in Chapter 2, Section 4.4.7 while assessing the topography of CD271+ MSCs. 
The areas of interest were traced selecting out the bone tissue while the percentage of 
positive area in relation to total stromal compartment area was calculated based on the 
signal detected (Figure 5.3C and D) by Nuance software as described in Chapter 2, 
Sections 2.6.4. and 2.6.5.  
The area of CD56 positivity was expected to be higher in S areas due to increased 
presence of osteoblasts and osteoclasts in S areas (Chapter 4, Section 4.4.6), as well as 
higher concentrations of CD56+ cells near the areas of new bone formation.  
Area analysis revealed that indeed the CD56 positive areas were significantly increased 
in the S areas from all four femoral heads of OA donors in comparison to donor matched 
NS areas (Figure 5.3E). This trend was found to be consistent across all four femoral 
heads and indicated a similar pattern to the increased presence of CD271+ MSCs in the 
same areas of the same femoral heads, described previously in Chapter 4, Section 4.4.7. 
Based on median values it was determined that the CD56 presence was 5.8-fold higher in 
S areas (p<0.0001, Figure 5.3F) compared to the NS areas of the same femoral head.  
The area analysis indicated that CD56+ cells are more abundant in areas of bone sclerosis 
in OA femoral heads, which point to their involvement in enhanced osteogenesis leading 
to bone sclerosis. However, the calculation included osteoblasts and scattered osteoclasts 
which also shown positivity for CD56 (Figure 5.2) but were negative for CD271 and 
therefore cannot be considered as MSCs. A new approach was adopted in order to obtain 
a more accurate quantification of the bone lining CD56+ cells in these areas. Specifically, 
since the osteoblasts and osteoclasts that showed positivity for CD56 were clearly not 
MSCs, confirmed by the negative expression of CD271, they were manually excluded 
leaving the possibility that the remaining cells positive for CD56 may contain an MSC 
subset.  
Since the presence of osteoblasts and osteoclasts was only observed in areas of bone 
sclerosis, only these areas were re-analysed. To this end, the positive areas that comprised 
osteoblasts and osteoclasts (Figure 5.4A) were excluded from the analysis as shown in 
Figure 5.4B and it was determined that the same trend for higher CD56 positivity in S 
regions was maintained (Figure 5.4C). New positivity area measurements comprising all 
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the cells without osteoblasts and osteoclasts in the S areas revealed that the CD56 
positivity was found to be 3.5-fold higher (p<0.0001) in the cells from S areas compared 
to the non-sclerotic areas (Figure 5.4D). Although osteoblasts and osteoclasts role is well 
established in bone turnover (Burr and Gallant, 2012) and their number were expected to 
be elevated in S regions, results presented here indicated that CD56+ BLCs may also be 
involved in the bone sclerosis given their elevated number in sclerotic areas.  
The increased expression of CD56 in the S areas was corroborated with a visible increase 
in the cell numbers that were lining the bone (Figure 5.5). This observation indicated that 
in the S regions of OA femoral heads, the bone surface was often lined by a multiple layer 
of cells and in some places, the cells were organised into a canopy, a structure known to 
be present in areas of active bone formation (Kristensen et al., 2014). 
This data suggests that the abundance of bone lining and canopy cells may account for 
the higher CD56 positivity observed in the S regions compared to NS, as determined by 
analysis of CD56 positivity in the whole FH of OA donors. This indicated that CD56+ 
cells may indeed represent a reservoir of osteoprogenitors that actively contribute to the 
enhanced bone formation activity associated with OA. Further in this chapter, their co-
localisation with CD271+ cells will be investigated, in order to ascertain if these cell 




   
Figure 5.3. Quantification of CD56 positive cells in OA femoral head bone. 
Representative images showing IHC of CD56 positive cells in OA femoral heads from S 
areas (A) and NS areas (B). The areas were selected for quantification using Nuance 
software by tracing a dotted line around the stromal compartment in S areas (C) and NS 
areas (D). The threshold was set according to control DAB+ only slides. The area 
measurements of CD56 positivity was graphed as percentage of total stromal area in all 
four femoral heads (FH) (D). Box plots show interquartile range, median and extreme 
values (empty boxes as NS areas, grey boxes S areas). All values from all four patients 
were pooled, the graph showing the percentage of CD56+ cells from NS (white box) and 
S (grey box) areas (F); Scale bar: 100 µm. Sample ID: DIFHOA016. 
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Figure 5.4. Quantification of CD56 positive cells in OA femoral head bone following 
osteoblasts and osteoclasts exclusion. In the S areas of OA bone, CD56 was expressed 
on all cells on the bone surface (A). Selection and measurement of area occupied by 
osteoblasts and osteoclasts positive for CD56 (B). Graph showing the areas occupied by 
other cells, after excluding osteoblasts and osteoclasts (C). All values from all four 
patients were pooled, the graph showing the percentage of CD56+ bone lining cells from 
NS (white box) and S (grey box) areas (F); Scale bar: 100 µm. Sample ID: DIFHOA016. 
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Figure 5.5. Representative IHC showing a sclerotic area of OA bone comprising the 
cells positive for CD56 on the bone surface. The CD56+ cells are only present at the 
bone surface, with no positive cells in the stromal compartment. The S areas of OA bone 
were characterised by the presence of CD56 positive bone lining cells as a single layer. 
These cells were observed to be more numerous in the presence of osteoblasts and pre-
osteoblasts, also CD56 positive, forming a canopy as a sealing zone for bone formation 
and osteogenic differentiation activities. Sample ID: DIFHOA010. 
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5.4.2 CD56+ cells in areas of new bone formation 
In order to obtain information with regards to new bone formation in the sclerotic areas 
of OA femoral heads as well as to corroborate this information with the spatial 
localisation of the CD56+ cells, PSR staining was employed together with CD56+ IHC. 
If CD56+ BLCs and canopy cells were directly involved in osteogenesis in S areas, their 
abundance would be co-localised to new bone formation areas. Since the tissue had been 
decalcified, assessment of new bone formation was assessed based on the colour profile 
and intensity of birefringence of the PSR-stained collagen fibres, bone formation and 
mineralisation undergoing changes in collagen fibrils thickness, orientation and their 
molecular packing (Viguet-Carrin et al., 2006).  
Adjacent slides from n=4 OA femoral heads were used for PSR staining and CD56 IHC. 
The expression of CD56 detected in areas of bone sclerosis were commonly associated 
with active bone remodelling activity based on the presence of osteoblasts and osteoclasts 
(Figure 5.6A). Within these same areas, the PSR slides were visualised under bright field 
microscopy revealing differences in the collagen content of the bone based on the 
intensity of red colouring. It was observed that the areas where the CD56+ bone lining 
cells and osteoblasts were present had a brighter red colour while the areas more distant 
from the bone surface where lighter. 
Under polarised light, the differences between the collagen fibres adjacent to the bone 
surface and the collagen content of the inside areas of the bone tissue were better revealed 
in the pattern of birefringence. With PSR staining under cross-polarized light, 
polarization colours of thin collagen fibres are green to greenish-yellow, and thick fibres 
range from yellowish-orange to orange to red. A predominance of green polarization in 
the OA sclerotic areas may indicate that the collagen molecules are loosely packed and 
could be composed of procollagens or intermediate collagens. The red areas proximal to 
the bone surface represent thicker collagen fibrils which may indicate newer laid collagen 
in the form of osteoid, due to an active bone formation process which corresponds to areas 
of CD56+ osteoblasts presence. The bone surface areas where CD56+ bone lining cells 
were present appeared yellow while the majority of the tissue appeared green.  
All together this data places the CD56+ cells in areas of bone with an increased immature 
collagen content, i.e. thicker collagen fibres, based on the yellow and red birefringence 
in the endosteal regions. Of importance, the gradual difference in collagen thickness could 
also be related to bone mineral deposition. Newly laid bone, also known as osteoid, 
represents sections of unmineralized matrix containing bundles of collagen fibrils which 
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would consequently be mineralised as the bone tissue mature (Reddi et al., 1977). These 
results confirmed that the CD56+ BLCs were localised in area of new bone formation. 
 
Figure 5.6. Representative photomicrographs of CD56 IHC and PSR staining in 
sclerotic area of OA bone. (A) CD56 is expressed by osteoblasts and bone lining cells 
(black arrows). (B) Picrosirius red staining of OA sclerotic bone visualised under bright 
field microscopy showing the different red colour intensities within the same area. (C) 
Polarised light microscopy showing red birefringence in areas of osteoblasts presence, 
yellow corresponding to areas occupied by bone lining cells and green for majority of 
bone tissue (magnified panels). Sample ID: DIFHOA016 
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5.4.3 Co-localisation of CD271 and CD56 using adjacent slides 
Current literature documented the existence of a CD271+CD56+ subset within the BM 
CD271+MSC population (Bühring et al., 2009). Together with data in Chapter 3 that 
revealed an osteogenic bias of the CD271+ MSCs in OA, it was hypothesised that the 
CD271+CD56+ MSCs would be the responsible subset driving the observed osteogenic 
commitment of CD271+ MSCs. Therefore, in order to demonstrate this, it was necessary 
to firstly prove the presence of double-positive cells in both healthy and OA bone. 
Next, IHC was further used to determine whether the CD56+ cells are unique to OA or 
they are present on other bone surfaces. So far it was shown that CD56+ cells were 
residing on the endosteal surface of the OA trabecular bone in both S and NS regions, 
although in higher numbers in the S regions. Similarly, in previous chapter it was shown 
that CD271+ MSCs were occupying the same locations, however they were also shown 
to be residing in the stromal and perivascular location as well, consistent with published 
literature (Tormin et al., 2011) and highlighted in Figure 5.7, right panels. Therefore, the 
topographic relationship of CD56+ cells with respect to CD271+ endosteal MSCs was 
assessed by using adjacent tissue slides in bone tissues from multiple sources and degree 
of pathology.  
To determine the co-localisation of CD271+ and CD56+ cells, IHC staining was 
performed using the antibodies against CD271 (as used in previous chapter) and against 
CD56. As shown in Figure 5.7, it was determined that both CD56 and CD271 were found 
expressed in bone from all tissue sources and their endosteal location was consistent 
across all samples, however a difference in the number of cells positive for the two 
markers was noted.  
As expected, the CD56 positive cells were found abundant in the S areas of OA bone, 
comprising osteoblasts and osteoclasts present in areas of bone remodelling, its 
expression being restricted to all the cells lining the bone (Figure 5.2A and 5.7, top panel). 
Meanwhile, consistent with data obtained in previous chapter, the CD271 expression was 
also found in the vast majority of cells within the same areas, including some stromal 
cells (Figure 5.7, top panel). Furthermore, noteworthy was the absence of CD271 staining 
in osteoclasts and osteoblasts, consistent with previously shown data in Chapter 4, Section 
4.4.7.  
In NS areas of OA bone, the expression of both markers was observed under the same 
pattern, with the CD56+ cells lining the bone while CD271+ was expressed by cells 
present both on the bone surfaces, as well as in the stromal compartment. When 
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comparing the sclerotic and non-sclerotic area of OA, there was notable difference in the 
number of cells in these areas. This confirmed the increased presence of CD271+ cells in 
S areas, presented and discussed in Chapter 4, Section 4.4.7 as well as the CD56+ 
accumulation in S areas presented in Section 5.4.1. 
Interestingly, the expression of both CD56 and CD271 in healthy iliac crest was similar 
to the NS areas from OA bone as expected. A single layer of cells appears to be lining the 
bone, showing positivity for both CD56 and CD271. The expression of CD271 in the 
stromal compartment of IC was also consistent with the NS area as previously 
documented in Chapter 4, Figure 4.25. 
When the expression of CD56 and CD271 was investigated in femoral head bone from 
non-OA donors, represented by femoral heads of neck of femur fracture patients, the 
positive cells showed the same topographical pattern although their number was notably 
lower. This may be due to decreased BM cellularity and its replacement with the apparent 
fatty stromal cells, which is commonly observed with increasing age of these patients. Of 
note, areas selected for comparison for the non-OA samples corresponded to the S areas 
from OA samples, both located in the subchondral zone.  
It was concluded therefore that CD56+ cells were present on bone surfaces irrespective 
of site or tissue status and it was noted that CD271+ cells in the endosteal regions were 
potentially co-localised with CD56+ cells. However, since the analysis was performed on 
adjacent slides it was still insufficient evidence to determine whether the CD56+ and 




Figure 5.7. The comparison of CD56 and CD271 positive cells in bone from multiple 
sources. Staining was performed in S and NS regions of OA bone, healthy IC and femoral 
head bone from femoral neck fractures (non-OA FH). The CD56+ cells were located 
lining the bone surfaces of all samples while CD271+ cells were in the same bone lining 
locations where CD56+ cells were present as well as in the stromal compartment. 
Arrows: CD271+ cells; arrow heads: CD56+ cells. Scale bar:100 µm. Sample IDs: OA: 
DIFHOA010; IC: DIHIC03; Non-OA: DIFHOP03. 
 228 
5.4.4 Co-localisation of CD271 and CD56 using immunofluorescence  
Following IHC staining it was determined that a subset of CD271+ cells and CD56+ cells 
was located in the endosteal region, lining the bone surface. However, this was not 
sufficient to determine whether the cells lining the bone were co-expressing both markers 
and therefore have one cellular identity characterised by CD271+CD56+ phenotype, or 
there are two distinct cell populations condensed within the same area. To validate the 
co-expression of CD56 and CD271 on the same cell as well as the endosteal topography, 
IF double staining was employed using the same antibodies from IHC experiments and 
visualised by confocal microscopy in OA bone sections. The antibody against CD56 was 
tagged with Alexa Fluor 647, emitting a red colour when excited by confocal microscopy 
lasers, while the antibody against CD271 were tagged with Alexa Fluor 488 which can 
be visualised in the green spectrum, as described in Section 5.3.3. Negative control using 
secondary antibodies only was used to detect any background fluorescence in order to set 
the threshold of fluorescence as well as to validate the antibody binding, described in 
Section 5.3.3.  
Initial examination confirmed the location of both markers as previously assessed by IHC. 
While CD56+ cells were located lining the bone surface, the CD271 positivity was 
detected in both endosteal and the stromal cells, consistent with the IHC findings (Figure 
5.8). The CD56+ cells coloured red could be observed in the bone lining region only 
(Figure 5.8A), consistent with the IHC data. Similarly, CD271+ cells stained green were 
found localised both on the endosteal surface as well as throughout the stromal tissue 
(Figure 5.8B). When the images were merged by using the Elements software (Nikon), 
co-localisation of these molecules can be observed in yellow colour, marking the double 
positive cells as shown by the arrows in Figure 5.8D. By using immunofluorescence 
merged sections it is possible to also visualise the single positive cells, which based on 
the IHC data may belong to osteoblasts, osteoclasts or CD271+ MSCs which do not 
express CD56.  
This data confirmed the existence of CD271+CD56+ cells on the bone surface. While the 
presence of an individual marker (CD56) had been described by the literature on BLCs 
(Kristensen et al., 2013; Andersen et al., 2013; Kristensen et al., 2014), this was the first 
time when they were both shown on the same cells. Therefore, by using FACS, from the 
CD271+ MSCs population a novel endosteal CD271+CD56+ subset could be sorted, in 
addition to the already discovered perivascular CD271+CD146+ subset (Tormin et al., 
2011). 
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When visualised at a higher magnification (Figure 5.9) the presence of double positive 
cells can be observed more easily on the bone surface, while the positivity for CD271 
alone was found only in the stromal compartment (Figure 5.9). Some positive CD56 cells 
were also detected indicated by the red arrows in Figure 5.9 and based on their size and 
location they were potentially differentiated osteoblasts.  
 
 
Figure 5.8. Immunofluorescence staining of OA femoral head bone tissue from 
sclerotic area. (A) CD56+ cells found exclusively on the bone surfaces. (B) CD271 was 
expressed by cells within the stromal area as well as by the cells lining the bone. (C) 
DAPI nuclear staining showing the presence of all cells in the tissue slide. (D) Merged 
images of all planes of view showing the cells that only express CD56 (red arrows) and 
CD271 (green arrows) while the co-expression can be observed in yellow colour, but not 




Figure 5.9. High magnification IF image showing the co-localisation of CD56 and 
CD271 on cells in OA bone. The CD271+ cells (green arrows) can be seen in the stromal 
compartment while CD56+ cells (red arrows) are observed on the bone surface. When 
the two markers were detected by the software to be co-localised, it appeared yellow 
(yellow arrows). Scale bar: 50 µm. Sample ID: DIFHOA010 
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5.4.5 MSCs subsets enumeration and cell sorting by FACS 
The CD271 antigen represents a marker of native MSCs in the BM which can be further 
sub fractionated using additional cell surface markers. Following IHC and IF, the 
existence and topography of CD271+CD56+ phenotype was confirmed by FACS and 
compared to CD271+CD146+ phenotype, which was used as a comparator. Gating was 
set on the CD45-CD271+ phenotype as described in Chapter 2, Section 2.4 and was 
performed on enzymatically released cells form healthy (n=8) and OA (n=15) bone. 
Based on IHC data in Section 5.4.1 and the increased osteogenic commitment observed 
in CD271+ MSCs from Chapter 3, the presence of CD271+CD56+ subset was expected 
to be increased in the OA samples.  
The MSC subsets were then enumerated as percentage of CD271+ MSCs and 
phenotypically distinct MSC subsets could be distinguished based on the expression of 
CD56 and CD146 within the CD271 gated fraction (Figure 5.10). Unexpectedly, the 
double negative (DN) fraction of CD271+ MSCs was found to be the most numerous in 
comparison to the CD56+ and CD146+ fractions (Figure 5.10 and 5.11).  
A minimum number of 1x103 events were collected and cytometric analysis revealed that 
the percentage of CD56+ subset within the CD271+ MSC population, gated as CD45-
CD271+CD56+CD146- was 8-fold (p<0.0001) higher in OA samples in comparison to 
healthy IC controls. Based on median values, the CD56+ subset accounted for 0.52% of 
the CD271+ MSCs isolated from the healthy bone samples while in OA they represented 
4.21% (Figure 5.11A).  
The DN population gated as CD45-CD271+CD56-CD146- represented the majority of 
CD271+ population. Based on median values, the DN subset represented 70.7% of 
healthy CD271+ cells while in OA their frequency was found to be at 58.51%. Although 
notably different, their percentages were not significantly different between healthy and 
OA cells. No difference was also observed in the percentages of CD146+ subset, gated 
as CD45-CD271+CD56-CD146+ between healthy and OA, with medians of 14.26% in 
healthy samples and 17.31% in OA samples (Figure 5.11B). While a trend for higher 
expression in OA was observed, these data validated the increased transcriptional levels 
of MCAM (Chapter 3, Figure 3.14) at the protein level without reaching statistical 
significance. 
These results confirm the increased presence of the CD271+CD56+ subset in OA bone. 
However, in comparison to other subsets, the CD271+CD56+ subset represented only a 
small proportion of the entire CD271+ population, the majority of cells being actually 
 232 
DN. These are stromal reticular cells (non-BLCs, non-pericytes) which in OA can 
represent the stromal cells in the fibrovascular tissue previously documented in Chapter 
4, Figure 4.24.  
 
 
Figure 5.10. Enumeration by FACS of CD271+ MSCs subsets from healthy and OA 
bone. Dot plots showing FACS analysis of fresh, uncultured cells enzymatically extracted 
from healthy IC and OA FH bone, stained with BV421-CD56 and PE-CD146 following 
gating on the APC-CD271+ cell population and HLCs removal by negative gating with 
FITC-CD45. (A) Gates set using the isotype control IgG1 BV421 corresponding to CD56 
antibody conjugate and IgG1 PE for CD146 antibody on cells isolated from iliac crest. 
(B) Gates were set using isotype controls for each antibody used to stain the cells 
extracted from OA bone. 
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Figure 5.11. Comparison of CD271+ MSC subsets percentages between healthy and 
OA bone. Graphs showing the enumeration of CD271+ MSC subsets extracted and 
purified by FACS from healthy and OA bone. (A) Graphs representing the percentage of 
CD56+ cells out of CD45-CD271+ cells. (B) Graphs representing the percentage of 
CD146+ cells out of CD45-CD271+ cells (C) Graphs representing the percentage of DN 
population gated as CD56-CD146- cells out of CD45-CD271+ cells.  
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5.4.6 Gene expression analysis of native CD271+ MSC subsets 
In addition to enumeration, the CD271+ MSC subsets were also sorted for downstream 
analysis. This included investigation of gene expression levels of CD271+CD56+ subset 
in comparison to CD271+CD146+ and DN subsets as well as functional assessments. 
Based on the data cumulated so far, this further analysis aimed at testing the hypothesis 
that the increased osteogenic commitment observed in the CD271+ MSCs from Chapter 
3 was attributed to a specific osteogenic committed CD271+CD56+ subset. 
Donor matched FACS purified MSCs subpopulations from OA donors (n=6) were 
collected for gene expression analysis using TaqMan low density array (TLDA). Due to 
difficulties in obtaining large cell numbers from healthy iliac crest, cells of all three MSC 
subsets were only collected from OA bone. Analysis was performed using cells isolated 
from donor-matched subsets of n=6 OA samples comprising the CD45-CD271+CD146-
CD56+ (CD56+ subset), CD45-CD271+CD146+CD56- (CD146+ subset), CD45-
CD271+CD146-CD56- (DN subset) while CD45+CD271- (HLCs) were used as a control 
for all three subsets. All gene expression values were normalised to the housekeeping 
gene levels of HPRT1 and presented as 2-DCt, as described in Chapter 2, Section 2.5.4. 
The TLDA panel comprised a total number of 96 genes known to be specific to MSCs 
and influence their functional properties, summarised in Appendix 5. These included 
transcription factors and mature proteins as markers for osteogenic, adipogenic and 
chondrogenic differentiation, proliferation and migration as well as stimulation of 
angiogenesis.  These results were subjected to hierarchical clustering for visualization as 
described previously (Churchman et al., 2012), allowing fold differences to be observed 
more easily. Hierarchical clustering was performed based on Spearman rank correlation 
of the log transformed values, the software grouping the genes with similar differential 
expression between the MSC subsets. As expected, this analysis clustered the data from 
the four sorted fractions into two separate branches of the dendrogram, HLCs and MSCs 
respectively based on their level of expression and differences between the groups (Figure 
5.12). It can be observed a segregation between the genes expressed higher in the HLC 
lineage (Figure 5.12, white rectangle) than MSC subsets and similarly, the genes higher 
expressed in CD271+ MSCs subsets as compared to HLCs (Figure 5.12, blue rectangle). 
Furthermore, another group of genes clustered under the CD56+ subset (Figure 5.12, 




                         
Figure 5.12. Hierarchical cluster analysis of FACS sorted fractions isolated from OA 
bone. Dendrogram showing hierarchical cluster analysis of log2 transformed relative 
gene expression of FACS-purified native MSCs subsets and HLCs from OA bone (n=6). 
Values were calculated by the 2-∆Ct normalised to HPRT1. Green < HPRT1, 
Red>HPRT1, Black=HPRT1, Grey-missing values. White rectangle: HLCs specific 
cluster; blue rectangle: CD271+ common genes; yellow rectangle: CD271+CD56+ 
specific cluster, overlapping with DN. 
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It is known that data pre-processing steps, such as gene normalisation and how missing 
values are dealt with can affect the clustering outcome (D’haeseleer, 2005). Following 
hierarchical clustering it was decided that a more exhaustive comparison was needed for 
the genes that showed notable changes between the CD56+, CD146+ and DN subsets 
belonging to the CD271+ MSC population. The clusters obtained were not compact and 
well separated with regards to the genes within the CD271+ MSC population, which was 
comprised of three subsets as selected by FACS. Therefore, the genes were scrutinised 
individually to investigate their expression levels by direct comparison between the sorted 
fractions. 
But first, quality control was assessed at a transcriptional level to verify the sorting 
procedure and to test whether the isolated fractions under investigation actually belong to 
the corresponding populations. The cluster analysis segregation confirmed distinct 
molecular identities reflecting different cell lineages, the two clusters highlighted on the 
dendrogram including genes associated with the cellular identities of MSCs and HLCs. 
The HLCs group included genes associated with the haematopoietic lineage, such as 
GATA binding protein 2 (GATA2), RUNX1, interleukin 10 (IL10) and interferon gamma 
(IFNG) which were all differentially expressed in comparison to the MSC group. As 
shown in Figure 5.13, the expression levels of IFNG was only detected in HLCs with no 
detectable signals in any of the three subsets. Similarly, IL10 was only detected in some 
of the MSCs subsets and at lower levels in comparisons to HLCs.  
In addition, the levels of NGFR, the gene encoding the CD271 antigen was expressed at 
similar levels across the three MSC subsets, all significantly higher than HLCs. This 
confirmed at a transcriptional level the positive selection of the three MSCs subsets under 
the CD271 marker. Furthermore, the gene encoding CD146 marker (MCAM) also 
confirmed the FACS sorting procedure, the levels of expression being significantly higher 
in the CD146+ MSC subsets in comparison to the other two MSC fractions and HLCs. 
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Figure 5.13. Assessment of positive control gene expression in the FACS sorted 
fractions. Gene expression levels of CD45+ HLCs (IFNG and IL10) and CD271+ MSCs 
subsets (NGFR and MCAM) associated molecules were compared across all fractions. 
The expression levels confirmed the sorting procedure in sorted fractions from OA bone. 
Data represented as connecting dots for donor-matched samples and gene expression 
values as relative to HPRT1 on a log scale. 
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5.4.7 Osteo-chondrogenic gene expression profile of OA CD45-CD271+ 
CD56+ MSCs  
As previously stated, within the CD271+ MSCs there may be a subset of enhanced 
osteogenic commitment responsible for the altered MSC phenotype observed in OA. 
Based on histological assessment and in consensus with the published literature (Bühring 
et al., 2009), it was determined that the CD271+CD56+ exists and is located on the bone 
lining surface. In order to determine whether CD56+ MSC subset are the culprit fraction 
responsible for the osteogenic bias observed in OA MSCs, a detailed analysis of the gene 
expression differences between the three MSC subsets selected from the TLDA was next 
performed. This indicated a strong osteogenic commitment of the CD56+ MSC subset as 
well as an increase in some chondrogenic related molecules. Although the experiment 
was performed by using MSC subsets from n=6 OA donors, for a better interpretation of 
results, the analysis was performed only on the complete set of donor-matched gene 
expression values (Figures 5.14 and 5.15). 
The CD56+ subset gene expression profile was first determined to be significantly 
different in comparison to the CD146+ subset. Furthermore, it was noted that a trend for 
higher expression corresponds to the CD56+ subset in comparison to DN, however it 
failed to reach statistical significance between these two data sets (Figures 5.14). The 
gene expression levels of SPP1 were 508-fold higher in the CD56+ subset (p=0.0016) 
compared to CD146+ subset while BGLAP, a robust marker for bone formation and active 
osteoblasts (Wei and Karsenty, 2015) was 163-fold higher in the CD56+ subset 
(p=0.0045) compared to CD146+. The levels of OMD, encoding an extracellular matrix 
protein with important roles in osteoblasts formation and the mineralisation process 
(Rehn et al., 2008), were 86-fold higher (p=0.0047) in the CD56+ subset in comparison 
to the CD146+ subset. Furthermore, the levels of the key osteogenic transcription factors 
SP7 and RUNX2 were both significantly higher expressed in the CD56+ subset in 
comparison to CD146+ subset. The levels of SP7 were found to be 26-fold elevated 
(p=0.0140) in the CD56+ subsets while RUNX2 levels were 14-fold higher (p=0.0117) in 
comparison to CD146+ subset. Another molecule associated with the MSC’s osteogenic 
lineage commitment, ALPL, was 3-fold higher (p=0.0342) in the CD56+ subset compared 
to CD146+ cells. The analysis was performed based on median values, representing the 
medians calculated based on the donor matched expression levels for each gene and 
detailed in Table 5.1. 
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Figure 5.14. Gene expression levels of osteogenesis-related molecules in sorted 
CD271+ fractions from OA bone.  Data represented as connecting dots for donor-
matched samples and gene expression values as relative to HPRT1 on a log scale. 
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Following analysis of genes associated with osteogenesis, the CD56+ and DN subsets 
also expressed higher levels of molecules associated with the chondrogenic lineage 
compared to CD146+. The transcription factor SOX9, the main controller of the 
chondrogenic lineage commitment (Bi et al., 1999) was expressed at higher levels in the 
CD56+ subset compared to CD146+ cells (5-fold, p=0.0400). The expression levels of 
CHAD, another gene implicated in cartilage formation and MSC chondrogenic 
differentiation (Camper et al., 1997), were 221-fold higher in the CD56+ subset 
(p=0.0133) compared to CD146+ subset.  
Similar to the trend observed in the expression levels of osteogenic molecules, the DN 
subset also showed similar expression levels to the CD56+ subset with regards to the 
chondrogenic transcription factor SOX9, but was significantly higher than in CD146+ 
subset. The levels of CHAD were also higher in DN compared to CD146+, however it 
was not statistically significant.  
 
 
Figure 5.15. Gene expression of chondrogenic molecules SOX9 and CHAD in sorted 
cell fractions from OA bone. Data represented as connecting dots for donor-matched 
samples and gene expression values as relative to HPRT1 on a log scale. 
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Table 5.1. Fold differences in gene expression based on median values of CD56+ and 
CD146+ subsets sorted from OA bone 
Gene 






SPP1 508.62 ** 0.0016 10.68 NS 
BGLAP 163.11 ** 0.0045 7.23 NS 
OMD 86.02 ** 0.0047 2.58 NS 
SP7 25.78 ** 0.0140 1.99 NS 
RUNX2 13.57 * 0.0117 2.02 NS 
ALPL 2.78 * 0.0342 1.17 NS 
CHAD 221.22 * 0.0133 6.57 NS 
SOX9 4.53 * 0.0400 1.23 NS 
 
Taken together, this pattern of expression points to an osteo-chondro profile of both 
CD56+ and DN subsets of MSCs but although not statistically significant, the CD56+ 
subsets expressed higher levels of these genes compared to DN. Therefore, this is the first 
time when the gene expression profile of CD271+ subsets were analysed in native cells. 
While a chondrogenic bias of the CD271+CD56+ subset was previously documented in 
healthy BM MSCs (Battula et al., 2009), this analysis was done following culture 
expansion of the respective subset and knowledge about their native biology was lacking. 
The enhanced osteogenic profile documented in this chapter suggest a more complex 
molecular profile of the different subpopulations of native bone resident MSCs and may 
provide important insights with respect to MSCs implications in OA pathophysiology. 
5.4.8 Genes higher expressed in CD146+ and DN subsets 
Further analysis revealed the distinction between the CD56+ and DN subsets. It was 
found that CXCL12, a well-known stromal support chemokine (Greenbaum et al., 2013), 
showed significantly higher expression levels in DN compared to both CD56+ and 
CD146+ subsets (Figure 5.15A). Based on median values CXCL12 was 7-fold elevated 
in DN compared to CD56+ subset (p=0.0133) and 4-fold higher in comparison to the 
CD146+ subset, although the latter was not statistically significant. This was consistent 
with the stromal topography of this subset (Chapter 4, Figure 4.24) as CXCL12 encodes 
SDF-1, a critical chemokine with roles in MSC migration and stromal support (Kitaori et 
al., 2009; Greenbaum et al., 2013).  
 242 
While CXCL12 seemed to be higher expressed in DN subset and therefore indicating a 
separation of the three subsets, it was interesting to verify the identity of the CD146+ 
subset, which was only characterised based on functional assays and localisation in 
previous studies, with no indication of their molecular signature (Tormin et al., 2011). 
The gene that showed higher specificity to CD146+ compared to both CD56+ and DN 
was FABP4, encoding a mature adipogenic protein. In comparison to DN and CD56+ 
median values, the expression levels of FABP4 were 17-fold higher (p=0.0140) in 
CD146+ subset. Furthermore, the adipogenic transcription factor PPARg was also shown 
to be higher expressed in CD146+ subset compared to DN and CD56+, although it was 
not statistically significant.  
In addition, another gene that showed specificity for CD146+ perivascular subset was a 
transcript expressed by cells associated with a haematopoietic origin (Figure 5.15B). 
GATA2 is a transcription factor required for expansion and differentiation of 
haematopoietic stem cells (Tsai et al., 1994) but several roles have also been documented 
in MSCs, including roles in maintenance of stemness (X. Li et al., 2016). The GATA2 
expression levels were found to be 6-fold higher (p=0.0159) in CD146+ subset in 
comparison to DN and no expression was detected in the CD56+ subset.  
Transcriptional profile of the three subsets indicated so far distinct gene expression 
signatures in OA. It was shown that CD56+ cells had an enhanced osteochondro profile 
while DN is characterised by increased CXCL12, consistent with its location within the 
stromal compartment. Perivascular topography of CD146+ has been previously 
documented (Tormin et al., 2011) and here it was shown that this subset expressed low 
osteogenic related genes, but higher levels of GATA2 in addition to the fat associated 
molecules, FABP4 and PPARg.  
Based on the results following both topographical assessment and gene expression 
analysis, there has been an indication of a gradient gene expression pattern in MSCs from 
bone lining location towards the perivascular MSCs. The osteogenesis related genes were 
at low levels in the perivascular CD146+ subset which were observed at an intermediate 
level in DN and reaching significantly higher levels in the CD56+ subset, which was 
topographically shown to be located on the bone surface. Most importantly, this enhanced 
osteogenic profile was exhibited by the CD271+CD56+ cells lining the bone surface, 
excluding the bone forming osteoblasts, previously shown to be negative for CD271 




Figure 5.16. Gene expression levels of molecules expressed higher in DN and CD146+ 
in comparison to CD56+ subset. Higher gene expression levels of CXCL12 in the DN 
subset compared to CD56+ and CD146+ subsets (A) and the levels of higher expressed 
molecules in the CD146+ subset compared to DN and CD56+ subsets (B). Data 
represented as connecting dots for donor-matched samples and gene expression values 
as relative to HPRT1 on a log scale. 
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5.4.9 Differentiation assay 
One of the key biological properties of MSCs is their potential to differentiate into 
mesodermal lineages. Therefore, the phenotypical characteristics of the purified subsets 
were further tested for their multipotentiality in vitro. Based on gene expression data, it 
was expected that the in vitro osteogenic potential of CD56+ was higher in comparison 
to the other two fractions. Similarly, the adipogenic potential of CD146+ subset would 
also confirm the higher levels of adipogenic transcripts observed by gene expression 
analysis of this subset in comparison to DN and CD56+ subsets.  
By using enzymatically released cells from three OA donors, cultures were initiated from 
all three FACS-purified CD271+MSC subsets (CD56+, CD146+ and DN) and subjected 
to standard osteogenic, adipogenic and chondrogenic differentiation to determine which 
of these fractions represent a population of BM MSCs with enhanced osteogenic 
potential. The in vitro differentiation was evaluated by functional assays, histochemical 
and qPCR analysis. 
5.4.9.1 Cell culture 
The collected numbers of cells following cell sorting procedure ranged between 0.3x104 
– 2.2x104 cells for the lowest fraction (CD56) and were insufficient for the differentiation 
assays, therefore minimal culture expansion was performed to allow the cells to 
proliferate. Thus, between 0.5x104 - 1x104 cells from the three subsets were seeded in 6-
well culture dishes and allow to proliferate over the same period for 6 days post isolation 
by FACS. Following trypsinisation, the cells were seeded at a density of 5,000 cells/cm2 
and cultured for further 48 hours thereafter when they were trypsinised and seeded in the 
corresponding media for either osteogenic, adipogenic or chondrogenic assay. 
Altogether, the cells were in culture for 8 days and were used at passage 1 for these assays. 
The three MSCs cultured subsets were found to be heterogeneous regarding cell size and 
morphology immediately after they were placed in culture (Figure 5.16). The CD56+ 
subset took on a circular in shape, while the DN and CD146+ cells displayed an MSC-
like spindle shape (Figure 5.17). However, following 3 to 7 days respectively, all the cells 
adopted a similar fibroblastic morphology characteristic to cultured MSCs (Figure 5.17). 
No obvious differences were noted, all three subtypes displaying a morphology varying 
from elongate to broad as well as small flat cells. The HLCs (CD45+) isolated following 
FACS analysis were also cultured and displayed a morphology characteristic to 
haematopoietic cells, with spindle shaped monocytes progenitors attached while other 
CD45+ cells suspended in media were sequentially removed during media changes. 
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Following the 7 days in culture some of the attached CD45+ cells adopted a flat 
morphology, indicating differentiating monocytes (Figure 5.17). 
 
Figure 5.17. Cell cultures generated from the isolated cells following sorting by FACS 
from the four fractions. Photos were taken at Day 0, Day 3 and Day 7. While the cells 
showed different morphologies at Day 0, representing first day after sorting, they were 
all distinct from CD45+ cells and adopted a fibroblastic morphology after Day 3. Images 
were taken using an inverted microscope with a 20x objective and an Olympus camera. 
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Figure 5.18. Higher magnification of the FACS isolated cells from the four fractions 
at Day 0, Day 3 and Day 7. While the cells showed different morphologies at Day 0, 
representing first day after sorting, they were all distinct from CD45+ cells and adopted 
a fibroblastic morphology after Day 3. Note that morphology of some attached CD45+ 
cells changed from a spindle shape to flat shape through the 7 days in culture. Images 




In order to determine whether any of the three CD271+ MSC subsets have an enhanced 
osteogenic potential, osteogenic assays were next used. By using this assay, it was 
expected to obtain a confirmation of the gene expression data of enhanced osteogenic 
bias observed in native CD56+ subset.  
Osteogenesis was assessed following induction in standard commercially available 
osteogenic media of the three MSCs subsets expanded for 1 passage from the three 
donors. Following 14 days in culture under osteogenic conditions, the cells were stained 
to detect the ALP activity (Figure 5.19) showing positive results in all samples judged by 
the blue colour developed in the culture plate following incubation with ALP staining 
solution. The MSCs subsets displayed no visible differences between the subsets or the 
donors with regards to the intensity of blue colour, while a degree of variability was noted.  
Alizarin red staining was performed to assess the calcium production in the three MSCs 
subsets following 21 days’ post-induction. Similarly, no differences were observed in the 
calcium deposition marked by the red staining between the MSCs subsets from all three 
donors (Figure 5.20) while similar variability between donors and subsets was observed.  
Both staining methods provided a qualitative assessment of the osteogenic differentiation 
potential of the three subsets from three different donors. It was observed that all subsets 
responded well to osteogenic induction. This indicated a potential for in vitro osteoblastic 
lineage commitment of all the three MSC subsets, based on the positive alkaline 
phosphatase activity as well as their increased calcium production. In order to determine 
any potential differences between these subsets in their osteogenic potential, the three 
subsets were subjected to quantitative assessments, including measurements of calcium 
production and transcriptional analysis following osteogenic induction. 
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Figure 5.19. Assessment of alkaline phosphatase activity in the culture-expanded 
CD271+ MSCs subsets. Representative osteogenesis assay dishes showing ALP staining 
at 14 days post-induction using Fast Blue RR salt for all CD271+ MSC subsets following 
culture (n=3 donors, each subset in duplicate). No visible difference was observed 




Figure 5.20. Assessment of calcium production by Alizarin red in the culture-expanded 
CD271+ MSCs subsets. Osteogenesis assay dishes showing Alizarin red staining at 21 
days post-induction to assess calcium deposition of sorted MSC subsets (n=3 donors, 
each subset in duplicate) indicating inter-donor variability and no visible differences 
across the subsets. 
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Total calcium production per well was measured in triplicate in all MSC subsets from the 
three donors following 21 days under osteogenic conditions. Calcium was detected in all 
samples, and no statistically significant difference was observed between the MSCs 
subsets (Figure 5.21). Inter-donor variability was observed across all subsets and may be 
attributed to cell characteristics and their ability to adapt to in vitro conditions.  
Correspondence between total calcium measured and alizarin red staining was observed 
but not in ALP staining. For example, the CD146+ MSCs subset from Donor 1 showed 
stronger alizarin red staining in comparison to DN and CD56+ subset. The same trend 
was observed by calcium measurements where CD146+ MSCs produced on average 8 µg 
Calcium/well while DN and CD56+ only 19 µg/well and 24 µg/well respectively.  
Osteogenic differentiation was also quantified at a transcriptional level using gene 
expression by qPCR and analysing the mRNA levels of genes encoding lineage-specific 
markers, such as the key transcription factor RUNX2 and the mature bone protein BGLAP 
(osteocalcin).  
Interestingly, gene expression results were variable with regards to the MSC subsets’ 
response to osteogenesis induction. The levels of both transcripts varied among the three 
MSC subtypes without a clear trend that would be expected to reflect the results observed 
following functional assays. Moreover, it was observed that the levels of RUNX2 tend to 
decrease following induction in all three MSC subtypes which may be explained by 
previous studies suggesting that RUNX2 activity is more regulated at post-transcriptional 
level and was also shown to be elevated early during differentiation and decreased on day 
21 (Jaiswal et al., 1997). However, the functional assays quantifying alkaline phosphatase 
activity and calcium deposition indicated a positive and active osteogenesis.   
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Figure 5.21. Osteogenic differentiation assessment by Calcium assay and qPCR. (A) 
Calcium production of sorted cells following culture expansion represented as µg of 
calcium/well. Data presented as donor-matched connected dot plots with average values 
and bars as standard deviation of triplicate wells for each of the three MSC subsets in 
the three donors. (B) Transcriptional analysis at day 0 (left data set) and day 21 (right 
data set) post-osteogenic induction showing the fold changes in relative expression of 
RUNX2 and BGLAP in the three MSC subsets. Data represented as connected dot plots 
for donor-matched samples and fold changes calculated based on average values of 





In order to determine which of the three CD271+ MSC subsets have a more pronounced 
chondrogenic potential, functional assays were used on all three MSC subsets from the 
same three OA donors. These chondrogenic assays were expected to confirm the 
enhanced chondrogenic potential observed by gene expression and indicated by the 
published literature (Bühring et al., 2009; Sivasubramaniyan et al., 2018). 
Chondrogenesis was hereby investigated using pellet-cultured MSCs in chondrogenic 
media for 21 days. Pellets of the three MSC subsets from the same n=3 OA donors were 
used for toluidine blue staining, GAG assay and qPCR.  
After 21 days of differentiation, all MSC subsets undergone chondrogenesis and all 
samples formed large pellets with prominent matrix metachromasia (Figure 5.22A and 
B). Pellets were removed from media, photographed and diameter measured in duplicate 
(Figure 5.22B and C) then embedded in OCT for cryo-sectioning and toluidine blue 
staining in duplicate. All pellets had a similar shape and size with no obvious differences 
between subsets or donors. The diameter measurements of the pellets were averaged for 
each subset and then across all donors with no significant differences observed between 
the MSC subsets (Figure 5.22C).  
Toluidine blue is a standard procedure for the histological assessment of chondrogenic 
differentiated cells and cartilaginous tissue maturity and quality (Bergholt et al., 2018). 
This dye permits the visualisation of the proteoglycans presence in a tissue because of its 
high affinity for the sulphate groups of proteoglycans (Schmitz et al., 2010). As shown in 
Figure 5.22A, all pellets exhibited an intense blue/purple colour suggesting a high 
proteoglycan content present in the pellets formed by the differentiated cells. However, 
no visible differences were observed between the three subsets with regards to matrix 
composition. Toluidine blue was used to stain the chondrogenic pellets formed by the 
differentiating cells as a qualitative assessment of the chondrogenic induction. Therefore, 
the potential to differentiate towards a chondrogenic lineage was positive for all MSCs 
subset, however this assay was insufficient for a quantitative assessment. 
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Figure 5.22. Assessment of chondrogenic pellets formation in the culture-expanded 
CD271+ MSCs subsets. (A) Representative sections of chondrogenic pellets stained with 
Toluidine blue from the three FACS sorted fractions following culture expansion and 
chondrogenic induction. (B) Photograph of the chondrogenic pellets before embedding 
in OCT and snap freezing in liquid nitrogen. (C) Graph showing the diameter in mm of 
the two pellets represented as averages and standard deviation as connecting dots for 
donor matched samples.  
Following histological evaluation, GAGs were measured in pellets from all MSC subsets 
as processed after the overnight papain digestion from the three donors. The accumulation 
of GAGs in chondrogenic pellets was assessed in triplicate pellets for each MSCs subset. 
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Mean values for the 6 measurements for each subset (i.e. 3 pellets/subset in triplicate) 
were pooled and shown in Figure 5.21 indicating that although a degree of inter-donor 
variability was observed in the chondrogenic capacity, there were no differences between 
the MSCs subsets in their GAG production (Figure 5.23).  
Chondrogenesis was also assessed at a transcriptional level. Gene expression of the cells 
contained in the chondrogenic pellets was evaluated by qPCR using the lineage-specific 
transcripts, SOX9 and COL2A1. Analysis revealed that the CD56+ MSC subset responded 
better to chondrogenesis induction in comparison to the other subsets. The increase in 
gene expression levels of both transcripts following chondrogenic induction was higher 
in the CD56+ subset in comparison to CD146+ and DN subsets. Based on median values, 
the increase in SOX9 following 21 days of chondrogenic induction in CD56+ derived 
cells increased 8.4-fold compared to Day 0, while the increase was in CD146+ and DN 
was 2.3- and 3.4-fold respectively. Similarly, the expression of the mature chondrogenic 
molecule COL2A1 was almost below detection before chondrogenic induction but 
elevated significantly (more than 20,000-fold) in the CD56+ cells. In comparison, the 
levels of COL2A1 following chondrogenic induction were lower in the other two subsets, 
similar to the trend observed in SOX9 expression. The expression levels in some samples 
were below the detection level and therefore the fold changes were calculated based on 
the median values for the paired data sets.  
Although all three subsets were able to form cartilage in vitro, these results indicate that 
at least at a transcriptional level CD56+ and DN cells, may have an increased 




Figure 5.23. Chondrogenic differentiation assessment by GAG assay and qPCR. (A) 
Quantification of GAG in µg per chondrogenic pellet obtained from FACS sorted 
fractions following culture expansion and chondrogenic induction represented as 
connected dot plots of the average value of donor-matched MSC subsets with bars as 
standard deviation. (B) Transcriptional analysis before and after chondrogenic induction 
showing the fold change differences in relative expression of SOX9 and COL2A1 in the 
three MSC subsets. Data represented as connected dot plots for donor-matched samples 
and fold changes calculated based on average values of each sample. Missing dots 
represent values below detection, fold change calculate based only on the average values 
of paired data sets.  
 256 
5.4.9.4 Adipogenesis 
Adipogenic potential of the different MSCs subsets was investigated using the sorted cells 
from the three donors expanded to passage 1 and cultured thereafter in adipogenic media 
for 21 days.  
The accumulation of lipid vacuoles was assessed in the MSC subsets using bright-field 
microscopy following Oil red staining. This assay confirmed the presence of adipogenic 
droplets in all three MSC subsets, but no obvious differences were observed across the 
three fractions as highlighted by the uptake of oil red (Figure 5.22). Inter-donor variability 
was noted, more oil red positive lipid vacuoles being detected in the third donor in 
comparison to the other two donors. The representative photomicrographs were taken 
using bright-field inverted microscope with a x20 objective directed in the middle of each 
well of the assay following Oil red staining. 
Oil red staining provided a qualitative assessment of the adipogenic differentiation but in 
order to quantify the extent of adipogenesis in the three subsets, a more exhaustive 
method was then chosen. Quantitative analysis was employed using Nile red staining in 
order to investigate further any potential differences between the MSC subsets. 
Fluorescence emission following Nile red staining was measured in all samples and no 
significant differences were observed between the MSCs subsets from the three donors 
based on the median measured fluorescence. To ensure this was not due to a result of cell 
proliferation and hence, increased adipogenic induction, the ratio of Nile red to DAPI 
fluorescence was compared between the two sets (Figure 5.23A). Although not 
statistically significant, a trend for higher NR/DAPI ratio in the CD146+ MSC subset 
compared to DN and CD56+ MSCs was noted. This may be caused by the lower 
fluorescence levels of nuclear stain DAPI, suggesting a smaller number of cells in that 
subset due to different rates of proliferation. 
Indication of higher adipogenic potential of the CD146+ MSCs compared to CD56+ and 
DN was further observed by qPCR using genes specific to adipogenic lineage cells. 
Although all subsets responded to adipogenic induction by increasing the expression of 
FABP4 and PPARG, the fold change between Day 0 and Day 21 post-induction of these 
two adipogenic lineage markers were notably higher in the CD146+ MSC subset as 
compared to DN and CD56+ MSCs (Figure 5.23B). This suggested that the CD146+ 
subsets responded better to adipogenic induction since the transcription factor PPARG 
was increased 8-fold in this subset, while in CD56+ and DN cells the detected levels were 
only elevated 4-fold and 3-fold, respectively. Similarly, the expression levels of the 
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adipogenic protein FABP4 increased almost 2000-fold in the CD146+ subset following 
adipogenic induction, while in the CD56+ and DN subsets this gene increased 100-fold 
and 70-fold, respectively. 
 
Figure 5.24. Assessment of lipid accumulation by Oil red following adipogenic 
induction in the culture-expanded CD271+ MSCs subsets. Oil red staining of lipid 
droplets accumulation in the FACS sorted fractions following culture expansion and 
adipogenic induction from OA bone at 21-days post-induction. Images were taken at the 





Figure 5.25. Assessment of adipogenesis in the culture-expanded CD271+ MSCs 
subsets by Nile red assay and qPCR. (A) Adipogenic quantification by uptake of Nile red 
following 21 days post-adipogenic induction. Average fluorescence absorbance of Nile 
red and DAPI was measured and the ratio calculated, data represented as donor-matched 
connected dot plots of triplicate wells average with bars as standard deviation for the 
three MSC subsets in all donors. (B) Transcriptional analysis before and after adipogenic 
induction showing the fold change differences in relative expression of PPARG and 
FABP4 in the three MSC subsets. Data represented as connected dot plots for donor-
matched samples and fold changes calculated based on median values of each set of 
paired data. 
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Overall data presented in this section provides evidence of multipotentiality for all the 
OA CD271+ MSCs subsets investigated. It was shown that the perivascular, stromal and 
bone lining MSCs, as selected based on surface marker expression by FACS, possessed 
and maintained their capacity to adhere, grow and differentiate under culture conditions. 
While no major differences were observed between the three MSC subsets with regards 
to their multipotential in vitro, it was observed that CD56+ MSC subset responded better 
to chondrogenesis compared to CD146+ and DN MSC subsets. While the functional 
assays demonstrated an enhanced chondrogenic potential of the CD56+ subset, the strong 
osteogenic commitment observed by gene expression in the native cells was not reflected 
during the in vitro assays. Furthermore, it was also noted a trend of higher adipogenic 
potential of the CD146+ MSC subset, based on gene expression analysis following 
adipogenic induction. 
Taken together, these results indicate that the native CD45-CD271+ phenotype represents 
a heterogeneous population of MSCs comprising of multiple subsets differing in their 
lineage commitment bias. It was demonstrated that in vivo the CD271+CD56+ had an 
increased osteogenic gene expression and was found in higher proportions in OA 
compared to healthy bone. The differences in gene expression observed in the native state 
of these subsets in OA bone had a greater amplitude which were not faithfully maintained 




The cellular mechanisms behind bone sclerosis observed in OA is still poorly understood, 
however previous chapters revealed new evidence indicating involvement of both MSCs 
and osteocytes in the pathological mechanisms behind bone sclerosis. An aberrant 
CD271+ MSCs accumulation was observed in the sclerotic areas of OA femoral heads 
bone, putatively participating in an active bone formation process evident by the 
abundance of new and immature osteocytes inhabiting those areas (Chapter 4). As shown 
in Chapter 3, these MSCs also had an enhanced osteogenic commitment evidenced by 
their increased gene expression of molecules associated with osteogenesis and bias for 
bone formation. Additionally, as described in Chapter 1 and thoroughly documented by 
decades of research, it is clear that an abnormal bone phenotype dominate the late stage 
of disease (Lajeunesse et al., 2003; Suri and Walsh, 2012; Burr and Gallant, 2012). By 
dissecting the CD271+ MSC population into phenotypically different subsets, work in 
this chapter tested the hypothesis of the existence of an osteogenically committed MSC 
subpopulation that may be increased and OA and have possible implications in the bone 
sclerosis of late stage hip OA. 
5.5.1 Bone lining resident CD271+CD56+ MSC subset 
Data presented here showed that the CD271+CD56+ MSCs are restricted to the bone 
lining region of the stromal compartment in bone tissue from multiple sites and donors 
with the remaining CD271+ population located within the stromal architecture and 
around the blood vessels. Among the stromal CD271+ population,  the perivascular 
fraction had been demonstrated previously to be represented by the CD146 expression 
(Tormin et al., 2011) while the remaining subset, represented by the CD271+CD56-
CD146- (DN), comprises the population of MSCs in the stromal reticular net. 
The presence of CD56 in cells at the bone surface has been previously documented as a 
transient molecule during osteoblast differentiation (Lee and Chuong, 2009). The CD56 
expression was described as transient because was not found expressed in MSCs before 
osteogenic initiation and was lost in osteocytes in later stages (Lee and Chuong, 2009). 
This indicated that CD56 may be a marker for osteogenically committed cells and 
represented a viable molecule of choice for work in this chapter. It was shown however 
that the expression of CD56 was present in all bone surface cells, including the osteoblasts 
and osteoclasts present at the bone remodelling sites on the bone surface as well as BLCs 
(Andersen et al., 2009). Although these same locations have also been shown in Chapter 
4 and by others (Tormin et al., 2011; Campbell et al., 2016) to be inhabited by CD271+ 
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MSCs, data in Chapter 4 also indicated that both osteoblasts and osteoclasts were negative 
for the CD271 MSC marker. With this in mind, the CD271 and CD56 markers were 
chosen to identify a putative osteogenic committed MSC subset, suspected to drive 
abnormal bone formation in OA. 
Data presented in this chapter confirmed the expression of CD56 in all bone surface 
bound cells, including osteoblasts and osteoclasts, consistent with previous studies 
(Andersen et al., 2009). Performing area expression quantification, it was determined that 
the expression of CD56 was increased in areas of bone sclerosis. This was not surprising 
considering the increased remodelling activities characteristic to subchondral areas (Burr 
and Gallant, 2012). Therefore, by excluding the osteoblasts and osteoclasts from area 
measurements, it was determined that the remaining CD56+ cells were increased in areas 
of bone sclerosis and bone formation, confirmed by PSR staining. Immunohistochemical 
analysis in this chapter placed these CD56+ cells in the vicinity of bone forming 
osteoblasts which were also shown to be increased particularly in areas of bone sclerosis, 
indicating a potential involvement in this pathological event. The PSR staining confirmed 
areas of bone formation by facilitating the visualisation of collagen content in proximity 
of CD56+ cells. The new bone formation was judged by the presence of immature 
collagen fibrils (Paschalis et al., 2003) in the vicinity of CD56+ cells. This was consistent 
with previous studies showing that CD56 was strongly expressed in cells along bone 
trabeculae that coincided with the presence of markers of new bone formation, such as 
collagen I and ALP (Lee and Chuong, 2009). 
The presence of CD56+ cells was also documented in this chapter in the canopy cells 
covering areas of bone remodelling. This may confirm a theory suggested by Kristensen 
et al. that canopy cells represent a route of recruitment for osteoblasts (Kristensen et al., 
2014). The CD56+ cells identified in this chapter in areas of bone sclerosis were found 
occasionally to resemble previous descriptions by the literature. Canopies have been 
described as specialised structures comprising cells expressing osteoblastic markers 
overarching the BMUs and separating this area from the BM (Hauge et al., 2001). The 
location of CD56+ as BLCs make them ideal candidates as osteoprogenitors. By 
demonstrating the co-localisation of the MSC marker CD271 it further extended the 
characterization of this cell type which so far has been limited. While evidence so far has 
indicated BLCs as being an osteoblast precursor (Kristensen et al., 2014; Matic et al., 
2016), data in this chapter showing the enhanced osteogenic profile and proximity to bone 
formation areas of the CD271+CD56+ cells indicate that this MSC subset may be an 
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excellent candidate. In a previous mouse study it was already demonstrated that osterix 
expressing BLCs have the ability to proliferate, activate and become osteoblasts (Matic 
et al., 2016), which in this chapter was shown to be highly expressed by the 
CD271+CD56+ MSCs.  
It has been established that bone restoration during remodelling demands recruitment of 
osteoprogenitors onto reversal surfaces, possibly from the canopy cells or nearby BLCs 
(Jensen et al., 2015). Data here has established the co-expression of CD271+ and CD56+ 
as new markers for the BLCs and demonstrated their presence both on the bone lining 
surface and in the adjacent bone remodelling canopies which point to their roles in bone 
formation process.  
5.5.2 Overview of the CD271+ MSCs subsets 
The inherent heterogeneity of MSC populations can present problems that obscure gene 
expression in a particular subset of cells. To circumvent these obstacles and obtain cell-
type-specific native expression profiles, the approach adopted in this study was cell 
surface marker-based cell purification in order to isolate more homogeneous subsets of 
MSCs. This procedure utilized FACS sorting of cells that have been enzymatically 
released from healthy and diseased bone tissue. Utilizing this approach and by avoiding 
in vitro cell manipulation, facilitated gene expression analysis of the different MSCs 
subtypes reflecting their native phenotypes.  
Previous studies have reported on the co-existence of distinct MSC subsets within the 
same MSC pool, both CD146 and CD56 have been used for investigating the different 
subsets of the CD271+ MSC population (Bühring et al., 2007; Battula et al., 2009; Tormin 
et al., 2011), but this is the first time when these markers were used together. This 
facilitated the segregation of CD271+ MSCs based on their topography, thus identifying 
the bone lining fraction by using antibodies for CD56 and the perivascular fraction by 
using CD146. Furthermore, this resulted in a third double negative fraction (DN), 
represented by the CD271+ MSCs resident in the stromal reticular net. The results 
determined that the CD271+CD146-CD56+ MSCs have distinct phenotypic and 
functional properties resembling an osteogenic committed cell population, differentiating 
them from the DN and CD146+ subsets. 
Their most remarkable osteogenic commitment was evidenced not only by their in vitro 
potential to generate bone but also by the increased expression of a vast array of bone 
formation associated genes in their native state. In comparison to the other two subsets, 
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the CD56+ subset in OA was characterised by significantly higher levels of SPP1 and 
BGLAP, two major components of extracellular matrix and bone formation markers 
(Denhardt and Noda, 1998; Wei and Karsenty, 2015). Additionally, both transcriptional 
regulators of osteogenesis, RUNX2 and SP7 (Komori, 2006), were also highly expressed 
by this subset. It has been shown previously that proliferating cells may contain more 
RUNX2 (Schroeder et al., 2005), thus proliferating RUNX2-rich MSCs would enter 
osteogenic differentiation more efficiently. OMD encodes osteomodulin, a minor 
proteoglycan found in the mineralized matrix of bone, where it binds to hydroxyapatite 
(Wendel et al., 1998). It was previously shown to be expressed in healthy BM CD271+ 
MSCs (Churchman et al., 2012) as well as in mature osteoblasts located superficially on 
trabecular bone and has been proposed as an organiser of mineral formation (Sommarin 
et al., 1998). Thus, the high expression levels of OMD found in OA CD271+CD56+ 
MSCs may account for mineralization changes in OA (L.G. Cox et al., 2012). 
Furthermore, OMD is known to regulate the extracellular matrix during bone formation, 
by controlling the diameter of type I collagen fibrils (Tashima et al., 2015), which may 
explain the differences in birefringence and sizes of collagen fibrils observed following 
PSR staining, with thicker collagen fibres present in the proximity of CD56+ cells.  
By gauging their native differentiation potential with a variety of stringent differentiation 
assays, it was demonstrated that CD271+CD56+ cells are inherently geared to generate 
bone, cartilage and fat. However, it was expected that their native documented prominent 
osteogenic bias would be reflected in vitro but this was not the case. This may be due to 
the thoroughly documented effects of culture conditions which may have interfered with 
these results fading the differences observed in their native counterparts.  
The surface marker CD56 was first described by work of Buhring et al. research group in 
2007 and 2009 (Bühring et al., 2007; Battula et al., 2009; Bühring et al., 2009). Using 
antibodies against CD271+ and CD56+ they identified distinct CD271+ MSCs 
subpopulations from healthy BM (Battula et al., 2009). The resulted CD271+CD56+ 
subset displayed distinct phenotypic and functional properties from its negative 
counterpart, with an increased chondrogenic potential of these cells based on standard in 
vitro functional assay.  
Data in this chapter on the native gene expression of the CD56+ subset showed higher 
levels of SOX9, a major transcription factor that controls chondrogenesis (Bi et al., 1999) 
as well as high levels of CHAD, a major component of cartilage (Camper et al., 1997) in 
comparison to the other CD271+ subsets. This may indicate a ready-state of this subset 
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for chondrogenic differentiation considering the SOX9 and COL2A1 upregulation 
following chondrogenesis induction in vitro. However, this was only evident based on a 
limited number of samples. While transcriptional evaluation of the differentiated cells in 
this chapter pointed to a chondrogenic bias of CD56+ subset in comparison to the other 
two CD271+ MSC subsets, judging by the pellet sizes and GAG concentration following 
culture, there was no difference between all three MSC subsets. Importantly, the samples 
analysed in this chapter were obtained from OA donors, which may also be an influencing 
factor, data in Chapter 1 showing a significantly lower level of these molecules in OA 
bone derived CD271+ MSCs compared to healthy bone (Figure 3.12). Previous studies 
had assessed the chondrogenic potency of the CD271+CD56+ MSC subset isolated from 
healthy BM and shown a higher capacity of these cells to form chondrocytes in 
comparison to CD271+CD56- counterpart (Battula et al., 2009). Unfortunately, the 
analysis of healthy CD271+MSC subsets was not possible in this project due to the low 
cell numbers obtained following FACS purification procedure. This is needed to establish 
whether the phenotype of these subsets is associated with the disease.  
Recently, a study showed that MSCs isolated after rasping of the femoral canal resulted 
in a higher percentage of CD271+CD56+ cells compared to donor-matched aspirate and 
these cells were significantly more chondrogenic than the CD271+CD56- cells 
(Sivasubramaniyan et al., 2018). Histological assessment presented in this chapter clearly 
indicated the bone lining location of the CD271+CD56+ MSCs both by IF and IHC 
(Sections 5.4.3 and 5.4.4). Thus, the findings in Sivasubramaniyan et al. study 
(Sivasubramaniyan et al., 2018) that bone rasping contained higher numbers of 
CD271+CD56+ cells in comparison to aspiration was in agreement with data found in 
this chapter. The histological appearance of the chondrogenic pellets indeed showed a 
correlation with the number of CD271+CD56+ cells (Sivasubramaniyan et al., 2018), 
however this may not reflect the nature of the specific CD271+CD56+ population. This 
is because in contrast to work presented here, that study (Sivasubramaniyan et al., 2018) 
investigated the difference in chondrogenic potential of MSCs isolated by different 
methods (rasping and aspiration) followed by plastic adherence, thus the cells were not 
selectively purified by surface marker expression, but belonged to a heterogeneous 
population of MSCs. Hence, the cells with an increased chondrogenic potential shown by 
Sivasubramaniyan et al isolated by rasping of the femoral canal of OA donors may indeed 
be attributed to CD271+CD56+ MSCs, but it may as well be influenced by any of the 
other CD271+ fractions. Although, this may also be explained by the distant MSC 
extraction sites. Data presented here was obtained from cells isolated from OA femoral 
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heads, while that study used MSCs isolated from the femoral shaft of OA donors, which 
are relatively distant from each other.  
Cytometric analysis presented in Section 5.4.5 showed an increases proportion of 
CD271+CD56+ MSCs within the CD271+ MSC population in OA femoral heads 
compared to healthy bone. Corroborated with data in Chapter 3, this suggested that the 
osteogenic profile of CD271+ MSCs may be linked to one candidate subpopulation, 
hereby determined to be the CD56+ subset. However, this subset only accounted for a 
small percentage of the whole CD271+ MSCs. Meanwhile the DN subset accounted for 
the majority of the CD271+ cell population (about 70%) therefore, it may be possible that 
this may be increased in OA as well. Although no statistical significance was found, a 
trend for an increased DN subset in OA was indeed observed by FACS and it may become 
statistically significant if more samples would be analysed. In support to this idea, the DN 
subset resides in the stromal reticular net which in Chapter 4, Section 4.4.7 was shown to 
accommodate the fibrovascular tissue in areas of bone sclerosis. Based on the increased 
expression of CXCL12 (SDF-1) in DN, it may be possible for this subset to diverge from 
the perivascular location, occupied by the CD271+CD146+ subset, which may represent 
a more primitive MSC subpopulation. Thus, what differentiate DN from the two subsets 
is the distinct localisation in the stromal reticular net and the high transcriptional levels 
of CXCL12. Given the well explored roles played by the MSC-derived CXCL12 in 
stromal support, haematopoiesis and migration (Sugiyama et al., 2006; Kitaori et al., 
2009; Greenbaum et al., 2013), this suggests that the DN subset may be involved in 
facilitating the migration, proliferation and re-location to the bone surface of more 
osteogenic committed progenitors in the OA CD271+ MSC population (Figure 5.26).  
While the osteogenic commitment of DN subset was similar to CD56+ and CD146+, the 
endosteal CD56+ subset had the most osteogenic gene expression signature of all three 
subsets. However, transcriptional analysis identified progressive changes between the 
subsets which may correlate with their topography in OA. While the CD146+ subset is 
located perivascular (Tormin et al., 2011) and CD56+ lining the bone surface, the 
remaining CD271+ subset resides as an intermediate MSC population with a progressive 
osteogenic commitment. This was shown to be lowered to an intermediate level in the 
stromal-resident DN and a significant reduction in all osteogenesis related genes was 
observed in the perivascular CD146+ subset, which revealed higher expression of 
transcripts associated with fat, indication of an early MSC phenotype. Given the high 
osteogenic profile similar across both CD56 and the most numerous DN subset, from a 
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therapeutic perspective, targeting the CD271+ MSC population in OA as a whole seems 
favourable while the exact nature of these subtypes is still under investigation. 
As previously discussed in Chapter 1, Tormin et al. (Tormin et al., 2011) also showed 
that the CD271+ MSC population from healthy BM has distinct topography based on the 
CD146 surface marker expression. Thus, it was shown that CD271+CD146+ MSCs were 
located in a perivascular location while the CD271+CD146- were mostly lining the bone 
surface. However, transcriptional differences of these subsets were not described in that 
study and all experiments were performed using cells isolated from the BM of healthy 
donors. Their MSC identity was however demonstrated, showing that both subsets can 
form bone and haematopoietic stroma in vivo (Tormin et al., 2011). Data presented in this 
chapter further characterised this perivascular fraction by similarly using the 
CD271+CD146+ phenotype, obtaining more knowledge about their nature in both 
healthy and OA bone, expressing more fat and early-MSCs transcripts. This was also 
demonstrated in vitro, transcriptional analysis of the differentiated cells having showed 
an overall lower osteogenesis in the CD146+ compared to both DN and CD56+.  
In this chapter, the CD271+CD146- fraction described by Tormin et al. has been further 
separated by using the novel marker CD56, while the CD271+CD146+ fraction served as 
comparator. In the study by Tormin et al., no gene expression analysis was performed in 
the native subsets represented by the aforementioned phenotype. Another study suggested 
that the two MSC subsets may not necessarily be distinct cell types, but a reflection of 
the distinct microenvironments due to access to different oxygen levels (Maijenburg et 
al., 2011). Data in this chapter however documented some transcriptional differences 
between the CD271+CD146+ subset and the other CD271+ MSCs subsets. Gene 
expression analysis showed significantly higher levels of GATA2 in the CD146+ subset, 
while this molecule was significantly lower in the DN subset and below detection levels 
in the CD56+. The roles of GATA2 in the mesenchymal lineages based on in vitro studies 
suggests that GATA2 maintains MSCs in an undifferentiated state and loss of this gene in 
osteogenically differentiating MSCs has detrimental effects on bone formation (X. Li et 
al., 2016; Tolkachov et al., 2018). In addition, GATA2 was shown to positively modulate 
adipocyte differentiation (Kamata et al., 2014). Gene expression indicated that CD146+ 
subset may represent early adipogenic progenitors. This was backed up by the 
significantly higher levels of adipogenic molecule FABP4 expressed in the CD146+ 
subset in comparison to both DN and CD56+ subsets. An increased capacity of CD146+ 
subset to differentiate towards the adipocytic lineage was evidenced by the in vitro 
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adipogenic differentiation potential, showing consolidating evidence of its adipogenic 
bias. 
While previous studies have already documented the MSCs characteristics of CD271+ 
MSCs (Jones et al., 2010; Tormin et al., 2011; Li et al., 2014), this is the first study were 
the CD271+ native MSCs were dissected into multiple subsets and compared between 
each other, revealing the distinct phenotypes of its subpopulations in their native state. 
Furthermore, this was the first time to compare the differentiation capacity across 
topographically different CD271+ MSC subsets in vitro, all three MSC subsets showing 
multipotentiality with some expected variation between donors.  
5.5.3 Final considerations 
A major limitation of this study is represented by the low number of cells obtained from 
the healthy control IC bone. While FACS and IHC provided evidence pertaining the 
different presence of the CD56+ MSCs subset in bone from healthy and OA, gene 
expression analysis was not successful using the cells from IC and was only assessed in 
the OA group. A more sensitive approach is therefore needed to obtain a gene expression 
profile of these cells from their healthy environment and thus allowing a direct 
comparison to their diseased counterpart. This would provide more information about 
how OA environment modulate the changes in gene expression and confirm whether the 
CD56+ subset of MSCs are indeed responsible for the abnormal bone formation at the 
end-stage OA. As shown in this chapter and by others (Bühring et al., 2007; 
Sivasubramaniyan et al., 2018), the CD56+ MSC subset is not unique to OA and is present 
on other bone surfaces. More work is needed to establish whether the osteochondrogenic 
profile of the CD56+ MSC subset is mediated by the OA environment or it is due to their 
progressive commitment as they migrate towards the bone surface. This information may 
have great consequences with regards to novel cellular targets and open new avenues for 
treatment strategies in many bone-associated pathologies, including OA. 
In a recent study involving nearly 100 OA patients, gene expression alterations were 
documented in BMLs of knee OA. Genes associated with neuronal, osteogenic and 
chondrogenic pathways, such as stathmin 2, thrombospondin 4, matrix metalloproteinase 
13 and Wnt/Notch/catenin/chemokine signalling molecules were shown to be the most 
up-regulated in bone from BMLs of knee OA in comparison to non-affected areas 
(Kuttapitiya et al., 2017). While this study showed strong indication of gene expression 
changes in bone affected by OA, more work is needed to establish the exact cellular 
source of these aberrant signals. Of great interest would represent an investigation of these 
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genes in the MSCs subsets presented here. More intriguing is the potential role that 
CD271+ MSC population may play in modulating the pain pathways in OA. 
This study brought forward the importance of BLCs in OA and offers new insights in the 
identity of the bone lining CD271+ MSCs previously documented. Work in this chapter 
uncovered a new phenotype of bone lining osteoprogenitors and while the native 
osteogenic profile of CD271+CD56+ cells was demonstrated, their roles in the BM 
environment are still being unravelled (Figure 5.26). 
Identifying and characterising these osteoprogenitor cells may provide novel therapeutic 
targets not only for diseases associated with an abnormal bone forming phenotype, such 
as osteoarthritis or spondyloarthropathies but can also be extended to other conditions 
where bone formation is lacking, such as osteoporosis 
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Figure 5.26. Illustration of CD271+CD56+ subset in OA bone. Bone lining MSCs 
identified by CD271+CD56+ phenotype represent a reservoir of osteoprogenitors for the 
bone remodelling compartment (BRC) marked by the presence of osteoblasts and 
osteoclasts. The MSC subset marked by the CD271+CD146+ phenotype reside in 
perivascular location possibly supplying the pool of stromal reticular population of 
CD271+ MSCs, which are negative for both CD56 and CD146 and acts as an 
intermediate osteoprogenitor subset.  
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Chapter 6 General discussion 
6.1 Main findings 
Osteoarthritis is an undisputedly complex disease and is a growing worldwide problem. 
As a reflection of the anabolic bone in the late stages of the disease, this project confirmed 
the hypothesis that there is an accumulation of MSCs in hip OA femoral heads and they 
exhibit an osteogenic phenotype. This aberration was further found to be partially 
attributed to a novel MSC subset marked by the CD271+CD56+ phenotype and reflected 
in the increased presence of young immature osteocytes in OA bone. An improvement of 
the MSC extraction procedure may have contributed to the release of these previously 
inaccessible bone resident MSCs and their proportion was shown to be higher in OA 
compared to healthy bone by both IH and flow cytometry. Furthermore, this method 
allowed the study of osteocytes in their native state for the first time, revealing for the 
first time their transcriptional and topographical differences between healthy and OA 
bone. 
This study represents a novel aspect in the MSC field by investigating distinct subsets of 
MSCs within the native CD271+ population from OA and healthy bone. Although various 
surface markers were reported for association with MSC populations while echoing their 
heterogeneity, the current study isolated and investigated at a transcriptional level the 
MSC subpopulations based on their natural topography in the BM. By using the 
CD271+CD56+ phenotype, work in this thesis established a novel marker to the bone 
lining MSCs in addition to their perivascular location marked by expression of CD146 
(Tormin et al., 2011). Furthermore, transcriptional analysis provided evidence of an 
osteogenic profile of this MSC subset in OA, although this remains to be tested in healthy 
bone to ascertain whether this was modulated by the disease or it reflects the actual cell 
identity as an osteoprogenitor MSC subset. 
Although osteocytes are by far the most numerous cells in the bone, making up more than 
90% of all bone cells (Prideaux, Findlay, et al., 2016), due to their inaccessibility there is 
a paucity of data on human osteocytes, this being the first study to investigate their native 
gene expression in healthy and OA bone. Of importance, this study revealed an immature 
phenotype of bone resident osteocytes in OA both by gene expression and IHC. While 
the different maturation stages during osteoblasts to osteocyte transition can be 
recognized morphologically using in vitro studies while documenting the molecular 
changes during these transformations, some questions still remained unanswered. For 
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example, the decision for an osteoblast to become an osteocyte is still ambiguous. It is 
unknown whether all osteoblasts are equally capable of embedding as osteocytes or their 
fate is predefined by osteoprogenitors cells, possibly by the CD271+CD56+ MSCs. It is 
still unclear whether the osteoblast’s fate is dictated by a specific gene expression pattern 
in this subset of osteogenic precursors and also whether this is a cell-autonomous 
response or one that is controlled via the bone surface cells receiving signals from the 
already embedded osteocytes (Dallas and Bonewald, 2010). Answering these questions 
may provide a mechanistic explanation of the enhanced bone formation and remodelling 
activities dominating the late stages of OA bone which may be further explored in other 
bone associated conditions. 
6.2 Study limitations 
Most of the recruited patients in these studies were diagnosed with OA and the samples 
used for this study were at the late stage of the disease, collected following joint 
replacement. OA is known to be a progressive degenerative disease (Lajeunesse and 
Reboul, 2003; Martel-Pelletier et al., 2016) exhibiting various bone-related pathological 
manifestations and bone remodelling imbalances at different stages, such as an enhanced 
bone resorption activity at the early stages progressing to prominent bone formation and 
sclerosis in the late stages (Burr and Gallant, 2012). An investigation of osteoprogenitors 
in relation to other cellular components in this strenuous environment at different stages 
of disease progression is preferable. This would provide a more detailed picture of the 
putative cellular events that trigger and allow the progression of OA with respect to the 
subchondral bone. 
Another limitation of this study was the number of samples, which were not 
representative of all disease phenotypes. As a multifactorial disease, the late stage 
pathological manifestations may be different considering the patient variability with 
regards to age, sex, body mass index, genetics or level of activity, all of which may be 
highly influential in a biomechanical condition like OA. Furthermore, as discussed in 
Chapter 1, Section 1.1, initiation of disease may take place at different sites in the joint. 
It is possible that progression of the disease from subchondral bone towards the cartilage 
may resemble different pathologies in comparison to secondary OA where the initiation 
factor may be ligamentous or cartilage damage. Data in Chapter 4, Section 4.4.6 presented 
highly heterogeneous expression of RANKL and OPG in two OA patients. This may 
reflect different stages of disease progression previously suggested by Burr et al. (Burr 
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and Gallant, 2012), but it could also represent different tissue responses to the site of 
initiation. 
The control bone used for this study was IC. Femoral head and iliac crest are distant sites 
and may present major differences with regards to the cellular activities and 
biomechanics. The iliac crest is not generally a weight bearing zone as opposed to the 
femoral head. Since osteocytes are established mechanosensory cells (Klein-Nulend et 
al., 2013), their gene expression profile may be different between femoral head and iliac 
crest even under normal conditions. Furthermore, their response to altered biomechanics 
can also be different since the osteocytes resident in the femoral head are being exposed 
and possibly adapted to different strains in comparison to iliac crest bone. However, 
recent published data showed that gene expression and morphology of osteocytes are 
comparable between the two sites with regards to both gene expression and IHC 
evaluation of molecules of interest (Ilas et al., 2019). Similarly, when compared to similar 
weight-bearing sites, such as the femoral heads of NFF donors, the changes in gene 
expression were similar to healthy IC bone (Ilas et al., 2019) while the MSC topography 
seemed notably similar to healthy IC and NS areas from OA bone, however no 
quantification was performed to confirm. This indicates that their accumulation in 
sclerotic areas is modulated by OA and not by tissue distribution or mechanical load.  
The changes observed in both osteocytes and MSCs in this study would be ideally 
analysed by comparing them to non-OA femoral heads, but the availability of these 
samples is very low. While it may be possible to obtain normal femoral heads from 
recently deceased donors, studies have shown that RNA degradation in femoral head bone 
occurs at fast rates and is recommended to be extracted within a 48 hours window post-
mortem (Kuliwaba et al., 2005). Another option would imply the isolation of MSCs and 
osteocytes from segregated regions of damaged and unaffected areas within the same 
femoral head. This may involve high technical difficulty and subjectivity, especially with 
regards to visual assessment of damaged areas. To overcome this, MRI can be used 
immediately after sample collection, as described in previous studies (Campbell et al., 
2016; Kuttapitiya et al., 2017). 
Knowing the biology of MSCs in their native state is crucial when aiming to characterise 
the fundamental differences between health and disease. It only emphasises that however 
convenient, in vitro studies are not sufficient neither for a correct assessment of the 
disease process nor for the deduction of the MSC biology in vivo. A better understanding 
of native MSCs phenotype would contribute considerably to development of better 
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treatment strategies for OA that are efficient, correctly targeted, more financially viable 
and less invasive. 
6.3 Future directions and clinical implications 
As stated in Chapter 1, Section 1.1.5, due to the lack of effective treatment strategies, the 
cell-based therapies have surfaced as alternative methods for treatment of OA (Zhang, 
Ouyang, Crispin R Dass, et al., 2016), however only limited data proved their efficacy. 
Furthermore, as shown in Chapter 3, with an increased number present in the joints 
already, the addition of exogenous MSC may prove redundant, especially without 
properly characterising the MSCs used for therapy. Evidence discussed so far indicate a 
defective phenotype in OA and drastic changes following culture expansion. Thus, more 
efforts should be made to target the existent endogenous pool of MSCs with the aim to 
restore the homeostasis and trigger a natural healing mechanism. Such approaches have 
recently emerged involving mobilisation of synovial MSCs in order to populate and repair 
the cartilage defects in OA (Baboolal et al., 2018). 
Some cell-based therapies may aim to stimulate the biological restoration of the damaged 
tissues in OA, such as the subchondral bone. The MSCs might be capable of facilitating 
tissue repair through paracrine signalling, immunomodulation and extracellular vesicles 
(EVs), with direct MSC differentiation likely playing a minor role in some instances 
(Barry and Murphy, 2013; Cosenza et al., 2017). The ‘secretome’ of MSCs, although not 
fully understood, generally has functions associated with chemoattraction and modulation 
of immune cells, angiogenesis, and support of cellular growth and proliferation (da Silva 
Meirelles et al., 2009). Extracellular vesicles are predominantly endosomal in origin, 
comprising mainly of exosomes and microvesicles containing a cargo of miRNA, mRNA, 
and proteins usually delivered to the target cells (Keshtkar et al., 2018). Hence, this may 
facilitate the use of intra-articular healthy EV delivery with the aim to enhance the 
inherent repair mechanisms of resident MSCs at the sites of damage. In fact, EVs derived 
from MSCs could potentially be easier to manage and be safer due to the lower extra-
cellular proteins, such as the major histocompatibility complex (MHC) molecules and 
their ability to form tumours (Yu et al., 2014). This may provide MSCs-derived EVs with 
a great therapeutic advantage and be superior to whole cells treatments. 
It is still unknown whether the osteogenic commitment and increased numbers described 
in this thesis have any deleterious impact on the joint and whether inhibiting the 
osteocytic maturation program in MSC-lineage cells could be beneficial to the joint. 
Increased accumulation of MSCs in areas of bone formation may represent a reparative 
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response mechanism. The immature osteocytes inhabiting the sclerotic bone indicated the 
bone was newly formed and therefore may provide support for the joint in compensation 
to cartilage damage. In any case, the high bone remodelling activity observed in this study 
and documented extensively by others (Burr and Gallant, 2012) point to increased repair 
capacity, which seems the key for the spontaneously reversible course of this disease. 
Evidence pertaining E11 is of great importance as it may be harnessed therapeutically. 
Inhibition of osteocytic maturation program in MSC-lineage cells may re-establish the 
bone homeostasis in late stage OA by preventing early osteocyte differentiation 
concomitantly with bone formation. Its protective role against OA has been recently 
evidenced in a mouse model of OA showing that bone-specific conditional deletion of 
E11 protects against load-induced OA (Staines et al., 2018). 
Progression of OA has been described as a bi-phasic process, with increased remodelling 
during early disease and its reduced rate as the disease progresses (Burr and Gallant, 
2012). Given the emerging insights into the osteocytes’ role in regulating bone 
homeostasis (Prideaux, Findlay, et al., 2016), and therapies for targeting them 
pharmacologically (Plotkin and Bellido, 2016), data in this thesis provided a conceptual 
basis for targeting their precursors MSCs in OA. Specifically, the high levels of OPG in 
OA-osteogenic lineage cells caution against a subchondral bone manipulation strategy 
aimed at osteoclast inhibition in advanced stages of OA. The use of anti-resorptive 
therapeutic agents in OA, such as bisphosphonates and cathepsin K inhibitors, requires a 
better understanding of the ‘window of opportunity’ in which these therapies could lead 
to restoration of normal bone homeostasis.  
Subchondral bone has been considered as one of the most promising targets for OA drug 
development (Hayami et al., 2004). Identification and prospective isolation of tissue-
residents MSCs with known and different functionalities may provide novel approaches 
for targeted tissue repair in regenerative medicine. These findings could provide the basis 
for the use of osteochondroprogenitors purified from different sources in clinical 
protocols of cell-based therapies for the repair of osteochondral defects. These cells may 
as well be targeted by bisphosphonates. Bisphosphonates can attach to hydroxyapatite 
binding sites in bone lining locations, particularly those which are undergoing active bone 
resorption (Walsh and Chapman, 2011). The location of CD271+CD56+ MSCs lining the 
bone surface may also facilitate the development of novel biologics allowing to target 
these cells similarly to bisphosphonates in order to re-establish the normal bone turnover. 
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6.4 Concluding remarks 
With the increasing life span of the human population, the need to maintain bone quality 
and strength is more relevant as ever, and significant effort is being put into studying bone 
remodelling and additional factors influencing bone quality. Due to ageing everyone has 
some degree of wear and tear damage in the joints, however not everyone develops OA. 
Therefore, while the initiation of the disease may be imminent, therapeutic strategies 
aimed at stopping or slowing the progression of the disease may prove more efficient. 
Early correction of the MSCs abnormal migration and osteogenesis bias could prevent an 
excessive bone formation and the corresponding cartilage destruction in this disease. 
This project has revealed important roles played by the MSCs and their osteogenic lineage 
progenies in OA pathophysiology. Little is known about the native biology of MSCs 
while their roles in bone remodelling activities have not been investigated so far. Using 
native and minimally manipulated cells provided more relevant information regarding 
cellular aberrations, the results not being biased by culture induced transcriptional and 
functional changes. Furthermore, this study revealed the existence of a novel osteogenic 
MSC subset residing on the bone surface with potential implications in driving the OA 
bone sclerosis. So far neglected, discovering the increased accumulation of young and 
immature osteocytes in the vicinity of MSCs of OA sclerotic bone revealed the buried 
proof that clearly implicates the MSCs and its entire osteogenic lineage in the subchondral 
bone alterations in OA. 
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Appendix 1. Reagents 
Manufactured reagents 
Product Manufacturer 
Absolute Ethanol Sigma 
Acetone Sigma 
Alizarin Red Sigma 
b-Mercaptoethanol Sigma 
Bovine Serum Albumin Sigma 
Citrate Concentrated Solution Sigma 
Collagenase I Type A, AOF Worthington 
Dimethyl Sulfoxide (DMSO) Sigma 
Disodium Tetraborate Sigma 
Disodium Tetraborate Fisher Scientific 
DNase (cell culture) Sigma 
DNase I (RNA) Norgen Biotek 
DPX Mounting Media Sigma 
Dulbecco’s Modified Eagle Medium Gibco 
Dulbecco’s Phosphate Buffered Saline Gibco 
Eosin Y Sigma 
Ethylene Glycol Monoethyl Ether Sigma 
Ethylenedinitrilotetraacetic Acid (EDTA) Fisher Scientific 
Fast blue RR Salt (tablets) Sigma 
Fast Green FCF Alfa Aesar 
Foetal Bovine Serum Biosera 
Formalin (10% neutral buffered) Sigma 
Guanidine Isothiocyanate Solution Invitrogen 
Haematoxylin (Harris) Fisher Scientific 
Haematoxylin (Weigert’s) Sigma 
Human Serum Sigma 
Hydrochloric Acid Fisher Scientific 
Isopropanol Sigma 
L-Cysteine Sigma 
Live/dead staining kit (contains calcein AM and 
ethidium homodimer-1) Invitrogen 
Magnesium Sulphate Sigma 
Methanol Sigma 
Methylene Blue Sigma 
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Naphtol AX-MX Phosphate Sigma 
Nile Red Thermo Fisher 
Nuclear Fast Red Sigma 
Nuclease-free Water Ambion 
Oil Red O Sigma 
Optimal Cutting Temperature (OCT) compound VWR 
PBS Tablets Sigma 
Penicillin/streptomycin (Pen/Strep) Gibco 
Phenol : Chloroform : Isoamyl Alcohol (25:24:1) Sigma 
Phosphate buffered saline (without calcium and 
magnesium) Gibco 
Picric Acid (Saturated, Aqueous) Fisher Scientific 
Potassium Chloride Sigma 
Saponin Sigma 
Sirius Red F3B Sigma 
Sodium Acetate Anhydrous Sigma 
Sodium Bicarbonate Sigma 
Sodium Hydroxide Sigma 
StemMACS AdipoDiff Media Miltenyi Biotec 
StemMACS ChondroDiff Media Miltenyi Biotec 
StemMACS MSC Expansion Media Miltenyi Biotec 
StemMACS OsteoDiff Media Miltenyi Biotec 
TaqMan Gene Expression Master Mix Applied Biosystems 
Toluidine Blue Sigma 
Tris Base Fisher Scientific 
Trypan Blue Solution Sigma 





Activated papain enzyme digestion solution (GAG assay) 
For 100 mM sodium phosphate buffer/5 mM EDTA/10 mM L-cysteine (0.125 mg/ml 
papain): Just before use, add 63 mg of L-cysteine hydrochloride hydrate in 40 ml papain 
buffer and sterile filter using syringe and 20 µm filter. Transfer 1 ml of papain solution 
to a microcentrifuge tube using a syringe and 20-gauge needle then add 125 µg/ml papain 
enzyme. 
Alizarin red staining solution (Osteogenesis) 
Prepared by dissolving 342 mg Alizarin Red (Sigma) in 25 ml of dH2O and pH adjusted 
to 4.1 
Borate buffer (CFU-F assay) 
10mM borate buffer: 1.91g disodium tetraborate dehydrate (Sigma) dissolved in 500 ml 
dH2O and pH adjusted to 8.8 with 1M boric acid (made up by dissolving 6.183g boric 
acid (Sigma) in 100 ml dH2O = 1M) 
Cell freezing media 
90% FCS (Biosera) + 10% DMSO (Sigma). 
Citrate fixative (ALP assay) 
6 ml acetone (Sigma) and 4 ml of 1:50 dilution of citrate concentrate solution (Sigma) 
EDTA decalcification solution 
0.5 M EDTA solution (pH 7.4): 186.1 g EDTA disodium dehydrate (Fisher Scientific) 
dissolved in 800 ml dH2O. The disodium salt of EDTA will not go into solution until the 
pH of the solution is adjusted to ~8.0 by the addition of NaOH. The pH was therefore 
first adjusted to 8.0 with approximately 20 g of Sodium Hydroxide pellets (NaOH) (Fisher 
Scientific) and following complete dissolution adjusted to 7.4 with neat HCl (Sigma).  
Fast Blue solution (ALP assay) 
One Fast blue salt tablet (Sigma) dissolved in 48 ml of dH2O with the addition of 2 ml of 
0.25% Naphtol AX-MX phosphate solution (Sigma)  
Fast Green staining solution (Safranin O staining) 
0.02% solution by dissolving 0.05 g Fast Green FCF (Sigma) in 250 ml dH2O 
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FACS Buffer  
500 ml PBS + 1% w/v bovine serum albumin (5 g) (Sigma) + 200 µl EDTA 0.5M (Fisher 
Scientific)  
Fc blocking buffer  
1 ml aliquots containing 10% mouse serum (Sigma), 1% human IgG (Sigma) in FACS 
Buffer  
GITC lysis buffer 
GITC solution (Invitrogen) containing 0.4% sodium citrate (Sigma), 1% N-lauryl 
sarcosine (Fisher Scientific) and 0.5% b-mercaptoethanol (Sigma). 
HCL solution (Calcium assay) 
0.5N HCl; 26.5 ml of 37% HCl (Fisher Scientific) in 473.5 ml dH2O. 
Methylene blue solution (CFU-F assay) 
1% w/v methylene blue solution: 1 g methylene blue (Sigma) dissolved in 100 ml of 
10mM borate buffer (pH 8.0). 
Naphthol AS-MX Phosphate Substrate  
20 mg of Naphtol AX-MX phosphate (Sigma) dissolved in 1 ml Ethylene Glycol 
Monoethyl Ether (Sigma) 
Nile red 
Make up Nile red stock solution at 0.1 mg/ml in methanol. Before use, add 4 µl Nile red 
stock in 80 µl PBS to obtain 1:2000 working dilution. 
Oil red (Adipogenesis) 
Prepared at 0.5% by dissolving 50 mg Oil red (Sigma) in 10 ml of isopropanol (Sigma), 
incubated for 30 minutes at 37° C and then diluted 3:2 w/v with dH2O, filtered twice 
using a 45 µm filter (Millex) for first filtration followed by a 22 µm filter (Millex) to 
remove any undissolved material.  
Papain buffer extract (PBE) (GAG assay) 
For 100 ml of 100 mM sodium phosphate buffer/5 mM EDTA (pH 6.5): To 90 ml of 
dH2O add 0.653 g sodium phosphate dibasic (Na2HPO4, MW 142.0), 0.648 g of sodium 
dihydrogen phosphate (NaH2PO4, MW 120.0) and 1 ml of 500 mM EDTA (Sigma). 
Adjust pH to 6.5 using HCl and make up volume to 100 ml using dH2O then filter sterile. 
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Phosphate buffer saline 
1 PBS tablet (Sigma) dissolved in 200 ml dH2O 
Picrosirius red  
0.1% Picrosirius red solution: dissolve 0.25g Sirius red F3B (Sigma) in 250 ml saturated 
aqueous picric acid (Fisher scientific) 
Scott’s tap-water substitute  
3.5 g of 42 mM Sodium bicarbonate (NaHCO3) (Sigma), 20 g of 8 mM magnesium 
sulphate (MgSO4) (Sigma) dissolved in 1L of dH2O. 
Toluidine blue solution (Chondrogenesis) 
1% Toluidine Blue (Sigma) in 50% v/v isopropanol (Sigma) 50% v/v dH2O: Dissolve 2 
g of Toluidine Blue in a mix of 100 ml isopropanol and 100 ml dH2O. 
TRAP basic incubation media 
1 L of 50 mM tartrate solution: 9.2 g Sodium Acetate Anhydrous (Sigma) + 11.4 g L-(+) 
Tartaric Acid (Sigma) + 950 ml dH2O; pH adjusted to 4.7-5 with 5M Sodium Hydroxide 
(Fisher Scientific) to increase or more HCl (Sigma) to decrease. 
TRAP staining solution mix 
200 ml of 0.06% Fast Red: dissolving 120 mg Fast Red/Violet LB (Sigma) in 200 ml 
TRAP basic incubation media with the addition of 1 ml Naphthol AS-MX Phosphate 
Substrate mix 
Tris-buffered saline 
16 g Sodium chloride (NaCl), 0.4 g Potassium chloride (KCl) and 6 g Tris base (all from 




Appendix 2. Plasticware, consumables and equipment 
Plasticware and Consumables 
Item Manufacturer 
12-well Culture Plate Corning 
24-well Culture Plate Corning 
384-well PCR Plate Thermo Fisher 
48-well Culture Plate Corning 
6-well Culture Plate Corning 
60 mm Culture Dish Corning 
Bijous (5 ml) Star Lab 
Cell strainer (72 µm) Corning 
Cryo Boxes Sarstedt 
Cryovials (2 ml) Sarstedt 
Falcon Tubes (15 ml and 50 ml) Corning 
Falcon Tubes (5 ml polypropylene FACS) Corning 
Filter (0.22 µm) Millex 
Histology Cassettes Scientific Laboratory Supplies 
Microtome Blades (CellEdge R+) Cell Path 
PCR Tubes and Caps Star Lab 
Pipette Tips (10 µl, 200 µl and 1000 µl) Gilson 
Safe-lock Tubes (0.5 ml and 1.5 ml) Eppendorf 
Scalpel (blade sizes 10 and 22) Swann-Morton 
Sterile Pot (150 ml) Medfor 
Stripette (5 ml, 10 ml and 25 ml) Corning 
SuperFrost Plus Microscope Slides Thermo Fisher 
T25, T75, T150 Culture Flask Corning 






Bone Cutting Forceps (Stille-Liston) Sklar 
Bone Rongeur (Stille-Luer) Sklar 
Bone saw Exakt 
Cell Culture Cabinet (Class II) Nuaire 
Centrifuge (5424 R - for molecular biology) Eppendorf 
Centrifuge (5810 R - for cell culture) Eppendorf 
Centrifuge (Heraeus™ Multifuge™ - TLDA) Thermo Fisher 
Digital Camera (for microscope) Olympus 
Freezer (-20° C) Liebherr 
Freezer (-80° C) Panasonic 
Freezing Container (Mr.Frosty) Nalgene 
Fridge (2°-4° C) Zanussi 
Fume Hood  
Haemocytometer Hawksley 
Hot plate – SH3 (histology) Stuart Scientific 
Hot plate stirrer (PC-351) Corning 
Incubator (37° C) Sanyo 
Metal Mesh Glove Niroflex 
Microcentrifuge Star Lab 
Microscope (Brightfield) Leica Microsystems 
Microscope (Confocal) Nikon A1R 
Microscope (Fluorescent) Nikon Eclipse 
Microscope (Inverted) Olympus 
Microtome – RM2235 Leica 
Nanodrop Spectrophotometer Thermo Fisher 
pH Meter Jenway 
Plate reader (Mithras LB 940) Berthold 
QuantStudio™ 7 Flex Real-Time PCR System Applied Biosystems 
Rotator/hybridisation Oven (HB-500) Ultra-Violet Products 
Vortex Star Lab 
Water Bath Grant 
Weighing Scale Mettler Toledo 
X-Ray Machine (CS2200) Carestream Health 
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Appendix 4. Patient details 
OA 
Sample ID Age Sex  Sample ID Age Sex 
OA01 89 Female  OA022 53 Male 
OA02 82 Male  OA023 71 Male 
OA03 75 Male  OA024 68 Male 
OA04 79 Female  OA025 67 Male 
OA05 77 Female  OA026 69 Male 
OA06 84 Female  OA027 67 Male 
OA07 82 Female  OA028 69 Male 
OA08 77 Male  OA029 82 Male 
OA09 57 Female  OA030 40 Male 
OA010 75 Female  OA031 57 Female 
OA011 60 Female  OA032 74 Male 
OA012 55 Female  OA033 74 Female 
OA013 56 Female  OA034 67 Male 
OA014 71 Female  HO13 72 Female 
OA015 57 Female  HO19 73 Female 
OA016 68 Male  HO44 70 Female 
OA017 82 Female  HO41 43 Male 
OA018 74 Female  HO55 78 Female 
OA019 81 Female  HO27 59 Male 
OA020 72 Female  HO40 63 Male 
OA021 61 Female  HO13 72 Female 
Controls 
Sample ID Age Sex  Sample ID Age Sex 
IC01 58 Male  APB22 31 Male 
IC02 58 Male  APB23 87 Female 
IC03 55 Female  APB24 24 Male 
IC04 49 Male  APB1 54 Male 
IC05 46 Male  APB2 70 Female 
IC06 53 Female  APB3 24 Female 
IC07 38 Female  APB13 39 Female 
IC08 78 Male  NFF01 88 Female 
IC09 42 Male  NFF02 54 Female 
IC10 40 Female  NFF03 93 Female 




Appendix 5. TaqMan assays 
TaqMan probes used for MSC gene expression analysis in Chapter 3 and 5 
Assay ID Gene Symbol Synonyms Group 
Hs00244715_m1 ACVR1B activin A receptor, type IB Bone 
Hs00155658_m1 ACVR2A activin A receptor, type IIA Bone 
Hs00758162_m1 ALPL alkaline phosphatase, liver/bone/kidney Bone 
Hs01101127_m1 ANGPTL4 angiopoietin-like 4 Bone 
Hs03044164_m1 BAMBI BMP and activin membrane-bound inhibitor homolog Bone 
Hs00609452_g1 BGLAP bone gamma-carboxyglutamate protein (osteocalcin) Bone 
Hs00154192_m1 BMP2 bone morphogenetic protein 2 Bone 
Hs00370078_m1 BMP4 bone morphogenetic protein 4 Bone 
Hs00234930_m1 BMP5 bone morphogenetic protein 5 Bone 
Hs00403062_m1 BMPER BMP binding endothelial regulator Bone 




CD209 molecule,C-type lectin 
domain family 4, member M Bone 
Hs01076777_m1 COL1A1 collagen, type I, alpha 1 Bone 
Hs01028971_m1 COL1A2 collagen, type I, alpha 2 Bone 
Hs00322497_m1 DAAM2 dishevelled associated activator of morphogenesis 2 Bone 
Hs00182901_m1 DVL2 dishevelled, dsh homolog 2 Bone 
Hs00241111_m1 FGFR1 fibroblast growth factor receptor 1 Bone 
Hs00179829_m1 FGFR3 fibroblast growth factor receptor 3 Bone 
Hs00173503_m1 FRZB frizzled-related protein Bone 
Hs00268943_s1 FZD1 frizzled homolog 1  Bone 
Hs00201853_m1 FZD4 frizzled homolog 4  Bone 
Hs00275833_s1 FZD7 frizzled homolog 7 Bone 
Hs00259040_s1 FZD8 frizzled homolog 8 Bone 
Hs00268954_s1 FZD9 frizzled homolog 9 Bone 
Hs01075601_m1 GHR growth hormone receptor Bone 
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Hs00181211_m1 IGFBP3 insulin-like growth factor binding protein 3 Bone 
Hs02379661_g1 MT2A metallothionein 2A Bone 
Hs00182120_m1 NGFR nerve growth factor receptor (TNFR superfamily, member 16) Bone 
Hs00271352_s1 NOG noggin Bone 
Hs00192325_m1 OMD osteomodulin Bone 
Hs00170179_m1 PCOLCE procollagen C-endopeptidase enhancer Bone 
Hs00998018_m1 PDGFRA platelet-derived growth factor receptor, alpha polypeptide Bone 
Hs00185122_m1 PDGFRL platelet-derived growth factor receptor-like Bone 
Hs01370291_g1 PHOSPHO1 phosphatase, orphan 1 Bone 
Hs00231079_m1 RUNX1 runt-related transcription factor 1  Bone 
Hs00231692_m1 RUNX2 runt-related transcription factor 2 Bone 
Hs00173499_m1 S1PR1 Sphingosine-1-Phosphate Receptor 1 Bone 
Hs00610060_m1 SFRP1 secreted frizzled-related protein 1 Bone 
Hs00180066_m1 SFRP4 secreted frizzled-related protein 4 Bone 
Hs00361747_m1 SORT1 sortilin 1 Bone 
Hs00541729_m1 SP7 Sp7 transcription factor Bone 
Hs00277762_m1 SPARC secreted protein, acidic, cysteine-rich (osteonectin) Bone 
Hs00959010_m1 SPP1 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I) Bone 
Hs00559661_m1 TGFBR2 transforming growth factor, beta receptor II (70/80kDa) Bone 
Hs00234257_m1 TGFBR3 transforming growth factor, beta receptor III Bone 
Hs00900360_m1 TNFRSF11B 
tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 
Bone 
Hs00361186_m1 TWIST1 twist homolog 1 Bone 
Hs00382379_m1 TWIST2 twist homolog 2 Bone 
Hs00183662_m1 WIF1 WNT inhibitory factor 1 Bone 
Hs00153936_m1 ACAN Aggrecan Cartilage 
Hs00154382_m1 CHAD Chondroadherin Cartilage 
Hs00166657_m1 COL10A1 collagen, type X, alpha 1 Cartilage 
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Hs00264051_m1 COL2A1 collagen, type II, alpha 1 Cartilage 
Hs00164359_m1 COMP Cartilage Oligomeric Matrix Protein Cartilage 
Hs00191912_m1 EPYC epiphycan Cartilage 
Hs00167060_m1 GDF5 Growth Differentiation Factor 5 Cartilage 
Hs00157103_m1 HAPLN1 Hyaluronan And Proteoglycan Link Protein 1 Cartilage 
Hs00190682_m1 PAPSS2 3'-Phosphoadenosine 5'-Phosphosulfate Synthase 2 Cartilage 
Hs00160431_m1 PRELP Proline and Arginine Rich End Leucine Rich Repeat Protein Cartilage 
Hs00165814_m1 SOX9 SRY (sex determining region Y)-box 9  Cartilage 
Hs01113602_m1 TNFAIP6 TNF Alpha Induced Protein 6 Cartilage 
Hs01097550_m1 UGDH UDP-Glucose Dehydrogenase Cartilage 
Hs00170454_m1 FGF5 fibroblast growth factor 5 Early/ES/neural 
Hs02387400_g1 NANOG Nanog homeobox Early/ES/neural 
Hs00707120_s1 NES nestin Early/ES/neural 
Hs00999632_g1 POU5F1 POU class 5 homeobox 1 Early/ES/neural 
Hs01053049_s1 SOX2 SRY (sex determining region Y)-box 2 Early/ES/neural 
Hs00181613_m1 ANGPT1 angiopoietin 1 Endo/ mural 
Hs00156438_m1 CDH11 cadherin 11, type 2, OB-cadherin Endo/ mural 
Hs00901463_m1 CDH5 cadherin 5, type 2, VE-cadherin Endo/ mural 
Hs00426981_m1 CSPG4 chondroitin sulfate proteoglycan 4 Endo/ mural 
Hs00358886_m1 EFNA1 ephrin-A1 Endo/ mural 
Hs00174752_m1 EPHB4 EPH receptor B4 Endo/ mural 
Hs00748445_s1 GJA1 gap junction protein, alpha 1, 43kDa Endo/ mural 
Hs00174838_m1 MCAM melanoma cell adhesion molecule Endo/ mural 
Hs00269972_s1 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha Fat 
Hs00609791_m1 FABP4 fatty acid binding protein 4, adipocyte Fat 
Hs00174492_m1 LEPR leptin receptor Fat 
Hs01012571_m1 LPL lipoprotein lipase Fat 
Hs01115513_m1 PPARG peroxisome proliferator-activated receptor gamma Fat 
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Hs00231119_m1 GATA2 GATA binding protein 2 Haematopoietic 
Hs99999041_m1 IFNG interferon, gamma, Haematopoietic 
Hs00961622_m1 IL10 interleukin 10 Haematopoietic 
Hs99999905_m1 GAPDH glyceraldehyde-3-phosphate dehydrogenase Housekeeping 
Hs99999909_m1 HPRT1 hypoxanthine phosphoribosyltransferase 1  Housekeeping 
Hs00909449_m1 ACTA2 actin, alpha 2, smooth muscle, aorta Muscle 
Hs00178815_m1 DDR2 discoidin domain receptor tyrosine kinase 2 Muscle 
Hs00427183_m1 MSX1 msh homeobox 1 Muscle 
Hs00159522_m1 MYH9 myosin, heavy chain 9, non-muscle Muscle 
Hs00171022_m1 CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) Stromal 
Hs00601975_m1 CXCL2 C-X-C Motif Chemokine Ligand 2 Stromal 
Hs00174202_m1 IL7 interleukin 7 Stromal 
Hs01070036_m1 JAG1 jagged 1 Stromal 
Hs00900058_m1 VEGFA vascular endothelial growth factor A Stromal 




TaqMan probes used for osteocytes and MSC gene expression analysis in Chapter 4 
Assay ID Gene Gene name Role 
Hs00366766_m1 PDPN Podoplanin/E11/gp38 
Early osteocyte 
development 
Hs00237119_m1 MMP14 Membrane-Type-1 Matrix 
Metalloproteinase 





Hs00189368_m1 DMP1 Dentin matrix acidic phosphoprotein 1 
Hs00220237_m1 MEPE Matrix Extracellular 
Phosphoglycoprotein 
Hs00221003_m1 FGF23 Fibroblast growth factor 23 
Hs00228830_m1 SOST Sclerostin 
Bone 
remodelling 




Tumor necrosis factor receptor 
superfamily, member 11b (OPG) 
Hs01092186_m1 TNFSF11 Tumor necrosis factor (ligand) 
superfamily, member 11 (RANKL) 
Hs00166156_m1 CTSK Cathepsin K 
Hs00356261_m1 ACP5 Acid Phosphatase 5, Tartrate Resistant 
(TRAP) 
Hs00758162_m1 ALPL Alkaline phosphatase 
Native MSC 
markers 
Hs00541729_m1 SP7 Sp7 Transcription Factor 
Hs00171022_m1 CXCL12 Chemokine (C-X-C motif) ligand 12 
*Hs99999909_m1 HPRT1 Hypoxanthine 
phosphoribosyltransferase 1 
Housekeeping 
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